Calpains in the Molecular Pathogenesis of Polyglutamine Disorders and Their Potential as a Therapeutic Target by Weber, Jonasz Jeremiasz
 Calpains in the Molecular Pathogenesis of 
Polyglutamine Disorders and their Potential as a 
Therapeutic Target  
 
 
 
 
Dissertation 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines  
Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
vorgelegt von 
Jonasz Jeremiasz Weber 
aus Gera 
 
 
Tübingen 
2017 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Eberhard Karls Universität Tübingen. 
 
 
Tag der mündlichen Qualifikation:  23.02.2018 
Dekan: Prof. Dr. Wolfgang Rosenstiel 
1. Berichterstatter: Prof. Dr. Olaf Rieß 
2. Berichterstatter: Prof. Dr. Ludger Schöls 
3. Berichterstatter: Prof. Dr. Susann Schweiger 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Meiner Familie 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  "...to boldly go where no man has gone before." 
James Tiberius Kirk 
  
 
i 
Table of contents 
Abbreviations ......................................................................................................................... v 
Summary .............................................................................................................................. vii 
Summary (English) ......................................................................................................... vii 
Zusammenfassung (Deutsch) ....................................................................................... viii 
List of publications ................................................................................................................. ix 
Personal Contribution ............................................................................................................ xi 
Introduction ........................................................................................................................... 1 
Neurodegenerative diseases: the quest for new therapies .......................................... 1 
Preface ........................................................................................................................... 1 
Neurodegeneration and ageing ...................................................................................... 1 
Factors contributing to neuronal ageing and neurodegeneration .................................... 2 
Psychosocial stress .................................................................................................... 2 
Obesity and diabetes .................................................................................................. 3 
Vascular risks ............................................................................................................. 3 
Environmental neurotoxins ......................................................................................... 4 
Neuroinflammation ...................................................................................................... 4 
Genetics ..................................................................................................................... 5 
Cellular and molecular changes during neuronal ageing and degeneration .................... 7 
Disturbances in energy metabolism and mitochondrial function .................................. 7 
Impact of oxidative stress ........................................................................................... 8 
Calcium dyshomeostasis ............................................................................................ 9 
Detrimental accumulation and aggregation of proteins...............................................10 
Polyglutamine diseases as a monogenic model for neurodegeneration ...................12 
The group of polyglutamine diseases ............................................................................12 
Clinical features of Huntington disease and spinocerebellar ataxia type 3 .....................13 
Huntington disease ....................................................................................................13 
ii 
Spinocerebellar ataxia type 3 .....................................................................................15 
Molecular characteristics of Huntington disease and spinocerebellar ataxia type 3 .......17 
The disease protein huntingtin ...................................................................................17 
The disease protein ataxin-3 ......................................................................................19 
Divergent and common molecular pathomechanisms ................................................23 
The role of proteolysis in neurodegenerative diseases ...............................................26 
The toxic fragment hypothesis of neurodegeneration ....................................................26 
Sources for toxic fragments ...........................................................................................28 
Proteolytic machineries of the cell ..............................................................................28 
Caspases as mediators of apoptosis and disease protein cleavage ...........................30 
Calpains and their involvement in health and disease ................................................33 
Calpains and their role in Huntington disease and spinocerebellar ataxia type 3 ...........37 
Calpains and Huntington disease ..............................................................................37 
Calpains and spinocerebellar ataxia type 3 ................................................................38 
How to target the calpain proteolytic pathway as a therapeutic approach ......................39 
Direct and indirect modulation of calpain activity ........................................................39 
Rendering disease proteins resistant to proteolysis by calpains .................................41 
Objectives of the study .........................................................................................................45 
Results and discussion .........................................................................................................47 
Investigating calpain activation in cell and animal models of polyQ diseases ..........47 
Preliminary considerations .........................................................................................47 
Calpain activation in cell models of HD and SCA3 .....................................................49 
Calpain activation in animal models of HD .................................................................51 
Amplifying calpain activity by genetically depleting calpastatin ...................................54 
Summary and outlook ................................................................................................57 
Modulation of calpain activity as a therapeutic approach ...........................................59 
Preliminary considerations .........................................................................................59 
Inhibition of calpains in cell models of HD and SCA3 .................................................60 
iii 
Calpain suppression by the VDAC1-targeting compound olesoxime in vivo ...............62 
Reduction of ataxin-3 fragmentation by genetic ablation of calpain-1 in vivo ..............66 
Summary and outlook ................................................................................................68 
Characterisation of polyglutamine disease protein fragmentation by calpains ........70 
Preliminary considerations .........................................................................................70 
Identification of calpain cleavage sites in huntingtin ...................................................71 
Identification of calpain cleavage sites in ataxin-3 ......................................................73 
Summary and outlook ................................................................................................77 
Conclusion ......................................................................................................................79 
Funding ................................................................................................................................81 
Acknowledgements ..............................................................................................................83 
References ...........................................................................................................................85 
Appendix I: Unpublished project manuscripts ..................................................................... 123 
A. The calpain system in cell models of HD ............................................................... 124 
B. Calpain activation in the YAC128 mouse model of HD.......................................... 135 
C. Calpastatin ablation in the HDKI mouse model of HD ........................................... 144 
D. Calpain-1 ablation in the YAC84 mouse model of SCA3 ....................................... 155 
E. Calpain-dependent cleavage of huntingtin............................................................. 164 
Appendix II: Accepted papers ............................................................................................. 177 
a. Hübener et al., 2013, Human Molecular Genetics. .................................................. 178 
b. Nguyen et al., 2013, PLoS One................................................................................. 205 
c. Weber et al., 2014, BioMed Research International. ............................................... 215 
d. Clemens et al., 2015, Brain. ...................................................................................... 238 
e. Weber et al., 2016, Rare Diseases. ........................................................................... 290 
f. Schmidt et al., 2016, Journal of Neurochemistry..................................................... 300 
g. Weber et al., 2017, Brain........................................................................................... 314 
 
  
iv 
 
Abbreviations 
v 
Abbreviations 
aa    amino acid 
Aβ   amyloid-β  
AD   Alzheimer disease 
ALS    amyotrophic lateral sclerosis 
ALLN  N-acetyl-L-leucyl-L-leucyl-L-
norleucinal 
APP   amyloid precursor protein 
BACE1  β-site APP cleaving enzyme 1 
BACHD   bacterial artificial chromosome 
containing full-length huntingtin 
bdp   breakdown product 
Ca2+    calcium (ions) 
CaCl2  calcium chloride  
CAPN  calpain 
CAPNS1 calpain small subunit 1 
CAST  calpastatin 
CI III   calpain inhibitor III 
CMA   chaperone-mediated 
autophagy 
CNS    central nervous system 
DRPLA  dentatorubropallidoluysian 
atrophy 
DUB   deubiquitinating enzyme 
ER   endoplasmic reticulum 
FTLD  frontotemporal lobar 
degeneration 
HD    Huntington disease 
Hdh    mouse huntingtin gene 
HTT    human huntingtin gene  
Htt    huntingtin protein 
iCN  iPSC-derived differentiated 
cortical neuron 
iHF  SV40-immortalised human 
fibroblast 
IP3R   1,4,5-trisphosphate receptor 
iPSC   induced pluripotent stem cell 
JD   Josephin domain 
MAM  mitochondria-associated 
membrane 
MJD1  human ataxin-3 gene 
mPT  mitochondrial permeability 
transition 
MSNs  medium-sized spiny neurons 
NES   nuclear export signal 
NLS   nuclear localisation signal 
NMDA   N-methyl-D-aspartate 
PC   protease core domain 
PD   Parkinson disease 
PEF    penta-EF-hand domain PD 
polyQ   polyglutamine 
ROS    reactive oxygen species 
RyR   ryanodine receptor 
Abbreviations 
vi 
SBMA  spinal and bulbar muscular 
atrophy 
SCA3  spinocerebellar ataxia type 3 
SMA    spinal muscular atrophy 
STHdh   SV40-immortalised striatal 
mouse precursor cells 
SV40   Simian virus 40 
TDP-43  TAR DNA-binding protein-43 
TR-FRET time-resolved Förster 
resonance energy transfer 
TSPO  translocator protein/ 
tryptophan-rich sensory protein 
UPS   ubiquitin-proteasome system 
UTR   untranslated region 
VDAC   voltage-dependent anion 
channel 
YAC   yeast artificial chromosome
Summary 
vii 
Summary 
Summary (English) 
Together with cancer and cardiovascular disorders, neurodegenerative diseases such as 
Alzheimer and Parkinson disease are an increasingly important medical issue for the aging 
society of the 21st century. Multiple factors such as environmental influences and individual 
living conditions act as important modulators of neuropathology. Despite various forms of 
neurodegenerative diseases, many similarities exist in the underlying molecular 
pathomechanisms. These are thus promising targets for medical interventions. Therefore, 
research on genetically determined forms featuring a singular trigger allows to understand 
these common processes and to transfer acquired knowledge to other neurological diseases. 
In view of this fact, the current work investigates the validity of the toxic fragment hypothesis 
using the example of two polyglutamine diseases, Huntington disease and spinocerebellar 
ataxia type 3. This widely-described theory assumes that molecularly processed disease 
proteins in the form of toxic and aggregation-prone fragments enhance neurodegenerative 
effects. Amongst others, endogenous enzymes such as caspases and calcium-dependent 
calpains have been associated with the proteolytic cleavage of the disease-causing proteins, 
a source for toxic fragments. The present study focused on the analysis of the calpain-
mediated fragmentation of the mutant proteins huntingtin and ataxin-3, as well as on the 
detection of the enzymatic overactivation of calpains in cell and animal models of Huntington 
disease and spinocerebellar ataxia type 3. 
The investigations carried out here confirmed the influence of calpains on neurodegenerative 
processes in both polyglutamine diseases. Moreover, huntingtin and ataxin-3 were found to 
be cleaved at specific amino acid positions within the protein, and the resulting fragments 
exhibited both an increased toxicity and aggregation propensity. In addition, direct as well as 
indirect pharmacological inhibition of calpains and genetic modification of cleavage sites 
within the disease protein attenuated these processes, yielding positive effects on the 
respective molecular pathology. Future studies including the extension to other 
neurodegenerative diseases are necessary to further investigate the general validity of this 
pathomechanism. In this way, therapeutically applicable and effective strategies against 
neurodegeneration may be developed. 
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Zusammenfassung (Deutsch) 
Zusammen mit Krebs und kardiovaskulären Erkrankungen, stellen neurodegenerative 
Krankheiten wie Alzheimer und Parkinson ein immer wichtiger werdendes medizinisches 
Problem der alternden Gesellschaft des 21. Jahrhunderts dar. Multiple Faktoren wie 
Umwelteinflüsse und individuelle Lebensbedingungen agieren hierbei als bedeutende 
Modulatoren der Neuropathologie. Trotz diverser Ausprägungen neurodegenerativer 
Erkrankungen, existieren viele Gemeinsamkeiten in den zugrundeliegenden molekularen 
Pathomechanismen. Diese stellen somit vielversprechende Angriffspunkte für medizinische 
Interventionen dar. Insbesondere die Forschung an genetisch bedingten Formen, die einen 
singulären Auslöser besitzen, ermöglicht es diese gemeinsamen Prozesse zu verstehen und 
erworbene Kenntnisse auf andere neurologische Krankheitsbilder zu übertragen. 
In Anbetracht dessen ergründet diese Arbeit die Gültigkeit der Hypothese der toxischen 
Fragmente am Beispiel zweier Polyglutamin-Erkrankungen, der Chorea Huntington und der 
Spinozerebellären Ataxie Typ 3. Diese weithin beschriebene Theorie stützt sich auf die 
Annahme, dass Krankheitsproteine, bedingt durch molekulare Prozesse, als toxische und zur 
Aggregation neigende Fragmente neurodegenerative Effekte verstärken können. Unter 
anderem wurden endogene Enzyme wie Caspasen und Calcium-abhängige Calpaine mit der 
proteolytischen Spaltung krankheitsauslösender Proteine assoziiert, einer Quelle für toxische 
Fragmente. Der Fokus der vorliegenden Studie lag hierbei auf der Analyse der Calpain-
vermittelten Fragmentierung der pathologisch-veränderten Proteine Huntingtin und Ataxin-3, 
wie auch auf dem Nachweis der enzymatischen Überaktivierung von Calpainen in Zell- und 
Tiermodellen des Morbus Huntington und der Spinozerebellären Ataxie Typ 3.  
Die hier vorgenommenen Untersuchungen bestätigten zum einen den Einfluss von 
Calpainen auf die neurodegenerativen Prozesse beider Polyglutamin-Erkrankungen. Zum 
anderen wurde gezeigt, dass Huntingtin und Ataxin-3 an spezifischen Aminosäurepositionen 
im Protein geschnitten werden und daraus resultierende Fragmente sowohl eine erhöhte 
Toxizität als auch Aggregationsneigung besitzen. Darüber hinaus schwächten die direkte wie 
auch indirekte pharmakologische Inhibition von Calpainen und die genetische Modifikation 
von Schnittstellen im Erkrankungsprotein diese Prozesse ab, mit positiven Auswirkungen auf 
den jeweiligen molekularen Krankheitsverlauf. Zukünftige Untersuchungen wie auch die 
Ausweitung auf andere neurodegenerative Erkrankungen sind nötig, um die 
Allgemeingültigkeit dieses Pathomechanismus weiter zu erforschen. Auf diese Weise 
könnten therapeutisch anwendbare und wirksame Strategien gegen Neurodegeneration 
entwickeln werden. 
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Introduction 
Neurodegenerative diseases: the quest for new therapies 
Preface 
Enabled by a strong synergy of the scientific disciplines biology, chemistry and physics with 
applied medical research, our understanding of human physiology and pathology has been 
immensely widened in the last two centuries. One of the most important achievements in 
public healthcare constitutes the control of infectious diseases, which were the scourge of 
mankind over the last millennia and contributed to a high mortality and decreased lifespan. 
This development, which grounded on Louis Pasteur’s (1822 – 1895) germ theory, was 
facilitated by the combination of sanitation (Edwin Chadwick, 1800 – 1890) and hygiene 
(Ignaz Semmelweis, 1818 – 1865), vaccination (Edward Jenner, 1749 – 1823) and discovery 
of antimicrobial medicines, with penicillin leading the way (Alexander Fleming, 1881 – 1955) 
(Chew and Sharrock, 2007). While human life expectancy gradually increases as a result of 
the advances in medicine and improvements in living conditions, the ageing mankind is now 
confronted with new health-threatening challenges: cancer, cardiovascular diseases, and 
neurodegenerative disorders (Harper, 2014). To provide adequate answers to these 
problems is one of the most important endeavours of medicine and medicine research in the 
21st century. 
 
Neurodegeneration and ageing 
In the latest report on world population ageing, the United Nations projected that the 
percentage of people aged 60 or over will account for more than 20 per cent of the global 
population by the middle of the 21st century. In highly developed industrial nations, such as 
Japan or Germany, the proportion of people of this age has already reached one third of the 
total inhabitants in 2015 (United Nations, 2015). This demographic evolution is attributed to 
economic and social improvements, rising living standards, and medical advancements. In 
summary, the result is not only a prolonged but also healthier human life. However, ageing is 
also accompanied by the occurrence of age-related diseases, which, in particular, also 
include neurological manifestations. Unipolar depressive disorders, stroke, neuropathy, 
Parkinson disease (PD), Alzheimer disease (AD) and other dementias are among these 
highly disabling or life-threatening health conditions (Fratiglioni and Qiu, 2009; Hindle, 2010; 
United Nations, 2015). 
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AD, Lewy body dementia (LBD) and PD are the most common neurodegenerative disorders 
amongst the elderly (Bertram and Tanzi, 2005; de Lau and Breteler, 2006). In 2012, 
5.4 million cases of AD were reported in the U.S. and AD prevalence is predicted to reach 
13.8 million by 2050 (Alzheimer Association, 2016). Worldwide, 47 million people are 
suffering from dementia and this number will increase to over 100 million until the mid-21st 
century (Prince et al., 2016). The prevalence estimates of PD in industrial nations range 
between 0.3% of the total population and approximately 1% in people aged 60 years and 
over and will double by 2030 (de Lau and Breteler, 2006; Dorsey et al., 2007). All these 
figures presage the massive impact of neurodegenerative diseases not only on the individual 
but also social well-being and call for a clarification of the determinants underlying 
neurodegeneration. 
 
Factors contributing to neuronal ageing and neurodegeneration  
A variety of general environmental factors and individual living conditions are known to affect 
neuronal ageing and induce neurodegeneration throughout our lives. Equally, the efficiency 
of cellular rejuvenation and the maintenance of biological functions dwindle with advancing 
age rendering the organism more susceptible to external deleterious stressors. Based on 
aetiological considerations from the fields of AD, amyotrophic lateral sclerosis (ALS), 
dementia, depressive disorders, and PD (Fratiglioni et al., 2004; Mattson and Magnus, 2006; 
Fratiglioni and Qiu, 2009), a set of hypotheses might explain the causes of age-dependent 
neurodegeneration (FIGURE 1). 
 
Psychosocial stress 
Human life is characterised and imprinted by the interactions with its social environment and 
influencing life events. Negative experiences, acute anxiety reactions, and persistent severe 
psychological stress were shown to trigger depression-like behaviours, neuronal aging and 
the onset of degenerative diseases (Tsolaki et al., 2009; Alkadhi, 2011; Kubera et al., 2011; 
Tran et al., 2011; Miller and Sadeh, 2014; Austin et al., 2016). These observations can be 
linked to the release of stress-related corticosteroids, which are known to increase the 
vulnerability and mediate neuronal damage of specific brain areas through various cellular 
pathways (Swaab et al., 2005; Toda et al., 2016; Vyas et al., 2016). Correspondingly, 
antidepressant therapies, cognitive enrichments and socially integrated lifestyles can protect 
against these pathologies (Fratiglioni et al., 2004; Alkadhi, 2011; Kubera et al., 2011). 
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Obesity and diabetes 
Rising living standards in the western world are accompanied by an increasing percentage of 
people with obesity, which is considered as the single most important predictor of type 2 
diabetes (Chan et al., 1994; Hu et al., 2001; Hjerkind et al., 2017). In the U.S., more than one 
third of adults aged 65 and over is obese and the prevalence of diabetes amongst people of 
the same age ranges from 22-33% (Fakhouri et al., 2012; Kirkman et al., 2012). Aside from 
the implications on health such as cardiovascular diseases, both obesity and diabetes have 
been associated with accelerated neuronal aging and an elevated risk of cognitive 
impairments, dementia, AD and PD (Whitmer et al., 2005; Epel, 2009; Doherty, 2011; 
Strachan et al., 2011; Awada et al., 2013; Rajamani, 2014). In addition, obesity was shown to 
constitute a risk factor for chemically induced neurodegeneration (Sriram et al., 2002). On 
the other hand, a healthier lifestyle as defined by caloric restriction and increased physical 
activity, or bariatric interventions can be protective against neurodegenerative diseases like 
AD or PD (Wu et al., 2008; Contestabile, 2009; Ashrafian et al., 2013; Gräff et al., 2013). 
 
Vascular risks  
The maintenance of brain functions is dependent on its cerebral circulation, which provides 
oxygenated blood and glucose, and removes unwanted metabolites. Ageing contributes to 
an impairment of the vascular system, which can lead to a chronic hypoperfusion of neuronal 
tissues an eventually to a cognitive decline (Akinyemi et al., 2013; Bangen et al., 2014). 
Moreover, ischemic and hemorrhagic stroke can be the consequence of a poor blood flow 
and survivors of stroke are reportedly at a high long-term risk for dementia (Corraini et al., 
2016). As vascular dysfunctions represent a risk factor for neurodegeneration, there is, 
however, a gradual transition from post-stroke and vascular dementia to AD (Viswanathan et 
al., 2009). Furthermore, elevated blood pressure and high serum cholesterol are known to 
increase the chance to develop AD (Skoog et al., 1996; Kivipelto et al., 2001). Improving 
cerebral blood supply or reducing additional risk factors for vascular deficits, such as 
diabetes or obesity, constitute a potential intervention to sustain cerebral function and 
counteract neurodegeneration (Forette et al., 1998; Akinyemi et al., 2013). 
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Environmental neurotoxins  
Nutrition and the living environment entail the exposure to natural and synthetic toxins which, 
in turn, can compromise human health. The accumulation of certain neurotoxins was shown 
to induce neurodegeneration and thereby conditions reminiscent of specific disorders. A 
classic example is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a by-product of 
desmethylprodine synthesis, whose metabolite MPP+ selectively kills dopaminergic neurons 
and induces Parkinsonism (Langston et al., 1983). Moreover, pesticides like paraquat or 
rotenone were shown to have comparable effects, and like MPP+ act via the impairment of 
mitochondrial function (Cicchetti et al., 2009). The excitatory amino acids kainic acid and 
domoic acid, which act as glutamate receptor agonists, can damage hippocampal pyramidal 
neurons and cause AD-like symptoms (Perl et al., 1990; Ben-Ari and Cossart, 2000). 
Likewise, N-methyl-D-aspartate (NMDA) injection into neuronal tissue leads to an NMDA 
receptor-mediated excitotoxicity and neuronal lesioning (Dong et al., 2009; Rambousek et 
al., 2016). 3-nitropropionic acid (3-NP) was shown to induce a striatal phenotype reminiscent 
of Huntington disease (HD) and the endogenous neurotoxin quinolinic acid (QA) has been 
linked to various neurological disorders including AD, ALS, HD, and PD (Ludolph et al., 1991; 
Guillemin, 2012; Lugo-Huitrón et al., 2013). Despite all the negative effects of neurotoxins on 
human health, the elucidation of the corresponding causalities provided new possibilities to 
explore – with certain limitations - principles of neurological diseases. To this day, toxin-
induced cell and animal models are used to investigate pathological mechanisms of 
neurodegeneration and to develop therapeutic approaches (Bové et al., 2005; Ramaswamy 
et al., 2007; Toledano and Álvarez, 2011). 
 
Neuroinflammation 
A further contributing factor of neurodegeneration in the elderly is the age-dependent 
dysregulation of the immune system, which comprises chronic low-grade inflammation and 
dystrophic microglia in the central nervous system (CNS). The so called inflammaging and 
immunosenescence have been associated with clinical conditions like mild cognitive 
impairment, AD, ALS, PD, and MS (Franceschi et al., 2007; von Bernhardi et al., 2010; 
Deleidi et al., 2015). On the other hand, an inflammatory response can be an effect of an 
emerging neurodegenerative disorder and has been described as a concomitant feature of 
neurodegeneration (Frank-Cannon et al., 2009; Amor et al., 2010; Glass et al., 2010). 
Neuroinflammation can, moreover, impair regulatory pathways of metabolism and energy 
balance in the brain (Cai, 2013). The thereby induced obesity, diabetes, and vascular 
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dysfunction can conversely amplify neurodegeneration and neuroinflammation, thus forming 
a vicious circle. However, neuroinflammation itself can represent a therapeutic target to 
potentially reverse or slow down the process of neurodegeneration (Amor et al., 2010; Glass 
et al., 2010). 
 
Genetics 
The environmental effects and individual circumstances which are linked to neuronal ageing 
and degeneration show a large spectrum in their manifestation. Diseases like AD, ALS, HD 
or PD are different in their symptoms, age of onset or pathophysiology. These variations are 
also characterised by the selective neuronal vulnerability which is specific for every single 
disorder. An important player in this determination of neuronal ageing and degeneration is 
the individual genetic background. Several evolutionarily conserved genes are playing an 
important role in cellular aging processes. These genes are involved in pathways or 
represent regulatory elements such as DNA repair and modification, insulin/IGF1 signalling, 
lipid metabolism, mitochondrial function, mTOR signalling and sirtuins (Wolkow, 2002; 
Yehuda et al., 2002; Mattson, 2003; Lu et al., 2004; Bishop et al., 2010; Alcedo et al., 2013; 
Chow and Herrup, 2015). Furthermore, changes in the expression of these genes are 
reported to accompany neuronal ageing and emerge as an upregulation of inflammatory and 
stress response, or a downregulation of protein turnover and growth factors (Lee et al., 
2000). Several genes have been shown to increase the risk for developing a 
neurodegenerative disorder depending on the occurrence of certain polymorphisms. In 
sporadic late-onset AD, the ε4 allele of the apolipoprotein E gene (APOE) has been identified 
as significant risk factor (Bird, 2008; Liu et al., 2013). Variants of genes like α-synuclein 
(SNCA), leucine-rich repeat kinase 2 (LRRK2) and β-glucocerebrosidase (GBA) are 
considered as risk factors of late-onset PD (Klein and Westenberger, 2012). Intermediate-
length CAG repeat expansions in the ATXN2 gene were associated with increased risk for 
ALS (Elden et al., 2010). Around 25% of AD patients, 10% of PD patients and 10-15% of 
ALS patients have a positive family history, leaving the majority of sporadic cases genetically 
unsolved (Thomas and Beal, 2007; Bird, 2008; Byrne et al., 2011). However, a set of genetic 
mutations have been linked with the recessive or dominant form of these diseases. Amongst 
them, mutations in the genes for amyloid precursor protein (APP), presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) are causative for autosomal dominant early-onset forms of familial AD 
(Blennow et al., 2006). Mutations in the previously mentioned genes SNCA and LRRK2 
together with at least five other genes, e.g. encoding parkin (PARK2) and PTEN-induced 
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putative kinase 1 (PINK1), cause monogenic forms of PD (Trinh and Farrer, 2013). Familial 
forms of ALS include mutations in genes of superoxide dismutase 1 (SOD1), the TAR DNA-
binding protein-43 (TDP-43; TARBDP), and the protein C9orf72 (C9orf72) (Renton et al., 
2013). In addition, multiple rare neurodegenerative diseases have a solely monogenic 
background, including the polyglutamine (polyQ) disorders HD, dentatorubropallidoluysian 
atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and six different forms of 
spinocerebellar ataxia (SCA) (Gusella and MacDonald, 2000). The identification of mutations 
underlying monogenic neurodegenerative diseases has enabled scientists to generate 
adequate model organisms which reproduce disease-related characteristics (Marsh et al., 
2009; Jucker, 2010). These disease models have, furthermore, paved the way for exploring 
common pathomechanisms and, thereby, for developing future treatment approaches 
including therapies, which directly target mutant genes or respective disease proteins 
(Ciechanover and Kwon, 2015; Heidenreich and Zhang, 2015; O’Connor and Boulis, 2015). 
 
 
Figure 1. Overview of factors contributing to neuronal ageing and neurodegeneration. 
Environmental factors, living and health conditions and the individual genetic background (highlighted 
in red) form the basis of neuronal ageing and susceptibility to neurodegeneration. These factors can 
be countered by a healthier, enriched lifestyle and medical interventions (highlighted in blue). 
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Cellular and molecular changes during neuronal ageing and degeneration 
External and internal effectors of neuronal ageing and neurodegeneration are triggering 
alterations on cellular and molecular level. These markers can be utilized to characterise the 
disease, to monitor disease progression and to delve into potential therapeutic points of 
action. Typical molecular alterations comprise disturbances of energy metabolism, 
mitochondrial function, elevation in levels of oxidatively modified molecules, Ca2+ 
dyshomeostasis and accumulation and aggregation of dysfunctional proteins (FIGURE 2) 
(Mattson and Magnus, 2006). 
 
 
Figure 2. Cellular and molecular changes during neuronal ageing and degeneration. Ageing and 
degeneration is accompanied by molecular disturbances in affected neurons (highlighted in red), 
which represent mediators or consequences of detrimental processes. 
 
Disturbances in energy metabolism and mitochondrial function 
Brain function is highly dependent on the unconfined supply of neurons with energy. The 
main source for this energy is glucose which is provided by the glucose metabolism. 
Although the human brain accounts for only 2% of the total body weight, it consumes nearly 
20% of the glucose-derived physiological energy (Raichle and Gusnard, 2002; Mergenthaler 
et al., 2013). However, with ageing, glucose uptake and utilization decrease in many brain 
areas (Mosconi, 2013). In a more drastic form, these effects precede the clinical onset in 
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patients suffering from neurodegenerative diseases like AD, PD or HD (De Volder et al., 
1988; Feigin et al., 2001; Patel and Brewer, 2003; Cunnane et al., 2011; Borghammer, 2012; 
Niethammer et al., 2012). In addition to these alterations, mitochondria, the main producers 
of the cellular energy currency adenosine triphosphate (ATP), and important regulators of 
energy metabolism, are compromised in their function. Especially, the activity of 
mitochondrial enzymes and enzymatic complexes, which are implemented in ATP 
production, have been shown to be negatively affected (Henchcliffe and Beal, 2008; Oliveira, 
2010; Hroudová et al., 2014). Moreover, many disease proteins like APP cleavage-derived 
amyloid-β (Aβ), α-synuclein or huntingtin have been directly linked with damaging 
mitochondria (Lin and Beal, 2006). PD-associated loss-of-function mutations in PINK1 and 
parkin were shown to impair mitophagy, a mitochondrial quality control mechanism (Youle 
and Narendra, 2011). As a consequence, energy-dependent cellular processes are impaired, 
neuronal structures like axons and synaptic termini degenerate and the functionality of 
neurons declines (Dutta et al., 2006; Du et al., 2010; Friese et al., 2014). Finally, as 
mitochondria play a central role in regulation of apoptosis, their impaired viability leads to an 
activation of the cell death-linked caspase cascades, eventually leading to neuronal demise 
(Mattson, 2000). 
 
Impact of oxidative stress  
Metabolism of glucose and environmental toxins are the main source for reactive oxygen 
species (ROS), which – if not eliminated beforehand by antioxidative mechanisms – have the 
potential to harm the cell. A direct effect of ROS is the oxidative modification of different 
biomolecules like proteins and lipids, which can render them dysfunctional (Birben et al., 
2012). Furthermore, the accumulation oxidatively mutated DNA in neurons, which lack many 
DNA repair mechanisms due to their post-mitotic nature, can determine neuronal ageing and 
death (Chow and Herrup, 2015). The additional loss of mitochondrial integrity during ageing 
and in neurodegenerative disorders can lead to progressive amplification of ROS levels and 
their damaging effects, thereby feeding a detrimental loop (Lin and Beal, 2006). Interestingly, 
mutations of the ALS disease protein SOD1, a superoxide radical-removing enzyme, mainly 
induce a toxic gain-of-function, which leads to a mislocalisation of SOD1 to the mitochondrial 
intermembrane space and thereby to an increased production of hydrogen peroxide 
(Goldsteins et al., 2008; Pickles et al., 2013; Vehviläinen et al., 2014). Ultimately, a 
permanent oxidative stress of mitochondria can trigger apoptosis by promoting excessive 
mitochondrial Ca2+ uptake and loss of membrane integrity (Mattson and Kroemer, 2003). On 
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the other hand, a downregulation of the mitochondrial activity by a dietary restriction-based 
reduction of glucose uptake has been shown to lower ROS levels and even exert anti-ageing 
effects (Walsh et al., 2014; Ruetenik and Barrientos, 2015). 
 
Calcium dyshomeostasis 
Calcium ions (Ca2+) represent one of the most important intracellular signals, regulating 
many essential physiological processes, which range from cell cycle regulation and gene 
transcription to ATP production and muscle contraction (Lu and Means, 1993; Dulhunty, 
2006; Bading, 2013; Brini et al., 2014). In neurons, Ca2+ is fundamentally involved in 
transmission of depolarization, neurotransmitter release, and synaptic plasticity (Zucker, 
1999; Neher and Sakaba, 2008; Brini et al., 2014). Cytosolic Ca2+ concentrations range from 
approximately 100 nM under resting conditions up to transient peaks of 1–10 μM upon 
membrane depolarization and opening of Ca2+ channels (Berridge et al., 2000). Ca2+ levels 
are strongly regulated within all cells and dysfunctional Ca2+ homeostasis may fatally perturb 
cell function and viability leading to apoptosis (Orrenius et al., 2003; Pinton et al., 2008). 
Important regulatory elements of Ca2+ homeostasis comprise cell compartments like the 
endoplasmic reticulum (ER) and mitochondria, Ca2+-binding proteins and a multitude of Ca2+ 
pumps and channels (Berridge et al., 2000; Clapham et al., 2007). In ageing neurons, Ca2+ 
homeostasis is known to be impaired, which is attributed to deregulated Ca2+ influx and 
extrusion through the plasma membrane, and disturbances of the internal Ca2+ buffering 
compartments ER and mitochondria (Murchison et al., 2004; Toescu et al., 2004; 
Nikoletopoulou and Tavernarakis, 2012). Levels of Ca2+-binding proteins like calbindin and 
calretinin are known to decrease, additionally affecting neuronal Ca2+ buffering capacity 
(Iacopino and Christakos, 1990; Bu et al., 2003). Knowing that excessive cytosolic levels of 
Ca2+ can ultimately trigger apoptosis, these processes may, altogether, contribute to aging-
dependent neuronal dysfunction and degeneration, which has been earlier conceived in The 
calcium hypothesis of brain ageing and Alzheimer’s disease (Khachaturian, 1994). Likewise, 
Ca2+ dyshomeostasis has been observed in neurodegenerative disorders and partly 
associated with the gain-of-function of specific disease proteins. In familial AD, mutant 
presenilins were shown to interfere with activities of the Ca2+ channels and pumps inositol-
1,4,5-trisphosphate receptor (IP3R), ryanodine receptor (RyR), and the sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) in the ER (Honarnejad and Herms, 2012). Monomers and 
oligomers of α-synuclein were shown to impair efflux and increase influx of Ca2+ by their 
interaction with membranes in PD (Angelova et al., 2016). PolyQ-expanded proteins like 
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mutant huntingtin were shown to sensitize IP3R1 to activation by its ligand IP3 (Tang et al., 
2003; Bezprozvanny, 2011). 
Detrimental accumulation and aggregation of proteins 
One of the most prominent hallmarks of neuronal ageing and neuronal proteinopathies is the 
accumulation of damaged and misfolded proteins in histologically traceable intracellular and 
extracellular insoluble aggregates. A typical example is lipofuscin, an autofluorescent age 
pigment of post-mitotic cells. These conglomerates are composed of oxidatively damaged, 
cross-linked proteins and lipids and may compromise cellular function and viability (Szweda 
et al., 2003; Gray, 2005; Jung et al., 2007). The formation of lipofuscin or other protein 
aggregates is linked to an age-dependent impairment of cellular quality control mechanisms 
such as the proteasomal system, autophagy or other degradative enzymes (Cuervo, 2008; 
Vilchez et al., 2014). Additionally, the amount of damaged and misfolded proteins increases 
with ageing due to elevated oxidative stress and a decline of molecular chaperone activity 
(Calderwood et al., 2009; Kikis et al., 2010; Wang and Michaelis, 2010). In many sporadic 
and inherited neurodegenerative disorders like AD, ALS, PD and HD, the same mechanisms 
were shown to be impaired and to mediate the detrimental effects on affected neurons (Son 
et al., 2012; Ciechanover and Kwon, 2015). In particular, these disorders are characterised 
by the accumulation and aggregation of specific proteins: For instance, Aβ forms 
extracellular amyloid plaques in AD, and tau intracellular neurofibrillary tangles not only in AD 
but also many other neurodegenerative diseases termed tauopathies, including progressive 
supranuclear palsy (PSP) or autosomal dominant frontotemporal lobar degeneration (FTLD) 
(Lee and Leugers, 2012; Bloom, 2014; Rojas and Boxer, 2016). The α-synuclein protein 
aggregates as Lewy bodies in PD, dementia with Lewy bodies, and multiple system atrophy 
(MSA), which are thereby classified as α-synucleinopathies (Goedert and Spillantini, 1998; 
Lashuel et al., 2012). Protein aggregates in ALS are composed of FUS, optineurin, SOD1, 
TDP -43, ubiquilin-2, and C9orf72 (Blokhuis et al., 2013). And polyQ-expanded proteins such 
as huntingtin, ataxin-3, and atrophin-1 form intranuclear or cytoplasmic aggregates in HD, 
spinocerebellar ataxia type 3 (SCA3) and DRPLA, respectively (Gusella and MacDonald, 
2000). Whether these protein aggregates have a detrimental or a rather protective function 
within neurons by sequestering toxic soluble species of the disease protein is, however, 
controversially discussed among scientists (Michalik and Van Broeckhoven, 2003). Besides 
initial mutations, many disease proteins are modified by further post-translational 
modifications, which can alter their aggregation propensity. For instance, zinc and copper 
ions were shown to modulate Aβ oligomerization into fibrils (Tanzi and Bertram, 2005). 
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Hyperphosphorylation of tau was shown to induce its accumulation into neurofibrillary tangles 
(Stoothoff and Johnson, 2005). Oxidation, nitration and metal ions like aluminium induce 
conformational changes of α-synuclein and modulate its fibrillation and toxicity (Breydo et al., 
2012; Chavarría and Souza, 2013). A widely occurring mechanism among 
neurodegenerative diseases is proteolytic cleavage, which releases toxic and aggregation-
prone fragments. Since the first description of the toxic fragment hypothesis, many enzymes 
have been associated with the detrimental fragmentation of disease proteins (Wellington and 
Hayden, 1997). For example, the β-site APP cleaving enzyme (BACE1) cleaves APP and 
releases Aβ, whereas desintegrins and metalloproteinases ADAM9, ADAM10 and ADAM17 
generate non-toxic forms of APP reducing the formation of Aβ (Zhang and Tanzi, 2012). The 
apoptosis-mediating protease family of caspases and Ca2+-activated calpains were 
associated with fragmentation of α-synuclein, tau, TDP-43 and of polyQ proteins like 
huntingtin and ataxin-3 (Dufty et al., 2007; Y.-J. Zhang et al., 2009; Hanger and Wray, 2010; 
Ehrnhoefer et al., 2011; Matos et al., 2011; Yamashita et al., 2012). 
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Polyglutamine diseases as a monogenic model for neurodegeneration 
The group of polyglutamine diseases 
Amongst the vast number of neurodegenerative disorders, which are mostly defined by 
unknown, complex or polygenic aetiologies, polyQ diseases constitute a genetically 
unambiguous class of medical conditions. Although multiple genes are causative for this 
class of disorders, they share many common molecular characteristics and 
pathomechanisms, rendering them an ideal scientific field to explore the bedrock of 
neurodegeneration. 
PolyQ diseases belong to a bigger group of disorders, whose genetics are based upon the 
pathological expansion of trinucleotide repeats. These disorders include, for instance, 
expansions of CGG repeats in the 5’ untranslated region (UTR) of the fragile X mental 
retardation 1 (FMR1) gene in fragile X syndrome, GAA repeats in the intron of the frataxin 
(FXN) gene in Friedreich’s ataxia, or CTG repeats in the 3’ UTR of the dystrophia myotonica 
protein kinase (DMPK) gene in myotonic dystrophy type 1 (Verkerk et al., 1991; Mahadevan 
et al., 1992; Campuzano et al., 1996; Budworth and McMurray, 2013). The distinctive 
characteristic of polyQ diseases, however, is the exonic localisation of a CAG triplet repeat, 
which is translated into an elongated polyQ motif rendering the encoded protein 
dysfunctional and aggregation-prone (Gusella and MacDonald, 2000). The underlying 
molecular mechanism of trinucleotide repeat expansions remains elusive. Well accepted 
explanations are the occurrence of polymerase slippages and DNA loop formations due to 
trinucleotide-dependent misalignments and replication restarts during germ line DNA 
replication. Arising loops can then be integrated via DNA repair mechanisms, leading to an 
elongation of the trinucleotide tracts (Mirkin, 2007; McMurray, 2010). The thereby evoked 
generational repeat instability is furthermore linked to a phenomenon called anticipation, a 
hallmark of trinucleotide disorders: repeat expansions show a propensity to further increase 
over generations, which leads to an earlier onset and greater severity of the disease 
(McMurray, 2010; Budworth and McMurray, 2013). 
The first disease which was identified as a polyQ disorder was the X-linked SBMA, also 
known as Kennedy disease featuring a CAG repeat expansion in the androgen receptor (AR) 
gene (La Spada et al., 1991). To the present day, nine polyQ disorders have been described, 
comprising DRPLA, HD, SBMA, and the spinocerebellar ataxias type 1, 2, 3, 6, 7 and 17, 
which exhibit a neuromuscular or neurodegenerative manifestation (Gusella and MacDonald, 
2000; Shao and Diamond, 2007). In contrast to trinucleotide expansions in UTRs or introns, 
which influence splicing, stability and expression of the affected mRNA, elongated glutamine-
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coding CAG repeats have a direct impact on structure and function of the encoded protein. 
These changes on the protein level are believed to be the main trigger of pathogenic effects. 
Moreover, cytoplasmic and intranuclear aggregation of the polyQ-expanded proteins are a 
typical histological feature of affected neurons in polyQ diseases (Shao and Diamond, 2007). 
However, several studies suggested that CAG repeat-containing mRNAs themselves may 
exhibit certain toxicity and the intrinsic repeats can lead to a mistranslation into deleterious 
proteinaceous by-products via a mechanism called repeat-associated non-ATG (RAN) 
translation (Li et al., 2008; Zu et al., 2011; Nalavade et al., 2013; Bañez-Coronel et al., 2015; 
Strzyz, 2016). 
 
Clinical features of Huntington disease and spinocerebellar ataxia type 3 
Huntington disease 
HD is a neurodegenerative disorder with a long history. Its principal symptom chorea, which 
is characterised by jerky, involuntary movements named after the ancient Greek circle dance 
choreia (χορεία), had been already described in the middle ages (Vale and Cardoso, 2015). 
In 1872, the first detailed clinical description on late-onset hereditary chorea was authored by 
George Huntington, who became the eponym for the disease (reprinted in: Huntington, 
2003). 
Although being firstly termed Huntington’s chorea, the disease was renamed HD due to its 
symptomatic complexity, which cannot be only reduced to the presence of chorea but 
consists of a clinical triad of progressive motor, cognitive, and psychiatric impairments (Roos, 
2010; Paulson and Albin, 2011). Aside from the characteristic chorea, which starts in early 
stages of HD, the motor disorder comprises dystonia, rigidity, dysphagia and dysarthria, gait 
impairments, and impaired eye movement. Cognitive dysfunctions are composed of slowed 
thinking, problems in information manipulation, dementia, deficient executive function and 
lowered skill and motor learning. Finally, psychiatric abnormalities range from irritability and 
aggression, over apathy, depression, mania, and psychosis, to sleep disturbances (Anderson 
and Marder, 2001; Roos, 2010). HD is a fatal disorder, and the majority of patients die from 
aspiration pneumonia as a consequence of dysphagia (Heemskerk and Roos, 2012). It is 
noteworthy, that people at risk or diagnosed with HD are suffering from suicidal ideation, and 
thus suicide represents the second most common death cause of this devastating disorder 
(Farrer et al., 1986; Paulsen et al., 2005; Roos, 2010). 
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The clinical triad of HD is strongly linked to the dysfunction and degeneration of parts of the 
CNS (FIGURE 3). Despite being primarily detectable as a neuronal decline of striatal 
structures, represented by an up to 95% loss of striatal gamma-aminobutyric acid 
(GABA)-ergic medium spiny neurons (MSNs), neurodegeneration can spread throughout the 
whole brain: cerebral cortex, subcortical white matter, thalamus, and hypothalamic nuclei can 
undergo atrophy with different degrees of severity (Halliday et al., 1998; Vonsattel, 2008; 
Costanzo and Zurzolo, 2013; Bañez-Coronel et al., 2015). Many of these features can be 
observed before clinical onset of HD and the variability of the degeneration accounts to a 
certain degree for the large spectrum of symptoms (Tabrizi et al., 2009, 2011). With the 
steady progress in medical sciences, many other and more subtle characteristics of HD on 
behavioural, physiological and molecular level are now detectable as biomarkers, which 
allow for improved and earlier diagnosis (Weir et al., 2011; Tabrizi et al., 2013). 
Classified as an autosomal-dominant inherited disorder, HD’s genetic aetiology is the 
expansion of a polymorphic CAG triplet repeat in exon 1 of the HTT gene, which is also 
known as interesting transcript 15 (IT15) mapping to the short arm of chromosome 4 
(4p16.3) (The Huntington’s Disease Collaborative Research Group et al., 1993). In 
unaffected humans, the CAG motif is ranging between 14 and 26 repeats. Exceeding the 
critical number of 40 repeats leads to a full penetrance, whereas 27-35 repeats constitute an 
intermediate, nonpathological range and 36-39 repeats are characterised by a reduced 
penetrance with a much later disease onset (Rubinsztein et al., 1996; Potter et al., 2004; 
Killoran et al., 2013). The length of the CAG repeat inversely corresponds with the age of 
onset, which is 40 years on average (Duyao et al., 1993; Myers, 2004). However, only 
around 60% of the variance in the age of onset can be attributed to the length of the repeat 
expansion, which is indicative for additional genetic and environment modifiers (Myers, 2004; 
Wexler et al., 2004). Although a monoallelic CAG expansion is sufficient for causing HD, 
homozygous cases were reported, whose disease onset was in the range of heterozygous 
patients but clinical course of the disease was more severe (Squitieri et al., 2003). The 
overall worldwide prevalence for HD is about 4 per 100.000, with its highest frequency in the 
Western world and the lowest in Asia amounting to 1-14 per 100.000 and <1 per 100.000, 
respectively (Pringsheim et al., 2012; Baig et al., 2016; Rawlins et al., 2016). 
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Spinocerebellar ataxia type 3 
In contrast to HD, the first descriptions of SCA3 were published one hundred years later in 
the 1970s. In the beginning, SCA3 was classified as three independent medical conditions 
named Machado disease, nigrospinodentatal degeneration, and autosomal dominant 
striatonigral degeneration, which reported in families of Azorean decent in the US (Nakano et 
al., 1972; Woods and Schaumburg, 1972; Rosenberg et al., 1976). After additional 
investigations of cases on the Azores, these diseases were unified and unlike other 
disorders, named Machado-Joseph disease (MJD, synonym for SCA3) as reference to two 
affected families: the Machado family from New England and the Californian Joseph family 
(Coutinho and Andrade, 1978; Lima and Coutinho, 1980). 
The main clinical feature of SCA3 is ataxia, a deficit in voluntary coordination of muscle 
movements generally manifesting as gait abnormalities. However, the phenotype comprises 
many additional characteristics including ophthalmoplegia, diplopia, dystonia, faciolingual 
fasciculation, dysarthria and dysphagia (Riess et al., 2008; Bettencourt and Lima, 2011). 
Cognitive dysfunction is rather mild and feature e.g. verbal and visual memory deficits or a 
visuospatial dysfunction (Bürk et al., 2003; Kawai et al., 2004). Due to its heterogeneity of 
symptoms, SCA3 was divided in four subtypes: type 1 (type Joseph) exhibits extrapyramidal 
and pyramidal signs with an early disease onset about 10-30 years; type 2 (type Thomas) 
features a true cerebellar deficit and other motor dysfunctions with an intermediate age of 
onset between 20 and 50 years; type 3 (type Machado) shows mainly cerebellar deficits and 
a peripheral neuropathy with a late disease onset of 40-75 years; the rare type 4 is 
characterised by a neuropathy and parkinsonism with a variable age of onset (Coutinho and 
Andrade, 1978; Suite et al., 1986; Riess et al., 2008; Bettencourt and Lima, 2011). 
Comparable to HD, early death from SCA3 is mainly caused by a dysphagia-dependent 
aspiration pneumonia (Rüb et al., 2006). 
Neuropathologically, SCA3 is characterised by an atrophy of different regions within the 
CNS, mainly restricted to the cerebellum, brainstem, and the spinal cord (FIGURE 3). 
However, further areas can be additionally impaired including the thalamus or the globus 
pallidus (Dürr et al., 1996; Paulson, 2012; Rüb et al., 2013). As for HD, search for accurate 
biomarkers as a tool for diagnosis and assessment of disease progression is ongoing, 
comprising studies, which focus on oculomotor deficits, functional magnetic resonance 
imaging (fMRI) or blood-based readouts (Raposo et al., 2015; Duarte et al., 2016; Wu et al., 
2017). 
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The polymorphic CAG trinucleotide repeat, which is expanded in SCA3, lies in exon 10 of the 
MJD1 gene mapping to chromosome 14q32.1 (Takiyama et al., 1993; Kawaguchi et al., 
1994; Schöls et al., 1995). CAG motifs in unaffected individuals count 12-44 repeats, and 
93.5% of those have fewer than 31 CAGs. In SCA3 patients the CAG number varies from 60-
87 repeats. Accordingly, there is an intermediate range of 45-59 CAGs, which leads to a 
reduced penetrance (do Carmo Costa and Paulson, 2012). In contrast to HD, rare 
homozygous cases of SCA3 do not only exhibit an increased severity in disease phenotype 
but also an earlier age of onset, suggestive of a possibly dominant negative effect of the 
mutation in the MJD1 gene (Takiyama et al., 1995; Lerer et al., 1996). As SCA3 is a very 
rare disorder, there is lack of precise and reliable data regarding its prevalence. However, 
with approximately 21% of all cases, SCA3 is considered as the most common form of 
autosomal dominant inherited cerebellar ataxias, with an estimated prevalence of 3 per 
100.000 individuals worldwide (Schöls et al., 2004). Strikingly, the number of SCA3 cases is 
the highest on the Azorean island Flores with a frequency of 1 per 239 in 2008 (Bettencourt 
et al., 2008). 
 
 
 
Figure 3. Brain regions primarily affected in Huntington disease and spinocerebellar ataxia 
type 3. The primary site of neurodegeneration in HD is the striatum (left side, red), however the 
degeneration can spread over the whole brain in late stages of the disease (indicated by red arrows). 
In SCA3-affected brain regions are mainly restricted to the cerebellum, brainstem and spinal cord 
(right side, red). 
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Molecular characteristics of Huntington disease and spinocerebellar ataxia type 3 
The disease protein huntingtin 
Characteristically for polyQ diseases in general, the CAG repeat in the HTT gene is 
translated into a polyQ tract, which is located at the N-terminus of huntingtin (UniProt 
identifier: P42858-1), a large soluble protein of more than 3100 amino acids. Huntingtin’s 
exact size and molecular weight of roughly 350 kDa varies depending on the length of its 
polymorphic polyQ stretch. 
HTT is an evolutionary old gene, which can be found in vertebrates, invertebrates but also 
some unicellular eukaryotes. Despite that, only in vertebrates, HTT is highly conserved 
sharing an 80% sequence homology (Baxendale et al., 1995; Cattaneo et al., 2005). In 
humans and rodents, huntingtin is expressed ubiquitously with high levels in brain neurons, 
but without enrichment in striatum, the site of greatest pathology in HD. On cellular level, 
huntingtin displays a mainly cytoplasmic distribution and was shown to be associated with 
membranes and the cytoskeleton. In neurons, the protein is found not only in the cell body, 
but also axons and dendrites, and is concentrated at nerve terminals (Sharp et al., 1995; 
Trottier et al., 1995). There, huntingtin was detected at microtubules and synaptic vesicles 
(DiFiglia et al., 1995; Gutekunst et al., 1995). 
Aside from the N-terminal polyQ stretch, the structure of the protein contains a subsequent 
polyproline motif and 28-36 HEAT repeats (FIGURE 4) (Takano and Gusella, 2002; 
Ehrnhoefer et al., 2011). These repeats are named after the first proteins in which these 
motifs were identified, namely huntingtin, elongation factor 3, protein phosphatase 2A and 
yeast target of rapamycin 1 (TOR1), and are organized in four main clusters (Andrade and 
Bork, 1995; Li et al., 2006; Warby et al., 2008). At its C-terminus, huntingtin features an 
active nuclear export signal (NES) (Xia et al., 2003). Furthermore, the first 17 amino acids 
were shown to be important for subcellular localisation and represent a target for regulatory 
post-translational modifications (Cornett et al., 2005; Arndt et al., 2015). In general, 
huntingtin undergoes many different post-translational modifications, including acetylation, 
lipidation, phosphorylation, ubiquinitination, SUMOylation or proteolytic cleavage, which are 
known to modulate its localisation and interaction with other proteins (Ehrnhoefer et al., 
2011). 
Due to its large size and characteristic occurrence of multiple HEAT repeats, huntingtin 
shows a big palette of interactions and functions within the cell, rendering it an important 
element of cellular function (Gusella and MacDonald, 1998; Goehler et al., 2004). Well 
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investigated is the role of huntingtin as a scaffold protein in vesicle trafficking in endocytic 
and secretory pathways (Velier et al., 1998). This function is mediated via the interaction with 
huntingtin-associated protein 1 (HAP1) and the dynein-dynactin complex (Li et al., 1995; 
Caviston et al., 2007, 2011; Zuccato and Cattaneo, 2009). In this regard, huntingtin was 
shown to facilitate vesicle transport from the ER to the Golgi apparatus, endosome motility, 
mitochondrial and in particular axonal transport (Gunawardena et al., 2003; Pal et al., 2006; 
Li et al., 2010; Brandstaetter et al., 2014; White et al., 2015). Aside from this, the protein has 
been associated with many further functions. Huntingtin was shown to modulate transcription 
directly via binding to the genomic DNA or via interaction with transcription factors and 
regulators (Holbert et al., 2001; S.-H. Li et al., 2002; Zuccato et al., 2003; Benn et al., 2008). 
Furthermore, it is involved in mRNA biogenesis by binding spliceosome proteins, and in 
protein translation (Faber et al., 1998; Passani et al., 2000; Culver et al., 2012). Huntingtin 
interacts in different ways with the cytoskeleton, and is involved in regulation of iron 
homeostasis, Ca2+ homeostasis, and energy metabolism (Bao et al., 1996; Burke et al., 
1996; Kalchman et al., 1997; Boutell et al., 1998; Hilditch-Maguire et al., 2000; Hoffner et al., 
2002; Tang et al., 2003; Lumsden et al., 2007; Rockabrand et al., 2007). In addition, it 
regulates epidermal growth factor (EGF)- and mammalian TOR1 (mTOR1)-dependent 
signalling (Liu et al., 1997; Pryor et al., 2014). Recently, huntingtin has also been shown to 
act as a scaffold protein in autophagy (Ochaba et al., 2014; Rui et al., 2015). 
Of particular interest are huntingtin’s neuron-specific functions. In this regard, the protein was 
found to interact with protein kinase C and casein kinase substrate in neurons protein 1 
(PACSIN1) or postsynaptic density 95 (PSD-95) and thereby regulate synaptic transmission 
(Sun et al., 2001; Modregger et al., 2002). Moreover, huntingtin was described as a 
neuroprotective protein. It amplifies the expression of brain-derived neurotrophic factor 
(BDNF), enhances the vesicular transport of BDNF and acts anti-apoptotic by inhibiting 
caspases-3 and -9 (Rigamonti et al., 2000, 2001, Zuccato et al., 2001, 2003; Gauthier et al., 
2004; Zhang et al., 2006). Overexpression of normal huntingtin attenuates excitotoxic effects 
as mediated by NMDA or kainate receptors in vitro and in vivo, and protects against brain 
ischemia (Sun et al., 2001; Zhang et al., 2003; Leavitt et al., 2006). Furthermore, wild type 
huntingtin was shown to reduce toxicity of its mutant counterpart in cell lines and in vivo (Ho 
et al., 2001; Leavitt et al., 2001). 
The vital role of huntingtin was demonstrated in several studies which knocked out the 
protein or reduced its expression. The homozygous knockout of the HTT gene in mice led to 
embryonic death around day 8.5 of gestation (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et 
al., 1995). Heterozygous knockout animals, furthermore, exhibited cognitive deficits and 
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increased motor activity which was accompanied by a neuronal loss in the subthalamic 
nucleus (Nasir et al., 1995). The conditional knockout of huntingtin in mouse forebrain and 
testes led to a progressive neuronal phenotype and sterility (Dragatsis et al., 2000). A further 
indication for huntingtin’s critical role in neurogenesis was shown in mice expressing 
huntingtin at a low level. These animals exhibited an aberrant brain development and 
perinatal lethality, whereas mice expressing polyQ-expanded huntingtin at normal levels did 
not feature these developmental impairments (White et al., 1997). Further knockout studies 
discovered that, from the earliest stage of embryogenesis on, huntingtin is necessary for 
mitochondrial structure and function (Ismailoglu et al., 2014). On the other hand, HTT 
knockout embryonic stem cells could be differentiated into functional post-mitotic neurons, 
demonstrating that huntingtin is not essential for neuronal differentiation in vitro (Metzler et 
al., 1999). Latest in vivo studies based on conditional knockout of HTT have shown both vital 
and negligible roles of huntingtin in the adult mouse (G. Wang et al., 2016; Dietrich et al., 
2017). 
 
The disease protein ataxin-3 
The CAG repeat in the MJD1 gene encodes a polyQ stretch at the C-terminus of ataxin-3, a 
deubiquitinating enzyme (DUB). This cysteine protease consists of around 350 amino acids 
and is approximately 40 kDa in size, which not only depends on the length of the variable 
polyQ stretch but also on the respective isoform (Goto et al., 1997). 
The ATXN3 gene is widely present amongst eukaryotic organisms, and many orthologues 
were identified in vertebrates and invertebrates, but also plants and unicellular eukaryotes 
(Albrecht et al., 2002, 2004; do Carmo Costa et al., 2004). The protein is not only expressed 
in neuronal tissues, like the SCA3-affected cerebellum or brainstem, but shows a ubiquitous 
tissue distribution which was found to be present at early stages of embryonic development  
(Paulson et al., 1997a; do Carmo Costa et al., 2004). On cellular level, ataxin-3 can be found 
in the cytoplasm, bound to mitochondria and inside of the nucleus. In neurons, ataxin-3 is 
localised mainly in the cell body, but also in processes like axons and dendrites (Tait et al., 
1998; Trottier et al., 1998; Pozzi et al., 2008). 
The structure of ataxin-3 (FIGURE 4) is characterised by its N-terminal, 180 amino acid-long 
proteolytic Josephin domain (JD), which is the eponym for a whole group of enzymes sharing 
this domain, the Josephin family (Albrecht et al., 2002). The JD exerts the deubiquinating 
activity based on cysteine residue at amino acid position 14 in the catalytic triad (Scheel et 
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al., 2003; Nicastro et al., 2005). The interaction with ubiquitinated substrates is facilitated by 
ataxin-3’s ubiquitin interacting motifs (UIMs) of which isoform 1 (UniProt identifier: P54252-1) 
carries two located between the JD and the polyQ stretch (UIM1 & UIM2), and isoform 2 
(UniProt identifier: P54252-2) features a third one downstream of the glutamine repeat 
(UIM3) (Burnett et al., 2003; Harris et al., 2010). The JD and the UIMs allow ataxin-3 to bind 
and modify ubiquitin chains, which are linked via K48, K63 or mix-linked via K48 and K63 
residues (Chai et al., 2004; Winborn et al., 2008). Furthermore, the ataxin-3 sequence was 
shown to contain two active NES within the JD, and a nuclear localisation signal (NLS) 
between UIM2 and the polyQ stretch (Tait et al., 1998; Antony et al., 2009; Macedo-Ribeiro 
et al., 2009). Ataxin-3 is modified by various post-translational modifications, including 
phosphorylation, SUMOylation, neddylation, ubiquitination and proteolytic cleavage (Matos et 
al., 2011). Phosphorylation by casein kinase-2 (CK2) and glycogen synthase kinase-3β (GSK 
3β) were shown to modify its localisation and ubiquitination at lysine 117 regulates the DUB 
activity (Fei et al., 2007; Mueller et al., 2009; Todi et al., 2009). 
Ataxin-3 was found to interact with different proteins, which are also indicative for its cellular 
function. Important interactors are the human homologues of the yeast DNA repair protein 
RAD23 protein A and B (HHR23A & B), and valosin-containing protein (VCP/p97) (Wang et 
al., 2000; Zhong and Pittman, 2006). These protein-protein interactions were shown to 
implicate ataxin-3 in the protein quality control mechanism by the ubiquitin-proteasome 
system (UPS), in particular the ER-associated protein degradation (ERAD) (Burnett et al., 
2003; Doss-Pepe et al., 2003; Chai et al., 2004). 
As it is typical for DUBs, ataxin-3 is closely interacting with different E3 ubiquitin ligases, 
which allows to determine substrate specificities (Durcan and Fon, 2013). Amongst these E3 
partners is C-terminus of Hsc70-interacting protein (CHIP), which is regulated by ataxin-3 in 
cooperation with the E2 ubiquitin conjugating enzyme Ube2w (Scaglione et al., 2011). 
Moreover, ataxin-3 is an interactor of the autosomal recessive juvenile PD-associated E3 
enzyme parkin, an important enzyme in the mitochondrial quality control mechanism of 
mitophagy. Ataxin-3 was shown to regulate parkin autoubiquitination and, through this, to 
play a role in regulating parkin’s stability and turnover (Durcan et al., 2011, 2012). However, 
a link between ataxin-3 and parkin-mediated mitophagy has not been investigated yet 
(Durcan and Fon, 2015; Nardin et al., 2016). In addition, ataxin-3 plays a role in aggresome 
formation and exhibits a deneddylase activity by modifying the ubiquitin-like developmentally 
downregulated 8 protein (NEDD8) (Burnett and Pittman, 2005; Ferro et al., 2007; H. Wang et 
al., 2012). A further important function of the protein was found in transcriptional regulation, 
where ataxin-3 acts as a repressor of transcription by interacting with histones and recruiting 
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deacetylases (F. Li et al., 2002; Evert et al., 2006). Moreover, ataxin-3 is important in 
myogenic differentiation, participates in cell signalling and may represent a target in cancer 
(Rodrigues et al., 2007; do Carmo Costa et al., 2010; Kuhlbrodt et al., 2011; Sacco et al., 
2013). 
Due to its activity as a DUB in UPS, ataxin-3 was suggested to exert neuroprotective effects 
(Warrick et al., 2005). In Drosophila, this neuroprotection was shown to depend on 
ubiquitination of ataxin-3 at amino acid position 117 and not on its E3 partner CHIP (Tsou et 
al., 2013). In a HD model background, however, knockout of ataxin-3 did not elevate toxic 
effects of polyQ-expanded huntingtin in vivo (Zeng et al., 2013). Likewise, overexpression of 
wild type ataxin-3 in SCA3 mice, could not mitigate the polyQ toxicity of the pathogenic 
variant (Hübener and Riess, 2010). 
In contrast to various detrimental effects induced by a genetic ablation of huntingtin, the 
knockout of ataxin-3 has not been associated with an overt phenotype in vivo. Still, ataxin-3 
knockout mice exhibited an increased anxiety and elevated levels of ubiquitinated proteins 
(Schmitt et al., 2007; Switonski et al., 2011). Furthermore, knockdown of ataxin-3 in murine 
and human cell lines led to defects in cytoskeletal organisation (Rodrigues et al., 2010). 
Interestingly, C. elegans deficient for the orthologues of VCP/p97 and ataxin-3 showed 
extended lifespan due to an altered insulin-like growth factor 1 (IGF1) signalling pathway 
(Kuhlbrodt et al., 2011). 
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Figure 4. Comparison between the disease proteins huntingtin and ataxin-3. The huntingtin 
protein is characterised by its N-terminal polyQ domain, followed by a proline-rich region (polyP) and 
four clusters of HEAT repeats, which facilitate protein-protein interactions. A nuclear export signal 
(NES) is localised at the C-terminus. Further hallmarks are polythreonine (polyT) and polyglutamate 
(polyE) motifs. The deubiquitinase ataxin-3 is composed of its N-terminal proteolytic Josephin domain 
(JD) and up to three ubiquitin interacting motifs (UIMs) at the C-terminus of the enzyme. Two UIMs are 
located upstream and a third, isoform-specific UIM is located downstream of the polyQ repeat. The 
subcellular localisation of ataxin-3 is determined by two NES within the JD and one nuclear 
localisation signal (NLS) between UIM2 and the polyQ stretch. Amino acid positions of the catalytic 
triad of ataxin-3 are indicated by vertical white lines. A relative size comparison between huntingtin 
and ataxin-3 is indicated by the red lines below the structural illustrations. 
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Divergent and common molecular pathomechanisms  
As described previously, huntingtin and ataxin-3 constitute two proteins, which significantly 
differ in their molecular weight, structure and function. On the other hand, both proteins 
cause neurodegeneration of the brain and share, as their main commonality, a polyQ stretch. 
The detrimental effects on neuronal health caused by the mutant protein can therefore be 
attributed to the specific negative impact of the polyQ expansion on their normal biological 
role. For both disease proteins a toxic gain or loss function have been hypothesised (Zuccato 
et al., 2010; Li et al., 2015). In the case of huntingtin, the protein’s involvement in cellular 
trafficking was found to be disrupted due to the mutation of the polyQ stretch. This can have 
a negative impact on secretory pathways or mitochondrial transport (Gauthier et al., 2004; 
Trushina et al., 2004; Li et al., 2010; Brandstaetter et al., 2014). Furthermore, the recently 
discovered role of huntingtin as a scaffold protein in autophagy suggested a mutant 
huntingtin-driven impairment of the autophagic pathway (Martin et al., 2015). In the same 
manner, specific functions of ataxin-3 may be compromised by the polyQ expansion. For 
instance, mutant ataxin-3 was shown to excessively bind its interaction partner VCP, thus 
pathologically deregulating its role in ERAD (Zhong and Pittman, 2006). Moreover, 
parkinsonian features of SCA3 are conceivably caused by an enhanced DUB activity of the 
polyQ-expanded protein, which increased deubiquitination and degradation of parkin (Durcan 
et al., 2011). 
Despite their functional disparities, the toxicity of mutant huntingtin and ataxin-3 are based on 
common molecular pathomechanisms. Hence, investigations on these pathways constitute 
an opportunity to unveil a general therapeutic approach not only for HD and SCA3, but also 
other polyQ or neurodegenerative disorders. Both mutant huntingtin and ataxin-3 were 
shown to accumulate in neuronal nuclei, which has been in particular associated with 
fragments of the disease proteins, and which is in contrast to the widely cytoplasmic 
distribution of the wild type full-length proteins (DiFiglia et al., 1997; Hackam et al., 1998; 
Schmidt et al., 1998; Breuer et al., 2010). A main common histological hallmark of the 
disease proteins is, however, the formation of intranuclear and cytoplasmic aggregates 
(DiFiglia et al., 1997; Paulson et al., 1997b; Gutekunst et al., 1999; Seidel et al., 2016). 
These aggregates were also shown to arise in axons and spatially block axonal transport, 
thereby contributing to neuronal dysfunction and degeneration (Gunawardena et al., 2003; 
Chang et al., 2006; Seidel et al., 2010). Furthermore, intranuclear inclusions of ataxin-3 and 
huntingtin can sequester vital transcription factors and cause transcriptional deregulation 
(Kazantsev et al., 1999; McCampbell et al., 2000; Jiang et al., 2003; Schaffar et al., 2004). 
Likewise, this detrimental effect can be triggered by soluble forms of both polyQ proteins, 
Introduction 
24 
which were found to functionally interact with transcription factors (Zuccato et al., 2001; F. Li 
et al., 2002; S.-H. Li et al., 2002). The proteotoxic stress, induced by the polyQ-dependent 
misfolding and aggregation of disease proteins, can additionally hamper protein quality 
control mechanisms. Chaperones, the UPS and autophagy were reportedly dysregulated and 
parts of the machinery depleted (Chai et al., 1999; Hazeki et al., 2000; Jana et al., 2001; 
Sakahira et al., 2002; Schmidt et al., 2002; Koga et al., 2011; Nascimento-Ferreira et al., 
2011; Park et al., 2013; Martin et al., 2015). 
Interestingly, many common pathomechanisms are apparently consequences of soluble 
polyQ proteins rather than of aggregates. An initial point for neurodegeneration is 
mitochondrial dysfunction. Full-length forms and fragments of polyQ-expanded huntingtin 
and ataxin-3 were shown to directly interact with mitochondria and thereby negatively 
influence mitochondrial vitality, eventually leading to cell death (Chou et al., 2006; Orr et al., 
2008; Yu et al., 2009; Song et al., 2011; Shirendeb et al., 2012; Yano et al., 2014). In 
addition, neuronal Ca2+ handling, which in a large part depends on mitochondrial function, 
was shown to be impaired in HD and SCA3. This dyshomeostasis of cellular Ca2+ levels can 
induce aberrant activation of Ca2+-dependent enzymes and promote cell death (Tang et al., 
2003; Choo et al., 2004; Rockabrand et al., 2007; Chen et al., 2008; Bezprozvanny, 2009, 
2011; Czeredys et al., 2013). 
A further neurotoxicity-mediating feature of HD and SCA3 is the occurrence of huntingtin and 
ataxin-3 fragments. These by-products have been suggested to play a pivotal role in 
triggering many subsequent pathomolecular effects in HD and SCA3 (FIGURE 5) (Tarlac and 
Storey, 2003; Ehrnhoefer et al., 2011; Matos et al., 2011). The origin and the implications of 
these pernicious protein species are diverse and will be the subject of the following pages. 
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Figure 5. The toxic fragment hypothesis. Fragments of disease proteins like polyQ-expanded 
huntingtin or ataxin-3 may represent a starting point for molecular pathomechanisms. Due to their 
increased aggregation-propensity, fragments can increase the formation of aggregates, which 
consequently lead to impairments of cell function, such as defects in protein quality control 
mechanisms, nuclear-cytoplasmic transport and transcription. Furthermore, fragments by themselves 
can directly affect cellular vitality by, for instance, damaging mitochondria or impairing autophagy. 
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The role of proteolysis in neurodegenerative diseases 
The toxic fragment hypothesis of neurodegeneration 
Since the 1990s, our understanding of the molecular basis for neurodegeneration has been 
considerably widened. Notably, causative mutations for monogenic disorders like HD or 
SCA3 were unveiled due to technical achievements in molecular biology. However, the exact 
mechanism of neurodegeneration as mediated by polyQ-expanded proteins remains 
complex and elusive. The detailed analysis of patient tissue and disease models provided 
the indication that fragments of mutant proteins may be mediators of pathogenicity. These 
truncated species were shown to display an increased toxicity and aggregation propensity 
when compared to the respective full-length protein. 
One of the first experimental proofs for the occurrence of toxic fragments was made in HD, 
when researchers performed immunohistochemical staining of huntingtin aggregates in post-
mortem tissue. Neuronal deposits of the mutant protein were detected with antibodies 
binding the polyQ-containing N-terminus of huntingtin, but not with antibodies specific for the 
C-terminus, suggestive of a lack of the respective portion of the protein in aggregates 
(DiFiglia et al., 1997). Together with the realization that the expression of an exon 1-based 
polyQ-expanded huntingtin fragment was sufficient to generate a severe progressive 
phenotype in mice, these findings led to formulation of the toxic fragment hypothesis 
(Mangiarini et al., 1996; Davies et al., 1997; Wellington and Hayden, 1997). The validity of 
this pathomolecular concept was corroborated by studies on additional neurodegenerative 
diseases. Early studies on SCA3 showed that the expression of polyQ-expanded truncated 
ataxin-3 in cell models and mice showed a markedly exacerbated phenotype compared to 
the expression of full-length ataxin-3 (Ikeda et al., 1996). Analogously to findings in HD, 
ataxin-3 aggregates in SCA3 post-mortem tissue were clearly detectable with antibodies 
directed against the polyQ-containing C-terminus but not against the N-terminus of ataxin-3 
(Schmidt et al., 1998). Moreover, the presence and accumulation of soluble huntingtin or 
ataxin-3 fragments was demonstrated in brain tissue of animal models and patients, and 
even observed in lymphoblasts (Kim et al., 2001; Toneff et al., 2002; Goti et al., 2004; Wang 
et al., 2008). Further in vitro analyses confirmed the increased toxicity of polyQ-containing 
protein fragments in HD or SCA3 cell models, and showed that fragments and not the full-
length protein formed intranuclear aggregates (Paulson et al., 1997b; Hackam et al., 1998; 
Martindale et al., 1998; Haacke et al., 2006). N-terminal fragments of huntingtin were found 
to accumulate at mitochondria and impair their function and trafficking (Orr et al., 2008). 
Comparable findings regarding a potential pathogenic role of fragments were also described 
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for further polyQ disorders including DRPLA, SBMA, SCA7 and SCA17 (Butler et al., 1998; 
Schilling, Wood, et al., 1999; Yvert et al., 2000; Garden et al., 2002; Nucifora et al., 2003; 
Friedman et al., 2008; Young et al., 2009). Interestingly, not all forms of polyQ-containing 
fragments show an increased toxicity. This has been reported for a transgenic mouse model 
of HD, where the expression of an N-terminal polyQ-expanded huntingtin fragment led to 
massive inclusions without evidence for neurodegeneration or behavioural abnormalities 
(Slow et al., 2005). Ataxin-1 fragments, which observed in SCA1 transgenic mice, were 
excluded as component of the pathogenic process in this disease model (Klement et al., 
1998). Likewise contrary to the toxic fragment hypothesis, truncated mutant ataxin-2, which 
is present in post-mortem SCA2 brain tissue, exhibited reduced toxicity when compared to 
the full-length protein in vitro (Huynh et al., 2000; Ng et al., 2007). Moreover, the polyQ-
dependency of fragment toxicity is not generally valid. A gene trap mouse model expressing 
the first 259 N-terminal amino acids fused to galactosidase and lacking the polyQ stretch 
developed cytoplasmic inclusion bodies and a neurological phenotype reminiscent of SCA3 
(Hübener et al., 2011). PolyQ-independent fragments of huntingtin were found to induce 
detrimental effects on autophagy and the ER, thus presumably contributing to neuronal cell 
death (Martin et al., 2014; El-Daher et al., 2015). Finally, in SCA6, it was hypothesized that 
the polyQ-expanded α1A Ca2+ channel is not toxic by itself, but renders arising toxic 
fragments resistant to further degradation by proteolysis (Kubodera et al., 2003). Beyond 
polyQ diseases, pathogenic protein fragments are found in many different neurodegenerative 
disorders. The Aβ peptide, the breakdown product of APP, or toxic fragments of tau are 
involved in AD and tauopathies, respectively (Lee and Leugers, 2012; Zhang and Tanzi, 
2012). Fragments of TDP-43 were present in post-mortem neuronal tissue of ALS and FTLD 
patients (Lee et al., 2011). And the C-terminal truncation of α-synuclein was shown to occur 
in vivo and to promote α-synuclein aggregation in PD (Li et al., 2005). 
Two molecular mechanisms have been described as potential sources for disease protein 
fragments: Aberrant splicing and proteolytic cleavage (FIGURE 6). Alternative splicing is an 
important cellular tool for increasing the functional pallet of genes on protein level. This is 
achieved by exclusion or inclusion of exons during the processing of the final mRNA (Matlin 
et al., 2005). Aberrant splicing, however, was described to produce truncated versions of 
proteins, which are toxic or tend to aggregate, as shown for huntingtin, TDP-43 or tau 
(Nishimoto et al., 2010; Sathasivam et al., 2013; Park et al., 2016). The second, presumably 
more significant mechanism is the proteolytic fragmentation of disease proteins by 
endogenous enzymes, which will be discussed in detail in the following chapter. 
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Figure 6. Sources for toxic protein fragments. Truncated forms of proteins can origin from aberrant 
splicing events omitting exons which normally ameliorate the toxicity or aggregation propensity. 
Alternatively, disease proteins can be fragmented by endogenous proteases, which separate toxic 
portions from the residual proteins.  
 
Sources for toxic fragments  
Proteolytic machineries of the cell 
Protein homeostasis is an important key element of cellular integrity. Only the proper 
turnover of proteins, the interplay of degradation and synthesis, can guarantee removal and 
replacement of unnecessary or defective proteins. During a protein’s life many different 
damages and unwanted modifications can occur, ranging from protein truncation, via 
deamination processes and carbonylation by oxidative stress, to aberrant disulphide 
crosslinking and protein aggregation (Toyama and Hetzer, 2012). Once detected by 
respective quality control mechanisms these impaired proteins are submitted to degradation 
by the two major catabolic mechanisms: the UPS and autophagy-lysosome system 
(FIGURE 7). In UPS, target proteins are tagged by ubiquitination and transported to the 26S 
proteasome, a proteolytic complex consisting of a barrel-shaped proteolytic 20S core particle 
and two 19S regulatory subunits. The 19S subunit recognizes ubiquitinated substrates, 
unfolds and deubiquitinates them, and mediates their translocation into the proteolytic 20S 
subunit, where the substrate is degraded to small peptides (Ciechanover, 2005). The second 
machinery, the autophagy-lysosome system, can be mainly divided into three sub-
mechanisms: chaperone-mediated autophagy (CMA), microautophagy and macroautophagy. 
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The CMA is characterised by substrate recognition via Hsc70 and its co-chaperones based 
on the consensus sequence KFERQ in the target protein. The substrate-chaperone complex 
binds to the lysosome-associated membrane glycoprotein-2A (LAMP2A), a receptor on the 
lysosomal membrane. Finally, the substrate is unfolded, translocated into the lysosomal 
lumen and degraded down to amino acids by a battery of cathepsins (Kaushik et al., 2011). 
Microautophagy is a mainly non-selective degradation process via the random engulfment of 
cytoplasmic cargo by membrane invagination at the lysosome (Li et al., 2012). 
Macroautophagy, the most investigated form and major mode of autophagy, is based on a 
characteristic double-membrane vesicle, the autophagosome. The formation mechanism of 
this organelle is still a matter of debate and many origins have been discussed including the 
ER, the Golgi apparatus, mitochondria-associated membrane (MAM), or mitochondria 
themselves (Lamb et al., 2013). Macroautophagy is regulated by two mechanisms, mTOR-
ULK1 and the beclin-1 pathway, and its steps can be subdivided in vesicle nucleation and 
expansion, substrate recognition and autophagosome formation, docking and fusion with the 
lysosome, and, finally, vesicle and cargo breakdown and degradation (He and Klionsky, 
2009; Lilienbaum, 2013). Once formed, autophagosomes can selectively engulf not only 
protein aggregates but also whole organelles like mitochondria, which are detected by p62 or 
neighbour of BRCA1 gene 1 (NBR1). These cargo receptors preferentially bind K63-
polyubiquitin-tagged substrates and bring them in contact with the autophagosomes via a 
linker protein at the autophagosomal membrane, the phosphatidylethanolamine-amidated 
microtubule-associated protein 1A/1B light chain 3A (LC3-II), a marker for autophagosomes 
formation and autophagic flux (Kabeya et al., 2000, 2004; Bjørkøy et al., 2005; Mizushima 
and Yoshimori, 2007; Kirkin et al., 2009). 
All these processes are not only important for degrading dysfunctional elements of the cell 
but also to supply it with new nutrients by recycling expendable substrates. However, 
dysfunction of these degradative systems has been associated with neuronal ageing and 
degeneration, and is in the focus for therapeutic research (Ciechanover and Kwon, 2015). 
Regarding immediate production of toxic protein species of disease proteins, UPS and 
autophagy are rather playing a minor role as they ideally fully degrade substrate proteins 
without yielding certain deleterious breakdown products. Nevertheless, lysosomal cathepsins 
were associated with the fragmentation of mutant huntingtin in HD or APP in AD, and 
inhibition of these enzymes led to positive effects on the molecular disease phenotype 
(Ratovitski et al., 2011; Kindy et al., 2012). 
The main source for toxic protein fragments is represented by non-UPS and non-lysosomal 
machineries, which comprise a large pallet of proteolytic enzymes. For instance, BACE1 or 
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the γ-secretase complex have been associated with APP truncation in AD, and matrix-
metalloproteinases were shown to cleave huntingtin and α-synuclein in HD or PD, 
respectively (Miller et al., 2010; Choi et al., 2011; Zhang and Tanzi, 2012). However, the key 
players in this regard are two classes of cysteine proteases, caspases and calpains 
(FIGURE 7). 
 
 
Figure 7. Proteolytic systems of the cell. Illustrative comparison between the degradative 
proteasome system and autophagy, which degrade substrate proteins to peptides and amino acids, 
with caspases and calpains, proteases which perform limited proteolysis and produce truncated forms 
of the target protein. 
  
Caspases as mediators of apoptosis and disease protein cleavage 
The name ‘caspase’ is an acronym for cysteine-dependent aspartate-specific protease. It 
summarized not only the occurrence of a cysteine residue in the enzyme’s catalytic dyad but 
also the cleavage-specificity after an aspartate at the P1 position, N-terminal of the scissile 
bond in the substrate protein (Pop and Salvesen, 2009). Caspases were firstly discovered as 
the mammalian interleukin-1β-processing enzyme (ICE), a pro-inflammatory cytokine 
processing protease (now caspase-1), and, at about the same time, the C. elegans cell death 
protein and ICE homologue cell death abnormality-3 (CED-3) (Cerretti et al., 1992; 
Thornberry et al., 1992; Yuan et al., 1993). 
As described for human and mice, there are 14 different caspases in mammals, of which 
caspase-11 is not present in humans and caspases-4, -5, and -10 lack in the mouse genome 
(Man and Kanneganti, 2015). The expression of caspases is relatively ubiquitous across all 
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tissues except for caspase-14 which is restricted to cornifying epithelia (Denecker et al., 
2008). Mammalian caspases can be divided in two groups based on the biological function: 
apoptotic and inflammatory caspases. The first group, which includes caspases-2, -3, and -6 
to -10 can be further subdivided into initiator and executioner caspases, which cleave 
specific substrate proteins to cause cellular destruction. Caspases-2, -8, -9, and -10 are 
initiators, whereas caspases-3, -6, and -7 are executioners of apoptosis (Man and 
Kanneganti, 2015). The mechanism of programmed cell death can be enforced in an intrinsic 
or extrinsic manner. The intrinsic pathway is based on the release of cytochrome c from 
membrane-permeabilized mitochondria. Cytochrome c then interacts with apoptotic 
protease-activating factor 1 (Apaf-1) in the cytoplasm, which recruits initiator caspase-9, 
inducing the formation of the apoptosome and initiating the caspase cascade via executioner 
caspases-3 and -7 (Tait and Green, 2010). The extrinsic pathway, by contrast, is based on 
an external stimulus which is transmitted via death receptors like Fas receptor (FasR), 
tumour necrosis factor receptor 1 (TNFR1), or TNF-related apoptosis-inducing ligand 
(TRAIL) receptors. Binding of respective ligands leads to the recruitment, dimerization and 
activation of initiator caspase-8 and -10, which initiate the apoptotic cascade via activation of 
executioner caspase-3 (Guicciardi and Gores, 2009). Moreover, caspase-8 converts BH3 
interacting-domain death agonist (BID) into tBID, which can in parallel activate the intrinsic 
apoptosis via mitochondria (Billen et al., 2008). The second group consists of caspases-1, -4, 
-5, -11 and -12, and is associated with the inflammatory response via the inflammasome. 
This multi-protein complex activates caspase-1, which drives the conversion of cytokines 
such as pro-interleukin-1β and -18 to their active forms. Furthermore, inflammatory caspases 
are initiating pyroptosis, an inflammatory and lytic form of programmed cell death (Man and 
Kanneganti, 2015). Caspase-14 occupies a special position as it is neither involved in 
apoptotic nor inflammatory processes, but plays a role in terminal keratinocyte differentiation 
(Denecker et al., 2008). 
Structurally, initiator caspases consist of the C-terminal catalytic caspase domain and two 
different types of N-terminal, regulatory pro-domains, which are not present in executioner 
caspases-3, -6, -7, and -14 (FIGURE 8). Caspases-8 and -10 exhibit two death effector 
domains (DED) and the remainder feature a caspase activation and recruitment domain 
(CARD), which are crucial for caspase dimerization and activation. The catalytic caspase 
domain consists of a small (p10) and a large (p20) subunit connected by a linker region 
(Riedl and Shi, 2004). Upon dimerization initiator caspases undergo autoproteolysis, which 
removes the pro-domain and cleaves the linker. The separation of the small and large 
subunits leads to the rearrangement and formation of the active caspase heterotetramers. 
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Dimers of executioner caspases, however, require proteolysis by active initiator caspases for 
triggering subunit separation, rearrangement and activation (Yang et al., 1998; Tait and 
Green, 2010). Several proteins were identified as direct or indirect inhibitors of caspases, 
which control their activation during cellular processes. The first potential inhibitor of 
caspases was the baculoviral p35 protein, which is known to potently inhibit most caspases 
and represents the prototype for the biggest group of endogenous mammalian inhibitors of 
apoptosis  proteins (IAP) (Bump et al., 1995; Xue and Robert Horvitz, 1995; Clem, 2001). 
They are characterised by their inhibitory baculoviral IAP repeat (BIR) domains. In addition, 
IAPs can feature a C-terminal really interesting new gene (RING) domain, which bears a E3 
ubiquitin ligase function to tag themselves or targeted caspases for degradation via the UPS 
(Riedl and Shi, 2004; Vaux and Silke, 2005). 
Besides their important role in regulating and executing apoptosis and inflammation, 
caspases are involved in many further biological processes including proliferation, 
differentiation, cell morphology and migration, and cell-autonomous immunity (Miura, 2012; 
Man and Kanneganti, 2015). In neurons, caspases control neuronal connectivity and signal 
transduction by mediating dendritic pruning, axon guidance, synaptogenesis and long-term 
depression (Hyman and Yuan, 2012). 
Likewise, caspases are involved in various disease mechanisms. Interleukin-1 production by 
caspase-1 is implicated in inflammatory and autoinflammatory disorders including gout, 
arthritis or type 2 diabetes. Under certain pathological conditions caspases act as 
executioners of apoptosis in tissue degeneration. And mutations of caspases and 
overexpression of IAPs have been associated with cancer (Degterev et al., 2003; McIlwain et 
al., 2013). Furthermore, caspases are known to play a role in acute and chronic neurological 
diseases. For instance, they are involved in cell death and inflammatory response during 
cerebral ischemic injuries and inhibiting caspases pharmacologically was shown to reduce 
detrimental effects of ischemic and excitotoxic neuronal damage in animal models (Hara et 
al., 1997; Fink et al., 1998; Friedlander, 2003; García de la Cadena and Massieu, 2016). In 
many neurodegenerative disorders like AD, ALS, FTLD, HD, SCA3 and SCA7 caspases 
were found to mediate neuronal cell death and toxic fragmentation of disease proteins like 
tau, TDP-43, huntingtin, ataxin-3 or ataxin-7 (Goldberg et al., 1996; Guégan et al., 2001; 
Hartmann et al., 2001; Berke et al., 2004; Rissman et al., 2004; Young et al., 2007; Y.-J. 
Zhang et al., 2009). Several cell and animal models treated with caspase inhibitors or 
expressing caspase-cleavage resistant variants of disease proteins furthermore showed 
improved molecular or behavioural phenotypes, underpinning the importance of caspases as 
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a potential therapeutic target in neurodegeneration (Graham et al., 2006; Jung et al., 2009; 
Leyva et al., 2010; Rohn, 2010).  
 
 
Figure 8. Domain composition of caspases. Caspases can be functionally subdivided in initiator 
and executioner caspases. Initiator caspases of the extrinsic apoptotic pathway like caspase-8, 
feature as a pro-enzyme two N-terminal death effector domains (DEDs), which are followed by a large 
and a small catalytic subunit, connected by a linker sequence. Upon interaction with an activator 
protein, the DEDs are cleaved off and the subunits are proteolytically separated. Initiator caspases 
triggering the intrinsic apoptosis, such as caspase-9, exhibit a caspase activation and recruitment 
domain (CARD) at their N-terminus. Comparably to the previous class, a linker sequence between the 
large and small subunit is cleaved, transforming the protease to its active state. Executioner caspases 
like caspase-3 do not feature pro-domains and are likewise activated by the proteolytic separation of 
their subunits. Amino acid positions of the catalytic dyad of caspases are indicated by vertical white 
lines. Illustrations of caspases are based on data retrieved from the UniProt database.  
 
Calpains and their involvement in health and disease 
The group of calpains was discovered and firstly described as a Ca2+-activated, neutral 
proteinase (CANP) by Gordon Guroff more than half a century ago (Guroff, 1964). The 
established name ‘calpain’ was proposed later and is a portmanteau consisting of the 
elements ‘cal’ as a reference to Ca2+ and Ca2+-binding proteins, and ‘pain’, which 
corresponds to structurally-related cysteine proteases from plants, papain or bromelain 
(Murachi et al., 1980).  
Calpains are characterised by their well conserved proteolytic domain (CysPc), which consist 
of two protease core domains (PC1 and PC2) (FIGURE 9). In a modular principle with more 
than 40 different other domains or motifs, the CysPc domain forms multiple variants of 
calpains, which are found in many species, from some bacteria via unicellular and 
multicellular eukaryotes through to vertebrates (Sorimachi et al., 2011). In humans, 15 
different calpains are described, which can be divided in conventional classical (calpain-1 
and -2), unconventional classical (calpains-3, -8, -9, -11 to -14) and unconventional non-
classical calpains (calpains-5, -6, -7, -10, -15, and -16). The main differences between these 
Introduction 
34 
groups are as follows: Conventional classical calpains are characterised by a C-terminal 
Ca2+-binding penta-EF-hand (PEF) domain and their vital interaction with the regulatory 
calpain small subunit 1 (CAPNS1, formerly known as calpain-4). Unconventional non-
classical calpains share the same structure as classical calpains including the PEF domain 
but without interacting with CAPNS1. Lastly, unconventional non-classical calpains lack both 
PEF domains and the regulatory subunit (Dayton et al., 1976; Sorimachi et al., 2011; Ono et 
al., 2016). Together with calpastatin (CAST), the only known endogenously expressed and 
highly specific, proteinaceous calpain inhibitor, they form the intracellular calpain system 
(FIGURE 9) (Nishiura et al., 1978; Wendt et al., 2004). The expression of calpains depends on 
the respective isoform. For instance, calpain-1, -2, or -10 are expressed ubiquitously or at 
least in most cells, whereas calpain-3 is solely expressed in skeletal muscle, calpain-11 and -
13 can be found in testes, and expression of calpain-12 is restricted to the skin (Ono et al., 
2016). 
How calpains are activated was controversially discussed and different explanatory 
scenarios were suggested, including autoproteolysis, protease dimerization, or dissociation 
from the regulatory subunit (Campbell and Davies, 2012). However, X-ray crystallography of 
Ca2+-bound calpain-2 together with CAPNS1 and CAST gave information about the precise 
mechanism: In a fully active state, calpain binds ten Ca2+ ions of which eight bind to the two 
PEF domains, and one Ca2+ binds each PC domain. This triggers structural rearrangements 
which then lead to the connection of the two protease core domains PC1 and PC2 to a 
closed active state (Moldoveanu et al., 2002, 2008; Hanna et al., 2008). In vitro studies 
normally utilize micro to millimolar Ca2+ concentrations to activate calpains, which are rather 
divergent from the nanomolar levels in cells under normal physiological conditions. However, 
this apparent contradiction is resolved, as sufficient Ca2+ concentration may be reached in 
the cellular microenvironment (Campbell and Davies, 2012). 
Calpains perform many regulatory functions in cells by executing limited proteolysis, a 
specific recognition motif-dependent cleavage of substrate proteins (Tompa et al., 2004; 
DuVerle et al., 2011). This allows them to modulate the activity of enzymes or structural 
proteins. Calpains are known to play a role in remodelling cytoskeletal elements, modulation 
of cell motility, cell cycle control and proliferation, regulation of gene expression, 
inflammation, autophagy, apoptosis, signal transduction, and synaptic plasticity in neurons 
(Goll et al., 2003; Ravikumar et al., 2010; Baudry and Bi, 2016; Ji et al., 2016). 
The important role of calpains in healthy biological system becomes clear, when considering 
the wide-ranging implication of their malfunction in human diseases. In cardiovascular 
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disorders, myopathies, ophthalmic diseases or cancer, calpains were found to be 
deregulated or to mediate certain molecular pathomechanisms. A whole group of medical 
conditions based on dysfunctions of calpains was termed calpainopathies comprising many 
different pathological manifestations (Ono et al., 2016). The first calpainopathy was limb-
girdle muscular dystrophy 2A, which is caused by mutations in the gene of muscular calpain-
3 (CAPN3) (Richard et al., 1995). Missense mutations in the calpain-5 gene (CAPN5) were 
associated with a form of autosomal-dominant neovascular inflammatory vitreoretinopathy 
(Mahajan et al., 2012). And an intriguing association of calpains was made with diabetes, 
when calpain 10 was identified as a susceptibility gene for type 2 diabetes (Horikawa et al., 
2000). Finally, calpains are also involved in neuronal injury, neurodegenerative disorders and 
neuronal ageing processes (Nixon, 2003; Mattson and Magnus, 2006). For instance, these 
proteases execute Wallerian degeneration, mediate degenerative effects in traumatic brain 
injury, and show detrimental overactivation or perform disease protein cleavage in 
neurodegenerative disorders like AD, ALS, or PD (Samantaray et al., 2008; Saatman et al., 
2010; Ferreira and Adriana, 2012; J.T. Wang et al., 2012; Ma et al., 2013; Wright and Vissel, 
2016). A neuronal calpainopathy caused by CAPN1-null mutations is characterised by 
cerebellar ataxia and limb spasticity (Y. Wang et al., 2016). In addition to it, calpains play a 
significant role in polyQ diseases, which will be discussed in detail for HD and SCA3 in the 
subsequent chapter. 
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Figure 9. Domain composition and structure of calpains and calpastatin. Conventional classical 
calpains are present as a large protease unit, such as calpain-1, and the calpain small subunit 1 
(CAPNS1). Both share a C-terminal Ca2+-binding penta-EF-hand (PEF) domain. Calpain-1 further 
contains an N-terminal proteolytic CysPc domain, consisting of core domains PC1 and PC2, which 
also bind Ca2+ ions. Amino acid positions of the catalytic triad of calpains are indicated by vertical 
white lines. In addition, a calpain-like β-sandwich domain (CBSW) is located between the CysPc and 
the PEF domain. CAPNS1 features, moreover, an N-terminal glycine rich (GR) hydrophobic domain. 
Unconventional calpains lack the interaction with a small subunit and non-classical calpains do not 
have a PEF domain, but other characteristic structural elements. The endogenous inhibitor calpastatin 
contains four structurally flexible inhibitory domains (ID1-4) of which each can inhibit one calpain 
molecule. Illustrations of calpain-1, CAPNS1 and calpastatin are based on data retrieved from the 
UniProt database. The binding of calpastatin's ID4 (purple ribbon schematic) to a calpain-CAPNS1 
heterodimer is illustrated as a space-filling crystal structure on the right side (adapted from Campbell 
and Davies, 2012). 
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Calpains and their role in Huntington disease and spinocerebellar ataxia type 3 
Calpains and Huntington disease 
Evidence for proteolytic fragmentation of huntingtin and ataxin-3 has been provided about 20 
years ago, when caspases were shown to cleave both polyQ proteins and thereby contribute 
to the formation of toxic and aggregation-prone fragments (Goldberg et al., 1996; Wellington 
et al., 1998). The association of calpains with huntingtin was revealed shortly after, when a 
further processing of caspase-3 cleavage-derived fragments by calpains was detected in 
human HD brain, suggestive of a sequential huntingtin proteolysis by both classes of 
enzymes (Kim et al., 2001). Additionally, further studies in different cell and animal models of 
HD demonstrated that wild type and mutant huntingtin are substrates of calpains (Gafni and 
Ellerby, 2002; Goffredo et al., 2002; Gafni et al., 2004; Landles et al., 2010). This has been 
also shown for wild type huntingtin in rat cortex and striatum after transient ischemic injury 
and 55 kDa large fragments were observed to translocate from injured neurons to astrocytes 
(Kim et al., 2003, 2011). In contrast to caspase-dependent fragmentation, the polyQ tract 
was shown to modulate the calpain cleavage propensity of huntingtin, rendering the polyQ-
expanded protein more sensitive to fragmentation by calpains in vitro (Wellington et al., 
1998; Gafni and Ellerby, 2002). Moreover, arising N-terminal calpain cleavage-derived 
fragments accumulate in the nucleus of HD cell models, which has been correlated with 
increased cytotoxicity (Hackam et al., 1998; Martindale et al., 1998; Gafni et al., 2004). On 
the other hand, researchers proposed a protective role of a calpain-dependent huntingtin 
degradation, which removes toxic N-terminal fragments arising from cleavage by enzymes 
such as bleomycin hydrolase or cathepsin Z (Ratovitski et al., 2007, 2011; Southwell et al., 
2011). Only few investigations were done on the determination of cleavage sites within the 
huntingtin protein. Two main sites were identified at amino acids 469 and 536, and the 
existence of further site between amino acids 510 and 654 was presumed (Gafni et al., 2004; 
Landles et al., 2010). Furthermore, calpain cleavage at amino acids 8 and 15 was linked to 
the degradation of N-terminal huntingtin constructs (Southwell et al., 2011). Aside from 
discovery of huntingtin as a calpain substrate, calpain activation has been shown to be a 
characteristic of the molecular pathogenesis of HD. Despite lacking a direct colocalisation of 
active calpain-2 with aggregates of mutant huntingtin in post-mortem tissue (Adamec et al., 
2002), calpain overactivation has been identified in human HD tissue and in cell and animal 
models of HD. This comprises increased expression levels of calpain-1, -5. -7, and -10 and 
an elevated enzyme activity as detected by increased breakdown of the calpain substrates α-
spectrin and huntingtin (Gafni and Ellerby, 2002; Gafni et al., 2004; Majumder et al., 2007). 
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Furthermore, the endogenous proteinaceous inhibitor CAST was shown to be decreased in 
cells expressing mutant huntingtin (Reijonen et al., 2010; Hyrskyluoto et al., 2013). As 
calpains play a role upon neuronal lesioning, these enzymes have been described as major 
effectors of striatal cell death in 3-NP models of HD (Bizat et al., 2003). The increased 
activation of calpains was shown to contribute to a loss of surface NMDA receptors and 
cleavage of striatal-enriched protein tyrosine phosphatase 61 in the YAC128 model of HD 
(Cowan et al., 2008; Gladding et al., 2012, 2014). Moreover, NMDA-induced calpain 
activation correlated with enhanced cell death in cultured MSNs (Cowan et al., 2008). 
Interestingly, the detected calpain overactivation in the striatum of YAC128 was shown to 
undergo an age-dependent attenuation, pointing to alterations in Ca2+ signalling mechanism 
with disease progression (Dau et al., 2014). 
 
Calpains and spinocerebellar ataxia type 3 
Analogous to the research history of huntingtin cleavage, ataxin-3 was firstly described as a 
substrate of caspases (Wellington et al., 1998; Berke et al., 2005). Although initial studies 
could not verify a role of calpains in the molecular pathogenesis of SCA3, subsequent 
investigations unequivocally demonstrated the occurrence of calpain-dependent ataxin-3 
cleavage in established cell models, SCA3 mice and patient-derived neurons (Berke et al., 
2004; Haacke et al., 2007; Koch et al., 2011; Simões et al., 2012). However, a direct proof 
for calpain-dependent ataxin-3 fragmentation in human MJD brain failed to materialize. First 
attempts to identify calpain cleavage sites within the ataxin-3 protein, narrowed the sites 
down to amino acid positions 60, 154, 190, 200, 220 and 260, without proving the exact 
localisation by site-specific mutagenesis (Colomer Gould et al., 2007; Haacke et al., 2007; 
Simões et al., 2012). Interestingly, most of the proposed cleavage sites are located between 
two N-terminal NES and the C-terminal NLS, and the separation of these signals by 
proteolytic events was suggested to trigger the mislocalisation of polyQ-containing fragments 
into the nucleus as a prerequisite of an enhanced intranuclear aggregation of mutant ataxin-3 
(Haacke et al., 2006; Antony et al., 2009). A clear general overactivation of the calpain 
system as a hallmark of the molecular pathogenesis of SCA3 has not been directly described 
yet as it was done for HD. However, levels of the CAST were shown to be lowered in SCA3 
mice and human SCA3 brain, indicative of an increased calpain activity (Simões et al., 2012). 
Furthermore, NMDA or glutamate treatment of neurons, derived from SCA3 patient-specific 
induced pluripotent stem cells (iPSCs), led to an excitotoxic activation of calpains, thus 
resulting in a fragmentation and aggregation of mutant ataxin-3 (Koch et al., 2011). 
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Taken together, a multitude of studies revealed the important contribution of the calpain 
system and calpain-dependent proteolysis to the molecular pathogenesis of HD and SCA3. 
The thereby generated quantity of information on this specific disease mechanism points out 
new possibilities for a therapeutic approach for both polyQ disorders by modulating calpain 
activity and cleavage of the disease proteins huntingtin and ataxin-3. 
 
How to target the calpain proteolytic pathway as a therapeutic approach 
Direct and indirect modulation of calpain activity 
The scientific evidence on contribution of the calpain system in polyQ disorders was 
consequently accompanied by developing and testing various strategies to suppress 
detrimental effects of calpain activation. 
A direct approach is the pharmacological inhibition of calpain activity using selective 
compounds. These molecules target the enzyme’s active site by mimicking a substrate or 
lower its activation allosterically by binding e.g. the PEF domain or protease core (Ono et al., 
2016). This strategy has been tested in several HD and SCA3 cell lines or animal models in 
order to decrease cleavage of the mutant protein or to counteract the negative effects of 
calpain overactivation. In HD cell lines, which exhibited an elevated calpain activation due to 
the expression of a polyQ-expanded huntingtin fragment, treatment with calpain inhibitors N-
acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) and Z-L-Abu-CONH(CH2)3-morpholine restored 
NF-κB-p65 levels and improved cell viability (Reijonen et al., 2010). Intracerebroventricular 
infusion of ALLN in 3-NP-treated rats reduced huntingtin cleavage, rescued full-length 
huntingtin levels, and alleviated the 3-NP-induced striatal loss (Bizat et al., 2003). Moreover, 
ALLN-treated primary cultures of MSNs derived from HD mice showed a normalized surface 
NMDA receptor expression and reduced NMDA-induced apoptosis to wild type levels 
(Cowan et al., 2008). Calpain inhibitors such as ALLN and calpeptin attenuated calpain-
dependent fragmentation of ataxin-3 in Ca2+-treated cell lysates or in cells incubated with the 
Ca2+-ionophore ionomycin (Haacke et al., 2007). In neurons derived from SCA3 patient-
specific iPSCs, incubation with calpain inhibitors abolished mutant ataxin-3 cleavage and 
aggregation upon excitotoxic stress by NMDA or glutamate treatment (Koch et al., 2011). 
The oral administration of the calpain inhibitor BDA-410 to a lentiviral mouse model of SCA3 
led to a diminished ataxin-3 cleavage, lower full-length levels and reduced aggregation of 
mutant ataxin-3. This was accompanied by an amelioration of striatal cells loss, rescue of 
cerebellar morphology, and improvement of motor behaviour deficits (Simões et al., 2014). 
Introduction 
40 
However, the therapeutic use of pharmacologic calpain inhibitors is strongly limited to their 
lack of isoform selectivity and side-effects like binding to other cysteine proteases (Donkor, 
2011). Peptides based on the only known selective calpain inhibitor, the endogenous CAST, 
might represent a promising alternative to other compounds (Gil-Parrado et al., 2003; Wu et 
al., 2003; Fiorino et al., 2007). Further investigations and the development of a new 
generation of calpain inhibitors is demanded and ongoing, but can only be achieved by 
intensifying the research on calpain function and biology (Ono et al., 2016). 
Alternatively, activation of calpains can be attenuated by targeting pathways, which are 
known to be deregulated and thereby induce calpain activity. An example is the 
administration of memantine, an antagonist to NMDA receptors and therapeutic targeting 
glutamate excitotoxicity in AD. This compound has been previously shown to reduce calpain 
activation in different models of AD (Nimmrich et al., 2008; Goñi-Oliver et al., 2009). 
Respectively, in a 3-NP rat model of HD, memantine was found to be neuroprotective and to 
act extenuatingly on the calpain system (Lee et al., 2006). On the other hand, treating the 
YAC128 mouse model of HD with memantine, attenuated, indeed, synaptic dysfunction and 
pro-death signalling, but without affecting the calpain system (Dau et al., 2014). A further 
indirect target is the Ca2+-sensitive sigma-1 receptor, which is known to be a regulator of 
Ca2+ homeostasis via interactions with binding immunoglobulin protein (BiP) and IP3Rs. 
Overexpressing sigma-1 receptor or administration of its agonist PRE084 was shown to 
upregulate CAST and reduce calpain-dependent cleavage of α-spectrin in mutant huntingtin-
expressing PC6.3 cells (Hyrskyluoto et al., 2013). 
Aside from these pharmacologic strategies, genetic approaches can be undertaken to target 
calpains like knocking-out specific calpain isoforms or overexpressing the endogenous 
inhibitor CAST. In PC6.3 cells, which express a polyQ-expanded fragment of huntingtin, co-
transfection with CAST reduced calpain overactivation and normalized aberrant NF-κB-p65 
signalling (Reijonen et al., 2010). The involvement of calpains in the regulation of autophagy 
was targeted in HD fly and mouse models, where the knockdown of a calpain homologue in 
Drosophila and the overexpression of CAST in a fragment mouse model of HD were 
protective against aggregation and herewith linked toxicity. Concurrently, it was found, that 
the knockdown of calpain exerted protective effects in a Drosophila model expressing the 
AD-associated protein tau. This observation further underlined the general validity of this 
approach for neurodegenerative diseases. Most importantly, the same study demonstrated 
that a constant overexpression of CAST did not lead to any overt deleterious phenotype in 
mice (Menzies et al., 2014). In SCA3, transfection with CAST abrogated fragmentation and 
aggregation of mutant ataxin-3 in cell culture (Haacke et al., 2007). Moreover, the adeno-
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associated virus (AAV)-based overexpression of CAST in a lentiviral mouse model of SCA3 
resulted in lower ataxin-3 proteolysis, decreased size and amount of intranuclear ataxin-3 
inclusions, and neuroprotection via calpain inhibition (Simões et al., 2012). 
All these positive results on pharmacological or genetic calpain inhibition in HD and SCA3 
are particularly promising and they emphasize that following this strategy might lead to the 
development of a therapeutic treatment not only of polyQ disorders, but also further 
neurodegenerative diseases. Nevertheless, attention should be paid to potential adverse 
effects of calpain inhibition as well: Calpains were shown to contribute to the degradation of 
mutant huntingtin by removing the very N-terminus of exon 1 constructs, which is known to 
play a substantial role in modulating protein function, localisation and toxicity (Southwell et 
al., 2011; Arndt et al., 2015). Furthermore, decreasing the enzymatic activity of calpains 
induced the accumulation of N-terminal huntingtin species and thereby increased 
aggregation of the disease protein (Ratovitski et al., 2007). Finally and most strikingly, as 
calpain-1 knockout animals were found to develop ataxia-like symptoms and calpain-2 mice 
exhibit embryonic lethality, special caution is demanded, when genetically targeting the 
calpain system as a therapeutic approach (Takano et al., 2011; Lopez et al., 2015). 
 
Rendering disease proteins resistant to proteolysis by calpains 
Following the toxic fragment hypothesis, proteolytic fragmentation of disease proteins like 
polyQ-expanded huntingtin or ataxin-3 generates breakdown products, which are more toxic 
and more aggregation-prone than the full-length protein. Thus, preventing the cleavage of 
disease proteins may ameliorate the molecular, physiological and behavioural disease 
phenotype. The inhibition of proteases responsible for the fragmentation represents a 
potential approach, especially, when these enzymes are known to be additionally 
upregulated in the disease context. However, the global downregulation of protease activity 
can interfere with their physiological function and lead to unwanted side effects (Howley and 
Fearnhead, 2008; Ono et al., 2016). Therefore, targeting the disease protein itself to 
decrease its cleavage propensity can constitute are more specific strategy, which 
circumvents influencing the complex cellular machineries. 
Proteases like caspases and calpains are known to cleave substrates at characteristic sites, 
which are defined by their amino acid sequence or three-dimensional appearance. A directed 
mutation or a targeted post-translational modification of these sites can render them 
unrecognizable for the respective proteases and block or, at least, diminish cleavage. 
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Caspase cleavage sites are highly conserved due to an aspartate residue at the P1 position 
in a core tetrapeptide motif (P4-P3-P2-P1), which is N-terminal of the scissile bond. An 
additional amino acid preferences at the P4 site was used for a cleavage site-based 
subclassification of caspases into three groups (Talanian et al., 1997; Nicholson, 1999). 
Mutating the aspartate residue at the P1 site to alanine or asparagine is sufficient to reduce 
caspase substrate recognition and thus cleavage, and was shown to reduce fragmentation, 
toxicity and aggregation of mutant huntingtin or ataxin-3 in vitro and in vivo (Wellington et al., 
2000; Berke et al., 2004; Graham et al., 2006; Jung et al., 2009). 
For calpains, the situation looks slightly different. Calpain substrate recognition was primarily 
reduced to a ‘P2-P1 rule’, with mainly arginine or tyrosine at the P1 and leucine or valine at the 
P2 position (Hirao and Takahashi, 1984; Sasaki et al., 1984). Studies in which a single amino 
acid mutation in the consensus motif was sufficient to abolish proteolysis of calpain 
substrates like α-spectrin or short transient receptor potential channel 5 (TRPC5) firstly 
validated the ‘P2-P1 rule’. However, other researchers could not confirm these observations 
on further calpain substrates such as histones, myelin basic protein, or tau (Sakai et al., 
1987; Banik et al., 1994; Garg et al., 2011). Reviewing these inconsistencies led to the 
conclusion that a combination of many features of the substrate protein, like primary and 
secondary protein structures, or the presence of sequences containing proline, glutamic acid, 
serine, and threonine (so called PEST regions), are determining the recognition by calpains 
(Tompa et al., 2004; DuVerle et al., 2011; Z. Liu et al., 2011). 
Due to the complexity of these motifs, many approaches to abolish calpain cleavage were 
based on polyalanine substitutions or cleavage site deletions, which can affect up to 10 
amino acids surrounding the cleavage site (Gafni et al., 2004; Wanichawan et al., 2014). In 
this context, the deletion of two identified cleavage sites at amino acid position 469 and 536 
in the polyQ-expanded human huntingtin resulted in a lowered calpain-dependent 
fragmentation, reduced aggregation and an attenuated toxicity (Gafni et al., 2004). As post-
translational modifications can also influence the steric nature of an adjacent calpain 
recognition motif, modulating these changes in a desirable direction can constitute an 
alternative option. For instance, the serine residue at the calpain cleavage site 536 in human 
huntingtin was shown to be phosphorylated, and substituting serine by aspartate to mimic 
phosphorylation inhibited cleavage and reduced toxicity of mutant huntingtin in cell culture 
(Schilling et al., 2006). However, translation of these results into in vivo models still lacks 
proof-of-concept, although beneficial effects were demonstrated in the caspase cleavage 
context (Graham et al., 2006; Jung et al., 2009). 
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Another interesting strategy in preventing disease protein cleavage is based on exon 
skipping, which omits the translation of protein regions containing cleavage sites. Via 
administration of specific antisense oligonucleotides, the skipping of exon 12 or both exons 8 
and 9 in huntingtin or ataxin-3, respectively, was prompted, which led to the expression of 
proteins lacking the known caspase or calpain recognition motifs (Evers et al., 2014; Toonen 
et al., 2016). Moreover, first in vivo trials for huntingtin exon 12 skipping in the YAC128 
mouse model of HD yielded promising results (Casaca-Carreira et al., 2016). Underlining the 
technical feasibility of this approach in patients, a therapeutic intervention for Duchenne 
muscular dystrophy using a morpholino antisense oligomer-mediated exon skipping has 
been recently approved by the FDA (Cirak et al., 2011; Young and Pyle, 2016). 
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Objectives of the study 
The well documented and frequently reported involvement of calpains in the molecular 
pathogenesis of many neurodegenerative disorders renders this group of Ca2+-dependent 
proteases a promising therapeutic target. However, our relatively shallow knowledge 
regarding calpain function and missing comparative approaches demand further 
investigations. Therefore, the current study focussed on three main aspects to elucidate the 
role of calpains in the pathomechanisms of two polyQ diseases, HD and SCA3: 
 
Aim 1: To investigate the calpain system activation in polyQ disease models  
For validating the impact of calpains under pathophysiological conditions, several cell and 
animal models of HD or SCA3 were analysed regarding the expression and activation of 
proteinaceous elements of the calpain system. Additionally, activation of calpains was 
genetically amplified in vivo by knocking out the endogenous inhibitor CAST in HD and SCA3 
mice to test its repercussion on the respective pathology.  
 
Aim 2: To assess the potential benefit of targeting calpains as a therapeutic approach 
Genetic and pharmacological strategies were pursued to attenuate the disease-relevant 
activation of calpains and calpain-mediated fragmentation of disease proteins in cellulo and 
in vivo. Calpain inhibitors were administered to HD and SCA3 cell lines to evaluate their 
protective effects. Two HD animal models were treated with the experimental compound 
olesoxime, which targets the mitochondrial Ca2+ channel VDAC1. Moreover, calpain-1 was 
knocked out in SCA3 mice to assess its impact on ataxin-3 fragmentation and aggregation in 
vivo. 
 
Aim 3: To characterise the calpain-mediated fragmentation of polyQ disease proteins 
Calpain cleavage sites within the disease proteins huntingtin and ataxin-3 were identified 
using a combinatorial approach. Strategies to reduce calpain-mediated polyQ protein 
breakdown based on modifications of cleavage sites were tested. Furthermore, the molecular 
impact of resulting fragments was analysed in cell-based assays for assessing their 
contribution to the molecular pathogenesis. 
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Results and discussion 
Investigating calpain activation in cell and animal models of polyQ diseases 
Preliminary considerations 
The disease-associated overactivation of the calpain system has been described as an 
important feature in neurodegeneration and might mediate the pathology on the molecular 
level. In HD and SCA3, an increased activity of calpains and dysregulation of elements of the 
calpain system have been unequivocally described. Therefore, the reproducibility of this 
pathological hallmark by cell and animal models may not only validate calpains as a mediator 
of neurodegeneration in general but also represent a relevant evaluation or selection criterion 
for appropriate disease models. 
To reliably ascertain calpain activity in cell lines and tissues, various molecular indicators can 
be utilized. An indirect approach is measuring the turnover of artificial fluorescent calpain 
substrates, which alter their emission properties upon cleavage (Rosser et al., 1993; Tompa 
et al., 2004). This method allows for tracking calpain activity even in living cells, but is 
currently limited to in cellulo experiments (Rosser and Gores, 2000; Niapour and Berger, 
2007; Farr and Berger, 2010). Second, as calpains feature many cellular substrates, an 
increased or reduced activity will lead to changes in the breakdown of these proteins. These 
substrates and their proteolytic fragments can be assessed by immunodetection-based 
methods like western blotting or immunohistochemistry. A well described and characterised 
calpain substrate is α-spectrin, a cytoskeletal protein in eukaryotes, which lines the 
intracellular side of the plasma membrane. Calpain cleavage results in the formation of a 
145 kDa and a 150 kDa fragment and neo-epitope antibodies directed against the cleavage 
site can specifically detect the occurring fragments. Interestingly, α-spectrin is also a 
substrate for caspases. However, proteolysis by the latter enzymes produces fragments of 
120 kDa and 150 kDa. Thus, comparison of the fragmentation pattern can help to 
differentiate between calpain and caspase activation (Wang et al., 1998; Warren et al., 2005; 
Z. Zhang et al., 2009). A substantial neuronal target of calpain cleavage is the cyclin-
dependent kinase 5 (CDK5) activator 1, also known as p35. Calpains mediate the conversion 
of p35 to p25, which is not only an indicator of calpain activation but can also lead to a 
pathological deregulation of CDK5 activity, a characteristic in AD (M. S. Lee et al., 2000; 
Taniguchi et al., 2001). Finally, a third strategy is the direct immunodetection of calpains and 
their endogenous inhibitor CAST. Changes in CAST levels can give evidence about the 
inhibitory state of the calpain system. Decreased amounts of CAST can be due to lower 
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expression or increased turnover as CAST acts as a suicidal substrate and is also cleaved 
by caspases (Wang et al., 1998; Kim et al., 2007; Rao et al., 2008). Likewise, expression 
levels of calpains can be analysed, but changes may not directly correlate with activity of the 
calpain system. Calpain-1 and calpain-2 were shown to undergo autoproteolysis, which can 
be detected by western blotting. For calpain-1, cleavage events at the protein’s N-terminus 
lead to a transition from an 80 kDa full-length enzyme, via a 78 kDa intermediate, to a 
75 kDa species (Michetti et al., 1996). Despite previous assumptions and unlike the 
proteolytic activatory processing of caspases, autoproteolysis of calpains was shown to be 
irrelevant for enzyme activation (Li et al., 2004; Campbell and Davies, 2012). However, as 
this process is a concomitant of protease activity, it is frequently used to evaluate calpain 
activation (Gafni and Ellerby, 2002; Yamashita et al., 2012; Diepenbroek et al., 2014). 
Based on these preliminary considerations, this work utilized western blotting and 
immunohistochemistry to analyse the activation and the cellular distribution of members of 
the calpain system, respectively. As primary markers, calpain-1 processing, CAST protein 
levels, and α-spectrin cleavage were detected. For neuronal tissues, cleavage of p35 was 
additionally investigated. Only a comparative analysis of all aforementioned proteins assures 
a robust judgement on calpain activation in cell and animal models of HD and SCA3. 
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Calpain activation in cell models of HD and SCA3 
(Covered in Unpublished project manuscript A; Weber et al., 2017) 
Cell lines and primary cells constitute a versatile, reproducible and relatively easy-to-use tool 
to investigate biological processes outside of the complexity of a multicellular tissue or 
organism. Therefore, first analyses on the calpain system were pursued in cell models of HD 
and SCA3. Protein lysates were assayed to detect expression and activation of 
representative calpain isoforms, levels of the endogenous inhibitor CAST and cleavage of 
the calpain substrate α-spectrin. 
For HD, immortalised striatal precursor cell lines (STHdh) and murine embryonic fibroblasts 
(MEFHdh) were utilised, which are both derived from HdhQ111 knock-in (HDKI) mice and 
respective wild type littermates (Wheeler et al., 1999; Trettel et al., 2000; Walter et al., 2016). 
The mutant STHdhQ111 cell line exhibited increased expression of full-length calpain-1 but 
reduced levels of full-length calpain-2 and -10 compared to wild type STHdhQ7 cells. Total 
amounts of CAST appeared unchanged. However, a putative breakdown product was 
increased in STHdhQ111 cells. Likewise, calpain cleavage-derived fragments of α-spectrin 
showed higher levels in the mutant cell line. Also of note is an elevation in α-spectrin full-
length levels. A qualitatively increased calpain-mediated fragmentation of α-spectrin has 
been described before (Paoletti et al., 2008). However, previous studies did not comment on 
alterations in full-length levels of α-spectrin (Trettel et al., 2000; Paoletti et al., 2008; Xifró et 
al., 2008).  
Comparative analyses were subsequently performed for MEFHdh. Analogous to the situation 
in STHdh, MEFHdhQ111 exhibited an overall activation of the calpain system featuring 
elevated levels of autoprocessed calpain-1, full-length calpain-2 and the calpain-dependent 
α-spectrin breakdown product. However, the observed effects did not reach statistical 
significance. This might be explained by the origin of embryonic fibroblasts, which usually 
represent a non-neuronal and heterogeneous population of mesenchymal cells (Singhal et 
al., 2016). Nevertheless, further affirmative investigations on this fibroblast cell lines 
regarding calpain activation should be undertaken, in particular, as MEFs are commonly 
used as a reliable primary cell model in HD research. 
In addition, both STHdh cells and MEFHdh were immunocytochemically stained for 
calpain-1. Qualitative microscopy analysis confirmed the stronger expression of calpain-1 in 
STHdhQ111 cells as observed before by western blotting. Interestingly, calpain-1 signals 
showed a distinct subcellular distribution. Double labelling together with mitochondrial 
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translocase of outer membrane 20 (TOM20) revealed an entire colocalisation of calpain-1 
with mitochondrial structures, which complies with previous findings on a mitochondrial 
targeting signal at the enzyme’s N-terminus (Badugu et al., 2008). 
Finally, calpain activation was explored in an immortalised human fibroblast (iHF) cell line of 
SCA3. These fibroblasts are derived from skin biopsies of an SCA3 patient and a healthy 
control, which were transduced using the Simian virus 40 (SV40) (Pipas, 2009). The calpain 
system of iHFs was investigated in relationship with calpain-mediated cleavage of ataxin-3. 
Although the administration of the calpain-specific inhibitor III reduced overall calpain 
activation and ataxin-3 cleavage, there was no difference between SCA3 patient and control 
cell lines in baseline calpain-1 autoprocessing, CAST levels or α-spectrin cleavage. In 
contrast to this observation, rat cerebellar granule neurons overexpressing polyQ-expanded 
ataxin-3 were reported to exhibit a slightly increased calpain-mediated α-spectrin cleavage 
compared to cells expressing the wild type protein (Simões et al., 2014). The lack of calpain 
overactivation in iHFs may be attributed to the strong molecular perturbations caused by their 
neoplastic character (Geraghty et al., 2014). Therefore, further specific and conclusive 
research on calpain activation, especially in SCA3 patient-derived cell lines, is necessary, as 
current studies on calpain-dependent ataxin-3 cleavage in fibroblasts or iPSCs have omitted 
this pathomolecular aspect (Koch et al., 2011; Hansen et al., 2016). 
The expression of mutant huntingtin in two investigated cell lines apparently caused elevated 
calpain activation, emphasizing the disease-related perturbation of this proteolytic system. 
Similar corroborative observations have been already described by other researchers, who 
analysed in vitro models of HD based on Neuro2a and PC6.3 cell lines, STHdh cells or 
cultured MSNs. On the other hand, no alterations in calpain activity were observed in 
immortalised SCA3 fibroblasts. Nevertheless, additional investigations on further SCA3 cell 
lines are demanded. The correct assessment of calpains in cell models of polyQ diseases 
can be conducive to reproduce and investigate the molecular aspects of these disorders. 
Furthermore, only selection of appropriate cell lines provides the basis for successfully 
testing calpain-targeting strategies as a therapeutic approach in vitro. 
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Calpain activation in animal models of HD  
(Covered in Unpublished project manuscript B; Clemens et al., 2015; Weber et al., 2016) 
In vivo models of human diseases do not only help to recapitulate pathological conditions for 
analysing their aetiology, they also serve as a means for screening and testing 
therapeutically promising interventions, which - not only from an ethical aspect - cannot be 
primarily tested in humans. Several, mainly rodent models have been developed and 
characterized for HD and SCA3, which, with certain limitations and variations, reproduce the 
known behavioural and molecular aspects of both diseases (Matos et al., 2011; Pouladi et 
al., 2013). To determine the role of calpain activation in disease-relevant tissues, three 
animal models of HD were analysed in this study: HDKI mice, YAC128 mice and BACHD 
rats (Wheeler et al., 1999; Slow et al., 2003; Yu-Taeger et al., 2012). 
HDKI mice represent a knock-in model carrying a chimeric murine huntingtin gene (Hdh), 
whose first exon was replaced by the human HTT exon 1 with 109 CAGs. The physiological 
expression of mutant huntingtin on an endogenous level resembles more the genetic 
condition in HD patients, and leads to a slow progressive phenotype with late gait 
abnormalities and mainly striatal nuclear huntingtin aggregation, which starts between 4 and 
6 months of age (Wheeler et al., 1999; Menalled, 2005). Therefore, the investigations on the 
calpain system were performed in striatal and cortical tissues of mice at 6 months of age 
using western blotting. Examination of calpain-1 autoprocessing and α-spectrin cleavage 
revealed an overactivation of the calpain system, which was interestingly restricted to HDKI 
striatum. By contrast, calpain activity and α-spectrin cleavage in cortex showed a trend 
towards reduction. It cannot be ruled out that with disease progression and spreading 
damage of adjacent neuronal tissues, increased calpain activation might be detected also in 
additional brain regions. However, respective analyses in HDKI mice at later time points are 
pending. Corresponding to this work, a previous study on HDKI mice featuring 150 CAGs 
and an aggravated phenotype showed an elevated, mutant huntingtin dose-dependent 
calpain activation, which was not only present in striatum but also cortex (Gafni et al., 2004). 
A second analysis was pursued in YAC128 mice, a yeast artificial chromosome (YAC)-based 
transgenic mouse model which carries the entire human HTT gene with 128 CAGs. This 
animal model features a motor phenotype beginning at 6 months, striatal neuronal loss by 9 
months and nuclear aggregation detectable by 12 months (Slow et al., 2003; Pouladi et al., 
2012). Investigations were performed on striatal and cortical lysates at presymptomatic 
stages (6 weeks) and on lysates and histological sections at symptomatic stages with 12 
months of age. Despite covering two brain areas, two distinct time points and a palette of 
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different calpains and calpain substrates, YAC128 mice did not show any strong alterations 
of the calpain system as detected by western blotting. A clear calpain overactivation was 
neither present at 6 weeks of age nor at 12 months, which was demonstrated by unchanged 
levels of calpain-1, -2, -5, and -10. At 6 weeks of age, CAST levels, calpain-dependent 
cleavage of α-spectrin and p35-to-p25 conversion were comparable between wild type and 
transgenic animals. However, at 12 months of age, expression of CAST was significantly 
increased in YAC128 striatum. This was accompanied by a trend towards reduced calpain 
levels and substrate cleavage, pointing to a general attenuation of the calpain system. 
Qualitative immunofluorescence microscopy of brain sections at 12 months confirmed 
findings obtained by western blotting. These observations stand in contrast with previous 
reports on YAC128 animals, which demonstrated an increased calpain activation by elevated 
cleavage of α-spectrin, NMDA receptors or striatal-enriched protein tyrosine phosphatase 61 
in presymptomatic 1- to 2-month-old transgenic mice (Cowan et al., 2008; Gladding et al., 
2012, 2014). An age-dependent attenuation of calpain activation has been reported for 
YAC128 mice at 4 and 12 months of age, which does not explain the herein described 
findings in 6-week-old animals (Dau et al., 2014; Gladding et al., 2014). 
Lastly, the in-house BACHD rat model was included in the analyses of the calpain system. 
This rodent model features a bacterial artificial chromosome (BAC)-based transgene, which 
encompasses the entire human HTT gene with 97 CAG/CAA repeats, but with shorter 
adjoining up- and downstream sequences than the YAC-based HTT construct. BACHD rats 
show a motor phenotype after 1 month, reduced brain volume by 12 month, and neuropil 
aggregates with a mainly cortical localisation by 3 months (Yu-Taeger et al., 2012). The 
calpain system of BACHD rats was investigated by western blotting of cortical and striatal 
lysates obtained at 13 months of age. In opposition to observations in HDKI mice, striatum of 
BACHD rats did not feature any elevation in calpain activation compared to wild type 
animals. However, a clear overactivation of calpains was present in BACHD cortex, as 
detected by increased autoprocessing of calpain-1, decreased CAST levels and raised α-
spectrin cleavage. It is noteworthy that the examination of heavy membrane fractions, 
isolated from cerebral hemispheres and enriched for mitochondrial and ER proteins, revealed 
the occurrence of calpain-1, CAST and α-spectrin, but without presenting differences in 
calpain activation. This finding suggests that the manifestation of calpain activation is rather 
limited to the cytosol or nucleus, excluding mitochondria and the ER. The specificity of 
calpain activation in cortex but not striatum correlates with the rather cortical accumulation of 
huntingtin aggregates despite equal expression of the mutant protein in both tissues (Yu-
Taeger et al., 2012). This might represent a characteristic of the BACHD rat model. In this 
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context, further analyses at earlier and later time points might help to identify time-dependent 
differences in the tissue specificity of calpain activation. In addition, a comparative 
exploration of the calpain system in the BACHD mouse model of HD, which is grounded on 
the identical transgene construct as the BACHD rat, can be useful to evaluate the transgene- 
and animal model-dependent variations in calpain overactivation (Gray et al., 2008). 
In total, two of three analysed HD animal models were showing a clear calpain overactivation 
in disease-affected brain tissues. HDKI mice exhibited a rather striatal and BACHD rats a 
cortical activation of calpains. However, further analysis of additional tissues at further time 
points might contribute to the discrimination of the overall activation pattern in these animal 
models. The general overactivation of the calpain system is in line with previous studies in 
knock-in and YAC128 mice (Gafni et al., 2004; Cowan et al., 2008; Dau et al., 2014). The 
reinvestigation of YAC128 in this study did, surprisingly, not recapitulate the previous reports. 
This might be attributed to different factors such as artefacts of strain backgrounds and 
inbreeding, which are known to modulate the manifestation of disease phenotypes, and 
demands further investigations (Lloret et al., 2006; Yoshiki and Moriwaki, 2006; Ehrnhoefer 
et al., 2009). The principally well-documented participation of calpains in the molecular 
pathogenesis of HD points to a putatively altered activation of these proteases in the context 
of SCA3. However, the precise assessment of calpain activation is outstanding except for 
reports on decreased CAST levels in SCA3 mice and post-mortem patient tissue (Simões et 
al., 2012). Future work on SCA3 models based on the methodology applied in HD research 
will complete our understanding of calpain activation and therapeutic targetability in polyQ 
diseases. 
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Amplifying calpain activity by genetically depleting calpastatin 
(Covered in Unpublished project manuscript C; Hübener et al., 2013) 
Several studies including the current work demonstrated an involvement of calpains in the 
molecular pathogenesis of HD and SCA3. Calpains were shown to proteolytically cleave the 
disease proteins huntingtin and ataxin-3 and to be upregulated in the disease context (Gafni 
and Ellerby, 2002; Gafni et al., 2004; Haacke et al., 2007; Cowan et al., 2008; Koch et al., 
2011; Simões et al., 2012). A sophisticated way to further dissect the underlying pathway 
and to evaluate the contribution of these enzymes to the respective aetiology is the 
manipulation of the calpain system by molecular biological strategies. A commonly used 
target in this connection is CAST, the only known endogenous inhibitor of calpains. 
Modulation of CAST expression can alter calpain activity and thereby its impact on the 
molecular pathogenesis. Several studies have shown that overexpression of CAST leads to 
a reduction of disease protein fragmentation, aggregation and toxicity in cell and animal 
models of HD and SCA3 (Haacke et al., 2007; Reijonen et al., 2010; Simões et al., 2012; 
Menzies et al., 2014). To investigate the impact of CAST ablation and the herewith provoked 
amplification of calpain activity on polyQ diseases, two animal models were generated which, 
besides expression of the mutant polyQ protein, feature a genetic knockout of CAST. 
For modelling this genetic situation in HD, HDKI animals were crossbred with a Cast-/- 
knockout mouse model (Takano et al., 2005). To assess firstly the molecular outcome of the 
knockout, wild type and Cast-/- mice were sacrificed at 10 months of age and whole brain 
lysates were investigated regarding the activation of the calpain system by western blotting. 
As expected, Cast-/- showed generally elevated calpain system activation, which was 
represented by an increase of autoprocessed calpain-1 and an elevated cleavage of α-
spectrin and p35. To evaluate the consequences of amplified calpain activation on mutant 
huntingtin, double mutant animals and their respective controls were sacrificed at 13 months 
of age. Whole brain lysates and homogenates were subjected to biochemical analysis for 
detection of calpain activation, huntingtin fragmentation and the aggregate load. Consistent 
with findings in mice at 10 months, 13-month-old Cast-/- and HDKI/Cast-/- mice exhibited an 
increased calpain activation when compared to wild type or HDKI controls. This 
overactivation led to a stronger fragmentation of wild type and polyQ-expanded huntingtin 
and to a higher amount of huntingtin aggregates. As fragments of huntingtin were shown to 
be more aggregation-prone, these findings are self-consistent (Hackam et al., 1998; 
Martindale et al., 1998; Gafni et al., 2004). However, calpains are known to negatively 
regulate autophagy, and the enhanced calpain activation might lead to reduced autophagic 
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flux and impaired aggregate removal (Yousefi et al., 2006; Williams et al., 2008; Russo et al., 
2011). This could increase the occurrence of huntingtin deposits in a fragmentation-
independent manner. In this context, an opposite effect of increased autophagy by CAST 
overexpression was described in a fragment model of HD, which resulted in reduced 
aggregation and polyQ toxicity (Menzies et al., 2014). To assess the impact of the genetic 
CAST depletion on autophagy, levels of the marker proteins LC3-II and p62 were detected. 
Interestingly, levels of LC3-II showed rather an increase and levels of p62 a decrease in 
Cast-/- and HDKI/Cast-/- mice, which actually point to an increased autophagic flux or at least 
hint at perturbations of autophagy in these animals (Mizushima and Yoshimori, 2007). To 
analyse effects on the dysfunction of dopaminergic neurons in HDKI/Cast-/- mice, expression 
of dopamine- and cAMP-regulated neuronal phosphoprotein-32 (DARPP-32), a marker for 
dopaminergic neurons such as the HD-affected MSNs, was investigated by western blotting. 
Full-length levels of DARPP-32 dropped not only as expected in HDKI but also in 
Cast-/- mice. However, this effect was not further enhanced in HDKI/Cast-/- animals. Although 
the loss of DARPP-32 can be indicative of a demise of respective neurons, calpains were 
shown to cleave this protein and hereby additionally contribute to reduced DARPP-32 full-
length levels (van Dellen et al., 2000; Jiang et al., 2012; Cho et al., 2015). 
For SCA3, Cast-/- animals were crossbred with mice overexpressing the cDNA of ataxin-3 
isoform 2 (UniProt identifier: P54252-2) with 148 CAGs under the murine prion protein 
promoter. The SCA3 mouse model is characterised by early neurological symptoms starting 
at 2 months, a decreased life span and widespread intranuclear inclusions in all brain regions 
(Bichelmeier et al., 2007). In contrast to analyses pursued in HDKI/Cast-/- animals, 
investigations on SCA3/Cast-/- mice mainly focused on the behavioural and neuropathological 
phenotype, two aspects which are still pending for modelling CAST depletion in the HD 
background. SCA3/Cast-/- animals showed an exacerbated phenotype regarding their motor 
performance as assessed by rotarod test and a trend towards decreased life span when 
compared to SCA3 mice. Furthermore, neuropathological analysis using toluidine blue 
staining of cerebellar sections revealed an increased number of atrophic and degenerated 
neurons in SCA3/Cast-/- mice. Cast-/- and wild type mice, on the other hand, did not show any 
neuronal degeneration. Also, the aggregate load was strongly enhanced in double mutant 
animals, correspondent with findings in HDKI/Cast-/- mice. Interestingly, ex vivo calpain 
activation assays demonstrated that the lack of CAST in lysates of SCA3/Cast-/- led to an 
intensified cleavage of ataxin-3, which might be considered as an indicator of the ongoing 
physiological processes in vivo. 
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The comparable observation of aggravated molecular, histological or behavioural 
phenotypes in HD and SCA3 caused by the genetic depletion of CAST is an important 
evidence for calpains as mediators of polyQ-dependent toxicity and neurodegeneration. It 
should be kept in mind that the knockout of CAST itself might cause a detrimental phenotype 
aside from the polyQ disease context. However, except for a decreased locomotor activity in 
stressful environments and impaired auditory startle response, Cast-/- mice did not exhibit 
negative effects regarding development, fertility or life span when compared to wild type 
animals. Interestingly, Cast-/- mice were shown to be more susceptible to kainate-induced 
excitotoxicity and thus suggesting CAST as a negative regulator of calpains under 
pathological conditions (Takano et al., 2005; Nakajima et al., 2008). Further behavioural 
analyses in HDKI/Cast-/- animals and molecular analyses in their SCA3 counterpart can help 
to complete the picture of the calpain-mediated pathogenesis and to draw conclusions about 
the molecular situation in other polyQ diseases. 
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Summary and outlook 
The activation of the calpain system has been investigated thoroughly in cell and rodent 
models of HD and SCA3 (TABLE 1). In addition to baseline measurements, further in vivo 
analyses were performed in disease models which exhibited a genetic knockout of the 
endogenous calpain inhibitor CAST. Despite inconclusive results in YAC128 mice and SCA3 
iHF cell lines, the general outcome of these investigations emphasises the important 
contribution of calpains to the molecular pathogenesis of both polyQ disorders and is 
consistent with previous findings. The herein undertaken research was, however, not 
exhaustive and is leaving further aspects unanswered, which can be employed as starting 
points for subsequent studies. The most interesting and important remaining questions are 
first, the further elucidation of a baseline calpain overactivation in cell and animal models of 
SCA3, and second, a more precise dissection of calpains’ general role in autophagy 
regulation. Especially the latter subject can be useful for understanding the autophagy 
dysregulation in neurodegenerative disorders and thereby for developing additional treatment 
strategies. 
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Table 1. The calpain system in cell and rodent models of HD and SCA3. Summary of findings on 
the calpain system in polyQ disease models obtained in this study. ms = mouse; rt = rat; huc = human 
cell line; msc = mouse cell line, light blue = HD; dark blue = SCA3; ↑ = upregulation; ↓ = 
downregulation; ↕ = unchanged; () = tendency; ctx = only in cortex; str = only in striatum; * = global; # = 
knockout effects relative to baseline; n/a = not available. 
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Modulation of calpain activity as a therapeutic approach 
Preliminary considerations 
Since overactivation of calpains as well as calpain-mediated fragmentation of disease 
proteins evidentially contribute to the molecular pathogenesis of neurodegenerative 
disorders, specific inhibition of these enzymes might represent a promising therapeutic 
target. As discussed earlier, several approaches are conceivable to reduce calpain activity, 
which include the application of specific inhibitors, the administration of compounds which 
influence activating pathways, and genetic approaches which eliminate calpain isoforms or 
overexpress calpain inhibitor CAST (Ono et al., 2016). 
Although these options can be easily tested in the field of biomolecular research, translation 
into clinics is strongly limited to factors such as safety, efficacy and costs. In particular, highly 
promising gene therapies for neurodegenerative disorders of the CNS are still in early stages 
of development, despite a great technological progress and successful proofs of concept in 
the last twenty years (Simonato et al., 2013; O’Connor and Boulis, 2015). For this reason, 
efforts must be intensified to allow this therapeutic strategy to be applied in the next decades. 
To bridge the gap between the current state of research and the future, it is important to 
make use of available pharmacological possibilities for treating neurodegenerative diseases. 
Although many calpain-targeting drugs are under preclinical or early clinical research, none 
of those has yet reached clinical applicability which might be also due to general limitations in 
translational research or obstacles in drug delivery (Jucker, 2010; Lang, 2010; Upadhyay, 
2014; Ono et al., 2016). 
To evaluate calpain inhibition as a treatment strategy in this study, conventional inhibitors 
and olesoxime, a potential mitochondria-specific modulator of calpain-activating pathways, 
were tested in cell and animal models of HD and SCA3. Molecular effects of these 
compounds were monitored by measuring calpain activation as well as disease protein 
cleavage and aggregation. In vivo trials additionally comprised an assessment of the 
pharmacological impact on the behavioural phenotype. Aside from drug-based studies, a 
genetical approach targeting calpain-1 was investigated in an SCA3 mouse model. 
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Inhibition of calpains in cell models of HD and SCA3 
(Covered in Unpublished project manuscript A and E; Weber et al. 2017) 
The most direct way to reduce calpain activation is the treatment with specific inhibitors. In 
the current work, three inhibitors were tested in cell-free and cell-based models of HD and 
SCA3, namely ALLN (N-acetyl-L-leucyl-L-leucyl-L-norleucinal), calpain inhibitor III (CI III) and 
PD150606. ALLN, also known as calpain inhibitor I, is a cell-permeable peptide aldehyde 
inhibitor of calpains with a certain affinity to cathepsins (Saito et al., 1987; Hiwasa et al., 
1990). CI III, also known as MBL-28170, is a synthetic, cell-penetrating inhibitor of calpains, 
but like ALLN also of cathepsins (Mehdi et al., 1988; Mehdi, 1991). On the contrary, the 
alpha-mercaptoacrylic acid derivative PD150606 constitutes an non-active site-binding 
allosteric calpain inhibitor (Wang et al., 1996). 
In the HD context, calpain inhibitors ALLN and CI III were shown to reduce calpain-mediated 
cleavage of wild type and mutant huntingtin. The parallel incubation with these inhibitors 
abolished the formation of huntingtin fragments upon administration of exogenous calpains 
or when activating endogenous calpains by CaCl2 addition to lysates. In cell-based 
experiments, preincubation of HEK 293T cells with CI III counteracted the Ca2+-ionophore 
ionomycin-facilitated calpain activation and fragmentation of substrates α-spectrin and 
huntingtin. To investigate the protective effects of calpain inhibition in HD cell lines, viability 
of STHdhQ111 cells treated with ALLN or PD150606 was measured using a resazurin-based 
approach. Both inhibitors significantly improved cell viability of the mutant cell line, which was 
previously found to exhibit a calpain overactivation when compared to wild type STHdhQ7 
cells. On the other hand, treating the STHdhQ7 line with the same inhibitors led to a reduction 
of their vitality, pointing to detrimental effects of reducing a non-pathological calpain activity. 
These observations regarding beneficial effects of calpain inhibition by ALLN accord to 
previous findings in other HD studies, which employed PC6.3 cells or cultured MSNs (Cowan 
et al., 2008; Reijonen et al., 2010). However, calpain inhibition in a PC12 cell line of HD was 
also shown to provoke negative effects as this might compromise a calpain-mediated 
clearance of mutant huntingtin (Ratovitski et al., 2007). 
Comparable to the afore-described effects of calpain inhibition in HD cell lines, administration 
of ALLN or CI III exerted beneficial effects on calpain-mediated ataxin-3 cleavage in SCA3 
cell lysates. Likewise, CI III blocked wild type and polyQ-expanded ataxin-3 fragmentation in 
HEK 293T and iHF cell lines treated with ionomycin and showed that the detected 
predominant ataxin-3 fragments are all calpain cleavage-derived. Despite lacking a baseline 
overactivation between patient- and healthy control-derived cell lines, CI III-treated iHF cells 
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showed in addition to reduced ataxin-3 cleavage an attenuated fragmentation of α-spectrin 
and elevated levels of CAST. Especially the latter marker is reportedly reduced in SCA3 
mouse brains and post-mortem patient brain tissue, suggestive of a calpain overactivation-
dependent depletion of CAST in SCA3 pathogenesis (Simões et al., 2012). Consistent with 
the results covered above, ALLN has been previously shown to prevent calpain-dependent 
cleavage of ataxin-3 in cell-free assays. Inhibitors like calpeptin and BDA-410 reduced 
calpain activation as well as mutant ataxin-3 fragmentation and aggregation in N2a cell lines 
or cultured rat cerebellar granule cells (Haacke et al., 2007; Simões et al., 2014). 
Considering that analysis on further disease hallmarks like polyQ protein aggregation are still 
due, targeting calpains with inhibitors resulted in promising effects, i.e. lower calpain 
activation, disease protein cleavage and viability in cell models of two polyQ diseases. These 
observations accord with findings from studies utilising cell culture or ex vivo models not only 
of HD and SCA3 but also of other neurodegenerative disorders such as AD, ALS or PD 
(Samantaray et al., 2006; Haacke et al., 2007; Cowan et al., 2008; Nimmrich et al., 2010; 
Gladding et al., 2012; Yamashita et al., 2012; Gold et al., 2015). Most importantly, further 
investigations have already applied specific calpain inhibitors in vivo with a largely positive 
outcome for prevention of neurodegeneration in multiple animal models (Trinchese et al., 
2008; Saatman et al., 2010; Simões et al., 2014; Samantaray et al., 2015). However, chronic 
calpain inhibition has been also associated with diverse detrimental repercussions which 
might be due to impairments of the healthy physiological function or to side-effects, attributed 
to the lack of a specificity (Ono et al., 2016). Therefore, continuing research on calpains and 
respective drug development is necessary. Novel molecules, like the α-ketoamide-based 
inhibitor A-705253 or its derivative ABT-957 as well as epoxide-based inhibitors such as 
NYC438 or NYC488, which have been already tested in AD research, might represent a 
subsequent step in the clinical applicability of pharmacological calpain inhibition (Lubisch et 
al., 2003; Trumbeckaite et al., 2003; Nikkel et al., 2012; Fà et al., 2015). On the other hand, 
focusing on calpain activating pathways might constitute an alternative approach, which 
circumvents the pitfalls of directly acting on calpains. 
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Calpain suppression by the VDAC1-targeting compound olesoxime in vivo  
(Covered in Clemens et al. 2015; Weber et al. 2016) 
Calpain overactivation in neurodegeneration might be a consequence of a pathological Ca2+ 
dyshomeostasis. In HD and SCA3, this cellular condition has been attributed to three 
different derangements: 1. PolyQ-expanded huntingtin or ataxin-3 have been shown to 
directly bind to the ER-located Ca2+ channel IP3R1, which causes its sensitization to 
activation by IP3 and the release of Ca2+ to the cytosol (Tang et al., 2003; Chen et al., 2008; 
Bezprozvanny, 2011). 2. Mutant huntingtin has been also reported to facilitate Ca2+ influx by 
enhancing NMDA receptor activity and thereby sensitise neurons to NMDA receptor-
mediated excitotoxicity (Zeron et al., 2002; Tang et al., 2005; Shehadeh et al., 2006). 3. 
Finally, mitochondria, which represent an important Ca2+ buffering compartment, are 
impaired in HD and SCA3 and their dysfunction may contribute to pathologically elevated 
cytosolic Ca2+ levels (Milakovic et al., 2006; Oliveira et al., 2006; Yu et al., 2009; Laço et al., 
2012). Therefore, targeting one of these dysfunctional elements might consequently 
attenuate the excessive activation of calpains. 
The HD-related mitochondrial impairment, its repercussion on the neuronal health and 
consequences on the behavioural phenotype were in the focus of a longitudinal therapeutic 
study, which applied the experimental, neuroprotective drug olesoxime. This cholesterol-
derivative, also known as TRO19622, has been identified in a cell-based drug screen for 
compounds counteracting ALS-associated motor neuron death. Olesoxime localises at the 
outer mitochondrial membrane, where it binds two components of the mitochondrial 
permeability transition (mPT) pore, the voltage-dependent anion channel (VDAC) and the 
translocator protein (TSPO) (Bordet et al., 2007). The compound has demonstrated 
therapeutic efficacy in cell and animal models of ALS, peripheral neuropathy, spinal muscular 
atrophy (SMA), and α-synucleinopathies (Bordet et al., 2007, 2008, 2010, Xiao et al., 2009, 
2012; Sunyach et al., 2012; Richter et al., 2014; Gouarné et al., 2015). Olesoxime’s 
neuroprotective function has been shown to be exerted via inhibition of mPT-mediated 
apoptosis and by promoting remyelination of neurons (Martin et al., 2011; Magalon et al., 
2012). Furthermore, in STHdhQ111 cells, isolated mitochondrial membranes of HDKI mice, 
and BACHD rats, olesoxime was shown to restore the pathologically increased mitochondrial 
membrane fluidity (Eckmann et al., 2014). 
To further assess olesoxime’s therapeutic value in an HD animal model, the drug was 
administered to BACHD rats via the food from 5 weeks to 13 months of age. Subsequent 
analyses comprised behavioural tests as well as metabolic and neuropathological 
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measurements. Moreover, primary molecular investigations included expression profiling of 
mitochondrial proteins and the assessment of huntingtin protein and aggregation levels. 
Analysis of the BACHD rat motor phenotype confirmed previously reported impairments as 
shown by hind limb clasping and rotarod performance, but without detecting any 
improvements upon olesoxime administration (Yu-Taeger et al., 2012). On the other hand, 
simple swim test and elevated plus maze demonstrated an amelioration of HD-reminiscent 
cognitive and psychiatric abnormalities by the treatment. Moreover, MRI scans of olesoxime-
treated rats detected reduced cortical thinning but without reducing overall cerebral or striatal 
atrophy when compared to the placebo group. 
Immunohistochemical analysis showed reduced amounts of mutant huntingtin aggregation 
and nuclear accumulation in cortex, hypothalamus, thalamus and amygdala of olesoxime-
treated rats. Detergent-insoluble species of the disease protein were reduced in both cortex 
and striatum as shown by filter retardation assays. Interestingly, protein quantification via 
time-resolved Förster resonance energy transfer (TR-FRET), a method based on the energy 
transfer between fluorophores coupled to two target-specific antibodies, found that soluble 
levels of mutant huntingtin appeared to be elevated upon treatment. This was also confirmed 
by increased levels of full-length huntingtin via western blotting. Remarkably, this effect was 
accompanied by a strongly reduced mutant huntingtin fragmentation in cortex and striatum of 
treated BACHD rats. As caspases and calpains are known to cleave mutant huntingtin, both 
proteolytic systems were examined for their activation. Although caspases 3 and 6 showed 
no changes in expression or activity, the calpain system activation was significantly elevated 
in cortex of BACHD rats compared to wild type animals. This overactivation was significantly 
alleviated upon administration of olesoxime as detected by reduced calpain-1 
autoprocessing, lower α-spectrin cleavage and increased levels of CAST. 
Interestingly, olesoxime also reduced the activity of calpains in cerebral heavy membrane 
fractions enriched for mitochondrial and ER proteins, despite lacking a genotype-specific 
difference at baseline. Further investigations on mitochondria of olesoxime-treated rats, 
showed a reduced HD-related mitochondrial respiration deficit, increased levels of 
mitochondrial fusion proteins such as mitofusin-1 and -2 and elevated levels of TOM20. As 
olesoxime is known to bind VDAC and this protein is involved in ER-mitochondrial Ca2+ 
shuttling via an mortalin/grp75-bridged interaction with IP3R, respective protein levels of both 
Ca2+ channels were investigated (Szabadkai et al., 2006). The expression of VDAC1 and 
VDAC2 was markedly increased in olesoxime-treated wild type and BACHD cortex and in 
BACHD striatum. Baseline levels of IP3R1 were elevated in cortex of BACHD rats, and 
reduced to wild type levels upon treatment. Overall, these findings suggest an olesoxime-
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mediated improvement of mitochondrial function and neuronal Ca2+ handling, which 
attenuates the Ca2+-dependent calpain overactivation. The lower activity of calpains resulted 
in a mitigated formation of toxic and aggregation-prone huntingtin fragments and thereby in 
reduced huntingtin aggregation. The rather cortex-restricted beneficial impact of olesoxime, 
which did not only occur on molecular but also behavioural level, might be explained by the 
compound enrichment in the prefrontal and frontal cortex as detected by high-performance 
liquid chromatography. 
To verify the observed effects of olesoxime in a further animal model, the trials were 
repeated in HDKI mice. To achieve the earliest possible start of the treatment, olesoxime 
was already administered to parental animals during breeding. The offspring was further 
treated until 3 months of age. Subsequent analysis focused solely on the reinvestigation of 
molecular markers, which were found to be altered in treated BACHD rats. Western blot 
analysis of half brain lysates of untreated HDKI mice showed reduced levels of mutant 
huntingtin, accompanied by elevated huntingtin fragmentation. Similar to findings in BACHD 
rats at baseline, the activation of the calpain system was increased, which was substantiated 
by elevated α-spectrin cleavage and reduced CAST levels. Administration of olesoxime 
resulted in an attenuation of calpain overactivation and thus mutant huntingtin cleavage. 
Comparable, although not significant effects of the treatment were observed for IP3R1 and 
VDAC1 levels. Surprisingly, detergent-insoluble huntingtin species were already detectable 
in half brain homogenates of HDKI mice at 3 months of age. However, olesoxime did only by 
tendency reduce their amount. Following these observations, olesoxime exerted similar 
beneficial effects in HDKI mice and BACHD rats on the molecular level. Nevertheless, 
molecular but also behavioural investigations at later time points with a clear manifestation of 
HD phenotype are necessary to fully evaluate the therapeutic efficacy of olesoxime in the 
HDKI mouse model. 
The amelioration of the molecular and behavioural phenotype in two HD animal models by 
olesoxime revealed its potential as a therapeutic compound in the treatment of HD. This is 
encouraged by findings in phase I clinical studies, which showed that this experimental drug 
is well tolerated by human subjects (Martin, 2010). Furthermore, olesoxime is orally active 
and sufficiently crosses the blood brain barrier (Bordet et al., 2010). In end stage ALS 
patients, a combinatorial treatment of olesoxime with riluzole in a phase II-III clinical trial did 
not show a significant beneficial effect, despite being well tolerated (Lenglet et al., 2014). On 
the other hand, treatment of SMA patients at an early stage strikingly prevented loss of motor 
function for 2 years in a phase II clinical study (Dessaud et al., 2014; Bertini et al., 2017). 
Therefore, olesoxime might only reach efficacy at early disease stages, emphasising its 
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function as a disease-modifying compound. This idea is further supported by the herein 
described findings in BACHD rats whose treatment commenced at 5 weeks of age and thus 
after onset of the earliest symptoms. 
Aside from the apparent effects on mitochondrial function, levels of VDACs and IP3R1, and 
their consequences for the HD phenotype, olesoxime’s precise molecular mode of action 
remains elusive. Nevertheless, the direct modulation of VDAC activity and mitochondrial Ca2+ 
is highly conceivable. First investigations on the Ca2+ retention capacity of isolated 
mitochondria found no alterations by olesoxime administration (Bordet et al., 2010). 
However, this observation might be due to the experimental setup lacking the cellular and 
inter-organelle context of mitochondrial function. A neurodegenerative disease-modulating 
potential of VDAC has been shown earlier in an AD mouse model, where the heterozygous 
knockout of VDAC1 rescued mitochondrial function and synaptic deficiencies (Manczak et 
al., 2013). Generally, the VDAC1-mortalin/grp75-IP3R Ca2+ bridges between mitochondria 
and the ER are suggested to play a crucial role in neurodegeneration and represent a 
potential therapeutic target (Calì et al., 2012; Krols et al., 2016; Paillusson et al., 2016). 
Correspondingly, modulation of proteins like sigma-1 receptor or RyR which both additionally 
mediate the ER-mitochondrial Ca2+ flux were shown to ameliorate disease-linked 
perturbations in cell or animal models of HD and SCA3. (Hayashi and Su, 2007; Chen et al., 
2008, 2011; Hyrskyluoto et al., 2013; Del Prete et al., 2014). An additional, herein not further 
investigated contribution of the second identified target of olesoxime TSPO is also very likely, 
as it bears a VDAC activating function (Veenman et al., 2008; Gatliff and Campanella, 2012). 
Future research should therefore utilise pharmacological and genetical strategies to 
modulate both VDAC1 and TSPO. Comparison with olesoxime’s effects and the assessment 
of the Ca2+ buffering capacities of treated cells might give a deeper insight in the underlying 
molecular pathways. Finally and most importantly, due to its highly probable impact on Ca2+ 
homeostasis, olesoxime should be tested in cell and animal models of further 
neurodegenerative disorders, as it might represent a widely useful candidate for therapeutic 
interventions. 
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Reduction of ataxin-3 fragmentation by genetic ablation of calpain-1 in vivo 
(Covered in Unpublished project manuscript D) 
Aside from pharmacological interventions, genetic approaches can be applied for modulating 
calpain activity. Corresponding to the administration of compounds, which inhibit calpains, 
the overexpression of the endogenous inhibitor CAST was shown to reduce calpain 
overactivation and linked detrimental effects in cell and animal models of neurodegenerative 
disorders including ALS, HD, PD, SCA3, and tauopathies (Rao et al., 2008, 2014, 2016; 
Tradewell and Durham, 2010; Simões et al., 2012; Diepenbroek et al., 2014; Menzies et al., 
2014). Concurrently, this work showed that knockout of CAST exacerbates the molecular 
and behavioural phenotype in HD and SCA3 mice (Unpublished project manuscript C; 
Hübener et al., 2013). Based on the findings from the CAST knockout study in a SCA3 
mouse model, which additionally showed that calpain-1 is efficiently cleaving mutant ataxin-3 
and might thereby contribute to the formation of toxic and aggregation-prone fragments, the 
genetic ablation of calpain-1 emerged as a promising target for ameliorating the disease 
phenotype. 
To test this hypothesis, a transgenic SCA3 mouse model was crossbred with homozygous 
calpain-1 knockout mice. The employed SCA3 mice hemizygously carry a YAC-based 
construct encompassing the MJD1 locus with 84 CAGs. This model features gait 
disturbances by 4 weeks, distinct neuronal loss by 12 months and nuclear ataxin-3 
accumulation detectable by 8 weeks (Cemal et al., 2002; do Carmo Costa et al., 2013). 
Previous characterizations of calpain-1 knockout mice have shown an unaffected viability 
and fertility, except for certain disturbances in platelet function (Azam et al., 2001). For 
confirmation of the knockout and its consequences on the calpain system, brain and skeletal 
muscle lysates of 3-month-old wild type, calpain-1 knockout, SCA3 and double mutant 
animals were investigated using western blotting. The analysis showed a successful 
depletion of the calpain-1 protein which was accompanied by a reduced cleavage of α-
spectrin in both examined tissues. CAST levels were markedly elevated in knockout and 
double mutant animals, with the strongest increase detectable in skeletal muscle. Moreover, 
the conversion of neuronal p35 to p25 was significantly reduced due to the absence of 
calpain-1. Despite an at least conceivable compensation of the calpain system, solely the 
knockout of calpain-1 clearly reduced the overall activity, as demonstrated by the effects on 
substrate proteins. As expected, subsequent assessment of ataxin-3 cleavage in brain tissue 
revealed a reduced formation of endogenous and transgenic, polyQ-expanded ataxin-3 
fragments. Interestingly, levels of a larger fragment increased upon calpain-1 knockout 
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pointing to a sequential cleavage of ataxin-3 by this protease. The cleavage pattern of 
ataxin-3 in skeletal muscle, on the other hand, differed from the pattern observed in brain, 
which might be due to a divergent involvement of muscle-specific proteases. Furthermore, 
the knockout of calpain-1 did not distinctly change fragmentation of ataxin-3 in muscle tissue 
but showed a trend comparable to the effects in brain of calpain-1 knockout and double 
mutant mice. TR-FRET analysis of brain homogenates found that depletion of calpain-1 
resulted in elevated levels of total ataxin-3. This observation might be in line with the 
previously described age- and presumably calpain-dependent decrease of ataxin-3 levels in 
a second SCA3 mouse model (Hübener et al., 2013; Nguyen et al., 2013). It was also 
demonstrated, that a decrease in soluble ataxin-3 levels correlates with elevated amounts of 
mutant ataxin-3 aggregates in SCA3 mouse brain (Nguyen et al., 2013). Considering a 
reduced cleavage and increased soluble levels of ataxin-3, the impact of calpain-1 knockout 
on aggregate formation was investigated in a following step. Surprisingly, ataxin-3 
aggregation at 3 months of age appeared unchanged as detected using filter retardation 
assays, when comparing double mutant animals with SCA3 mice. In respect to these 
findings, additional investigations at a later time point are necessary to fully assess the 
impact of an calpain-1 knockout on fragmentation and aggregation of ataxin-3. 
Contrary to expectations for the here investigated genetic approach, recent research on 
calpain-1 null and missense mutations in humans and dogs as well as on the knockout in 
mice revealed that the absence of the protease causes an ataxic phenotype. This is 
accompanied by limp spasticity, abnormal cerebellar development, and impairments in 
metabotropic glutamate receptor-dependent long-term depression as well as fear memory 
extinction (Forman et al., 2013; Y. Wang et al., 2016; Zhu et al., 2017). The negative impact 
of a loss of calpain-1 is corroborated by behavioural data in double mutant animals, which 
show a worsening of the motor phenotype. 
Taken together, genetically targeting calpain-1 appears to be an inapplicable strategy for 
SCA3. An alternative could be focussing on calpain-2, whose homozygous knockout in the 
maternal placenta, on the other hand, was shown to cause embryonic lethality in mice 
(Takano et al., 2011). Even the widely investigated overexpression of CAST has been 
recently linked to perturbations in scar healing during myocardial infarction, which can 
provoke an increased mortality, and to a higher susceptibility to lethal spleen tumours in mice 
(Wan et al., 2015; Hanouna et al., 2017). On this account, the genetic modification of the 
calpain system as a therapeutic approach in neurodegenerative disorders should be only 
followed with special caution. 
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Summary and outlook 
Targeting calpains constitutes an auspicious therapeutic strategy for neurodegenerative 
diseases. This work has tested three different approaches for decreasing calpain activity in 
models of HD and SCA3 (TABLE 2): First, direct lowering of calpain activity by specific 
pharmacologic inhibitors in cell culture resulted in reduced calpain overactivation, disease 
protein fragmentation and improved cell viability in mutant cell lines. Second, indirect 
reduction of calpain activation by improving mitochondrial function and Ca2+ handling by the 
experimental drug olesoxime improved the molecular and behavioural phenotype in two 
animal models of HD. Last, the genetic ablation of calpain-1 attenuated the fragmentation of 
mutant ataxin-3 in an SCA3 mouse model. Although all three molecular concepts 
successfully achieved the primary objectives of attenuating global calpain activity and 
disease protein fragmentation, several issues need to be taken into consideration. 
Especially, application of calpain inhibitors is limited to their imperfect specificity, and 
knockout of calpain isoforms can lead to disturbances due to the loss of their vital 
physiological implications. Olesoxime emerged as a promising drug candidate, which is 
reemphasized by its simple applicability, pharmacologic tolerance and neuroprotective 
properties. However, further investigations are demanded to fully understand its molecular 
mode of action and to improve its efficacy. 
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Table 2. Targeting calpains in cell and rodent models of HD and SCA3. Comparison of pursued 
pharmacologic and genetic strategies. ms = mouse; rt = rat; huc = human cell line; msc = mouse cell 
line, light blue = HD; dark blue = SCA3; ↑ = upregulation; ↓ = downregulation; ↕ = unchanged; (p) = 
pharmacological approach; (g) = gene knockout; n/a = not available. 
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Characterisation of polyglutamine disease protein fragmentation by calpains  
Preliminary considerations 
The localisation of cleavage sites within a substrate protein can help to understand the 
physiological function of a protein and evaluate the repercussion of proteolytic events. In the 
special case of disease proteins like mutant huntingtin or ataxin-3, knowledge on the exact 
scissile bond allows not only for characterising the toxicity of emerging breakdown products 
but also for developing molecular strategies to therapeutically modulate proteolysis. 
A set of different technical approaches can be utilised to first narrow down and then precisely 
determine the amino acid position of the specific cleavage site. An initial step is the 
confirmation of substrate recognition and proteolysis by the respective enzyme. This can be 
done in pure in vitro approaches by incubating recombinant substrate proteins with enzymes, 
but also in a more physiological context by inducing protease activity in cell-based or ex vivo 
experiments. Hereafter, samples can be analysed by western blotting ideally applying a set 
of antibodies specific for different portions of the substrate protein. The comparison of 
cleavage patterns, regarding the presence of certain antibody epitopes in detected protein 
fragments, represents a reference point for cleavage site localisation. In combination with in 
silico prediction tools like the ExPASy PeptideCutter, observed cleavage events can be 
spatially limited to a selection of computed sites (Gasteiger et al., 2005). However, only 
methodologies based on Edman N-terminal sequencing or mass spectrometry of breakdown 
products are sufficient to determine the sequence and position of a cleavage site (Edman, 
1950; Doucet and Overall, 2011; Van den Berg and Tholey, 2012). An indirect way for 
identifying recognition motifs is based on peptide libraries. Here, libraries of substrate 
peptides are used to reconstruct cleavage motifs and their sequences are then aligned with 
protein databases (Birkett et al., 1991; Turk et al., 2001; Schilling and Overall, 2008). To 
ultimately corroborate cleavage sites, site-directed mutagenesis or post-translational 
modifications are applied to block fragmentation of the substrate protein. 
Based on these principles, many studies have devoted themselves to the characterisation of 
calpain cleavage in disease proteins such as α-synuclein, TDP-43 or tau (Dufty et al., 2007; 
M. C. Liu et al., 2011; Yamashita et al., 2012). In this study, a combinatorial strategy 
consisting of several biochemical and cell biological methods has been deployed to further 
and robustly analyse calpain-dependent cleavage events in huntingtin and ataxin-3. 
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Identification of calpain cleavage sites in huntingtin 
(Covered in Unpublished project manuscript E; Clemens et al., 2015) 
Since the first reports on calpain-mediated proteolysis of huntingtin as a player in the 
molecular pathogenesis of HD, a couple of cleavage sites at the N-terminus of the disease 
protein has been identified (Gafni et al., 2004; Southwell et al., 2011). To reinvestigate 
huntingtin fragmentation, this study focused on the confirmation of calpain-dependent 
cleavage in additional cell models and ex vivo, together with the analysis of the 
fragmentation pattern and localisation of yet unknown cleavage sites. 
In a first experiment, proteolytic cleavage of wild type and mutant huntingtin was induced in 
lysates of respective STHdh cell lines by a time-dependent addition of exogenous 
recombinant calpain-1 or -2. Western blot analysis showed that both recombinant calpains 
could readily cleave murine huntingtin and generate comparable fragmentation patterns. This 
observation was confirmed in lysates of HEK 293T cells overexpressing human HA-tagged 
huntingtin with 15 and 128 glutamines and ex vivo in cortex samples of wild type and BACHD 
rats. Differences between the fragmentation of wild type and mutant huntingtin, on the other 
hand, could be explained by polyQ-dependent size shifts of certain cleavage bands. Thus, 
calpain-1 and -2 seem to generally target the same recognition motifs within the huntingtin 
protein. 
To reproduce calpain cleavage of huntingtin in a cellular context, further experiments were 
performed in HA-tagged huntingtin 15Q and 128Q overexpressing HEK 293T cells, which 
were treated with the Ca2+-ionophore ionomycin. This compound facilitates the increase of 
cytosolic Ca2+ levels and, hereby, calpain overactivation. The increased calpain activity led to 
a time-dependent accumulation of polyQ and non-polyQ fragments which were abolished by 
administration of the calpain inhibitor CI III. Interestingly, this cell-based approach and the in 
vitro cleavage assays revealed the formation of two large C-terminal huntingtin breakdown 
products lacking the polyQ stretch. Size estimations and detectability by different antibodies 
pointed to yet unknown calpain-mediated cleavage event downstream of amino acid position 
1000 as the source for these fragments. 
For identification of the cleavage site underlying the formation of the large C-terminal 
fragments, mass spectrometry analysis of calpain-cleaved human huntingtin was performed. 
Lysates of HEK 293T cells, which expressed HA-tagged huntingtin 15Q and 128Q, were 
incubated with CaCl2 for activating calpains. Proteins were then separated by polyacrylamide 
gel electrophoresis and respective bands of interests excised for mass spectrometry. 
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Comparison of peptides resulting from tryptic and non-tryptic digest uncovered a novel 
cleavage site at amino acid T1175 of human huntingtin (UniProt identifier: P42858-1 with 23 
glutamines), which was further corroborated by in silico predictions. Interestingly, this site 
colocalises with the C-terminal end of the HEAT cluster 2 (FIGURE 10). This corresponds to 
previous conjectures that caspase and calpain cleavage sites preferentially fall into the PEST 
motif-rich intervening sequences between huntingtin’s HEAT domains (Warby et al., 2008). 
However, further investigations are necessary to confirm calpain cleavage at this position 
and to evaluate the impact of the resulting fragments on the molecular pathogenesis of HD. 
The here described results are in line with previous reports on calpain-mediated 
fragmentation of huntingtin. Earlier studies have identified cleavage sites at amino acids 8 
and 15 and 469 and 536, respectively. Deletion mutagenesis of the latter sites did not only 
prevent cleavage of huntingtin but also reduced huntingtin aggregation and toxicity (Gafni et 
al., 2004). On the other hand, antibody-based blocking of the very N-terminal cleavage sites 
abrogated a calpain-dependent degradation of a mutant huntingtin exon 1 construct 
(Southwell et al., 2011). This rather protective effect of calpains has been also suggested by 
experiments, which pharmacologically inhibited these proteases (Ratovitski et al., 2007). 
Moreover, it was demonstrated, that huntingtin fragments are not by itself pathogenic but 
their specific amino acid range and cleavage site-defined margin determine their toxicity 
(Slow et al., 2005; Graham et al., 2006). Together with findings, that C-terminal and non-
polyQ-containing fragments of huntingtin can impair autophagy, ER function and 
endocytosis, the current work underlines the relevance of further research on calpain 
cleavage sites in huntingtin and fragment characterisation for understanding HD pathology 
(Martin et al., 2014; Ochaba et al., 2014; El-Daher et al., 2015). 
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Identification of calpain cleavage sites in ataxin-3 
(Covered in Hübener et al., 2013; Nguyen et al., 2013; Weber et al., 2017) 
Similar to developments in the field of HD research, scientists have investigated ataxin-3 
cleavage by calpains more closely. The position of calpain recognition motifs, however, 
remained mainly unsolved. The first analyses applied Edman N-terminal sequencing of in 
vitro calpain-2-digested ataxin-3 and localised cleavage sites around amino acids 60, 200, 
and 260, but without further confirmation (Haacke et al., 2007). Based on rough estimations 
or in silico prediction, several subsequent studies narrowed down additional sites around 
positions 154, 190, and 220 (Colomer Gould et al., 2007; Simões et al., 2012). Due to this 
insufficient evidence, this work aimed at precisely localising calpain recognition motifs in 
ataxin-3 and thereby reviewing the pathological relevance of calpain cleavage for SCA3. 
In the first in vitro and ex vivo experiments, it was tested whether both calpain-1 and 
calpain-2 can cleave ataxin-3 and whether there are differences between the resulting 
fragmentation patterns. For this purpose, lysates of HEK 293T cells overexpressing ataxin-3 
(UniProt identifier: P54252-2) with 15, 77 or 148 glutamines and of wild type and SCA3 
mouse brains were incubated with each of the recombinant proteases. Western blotting 
showed that both calpain-1 and calpain-2 cleave ataxin-3 in a time-dependent manner. 
Interestingly, calpain-2 showed a more efficient proteolysis in contrast to calpain-1, which 
occurred even more rapidly for polyQ-expanded ataxin-3. The general cleavage pattern 
generated by both enzymes, however, did not apparently diverge. However, further in vitro 
cleavage assays employing purified ataxin-3 did not reproduce these findings but showed a 
rather equipollent, polyQ-independent fragmentation. 
To proof that calpain cleavage of wild type and mutant ataxin-3 is a physiological and 
disease relevant process, patient-derived cells and SCA3 post-mortem brain tissue were 
investigated. Western blot analysis of fibroblasts, iHF cell lines, iPSCs and iPSC-derived 
differentiated cortical neurons (iCNs), all obtained from SCA3 patients and healthy controls, 
demonstrated the occurrence of calpain-cleaved ataxin-3 fragments at baseline. The 
observed fragmentation could be further amplified by addition of CaCl2 to iHF lysates or by 
ionomycin administration to cultured iHFs, iPSCs and iCNs. Correspondingly, treating iHFs 
with the calpain inhibitor CI III reduced the formation of ataxin-3 fragments. Most remarkably, 
the presence of calpain-cleaved ataxin-3 was revealed in post-mortem brain tissue of SCA3 
patients but also of healthy controls, confirming that this proteolytic process takes place 
under normal physiological conditions. 
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The calpain-mediated fragmentation of ataxin-3 was further tracked using a TR-FRET-based 
approach. This assay used two fluorophore-labelled antibodies, one binding to amino acids 
214-233 of ataxin-3 and the second recognizing the expanded polyQ tract localized after 
amino acid 292. Incubation of SCA3 mouse brain homogenates with CaCl2 for calpain 
activation led to a reduced FRET signal. This observation suggested a calpain-mediated 
separation of the bound antibodies and indicated the presence of a recognition motif 
between respective epitopes, consistent with reports on putative cleavage sites around 
positions 220 and 260 (Haacke et al., 2007; Simões et al., 2012). 
To dissect the ataxin-3 fragmentation pattern, arising cleavage products were mapped using 
a panel of antibodies, which bind along the entire ataxin-3 protein. By this means, the 
occurrence of five major N-terminal fragments was revealed. Comparison with ataxin-3 
deletion constructs, which lack C-terminal portions of the protein, narrowed down four 
recognition motifs to regions between amino acids 321–366, 244–259, 198–243, and just 
before position 198. To precisely map cleavage sites, quantitative mass spectrometry of 
heavy and light isotope-labelled ataxin-3 after calpain digest was performed. This analysis 
identified amino acids H187, D208, S256 and G259 as the P1 sites of four calpain recognition 
motifs. 
Validation of mapped cleavage sites was achieved by site-directed mutagenesis of amino 
acids within the recognition motif. For this purpose, two strategies were applied based on the 
substitution of five amino acids by alanine or three amino acids by tryptophan. The first 
approach has been commonly used (Wanichawan et al., 2014), whereas tryptophan 
substitutions were conceived by computing effects of randomly replacing amino acids on the 
site-specific calpain cleavage likelihood. Both strategies were firstly tested via calpain overlay 
assays of 20-mer ataxin-3 peptides which comprise respective calpain recognition motifs with 
or without respective substitutions. Overlay assays confirmed binding of calpain-1 and 
calpain-2 to peptides containing the cleavage sites H187, D208 and S256, plus the 
additionally predicted position T277. Notably and according to in silico projections, triple 
tryptophan exchanges showed a more efficient reduction of calpain binding than quintuple 
alanine substitutions. In a next step, these mutations were introduced into ataxin-3 constructs 
and the overexpressed proteins were subjected to in vitro and cell-based calpain activation 
assays. In line with the overlay assays, modified ataxin-3 carrying triple tryptophan mutations 
at sites D208, S256 or both showed significantly reduced formation of respective fragments 
when compared to the non-mutated protein. 
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To evaluate the pathomolecular consequences of calpain-mediated ataxin-3 breakdown, a 
set of truncated ataxin-3 constructs was generated, which represents fragmentation at amino 
acid positions D208 and S256. HEK 293T cells transfected with these fragment constructs 
were examined using aggregation assays and FACS-based viability analysis. 
Overexpression of C-terminal polyQ-expanded constructs resulted in a massive formation of 
ubiquitinated aggregates and an increased cytotoxicity when compared to the full-length 
protein. Both effects were even enhanced for the shorter C-terminal construct, which 
corresponds to cleavage at the S256 site. On the other hand, N-terminal ataxin-3 fragment 
constructs, which lack the polyQ stretch, did not form insoluble protein species or 
microscopically traceable aggregates. This observation stands in contrast with a previous 
report on a transgenic mouse model expressing a fusion protein of the first 259 amino acids 
of ataxin-3 and β-galactosidase but accord to earlier cell-based investigations (Perez et al., 
1998; Hübener et al., 2011). Furthermore, both N-terminal and C-terminal fragment 
constructs exhibited a mainly cytoplasmic or diffuse localisation as shown by subcellular 
fractionation assays and confocal microscopy. Other studies, however, demonstrated the 
nuclear occurrence of C-terminal ataxin-3 fragments or suggested their nuclear shift 
attributed to the absence of the N-terminally located NESs (Goti et al., 2004; Antony et al., 
2009). On a final note, the here identified calpain cleavage site at amino acid D208 is 
adjacent to phospho-site T207, and S256 itself has been shown to be phosphorylated 
(Schmidt et al., 1998; Trottier et al., 1998; Mueller et al., 2009). Two protein kinases, CK2 
and GSK 3β, respectively, have been predicted or proven to mediate these phosphorylations, 
most likely having consequences for the cleavage likelihood. Corresponding implications 
have already been demonstrated for calpain or caspase cleavage of huntingtin (Luo et al., 
2005; Schilling et al., 2006). Thus, modulating these specific post-translation modifications 
might represent a promising target to alter calpain-driven fragmentation of ataxin-3 as a 
potential treatment approach in SCA3. 
Taken together, the here presented investigations showed for the first time that calpain-
mediated fragmentation of ataxin-3 is present in patient-derived cells and SCA3 post-mortem 
brain tissue at baseline. Moreover, four cleavage sites were precisely localized. Mutating 
amino acids at two main recognition motifs to tryptophan nearly abrogated the formation of 
two predominant C-terminal fragments and their N-terminal counterparts. Further 
characterisation of these C-terminal breakdown products demonstrated an increased 
aggregation propensity and cytotoxicity compared to the polyQ-expanded full-length protein. 
The findings are in line with previous studies on the role of ataxin-3 fragmentation by 
calpains in the molecular pathogenesis of SCA3 (Haacke et al., 2007; Koch et al., 2011; 
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Simões et al., 2012). However, additional in vivo validation of these results, particularly 
regarding herein generated calpain cleavage-resistant forms of polyQ-expanded ataxin-3, is 
still pending. These future investigations might reveal whether targeting ataxin-3 cleavage 
constitutes a valuable therapeutic strategy in treating SCA3. 
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Summary and outlook 
Calpain-mediated fragmentation of disease proteins is a widely-described element of the 
molecular pathomechanism of neurodegenerative disorders. The current work on huntingtin 
and ataxin-3 cleavage emphasizes its general validity by proving its physiological 
occurrence, successfully localising novel cleavage sites and characterising emerging 
fragments. However, and despite ongoing efforts to identify further cleavage sites within 
these polyQ proteins, further steps need to be taken to enhance our understanding of 
consequent implications. In silico predictions yield 189 highly probable calpain cleavage sites 
for huntingtin and 36 sites for ataxin-3, which is in contrast with a relatively low number of yet 
confirmed sites (FIGURE 10). This complexity of proteolytic modifications is further enhanced 
by the circumstance that cleavage at distinct positions can result in various consequences for 
disease protein function, integrity and toxicity. Nonetheless, the herein before described 
results on calpain-resistant ataxin-3, together with therapeutically promising findings in other 
studies, remain encouraging for future investigations. Those efforts could also include the 
analysis of non-synonymous polymorphisms in the mutant HTT and MJD1 genes, which lead 
to amino acid changes at calpain cleavage sites and thereby alterations in cleavage 
likelihood. A correlation of the polymorphisms with the patient’s disease onset and 
progression might further unveil the clinical relevance of calpain-dependent disease protein 
fragmentation. 
Results and discussion 
78 
 
Figure 10. Overview of already known and newly identified calpain cleavage sites within 
huntingtin and ataxin-3. In silico prediction of calpain cleavage sites in huntingtin (UniProt identifier: 
P42858-1, 23Q) and ataxin-3 (UniProt identifier: P54252-2, 13Q) using the GPS-CCD tool. Cleavage 
likelihood scores (CLS) are plotted relative to their amino acid position. For comparison, respective 
protein structures are illustrated above. The red dotted line indicates maximum default cut-off value of 
0.654. Scatter plots show amino acid positions with a CLS above the cut-off value. Cleavage sites 
identified in this work are highlighted with red scissors and stars, previously known sites are 
represented by purple scissors and stars. Asterisk (*) = lacks confirmation by site-directed 
mutagenesis. For a detailed description of the indicated protein domains see FIGURE 4. 
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Conclusion 
The overall goal of this work was to shed new light on calpains as important players and 
therapeutic targets in neurodegeneration. Exemplified by investigations on the polyQ 
diseases HD and SCA3, three main aspects were scientifically covered, namely the 
pathologic overactivation of calpains, strategies to attenuate this activation, and 
characterisation of calpain-mediated disease protein cleavage. 
Biochemical analysis revealed a general disease-related increase of the calpain system 
activity in different cell and animal models. Triggering further overactivation amplified the HD 
and SCA3 pathology in two mouse models, whereas genetic or pharmacological inhibition of 
calpains or their activating pathways effectuated an amelioration of pathological hallmarks in 
vitro and in vivo. Unveiling the therapeutic efficacy of the experimental drug olesoxime, 
moreover, constitutes a major and perhaps trailblazing finding in treatment of polyQ 
disorders. Despite all these important insights, this work is just another puzzle piece in the 
breakdown of disease mechanisms and related interventions in neurodegeneration. 
The next decades will hopefully produce gene therapies capable of curing diseases with a 
clear monogenic aetiology such as HD and SCA3. On the other hand, genetic disorders 
represent only a fraction of neurodegenerative diseases and most of these medical 
conditions are still determined by environmental factors and the individual lifestyle. On these 
grounds, further efforts must be undertaken to explore common molecular pathomechanisms 
including calpains as mediators of neuronal demise. 
Future studies on calpains need to broaden the comparative spectrum of molecular analyses 
and treatment strategies between diseases, thus enabling the development of generally 
applicable therapies for neurodegeneration. 
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The following pages are dedicated to unpublished project manuscripts. The work described 
in these manuscripts is composed of additional or preliminary experiments, which were 
conducted as individual projects or as a part of the major published studies. 
Every single project is divided into a brief introduction, a result part and a discussion. 
Material and methods are only included if not already described in the published manuscripts 
in Appendix II. However, references to the respective publications are enclosed. An author 
contribution statement is given at the end of each section.  
 
The unpublished project manuscripts comprise: 
 A. The calpain system in cell models of HD 
 B. Calpain activation in the YAC128 mouse model of HD 
 C. Calpastatin ablation in the HDKI mouse model of HD 
 D. Calpain-1 ablation in the YAC84 mouse model of SCA3 
 E. Calpain-dependent cleavage of huntingtin 
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Introduction  
Proteolytic fragmentation of disease proteins has been discussed as an important step in the 
molecular pathogenesis not only of Huntington disease (HD) but also further 
neurodegenerative disorders (Accepted paper c). The so called toxic fragment hypothesis 
states that this post-translational modification represents an important source for breakdown 
products of disease proteins which, in comparison to the full-length protein, exhibit an 
increased toxicity and aggregation propensity (Wellington and Hayden, 1997). In HD, several 
groups of enzymes have been associated with the cleavage of mutant huntingtin such as 
caspases and calpains (Ehrnhoefer et al., 2011). Calpains, a class of Ca2+-dependent 
cysteine proteases, do not only cleave the disease protein, but also exhibit an overactivation 
in the molecular context of HD (Kim et al., 2001; Gafni and Ellerby, 2002; Gafni et al., 2004; 
Cowan et al., 2008; Dau et al., 2014; Accepted paper d & e). Furthermore, this overactivation 
seems be connected with synaptic dysfunctions via calpain-dependent loss of surface 
NMDARs (Cowan et al., 2008; Gladding et al., 2012; Dau et al., 2014). These observations 
emphasize that calpains represent an important player in the molecular pathogenesis of HD 
and targeting these enzymes might constitute a promising therapeutic strategy to treat this 
dreadful disease. 
To further assess the role of calpains, we analysed calpain activation in cell models of HD. 
By western blotting, we assessed expression levels of calpains and fragmentation of their 
substrates in STHdhQ7 and STHdhQ111 cells. These immortalized striatal precursor cells with 
a potential for an induced neuronal differentiation were generated from wild type mice and 
the homozygous HdhQ111 knock-in (HDKI) mouse model of HD (Trettel et al., 2000). To 
validate our results, we utilized primary murine embryonic fibroblasts, MEFHdhQ7 and 
MEFHdhQ111, which were retrieved from the same animal model as STHdh cells. 
Furthermore, we tested the effect of a calpain activity reduction by measuring viability of 
STHdh cells treated with specific pharmacologic inhibitors. 
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Materials and Methods 
Cell culture 
Generation of MEFHdhQ7 and MEFHdhQ111 has been described elsewhere (Walter et al., 
2016). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal calf serum and 1% penicillin/streptomycin (all Thermo Fisher Scientific) at 
37°C and 5% CO2. Fibroblasts in passages 4–12 were used for the experiments. For 
pharmacologic calpain inhibition, undifferentiated STHdh cells were treated with 5 µM N-
acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) or 25 µM PD150606 (both Sigma-Aldrich) for 24 
h. DMSO was used as a vehicle control. For measuring viability, STHdh were assayed using 
the resazurin-based PrestoBlue® Cell Viability Reagent (Thermo Fisher Scientific) and an 
Envision Multilabel Plate Reader (Perkin Elmer) according to the manufacturer’s protocol. 
Immunofluorescence staining of tissue culture cells 
Undifferentiated STHdh cells or MEFHdh were cultured on coverslips and pre-fixed in 0.4% 
paraformaldehyde in DMEM for 15 min at 37°C. Afterwards, cells were fixed in 4% 
paraformaldehyde in Dulbecco’s phosphate buffered saline (DPBS) for 10 min and washed 
three times with DPBS. Blocking solution (DPBS supplemented with 1% normal donkey 
serum and 0.1% Triton X-100) was added for 1 h at room temperature. After blocking, cells 
were incubated with rabbit anti-calpain-1 (1:100; ab39170, Abcam) and mouse anti-TOMM20 
(1:100; ab56783, Abcam) antibodies in blocking solution overnight. Subsequently, cells were 
washed three times with DPBS and incubated with the respective secondary antibodies goat 
anti-rabbit Alexa Fluor® 488 (1:1000; ab150077, Abcam) and goat anti-mouse Cy3 (1:1000; 
115-165-146, Dianova) diluted in blocking solution for 1 h at room temperature. Afterwards, 
cells were washed again three times with DPBS and nuclear counterstaining was performed 
using Hoechst 33342. Cells were embedded in a solution of Mowiol containing 2.5% 1,4-
diazobicyclo-[2.2.2]-octane (DABCO) (Sigma-Aldrich) and mounted on microscope slides. 
Images were taken with an Axioplan 2 microscope and imaging software AxioVision 4.7 (both 
Zeiss). 
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Antibodies for western blotting 
The following list contains information on additional antibodies used for western blot analysis 
in this study, which were not mentioned elsewhere: rabbit anti-calpain-2 (1:500; ab39168, 
Abcam); rabbit anti-calpain-10 (1:500; ab28220, Abcam). 
Further materials and methods 
Information on cell lysis and western blot analysis can be found under Accepted papers e 
and g. 
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Results 
Calpain-1 is overexpressed in STHdhQ111 cells  
For a better insight into activation patterns of the calpain system in cell models of HD, we 
performed western blotting of undifferentiated STHdhQ7 and STHdhQ111 lysates (Fig. 1). 
Immunodetection showed a significant increase in total calpain-1 levels in STHdhQ111 
compared to the wild type cell line. The calpain substrate α-spectrin showed an increased 
formation of cleavage fragment (Fig. 1a, upper black arrowhead). Interestingly, full-length 
levels of α-spectrin were also elevated in STHdhQ111. On the contrary, calpain-2 and calpain-
10 (bands a and b) showed a decrease in their full-length levels. The endogenous calpain 
inhibitor calpastatin (CAST) exhibited no differences in total levels (band a). However, levels 
of a probable fragment band of CAST (Fig. 1a, arrowhead b) appeared to be significantly 
increased. Taken together, STHdhQ111 cells exhibited elevated disturbances in the 
expression of members of the calpain system and an over-all increase in calpain activation. 
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Figure 1. Western blot analysis shows an increased activation of the calpain system in 
undifferentiated STHdhQ111 cells. (a) Lysates of undifferentiated STHdh cells expressing huntingtin 
with 7 or 111 glutamines were analysed by western blotting. Blots were stained with calpain-1, 
calpain-2, calpain-10, and CAST antibodies. For evaluating the effects on calpain substrates, 
fragmentation of α-spectrin was investigated. Actin served as a loading control. White arrowheads 
indicate full-length proteins, black arrowheads highlight proteolytically processed proteins. (b) Protein 
levels were quantified using the NIH software ImageJ. The calpain cleavage-dependent α-spectrin 
fragment band (upper black arrowhead) was quantified relative to full-length levels of α-spectrin. 
Horizontal lines represent the means ± s.e.m. of four independent experiments. Statistical significance 
was assessed by Student’s t-test, *: P < 0.1; **: P < 0.01. 
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Trend towards a calpain system overactivation in MEFHdhQ111  
To compare results of the calpain system activation as observed in STHdh cells, we 
analysed MEFs expressing wild type huntingtin (Q7) or mutant huntingtin (Q111) using 
western blotting. Immunodetection and quantification of calpain-1, calpain-2 and α-spectrin 
recapitulated by tendency the increased activation of the calpain system without reaching 
statistical significance (Fig. 2). 
 
 
Figure 2. Western blot analysis shows a trend towards increased calpain activation in 
MEFHdhQ111. (a) MEFs expressing huntingtin with 7 or 111 glutamines were lysed using RIPA-buffer 
and analysed by western blotting to detect levels of calpain-1, calpain-2 and the calpain substrate α-
spectrin. Actin served as a loading control. White arrowheads indicate full-length proteins, black 
arrowheads highlight proteolytically processed proteins. (b) Protein levels were quantified using the 
NIH software ImageJ. The calpain cleavage-dependent α-spectrin fragment band was quantified 
relative to full-length levels of α-spectrin. Calpain-1 activation was quantified by calculating the ratio of 
proteolytically cleaved (active) form to the inactive form of calpain-1. Horizontal lines represent the 
means ± s.e.m. of three independent experiments. 
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Calpain-1 colocalizes with mitochondria in STHdh cells and MEFHdhs 
As we observed increased levels of calpain-1 in STHdhQ111 cells by western blotting, we 
aimed for validating these alterations by microscopy. To investigate the cellular levels and 
the distribution of calpain-1, we performed immunofluorescence analysis of STHdh cells and 
MEFHdhs using an antibody specific to calpain-1. Fluorescence microscopy revealed, most 
strikingly, a distinct and organized distribution of calpain-1 reminiscent of mitochondrial 
structures in STHdh cells and MEFHdhs (Fig. 3). Double staining of calpain-1 together with 
the mitochondrial outer membrane protein TOMM20 confirmed the colocalization with 
mitochondrial structures in MEFHdhs (Fig. 3b). Furthermore, the intensity of calpain-1 
staining in STHdhQ111 cells appeared to be increased compared to STHdhQ7 cells, endorsing 
the previous observations by western blot analysis of STHdh cells. 
 
 
Figure 3. Immunofluorescence microscopy of STHdh cells and MEFHdhs reveals a 
mitochondrial association of calpain-1. (a) STHdh cells expressing huntingtin with 7 or 111 
glutamines were stained with an antibody specific for calpain-1 (green). (b) MEFs expressing 
huntingtin with 7 glutamines were double stained with antibodies specific to calpain-1 (green) and to 
the mitochondrial outer membrane protein TOMM20 (red). Both signals show a strong structural 
resemblance and colocalization (yellow). Nuclei were counterstained with Hoechst 33342 (blue). LM = 
low magnification; HM = high magnification. Scale bar = 20 µm. 
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Viability of HD cells increases upon calpain inhibition 
As proteolytic cleavage of huntingtin is reported to produce toxic fragments, we sought to 
investigate whether pharmacologic inhibition of calpains in STHdhQ111 would lead to 
increased cell viability due to a reduced calpain-dependent huntingtin cleavage. For this, we 
incubated STHdhQ7 and STHdhQ111 cells with calpain inhibitors ALLN or PD150606 for 24 h 
and measured viability using a resazurin-based fluorescent assay (Fig. 4). As hypothesized, 
STHdhQ111 cells showed a significantly increased viability when incubated with one or the 
other calpain inhibitor when compared to DMSO treated controls. Interestingly, the viability of 
STHdhQ7 cells was significantly reduced. 
  
 
Figure 4. Calpain inhibition leads to an increased viability of STHdhQ111 cells, but reduces 
viability of STHdhQ7 cells. STHdh cells were grown in a 96 well plate and incubated with 5 µM ALLN 
or 25 µM PD150606 for 24 h. Afterwards, cell viability was measured fluorometrically using the 
resazurin-based PrestoBlue® assay. Horizontal lines represent the means ± s.e.m. of four 
independent experiments. Statistical significance was assessed using one-way-ANOVA with Tukey 
post-test. Q7 Ctrl vs. treated: *; Q111 Ctrl vs. treated +; **/++: P < 0.01; ***/+++: P < 0.001. 
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Discussion 
Several studies have shown that calpain activity is upregulated in HD animal models and 
post mortem HD brain tissue (Gafni and Ellerby, 2002; Gafni et al., 2004; Accepted paper d 
& e). In order to further investigate this condition and to identify cell-based models 
recapitulating calpain overactivation, we analysed two cell models of HD derived from HD 
knock-in animals, the HDKI mice (Wheeler et al., 1999). 
By performing western blot analysis of STHdhQ111 cells and their respective control line 
STHdhQ7, we were able to reproduce the known dysregulation and increased activation of the 
calpain system. This observation is consistent with results retrieved from previous in vivo 
studies by other researchers and our lab, which investigated calpains in the HDKI animals, 
the source of STHdh cells, and in further mouse and rat models of HD (Gafni et al., 2004; 
Cowan et al., 2008; Dau et al., 2014; Accepted paper d & e). Furthermore, a study on HD-
associated dopamine and glutamate neurotoxicity qualitatively showed an increased calpain-
dependent fragmentation of α-spectrin in STHdhQ111 cells at baseline (Paoletti et al., 2008). 
When analysing fibroblasts generated from HDKI mice and wild type controls, MEFHdhQ111 
and MEFHdhQ7, we found a comparable trend towards an overactivation of calpains, but 
without reaching significance as for STHdhQ111 cells. The lacking reproducibility of the effects 
in MEFHdh might be due to multiple factors like the differing tissue origin of MEFs and 
STHdh cells. While STHdh cells are of striatal origin, MEF cultures are primarily considered 
as mesenchymal cells composed of highly heterogeneous populations (Singhal et al., 2016).  
In addition, we performed immunofluorescence analysis of STHdh cells and MEFHdhs to 
reassess the alterations of calpain-1 levels as seen in western blotting by microscopy. Most 
interestingly, we detected a specific spatial distribution of calpain-1 within the cell, which 
could be identified as a colocalization with mitochondria. Although it is known that calpains 
exhibit both a cytosolic and a mitochondrial distribution, and that calpain-1 is exhibiting a 
mitochondrial targeting sequence at its N-terminus, it was still surprising that the localization 
of calpain-1 appeared to be mainly mitochondrial (Badugu et al., 2008; Smith and 
Schnellmann, 2012). This observation could highlight a subcellular link between calpain-1 
activation and the effects of the compound olesoxime, which binds to the outer mitochondrial 
membrane protein VDAC1 and was shown to lead to an amelioration of calpain 
overactivation in animal models of HD in two of our studies (Bordet et al., 2010; Accepted 
paper d & e). 
As calpains are reported to be involved in the formation of toxic fragments of mutant 
huntingtin and, when overactivated, to trigger synaptic dysfunctions, we tested the effect of a 
A. The calpain system in cell models of HD 
133 
pharmacologic inhibition of calpains in STHdhQ7 and STHdhQ111 cell lines (Gafni et al., 2004; 
Cowan et al., 2008). Treatment with calpain inhibitors ALLN and PD150606 led to an 
increased viability of the mutant STHdhQ111 cells, whereas the wild type counterpart showed 
an impaired viability. These contrary effects could be due to a negative impact of inhibiting a 
non-pathologic calpain system in wild type cells, whereas the calpain overactivation in 
STHdhQ111 cells could be favourably decreased upon inhibitor addition. In this context, it is 
worth mentioning, that activation of the calpain system might not only trigger pathological 
conditions but may also mediate neuroprotective functions (Wu and Lynch, 2006; Baudry and 
Bi, 2016). 
In summary, STHdh cells and, to a limited extent, MEFHdhs constitute appropriate cellular 
models for investigating the HD-related calpain overactivation and for screening 
pharmacologic interventions, which target this condition as a therapeutic approach. 
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Introduction 
The identification and choice of an appropriate disease model is an important prerequisite for 
investigating molecular pathomechanisms and experimental treatment approaches not only 
in Huntington disease (HD) but medical life science in general. A long list of animal models 
has been generated for HD, which recapitulate to a greater or lesser extent the phenotypic 
and molecular hallmarks of this neurodegenerative disorder (Pouladi et al., 2013). Calpain 
overactivation, which has been described for patient post-mortem tissue, has also been 
identified in a variety of cell and animal models of HD (Gafni and Ellerby, 2002; Cowan et al., 
2008; Accepted paper d & e; Unpublished project manuscript A). A widely used and well 
characterized HD rodent model is the YAC128 mouse (Slow et al., 2003). Although calpain 
activation has previously been reported for these mice, we sought to investigate the calpain 
system more in detail (Cowan et al., 2008). For this, we focussed on the analysis of 
activation and expression patterns of different calpains and calpain substrates in striatum 
and cortex of YAC128 mice at different ages. 
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Materials and Methods 
Animals 
All animal experiments were conducted in accordance with protocols approved by the 
University of British Columbia Committee on Animal Care and the Canadian Council on 
Animal Care. Wild type and YAC128 mice bred on a FVB/N background were genotyped and 
housed as previously described (Slow et al., 2003). Animals were sacrificed at 6 weeks 
(presymptomatic) or 12 months (symptomatic) of age. Mouse brains were dissected for 
further western blot or histological analyses. 
Immunofluorescence staining of brain sections 
Dissected brains of YAC128 mice at 12 months of age were processed for fluorescence 
microscopy as described before (Casadei et al., 2014). 7-µm-sagittal sections were stained 
with primary antibodies rabbit anti-calpain-1 (1:200; ab39170, Abcam), rabbit anti-calpain-2 
(1:200; ab39168, Abcam), and rabbit anti-CAST (1:200; #4146, Cell Signaling) and the 
secondary antibody goat anti-rabbit Alexa Fluor® 488 (1:500; ab150077, Abcam). Nuclei 
were counterstained using 4′,6-diamidino-2-phenylindole (DAPI). 
Antibodies for western blotting 
The following list contains information on additional antibodies used for western blot analysis 
in this study, which were not mentioned elsewhere: rabbit anti-calpain-2 (1:500; ab39165, 
Abcam); rabbit anti-calpain-5 (1:500; ab38943, Abcam); rabbit anti-calpain-10 (1:500; 
ab28220, Abcam); mouse anti-NR2B (1:500; clone13/NMDAR2B, 610416, BD Biosciences); 
rabbit anti-p35 (1:500; clone C64B10, #2680, Cell Signaling). 
Further materials and methods 
Information on tissue preparation and lysis, western blot analysis, and antibodies can be 
found under Accepted papers d, e, and g. 
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Results 
Analysis of calpain activation in the YAC128 mouse model of HD at 12 months of age 
To assess calpain activity in cortex and striatum of YAC128 mice, we analysed the 
expression levels and activation state of members of the calpain system by western blotting. 
Furthermore, we detected fragmentation of the known calpain substrates α-spectrin and N-
methyl D-aspartate receptor subtype 2B (NR2B) (Cowan et al., 2008). As we expected an 
aggravation of calpain overactivation with aging as concluded from the previously analysed 
BACHD rats and HDKI mice, we first focused on investigating samples of 12-month-old 
animals (Accepted paper d & e). However, immunodetections did not show differences in the 
expression levels of calpains or in the fragmentation of their substrates in cortex (Fig. 1a). 
Interestingly, we observed a trend towards a reduced expression of calpains and a lowered 
formation of calpain cleavage-derived α-spectrin and NR2B fragments in striatum (Fig. 1b). 
Concordantly, CAST levels were significantly increased in striatum of 12-month-old YAC128 
mice, suggesting an inhibiting effect on calpain activation in these animals compared to wild 
type. 
To analyse calpain expression alterations in YAC128 mice at histological level, we performed 
immunofluorescence staining of paraffin-embedded brain sections of 12-month-old wild type 
and YAC128 mice. Using fluorescence microscopy, we evaluated signal distribution and 
intensity of calpain-1, calpain-2, and CAST (Fig. 2). Comparison of cortex, striatum and 
cerebellum showed no striking differences in signal intensities between genotypes. This 
observation accords to our results in western blotting, where calpain levels were unchanged 
or exhibited only tendencies in variation. Notably, the mainly cytoplasmic expression of all 
three immunodetected members of the calpain system appeared to be lower in striatum than 
in cortex and cerebellum. 
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Figure 1. Western blot analysis shows a trend towards decreased calpain activation in striatum 
of 12-month-old YAC128 mice. Cortical (a) and striatal (b) lysates of 12-month-old wild type (WT) 
and YAC128 mice were analysed using western blotting and immunostaining with antibodies against 
calpain-1, calpain-2, calpain-10, α-spectrin, NR2B, and CAST. Genotyping was confirmed using the 
polyglutamine (polyQ)-specific antibody 1C2. Actin served as a loading control. Protein levels were 
quantified using the NIH software ImageJ. Horizontal lines represent the means ± s.e.m. of three 
animals per genotype. Statistical significance was assessed by Student’s t-test, *: P < 0.05. 
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Figure 2. Immunofluorescence analysis of 12-month-old mouse brain sections show region-
specific differences in calpain expression. Sagittal brain sections of 12-month-old wild type (WT) 
and YAC128 mice were immunostained using calpain-1 (a), calpain-2 (b) and CAST (c)-specific 
antibodies in combination with an Alexa® 488-coupled secondary antibody (greyscale and green). 
Nuclei were counterstained using DAPI (blue). All three markers of the calpain system show no strong 
differences when comparing genotypes. Focussing on differences between brain regions, calpain-1, 
calpain-2 and to a lesser extent CAST exhibit a weaker staining of cell bodies in striatum than in 
cortex or cerebellum. Scale bar = 50 µm. 
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Analysis of calpain activation in the YAC128 mouse model of HD at 6 weeks of age 
In retrospect to absent calpain overactivation in 12-month-old YAC128 mice, we focused on 
analysing younger animals to examine possible age-dependent attenuation effects on 
calpain activity. For this purpose, we analysed cortical and striatal lysates of 6-week-old wild 
type and YAC128 mice by western blotting. Immunodetection of calpain-1, calpain-2, calpain-
5 and calpain-10 did not show alterations in expression levels or activation in cortex (Fig. 3a) 
or striatum (Fig. 3b). The endogenous inhibitor CAST showed no changes in expression 
levels despite observing an increase in striatum of 12-month-old YAC128 animals. Likewise, 
neither calpain substrates α-spectrin and p35 nor huntingtin exhibited differences in 
fragmentation. Interestingly, expression levels of full-length α-spectrin were significantly 
increased in YAC128 cortex. Comparably, striatal α-spectrin levels showed a trend towards 
an elevation in YAC128 mice compared to wild type animals. 
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Figure 3. Western blot analysis of cortex and striatum of 6-week-old animals shows no 
differences in calpain activation between wild type and YAC128 mice. Cortical (a) and striatal (b) 
lysates of 6-week-old wild type (WT) and YAC128 mice were analysed using western blotting and 
immunostaining with antibodies against calpain-1, calpain-2, calpain-5, calpain-10, p35, α-spectrin, 
and CAST. Mouse genotypes were confirmed and huntingtin fragmentation was investigated using the 
huntingtin-specific antibodies 2166 and D7F7. Tubulin served as a loading control. Protein levels were 
quantified using the NIH software ImageJ. Horizontal lines represent the means ± s.e.m of 7 wild type 
and 9 YAC128 animals. Statistical significance was assessed by Student’s t-test, *: P < 0.05. 
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Discussion 
As previous studies demonstrated that calpains are overactivated in brain of two HD animal 
models, the BACHD rat and the HdhQ111 knock-in (HDKI) mouse, we analysed the calpain 
activation in an additional, well characterized animal model, the YAC128 mouse (Slow et al., 
2003; Accepted paper d & e). 
We performed our first analyses in YAC128 animals at an age of 12 months since we 
expected a stronger activation of the calpain system with disease progression. Surprisingly, 
we did not detect elevated levels of calpains, increased calpain activation or a higher 
fragmentation of typical calpain substrates like α-spectrin. Investigations of cortex samples 
by western blotting did not show any alterations. However, striatal samples exhibited a trend 
towards a reduced calpain activation accompanied by significantly increased levels of the 
endogenous calpain inhibitor CAST. The decreased activation of the calpain system in 
YAC128 striatum at 12 months of age is consistent with recent findings (Dau et al., 2014), 
which showed elevated calpain activity in YAC128 mice at 6 weeks but not at 4 months of 
age. These observations suggest a possible attenuation of the calpain activity with aging in 
YAC128 mice. Therefore, we repeated our analyses using cortical and striatal samples of 
6-week-old wild type and YAC128 mice. However, we neither detected an increase in calpain 
activity nor an elevation in CAST levels, as observed in striatum of 12-month-old YAC128 
mice. 
Taken together, our results are in contrast to the previously described overactivation of 
calpains in the YAC128 model and demand further validations (Cowan et al., 2008; Gladding 
et al., 2012; Dau et al., 2014). A possible control experiment in this regard could be 
performed by altering the genetic background of YAC128 mice. It is known, that maintaining 
inbred mouse strains over many generations can lead to an accumulation of mutations, 
which can eventually alter the manifestation of a disease phenotype (Yoshiki and Moriwaki, 
2006). For HD mouse models it has been reported that breeding onto C57BL/6 or FVB/N 
background strains can modify the severity of a HD phenotype (Lloret et al., 2006; 
Ehrnhoefer et al., 2009). Although earlier investigations on calpains were performed using 
YAC128 mice on the FVB/N background, changing to the C57BL/6 strain could be a 
promising strategy as HDKI mice, which feature calpain overactivation, were bred on the 
latter background. 
Alternatively, an excitotoxic insult could be induced pharmacologically in YAC128 mice to 
trigger differences in the calpain activation. This can be performed by administering NMDA or 
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quinolinic acid, which both have been described as potent compounds for modelling HD or 
as an additional stressor in YAC128 animals (Beal et al., 1986; Graham et al., 2009). 
In summary, a clear activation of the calpain system in YAC128 mice, as described in several 
previous studies, could not be reproduced in our investigations. This circumstance questions, 
at least to some extent, whether overactivation of the calpain system plays a major role 
during the entire lifespan of the YAC128 mouse model. 
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Introduction 
One of the most investigated regulatory mechanisms for calpain activity is the inhibitory 
function of the endogenous proteinaceous calpain inhibitor calpastatin (CAST) (Wendt et al., 
2004; Hanna et al., 2008). Two in vivo studies conducted in our institute investigated the 
effect of a genetic CAST depletion on the pathogenesis of mutant synuclein-linked Parkinson 
disease (PD) and Spinocerebellar ataxia type 3 (SCA3) (Diepenbroek et al., 2014; Accepted 
paper a). Both studies showed that a CAST knockout led to an increase in calpain activation, 
an aggravation of disease-associated molecular hallmarks and a worsening of the disease 
phenotype. As calpains play an important role in Huntington disease (HD), we aimed for 
analysing the effect of a CAST ablation in a mouse model of HD. For this purpose, we 
crossbred HdhQ111 knock-in (HDKI) with Cast-/- mice and analysed HD-related molecular 
characteristics including calpain activation, and both fragmentation and aggregation of 
mutant huntingtin. 
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Materials and Methods 
Animals 
All mouse experiments were conducted after approval by the local ethics committee at the 
Regierungspraesidium Tuebingen in accordance with the German Animal Welfare Act and 
the guidelines of the Federation of European Laboratory Animal Science Associations, based 
on European Union legislation (Directive 2010/63/EU). Homozygous calpastatin knockout 
(Cast-/-) and heterozygous HdhQ111 (HDKI) mice bred on a C57BL/6 background were 
maintained and genotyped as previously described (Wheeler et al., 1999; Takano et al., 
2005). Both models were crossbred to obtain following groups of animals: wild type (WT), 
Cast-/-, HDKI, and HDKI/Cast-/-. Animals were sacrificed by CO2 inhalation. Whole brains 
were immediately dissected on ice, snap-frozen in liquid nitrogen and stored at –80°C for 
further analysis. 
Antibodies for western blotting 
The following list contains information on additional antibodies used for western blot analysis 
in this study, which were not mentioned elsewhere: rabbit anti-DARPP-32 (1:10.000; clone 
EP720Y, 1710-1, Epitomics), mouse anti-LC3 (1:200, clone 5F10, NanoTools), and rabbit 
anti-p62 (1:500; #5114, Cell Signaling). 
Further materials and methods 
Information on tissue preparation and lysis, western blot analysis, filter retardation assays 
and antibodies can be found under Accepted paper e.  
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Results 
Calpain activation is increased in brain of calpastatin knockout animals 
To assess the baseline activation of the calpain system in Cast-/- mice, whole brain lysates of 
10-month-old wild type and Cast-/- mice were analysed using western blotting (Fig. 1a). CAST 
knockout was confirmed by immunodetection. Calpain-1 autoprocessing and cleavage of 
calpain substrate α-spectrin were significantly elevated in Cast-/- animals compared to wild 
type controls. Correspondingly, the fragmentation of a second substrate protein p35 was 
increased as demonstrated by a higher p35-to-p25 conversion (Fig. 1b). These observations 
point towards a globally elevated calpain system activation upon genetic CAST depletion. 
 
 
Figure 1. Western blot analysis of brain tissue of 10-month-old animals shows increased 
calpain activation in CAST knockout brains. (a) Whole brain lysates of wild type (WT) and Cast-/- 
mice at 10 months of age were analysed by western blotting and immunostaining with antibodies 
against calpain-1, α-spectrin and p35. Mouse genotypes were confirmed by detection of CAST. Actin 
served as a loading control. (b) Protein levels were quantified using the LI-COR Image Studio 
Software. Horizontal lines represent the means ± s.e.m. of 4 animals per genotype. Statistical 
significance was assessed by Student’s t-test. *: P < 0.05, ***: P < 0.001. 
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Calpastatin ablation amplifies calpain activation in the HDKI brain  
After corroborating the increased calpain activation in brains of Cast-/- mice at 10 months of 
age, we analysed the effect of a CAST knockout in HDKI animals. We first confirmed the 
successful knockout of CAST in single mutant (Cast-/-) and double mutant (HDKI/Cast-/-) 
animals and investigated its implication on the calpain system. For this purpose, we 
performed western blotting of whole brain lysates of animals at 13 months of age using 
antibodies directed against CAST, calpain-1, α-spectrin and p35 (Fig. 2a). Detection of CAST 
showed the complete ablation of the protein in Cast-/- and HDKI/Cast-/- mice compared to wild 
type and HDKI mice. Furthermore, CAST knockout led to a significantly increased activation 
of calpain-1, to elevated levels of the calpain cleavage-derived α-spectrin fragment and to 
higher proteolytic conversion of the calpain substrate p35 (Fig. 2b). The increased calpain 
activation at baseline, which has been already observed in HDKI striatum at 6 months 
(Accepted paper e), was, by tendency, reproduced in whole brain at 13 months but without 
reaching significance. 
 
 
Figure 2. Western blot analysis of brain tissue of 13-month-old animals shows increased 
calpain activation upon CAST ablation. (a) Whole brain lysates of 13-month-old mice were 
analysed using western blotting and immunostaining with antibodies against calpain-1, CAST, α-
spectrin and p35. Actin served as a loading control. (b) Protein levels were quantified using the NIH 
software ImageJ. Horizontal lines represent the means ± s.e.m. of three animals per genotype. 
Statistical significance was assessed by one-way ANOVA with Fisher’s LSD post-hoc analysis, */#: P < 
0.05 and **/##: P < 0.01. 
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Calpastatin knockout elevates the cleavage of wild type and mutant huntingtin in vivo 
As CAST knockout led to an increased activation of the calpain system, we next analysed its 
impact on the fragmentation of wild type and mutant huntingtin in vivo. Western blotting and 
immunostaining for huntingtin using the antibodies 2166 (epitope between amino acids 443-
457) and D7F7 (epitope surrounding amino acid 1220) revealed an increased formation of N-
terminal, polyQ-dependent and C-terminal, polyQ-independent huntingtin fragments (Fig. 3; 
red and black arrowheads, respectively) in both Cast-/- and HDKI/Cast-/- animals. 
Interestingly, the majority of detected fragments appeared to originate from calpain-
dependent cleavage and only a small portion of breakdown products remained unchanged 
due to CAST knockout. 
 
 
Figure 3. CAST ablation results in an increased fragmentation of wild type and polyQ-expanded 
huntingtin. Whole brain lysates of 13-month-old mice were analysed using western blotting and 
immunostaining with the huntingtin-specific antibodies 2166 (a) and D7F7 (b). Red arrowheads 
indicate N-terminal, polyQ-dependent fragments and black arrowheads C-terminal fragments, which 
do not contain the polyQ stretch. Actin served as a loading control. exp. = exposure; flwt = full-length 
wild type huntingtin; flex = full-length expanded huntingtin. 
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Calpastatin knockout enhances aggregation of mutant huntingtin 
N-terminal fragments of polyQ-expanded huntingtin have been shown to be more 
aggregation-prone than the full-length protein (Cooper et al., 1998; Li and Li, 1998). Since 
genetic CAST ablation led to an increased formation of these fragments, we sought to study 
the aggregation of huntingtin in the brain of HDKI/Cast-/- mice in comparison to HDKI 
animals. For this, we performed filter retardation assays of whole brain homogenates and 
immunostaining with the 2166 antibody (Fig. 4a). While wild type and Cast-/- mice did not 
exhibit SDS-insoluble species of huntingtin, both HDKI and HDKI/Cast-/- mice featured an 
accumulation of huntingtin aggregates. As expected, CAST knockout led to elevated 
huntingtin aggregation, with levels 20% higher than in HDKI animals. 
To investigate whether CAST knockout further promoted striatal dopaminergic dysfunction in 
HDKI animals, we detected levels of DARPP-32, a marker for dopaminergic neurons, in 
whole brain lysates by western blotting (van Dellen et al., 2000; Slow et al., 2003; Jiang et 
al., 2012). Animals expressing polyQ-expanded huntingtin showed strongly reduced levels of 
DARPP-32 when compared to wild type animals (Fig. 4b). Interestingly, knockout of CAST 
alone led to lower amounts of DARPP-32 in Cast-/- mice, while an additional effect on 
HDKI/Cast-/- was unobvious. The decrease in DARPP-32 levels in Cast-/- mice was 
accompanied by a significant increase in fragments, suggestive of a calpain-mediated 
cleavage of the protein. 
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Figure 4. CAST ablation in HDKI animals leads to an increased formation of huntingtin 
aggregates. (a) The huntingtin aggregate load within whole brain homogenates of 13-month-old mice 
was analysed by filter retardation assay. Retained aggregates were stained using the 2166 antibody. 
Statistical significance was assessed by Student’s t-test. #: P < 0.05. (b) Striatal dopaminergic 
dysfunction was assessed by western blot analysis of DARPP-32, a phosphoprotein enriched in 
different types of striatal neurons in the basal ganglia. Black arrowheads indicate DARPP-32 
breakdown products (bdps), whereas the white arrow head points to the full-length protein. Actin 
served as a loading control. Aggregate and protein signals were quantified using the NIH software 
ImageJ. Horizontal lines represent the means ± s.e.m. of three animals per group. Statistical 
significance was assessed by one-way ANOVA with Fisher’s LSD post-hoc analysis. **: P < 0.01; ***: 
P < 0.001. 
C. Calpastatin ablation in the HDKI mouse model of HD 
151 
Calpastatin knockout perturbs the autophagy system  
A recent study reported on the degradation of mutant huntingtin aggregates via a calpain-
dependent regulation of the autophagy system. Overexpression of CAST led to a lowered 
calpain activity, which in turn increased autophagosome levels and reduced the aggregate 
load in Drosophila and HD mice (Menzies et al., 2014). Furthermore, calpains were shown to 
inhibit autophagy by inactivating key proteins of the autophagy pathway (Yousefi et al., 2006; 
Russo et al., 2011). Therefore, we investigated whether the observed increase of huntingtin 
aggregates in double mutant mice resulted not only from an elevated cleavage of polyQ-
expanded huntingtin but, in addition, from a calpain-dependent impairment of the autophagy 
system. To assess the state of autophagy in our mice, we detected by western blotting levels 
of LC3-II, a modified variant of LC3 and marker for the amount of autophagosomes, and p62, 
an autophagy adaptor protein which is degraded during the process of autophagy (Fig. 5). 
Surprisingly, levels of LC3-II were raised in Cast-/-, HDKI and double mutant animals, and 
p62 showed a significant decrease indicative of an upregulated autophagy system. 
 
 
Figure 5. Western blot analysis of brain tissue of 13-month-old animals reveals increased 
levels of autophagy marker LC3-II despite calpain system overactivation. (a) Whole brain lysates 
of 13-month-old mice were analysed using western blotting and immunostaining with antibodies 
against p62 and LC3. Actin served as a loading control. (b) Protein levels were quantified using the 
NIH software ImageJ. Horizontal lines represent the means ± s.e.m. of three animals per group. 
Statistical significance was assessed by one-way ANOVA with Fisher’s LSD post-hoc analysis, *: P < 
0.05; **: P < 0.01; ***: P < 0.001. 
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Discussion 
An increased activation of the calpain system is an important hallmark in the molecular 
pathogenesis of HD and might represent a key mediator of mutant huntingtin toxicity (Gafni 
and Ellerby, 2002; Gafni et al., 2004). In addition, we have demonstrated increased calpain 
activation in BACHD rats and HDKI mice (Accepted paper d & e). A genetic countermeasure 
is the overexpression of the endogenous calpain inhibitor CAST, which has been shown to 
ameliorate disease phenotype not only in an animal model of HD, but also of other 
neurodegenerative diseases (Simões et al., 2012; Diepenbroek et al., 2014; Menzies et al., 
2014; Rao et al., 2016). To further investigate the contribution of calpains in 
neurodegenerative processes in HD, we sought to increase calpain activity by knocking out 
CAST in vivo. 
After confirming that calpain activity is elevated in CAST knock-out mice at baseline, we 
crossbred them with HDKI animals. The lack of the endogenous calpain inhibitor in HDKI 
animals led expectedly to a further activation of calpains in vivo, which eventually resulted in 
elevated huntingtin fragmentation and aggregate formation. These observations are in line 
with findings in other mouse models of neurodegenerative diseases, which showed 
enhanced disease protein cleavage and aggregation accompanied by an increased neuronal 
loss (Diepenbroek et al., 2014; Accepted paper a). Regarding the latter, we investigated 
dysfunction of dopaminergic neurons by analysing levels of the specific marker DARPP-32. 
Interestingly, despite not observing an increased loss of DARPP-32 in HDKI/Cast-/- mice, we 
detected a reduction of the protein in Cast-/- mice, which was accompanied by an increased 
formation of presumably calpain-dependent fragments. Corresponding to our findings, 
DARPP-32 has been previously identified as a substrate protein of calpains in the context of 
Alzheimer disease (Cho et al., 2015). 
Active calpains have been shown to reduce autophagy and thereby contribute to the 
dysfunctional degradation of toxic protein species like mutant huntingtin aggregates (Yousefi 
et al., 2006; Sarkar et al., 2009; Russo et al., 2011). To investigate these circumstances as 
an additional factor in our HDKI/Cast-/- mice, we analysed levels of the autophagy proteins 
LC3-II and p62. Our results for both markers suggest rather an increase than a decrease in 
autophagy levels, which cannot account for the increased huntingtin aggregate load. 
However, an increased autophagy might be a compensatory effect bracing against the 
elevated huntingtin aggregation in HDKI/Cast-/- mice. Nevertheless, it is of note that 
huntingtin itself was shown to act as a scaffold in macroautophagy (Ochaba et al., 2014; Rui 
et al., 2015). Furthermore, animal models and human HD cells displayed an impairment of 
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autophagy which was characterized by an impaired cargo recognition (Martinez-Vicente et 
al., 2010). All these findings must be considered to correctly evaluate autophagy in a disease 
model like the HDKI/Cast-/- mouse. 
Although we investigated many molecular characteristics in HDKI/Cast-/- mice, which point to 
the strong involvement of the calpain system in HD, further investigations on the behavioural 
phenotype are still remaining. These assessments are necessary to entirely judge the impact 
of a genetic CAST depletion in our HD animals as previously done in a comparable mouse 
model of SCA3 (Accepted paper a). 
In summary, the knockout of CAST in a knock-in mouse model of HD resulted in a worsening 
of the molecular HD-related hallmarks including elevated formation of huntingtin fragments 
and increased amount of respective aggregates. These observations emphasize the 
important role of calpains in the pathogenesis of HD and suggest targeting this pathway as a 
therapeutic approach for this devastating disorder.  
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Introduction 
In our previous study, we reported on the exacerbation of the neurological phenotype in a 
SCA3 mouse model, which was caused by a genetic ablation of the endogenous calpain 
inhibitor calpastatin (CAST) (Accepted paper a). We showed that both calpain-1 and 
calpain-2 cleave wild type and mutant ataxin-3, and that the lack of CAST led to an elevated 
fragmentation and aggregation of ataxin-3 in vivo. This was accompanied by an accelerated 
neurodegeneration in the cerebellum. These observations emphasize the important role of 
the calpain system in the molecular pathogenesis of SCA3. In addition, our investigations 
highlighted two distinct genetic strategies to ameliorate the disease phenotype: First, the 
overexpression of CAST to suppress calpain activity and second, the knockout of calpain-1 
or calpain-2 to lower ataxin-3 cleavage. The first approach has already been reported in a 
recent study, where adeno-associated viral vector-based overexpression of CAST in mouse 
models of SCA3 improved both the molecular and histological phenotype (Simões et al., 
2012). Thus, we aimed at investigating the effect of a calpain-1 knockout (Capn1-/-) in a 
SCA3 animal model. For this, we crossbred the YAC transgenic mouse model for SCA3 
(YAC84) with mice featuring a genetically inactivated Capn1 gene (Azam et al., 2001; Cemal 
et al., 2002). 
To investigate the molecular effects of calpain-1 ablation in mouse brain, we analysed the 
activation state of the calpain system, including levels of CAST and fragmentation of the 
calpain substrates α-spectrin and p35. The impact on endogenous and transgenic, polyQ-
expanded ataxin-3 was surveyed by measuring full-length levels, cleavage and aggregation 
of ataxin-3. 
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Materials and Methods 
Animals 
All mouse experiments were conducted after approval by the local ethics committee at the 
Regierungspraesidium Tuebingen in accordance with the German Animal Welfare Act and 
the guidelines of the Federation of European Laboratory Animal Science Associations, based 
on European Union legislation (Directive 2010/63/EU). Homozygous calpain-1 knockout 
(Capn1-/-) and hemizygous YAC84 mice bred on a C57BL/6 background were maintained 
and genotyped as previously described (Azam et al., 2001; Cemal et al., 2002). Both models 
were crossbred to obtain for groups of mice with 3 animals per group: wild type (WT), 
Capn1-/-, hemizygous YAC84, and YAC84/Capn1-/-. Animals were sacrificed at 3 months of 
age by CO2 inhalation. Whole brains were immediately dissected on ice, snap-frozen in liquid 
nitrogen and stored at –80°C for further analysis. 
Further materials and methods 
Information on tissue preparation and lysis, western blot analysis, and antibodies can be 
found under Accepted papers e and g. Details on TR-FRET based measurements of ataxin-3 
are described in Accepted paper a. 
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Results 
Activation of the calpain system is reduced in Capn1-/- mice 
To confirm the knockout of calpain-1 in single (Capn1-/-) and double mutant animals 
(YAC84/Capn1-/-), we performed western blotting of whole brain samples at 3 months of age. 
Detection of calpain-1 showed the complete absence of the specific band below 80 kDa 
when compared to wild type and single mutant (YAC84) animals (Fig. 1a). As a response to 
the genetic calpain-1 depletion, levels of CAST increased and calpain-specific cleavage of α-
spectrin and p35 were reduced (Fig. 1a and b). This observation points to a substantial 
contribution of the calpain-1 enzyme to the baseline fragmentation of the analysed 
substrates, which was apparently not compensated by another member of the calpain family. 
 
 
Figure 1. Calpain-1 knockout leads to a downregulation of the calpain system. (a) To confirm the 
calpain-1 knockout (Capn1-/-) on protein level, whole brain lysates of 3-month-old mice were analysed 
using western blotting. Activation of the calpain system was assessed by detecting CAST levels and 
fragmentation state of calpain substrates α-spectrin and p35. Actin served as a loading control. White 
arrowheads = full-length proteins, black arrowheads = processed/fragmented proteins. (b) 
Quantification of protein levels and fragment ratio shows reduced overall calpain activation in Capn1-/- 
animals. Horizontal lines represent the means ± s.e.m. of two to three animals per group. 
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Ataxin-3 levels are elevated and cleavage is lowered in calpain-1 knockout animals 
As calpain-1 was shown to cleave ataxin-3 in vitro and its knockout might therefore reduce 
ataxin-3 fragmentation, we analysed whole brain samples of 3-month-old mice by western 
blotting to survey full-length levels and fragments of ataxin-3. Detection with the ataxin-3-
specific antibody 1H9 revealed a different fragmentation patter of ataxin-3 in YAC84 mice, 
when compared wild type animals, featuring additional cleavage bands (Fig. 2a, red 
arrowheads a2 and b2). These marginally bigger fragments appeared to be specific N-
terminal breakdown products of the transgenic human ataxin-3, which cannot be explained 
by an expectedly much stronger polyQ-dependent size shift. Furthermore, immunostaining 
with 1H9 showed a slight increase in full-length ataxin-3 (Fig. 2a and b). This was 
accompanied by a reduction of fragment b1 in Capn1-/- animals and b1 and b2 in double 
mutant YAC84/Capn1-/- mice (Fig. 2a and 2b). However, fragments a1 and a2 showed 
increased levels when knocking out calpain-1. This observation suggests that these larger 
fragments are further processed by calpain-1 and are themselves formed in calpain- or at 
least calpain-1-independent manner. 
To confirm the increase of full-length transgenic ataxin-3, we performed TR-FRET analysis to 
detect only the overexpressed, polyQ-expanded protein in whole brain homogenates. As 
seen in western blotting, TR-FRET measurements showed an increase of full-length ataxin-3 
in YAC84/Capn1-/- mice when compared to YAC84 animals (Fig. 3a), which seems to be a 
direct effect of the lowered calpain-dependent fragmentation. 
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Figure 2. Calpain-1 knockout reduces cleavage of ataxin-3. (a) The effect of calpain-1 knockout 
(Capn1-/-) on ataxin-3 cleavage was analysed in whole brain lysates of mice at 3 months of age using 
the ataxin-3 antibody 1H9. Ataxin-3 fragments are indicated with black and red arrowheads (labelled 
with a1, a2, b1, b2, and c). Red arrowheads indicate ataxin-3 fragments specifically formed in YAC84 
animals. Detection of the blotted stacking gel (SG) shows ataxin-3 aggregates in YAC84 animals. 
Actin served as a loading control. WT = wild type; fl = full-length; tg = transgenic ataxin-3; eg = 
endogenous ataxin-3. (b) Quantification of ataxin-3 full-length levels and fragment ratios. Full-length 
transgenic and endogenous ataxin-3 shows a slight increase in Capn1-/- animals. Fragment a1 and a2 
levels exhibit an increase, whereas levels of fragment b1 and b2 are reduced. Horizontal lines 
represent the means ± s.e.m. of two to three animals per group. 
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Ataxin-3 aggregation levels are not altered in mice with a calpain-1 knockout 
Proteolytic fragmentation of polyQ proteins has been suggested as the source of toxic and 
aggregation-prone breakdown products and thus as a contributing factor to the formation of 
protein aggregates. To investigate effects of the calpain-1 knockout on ataxin-3 aggregation 
in vivo, we performed filter retardation assays to measure the aggregate load in whole brain 
homogenates of YAC84 animals with and without the genetic depletion of calpain-1. 
However, detection with the ataxin-3-specific antibody 1H9 showed no major changes in the 
aggregate levels in YAC84/Capn1-/- animals of 3 months of age (Fig. 3b) when compared to 
YAC84 mice. 
 
 
Figure 3. Transgenic ataxin-3 levels increase upon calpain-1 knockout. (a) TR-FRET analysis of 
whole brain homogenates of 3-month-old mice was performed to further validate effects of the 
calpain-1 knockout (Capn1-/-) on ataxin-3 levels. Knockout of calpain-1 leads to an increase of the 
transgenic ataxin-3 signal in YAC84 animals, indicative of elevated levels as seen before by western 
blotting. (b) Ataxin-3 aggregation levels in whole brain homogenates were investigated using filter 
retardation assays. Signal quantification did not show any clear changes in the aggregate load of 
YAC84/Capn1-/- mice at 3 months of age, when compared to YAC84 animals. Horizontal lines 
represent the means ± s.e.m. of two to three animals per group. 
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Calpain-1 knockout leads to increased CAST levels in muscle tissue 
The knockout animals used in this study exhibit a global inactivation of calpain-1 in all 
tissues. To investigate the impact of the calpain-1 knockout in peripheral tissue, we analysed 
the calpain system and ataxin-3 cleavage in lysates of femoral muscle tissue. Western blot 
analysis confirmed the knockout of calpain-1 on protein level (Fig. 4a). The lack of calpain-1 
expression led to a distinct elevation of CAST levels, whereas alterations of α-spectrin 
cleavage were not clearly detectable (Fig. 4b). As ataxin-3 is also expressed in muscle 
tissue, we investigated full-length levels and ataxin-3 fragmentation in our samples. 
Compared to brain tissue, ataxin-3 showed a slightly different fragmentation pattern in 
muscle tissue with strongly elevated levels of fragment c (Fig. 4b). As seen for fragmentation 
of the calpain substrate α-spectrin, cleavage of ataxin-3 was not obviously changed and the 
samples showed certain variability. However, qualitatively, fragment b1 showed a trend 
towards reduced and fragment a1 toward increased levels (Fig. 4b). 
 
 
Figure 4. Calpain-1 knockout affects the calpain system in muscle tissue. (a) To analyse the 
calpain-1 knockout in non-neuronal tissue, lysates of femoral muscle tissue of 3-month-old mice were 
investigated by western blotting. Activation of the calpain system was assessed by detecting CAST 
levels and fragmentation state of calpain substrate α-spectrin. Citrate synthase (CS) served as a 
loading control. White arrowheads = full-length proteins, black arrowheads = processed/fragmented 
proteins. As in neuronal tissue Capn1-/- leads to a decrease of calpain system activation in muscle 
tissue. (b) Ataxin-3 fragmentation in femoral muscle tissue lysates was assessed by western blotting 
with the ataxin-3 antibody 1H9. Ataxin-3 fragments are indicated with black and red arrowheads 
(labelled with a1, a2, b1, b2, and c). Citrate synthase (CS) served as a loading control. fl = full-length, tg 
= transgenic ataxin-3, eg = endogenous ataxin-3. 
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Discussion 
We investigated the genetic inactivation of calpain-1 in the YAC84 mouse model of SCA3 as 
a possible strategy for lowering calpain-mediated cleavage of polyQ-expanded ataxin-3. The 
fragmentation of the disease protein is discussed as an important source for toxic fragments 
and seeds for formation of aggregates, and its reduction might alleviate the disease 
progression. 
Our previous study has shown that calpain-1 and calpain-2 cleave wild type and polyQ-
expanded ataxin-3 and overactivation of the calpain system by knocking out the endogenous 
inhibitor CAST led to a worsening of the SCA3 phenotype in vivo (Accepted paper a). 
Investigations performed by other researches demonstrated, that a reduction of calpain 
activity by overexpressing CAST or by pharmacological inhibition reduced ataxin-3 cleavage 
and fragmentation, and prevented cerebellar degeneration and motor behavioural deficits 
(Simões et al., 2012, 2014). Thus, genetic ablation of one of the calpain isoforms, which was 
associated with polyQ-expanded ataxin-3 cleavage, might represent a further option to 
ameliorate disease-related molecular and phenotypic abnormalities in a mouse model of 
SCA3. 
For this, we crossbred Capn1-/- animals with YAC84 SCA3 mice and investigated the effect of 
the knockout on ataxin-3 levels, fragmentation and aggregation at 3 months of age (Azam et 
al., 2001; Cemal et al., 2002). Using western blot analysis, we confirmed the knockout of 
calpain-1 not only in whole brain but also in muscle tissue, and observed a downregulation of 
the calpain system activity. Furthermore, we observed a reduction of specific calpain-
dependent breakdown products of ataxin-3 in Capn1-/- and YAC84/Capn1-/- mice and, as a 
consequence of it, an increase of ataxin-3 full-length levels. However, we did not observe the 
anticipated reduction of ataxin-3 aggregation in YAC84/Capn1-/- mice. 
The lack of a clear effect of the calpain-1 knockout on aggregation can be due to different 
factors. One limitation might be the comparatively early time point of investigations at three 
months of age, despite both hemizygous and homozygous YACQ84 mice were shown to 
have robust intranuclear accumulation of mutant ataxin-3 at as early as six to eight weeks of 
age (do Carmo Costa et al., 2013). However, there might be differences between cleavage of 
ataxin-3 by calpain-1 or by other calpains, producing fragments with different toxicities and 
aggregation propensities. For example, in Huntington disease (HD), a strong association of 
the disease phenotype especially with caspase-6-mediated cleavage of huntingtin was 
discovered, which was circumvented in a mouse model expressing caspase-6 cleavage-
resistant, polyQ-expanded huntingtin (Graham et al., 2006). In this regard, crossbreeding 
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YAC84 mice with a calpain-2 knockout model and a comparison with our YAC84/Capn1-/- 
might throw light on this matter. Of particular note in this regard is that a homozygous 
knockout of calpain-2 is lethal and obtaining adult mice is only possible under a conditional 
knockout in which calpain-2 is still expressed in the placenta (Takano et al., 2011). 
Furthermore, very recent publications are indicating that targeting calpain-1 as a therapeutic 
strategy should be approached with caution, as Capn1 null-mutations in patients resulted in 
cerebellar ataxia and limb spasticity and a calpain-1 knockout in mice led to an abnormal 
cerebellar development (Liu et al., 2016; Y. Wang et al., 2016). With reference to this, our 
rotarod assessments of YAC84/Capn1-/- but also Capn1-/- mice showed certain deficits in 
motor behaviour when compared to YAC84 or wild type animals (data not shown). 
Taken together, knockout of calpain-1 seems to reduce cleavage of endogenous and 
transgenic, polyQ-expanded ataxin-3 in animals, but without leading to a reduced 
aggregation in mice at 3 months of age. Our behavioural data and recent publications are 
pointing to rather diametrically opposite effects of the knockout as the genetic inactivation of 
calpain-1 might exacerbate the observed ataxic phenotype in SCA3 mice. Thus, genetically 
targeting calpain-1 as a treatment for SCA3 might represent a therapeutic impasse. 
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Introduction 
Following the toxic fragment hypothesis, proteolytic fragments of mutant huntingtin are 
suggested as mediators of neurotoxic effects, which ultimately cause neuronal death 
(Wellington and Hayden, 1997). Underpinning this conjecture, the accumulation and 
aggregation of N-terminal polyglutamine (polyQ)-containing fragments of the HD protein 
huntingtin has been observed in animal models as well as in HD patient brain tissue (DiFiglia 
et al., 1997; Mende-Mueller et al., 2001; Toneff et al., 2002; Wang et al., 2008). In 
consequence, a row of cell and animal models of HD overexpressing N-terminal huntingtin 
fragments has been generated, which display increased cell death, aggravated phenotypes 
or an earlier disease onset (Mangiarini et al., 1996; Cooper et al., 1998; Hackam et al., 1999; 
Schilling, Becher, et al., 1999; Igarashi et al., 2003). 
On these grounds, many researchers have focussed on the identification of enzymes 
responsible for proteolysis of huntingtin or on the localization of cleavage sites within the 
disease protein. Since then, various groups of proteases have been associated with the 
cleavage of huntingtin. Amongst them, caspases and calpains appeared to be the most 
important contributors and a long list of their cleavage sites has been identified, mainly 
localized between amino acids 400 and 600 of the huntingtin protein (Goldberg et al., 1996; 
Gafni and Ellerby, 2002; Ehrnhoefer et al., 2011). Further investigations demonstrated that 
preventing cleavage by inhibiting specific proteases or by mutating their recognition sites, 
ameliorated the disease phenotype both in cell and animals models of HD and might 
therefore represent an promising therapeutic approach to treat this fatal disorder (Wellington 
et al., 2000; Gafni et al., 2004; Graham et al., 2010). 
Several studies described calpain-dependent cleavage of huntingtin in cell models, neuronal 
tissue of animal models and post mortem patient brain (Kim et al., 2001; Gafni and Ellerby, 
2002). Calpains, a group of Ca2+-activated cysteine proteases, were reported to cleave 
huntingtin at residues 469 and 536 and mutating these sites for rendering huntingtin calpain-
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resistant reduced the formation of toxic and aggregation-prone fragments (Gafni et al., 2004). 
However, as huntingtin constitutes a large protein of more than three thousand amino acids 
and previously analysed calpain-dependent fragmentation patterns appeared to be more 
complex, the number of calpain cleavage sites within huntingtin is probably much higher. 
In our experiments, we focussed on analysing the proteolytic fragmentation of huntingtin by 
calpains. Our aims were to test whether huntingtin is cleaved by both calpain-1 and calpain-2 
in vitro and to model calpain-dependent cleavage in HD cell lines. Furthermore, using a mass 
spectrometry-based approach, we sought to identify further calpain cleavage sites in the 
huntingtin protein, which might contribute to the formation of toxic huntingtin fragments. 
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Materials and Methods 
Cell culture 
For overexpression of HA-tagged huntingtin 15Q and 128Q, HEK 293T (ATCC: CRL-11268) 
cells were transfected 24 h post-seeding with pCI-neo vectors containing the respective 
cDNA and harvested 48 h after transfection. Attractene (QIAGEN) was used as a 
transfection reagent according to manufacturer's instructions. Immortalized murine striatal 
precursor cell lines of HD (STHdh) were purchased from Coriell Cell Repositories (Coriell 
Institute for Medical Research) and utilized in an undifferentiated state. All cell lines were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal calf 
serum, 1% penicillin/streptomycin (all Thermo Fisher Scientific) at 37°C and 5% CO2. Media 
for STHdh cells was additionally supplemented with 1% geneticin (Biochrome). 
Calpain activation assays in vitro 
Calpain activation assays in vitro were described elsewhere (see Accepted paper g). A 
modification of the protocol comprises the application of the calpain inhibitor ALLN (N-Acetyl-
L-leucyl-L-leucyl-L-norleucinal) at a concentration of 100 µM as a negative control. 
Gel staining for mass-spectrometry sampling 
To obtain material for mass spectrometry analysis of cleavage sites in huntingtin, RIPA-
lysates of HEK 293T transfected with HA-huntingtin 15Q and HA-huntingtin 128Q, untreated 
or incubated with CaCl2 for calpain activation, were separated on NuPAGE Novex 7% Tris-
Acetate gels (Thermo Fisher Scientific). After electrophoresis, gels were stained using the 
Coomassie G-250-based protein gel stain SimplyBlue™ SafeStain (Thermo Fisher 
Scientific), following the manufacturer's protocol. Gel areas were excised with a scalpel, 
samples transferred to 1.5 ml reaction tubes and stored at 4°C. 
In silico cleavage site prediction using the GPS-CCD tool 
Cleavage likelihood score was computed using the using the GPS-CCD (group-based 
prediction system-calpain cleavage detector) software (Z. Liu et al., 2011). Predictions were 
based on a wild type huntingtin reference sequence (UniProt identifier: P42858-1 with 15 
glutamines). Scores for amino acid positions 1150-1200 were graphically visualized using 
GraphPad Prism 6.00 for Windows (GraphPad Software Inc.). 
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Further materials and methods 
Information on cell lysis, western blot analysis, and antibodies can be found under Accepted 
papers e and g. 
Mass spectrometry analyses and data interpretation was conducted as a service by the 
Proteome Center Tuebingen, Interfaculty Institute for Cell Biology, University of Tuebingen, 
Tuebingen, in collaboration with the Quantitative Biology Center (QBiC), University of 
Tuebingen, Tuebingen, Germany. 
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Results 
Calpain cleavage of huntingtin can be induced in immortalized striatal precursor cells of HD 
To reconfirm previous findings on calpain-dependent cleavage of huntingtin and to get a 
closer look at calpain-derived fragmentation patterns, we performed in vitro calpain cleavage 
assays using lysates of undifferentiated STHdhQ7 and STHdhQ111 cells. These cell lines were 
derived from wild type and homozygous HdhQ111 mice, and represent immortalized striatal 
precursor cells with a potential of differentiation into neuron-like cells (Wheeler et al., 1999; 
Trettel et al., 2000). 
We incubated respective cell lysates with recombinant calpain-1 and calpain-2 upon addition 
of calcium chloride (CaCl2) to activate the applied enzymes. The induced fragmentation was 
analysed by western blotting using the huntingtin-specific antibody (D7F7, epitope around 
amino acid position 1220). We observed a time-dependent increase in huntingtin fragments 
with a wide range of molecular weights and a correlating reduction of the full-length protein 
(Fig. 1a and b). Cleavage of huntingtin was abolished by the addition of the calpain-specific 
inhibitor ALLN. The fragmentation patterns did not show clear differences, when comparing 
huntingtin cleavage by calpain-1 with calpain-2. However, the over-all fragmentation 
appeared to be weaker in lysates of STHdhQ111, which can be explained by a decreased 
expression level of polyQ-expanded huntingtin in this cell line. Interestingly, detection of 
endogenous calpain-1 in samples incubated with recombinant calpain-2, showed a parallel 
activation of the endogenous enzyme due to addition of CaCl2 (Fig. 1b). 
To evaluate the effects of endogenous calpain activation, we incubated lysates of STHdhQ7 
and STHdhQ111 cells only with CaCl2 and performed western blotting of thereby generated 
samples. Successful induction of the calpain activity was validated by detecting the activation 
state of calpain-1 and the fragment formation of the known calpain substrate α-spectrin (Fig. 
1c). The calpain-dependent cleavage of huntingtin was reproduced, but occurred expectedly 
to a weaker extent then in set-ups with recombinant calpains (Fig. 1c). Interestingly, in all 
experimental set-ups, we observed a time-dependent generation of a calpain-independent 
cleavage product of huntingtin in lysates of STHdhQ111 but not of STHdhQ7 cells (Fig. 1a, b, c; 
black arrows), which was not prevented when incubating with calpain inhibitors ALLN or 
CI III. The origin of this fragment remains unclarified, but preliminary results from additional 
experiments, which included a pan-caspase inhibitor, ruled out a caspase-dependent origin 
of this breakdown product (data not shown). 
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Figure 1. Calpain activation assays in vitro with or without recombinant calpains confirm the 
calpain-dependent cleavage of huntingtin in STHdh cell extracts. STHdh cell lysates were diluted 
in calpain reaction buffer. After addition of recombinant calpain-1 (rCAPN1, a) or calpain-2 (rCAPN2, 
b), samples were incubated at room temperature for the indicated times. To inhibit calpain activity, 
100 µM of calpain inhibitor ALLN were added to the respective control reaction. Samples were 
analysed using western blotting and immunostaining with huntingtin (D7F7) and calpain-1 antibodies. 
(c) To activate endogenous calpains, STHdh cell lysates were diluted in calpain reaction buffer and 
incubated with 2 mM calcium chloride (CaCl2) for the indicated times at room temperature. To inhibit 
calpain activity, 100 µM calpain inhibitor III (CI III) were added. Samples were analysed using western 
blotting and immunostaining with huntingtin (D7F7), α-spectrin and calpain-1 antibodies. Tubulin 
served as a loading control. White arrowheads indicate full-length proteins; black arrowheads highlight 
proteolytically processed proteins. Black arrows indicate a calpain cleavage-independent fragment. flQ7 
and flQ111 = full-length huntingtin 7Q and 111Q. 
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Overexpressed human huntingtin is cleaved by calpains in vitro 
As STHdh cells express only wild type and polyglutamine-expanded huntingtin of murine 
origin, we sought to repeat our experiments with human huntingtin constructs. For this 
purpose, we transfected HEK 293T cells with HA-tagged huntingtin containing 15 or 128 
glutamines and subjected lysates to in vitro calpain activation assay with recombinant 
calpain-1 and calpain-2. Western blotting showed the formation of N-terminal and polyQ-
independent C-terminal fragments of huntingtin as detected with the antibodies 2166 
(epitope at amino acid 445-459) and D7F7 (epitope around amino acid position 1220) (Fig. 
2a-d). As known for calpain cleavage of huntingtin in STHdh cells, fragmentation patterns 
induced by calpain-1 and calpain-2 did not differ. This observation points to equivalent 
recognition of the same cleavage sites by both proteases. Likewise, the C-terminal cleavage 
pattern of HA-huntingtin 15Q and 128Q was comparable. However, N-terminal breakdown 
products induced by calpain activation could be hardly detected, pointing to a stronger further 
processing or aggregation of generated polyQ-containing fragments. 
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Figure 2. Overexpressed wild type and mutant huntingtin are cleaved by calpain-1 and 
calpain-2 in vitro. HEK 293T cells expressing human HA-tagged huntingtin with 15Q (a and b) or 
128Q (c and d) were lysed in calpain reaction buffer and incubated with recombinant calpain-1 
(rCAPN1, a and c) or calpain-2 (rCAPN2, b and d) for up to 15 min. To inhibit calpain activity, 100 µM 
ALLN were added to the respective control reaction. Subsequent western blot analysis using the 
huntingtin-specific antibodies 2166 (epitope at amino acids 445-459) and D7F7 (epitope around amino 
acid 1220) revealed several, mainly polyQ-independent huntingtin-fragments accumulating upon 
calpain activation (red and green arrowheads). fl = full length huntingtin. 
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Calpain activation leads to proteolysis of overexpressed human huntingtin in living cells 
To repeat our experiments under more physiological conditions, we treated HEK 293T cells 
transfected with HA-huntingtin 15Q and 128Q with the Ca2+ ionophore ionomycin to activate 
endogenous calpains. Western blotting of calpain-1 and a-spectrin cleavage confirmed the 
activation of the calpain system (Fig. 3b). When detecting huntingtin with the antibodies 2166 
and D7F7, differences in N-terminal fragmentation pattern could be observed, showing a set 
of fragments shifting upwards in a polyQ-dependent manner (Fig. 3a, red arrowheads). 
However, both huntingtin variants were proteolytically processed with a comparable 
efficiency, resulting in the formation of fragments of similar intensities. Interestingly, 
huntingtin fragmentation appeared to give rise to two large polyQ-independent fragments, 
which can be observed just below the full-length protein (Fig 3a, uppermost green 
arrowheads, bdpLCter). These fragments point to the existence to a yet unidentified, rather C-
terminal calpain cleavage sites. 
 
 
Figure 3. Cell-based activation of calpains leads to fragmentation of wild type and mutant 
huntingtin. HEK 293T cells expressing human HA-tagged huntingtin with 15Q or 128Q were treated 
with ionomycin to activate endogenous calpains for up to 4 h. To inhibit calpain activity, cells were pre-
incubated with 25 µM calpain inhibitor III (CI III) for 1 h before ionomycin treatment. (a) Western blot 
analysis using huntingtin-specific antibodies 2166 (epitope at amino acids 445-459) and D7F7 
(epitope around amino acid 1220) detected a time-dependent formation of several polyQ-containing 
and -non-containing fragments upon calpain activation (red and green arrowheads). fl15Q and fl128Q = 
full-length huntingtin 15Q and 128Q; bdp = breakdown product, LCter = large C-terminal fragments. 
(b) Activation of the calpain system was validated by detecting calpain-1 activation and α-spectrin 
cleavage. Actin served as loading control. Asterisk indicates redetection of huntingtin in the α-spectrin 
blot. 
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Identification of a calpain cleavage site between amino acids 1167 and 1168 
Calpain activation in cells expressing HA-tagged huntingtin, revealed the existence of two 
large calpain cleavage-dependent C-terminal huntingtin breakdown products. To localize the 
cleavage sites within huntingtin, which are responsible for the generation of these fragments, 
we performed mass spectrometric analysis of huntingtin and huntingtin fragments without or 
after calpain activation. For this, we incubated lysates of wild type and polyQ-expanded HA-
huntingtin transfected HEK 293T cells with CaCl2 to activate calpains and loaded the 
samples on Tris-Acetate gels. A control set of samples was transferred on nitrocellulose 
membrane and immunodetected with the D7F7 antibody to confirm a successful cleavage 
induction of huntingtin (Fig. 4a). After total protein staining of the gel, areas were excised 
which contain the full-length protein or the high-molecular huntingtin fragments of interest 
(Fig. 4b). Thereby isolated fractions were analysed using mass spectrometry to identify non-
tryptic peptides, when comparing samples with and without calpain activation. Despite 
limitations in coverage of the total huntingtin sequence, a peptide corresponding to cleavage 
between amino acid positions T1167 and N1168 in HA-huntingtin 15Q could be identified 
(Fig. 4c). In addition, computation of the likelihood for calpain cleavage within the region of 
interest of huntingtin further endorsed the identification of a cleavage site after amino acid 
T1167 (Fig. 4d). A potential cleavage at this site could explain the formation of one of the 
observed large C-terminal fragments, which can be detected by the D7F7 but not by the 
2166 antibody. 
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Figure 4. Identification of calpain cleavage sites within huntingtin by mass spectrometry. 
Lysates of HEK 293T cells transfected with HA-huntingtin 15Q and 128Q were incubated for 2 h with 
2 mM CaCl2 (+) to induce calpain-dependent cleavage of huntingtin and analysed via western blotting 
and mass spectrometry. (a) Western blot analysis using the huntingtin-specific antibody D7F7 shows 
decrease of full-length huntingtin (fl15Q or fl128Q) and an accumulation of polyQ-independent, high-
molecular huntingtin fragments (black arrowheads). (b) To prepare material for mass spectrometry 
analysis, samples were run on a Tris-Acetate gel and visualized using Coomassie. Respective areas 
in the gel (red boxes) were excised containing only full-length huntingtin (fl15Q or fl128Q) or sections 
enriched for high-molecular huntingtin fragments (bdps15Q or bdps128Q) with (+) or without (-) cleavage-
induction by addition of CaCl2. (c) Mass spectrometry analysis identified a specific non-tryptic and 
presumably calpain-dependent cleavage event located between amino acid (aa) positions T1167 and 
N1168 in the human huntingtin 15Q reference sequence. Representative peptide coverage blot of the 
huntingtin 15Q sequence between amino acids 1150 and 1995 shows tryptic and non-tryptic peptides 
as detected in the excised gel sections. (d) Calpain cleavage site prediction within in the region of 
interest using the GPS-CCD tool shows a high cleavage likelihood after amino acid T1167 of human 
huntingtin (UniProt identifier: P42858-1 with 15 glutamines). The red dotted line indicates maximum 
default cut-off value of 0.654. CLS = cleavage likelihood score. 
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Discussion 
Proteolysis of polyQ-expanded huntingtin was shown to be an important key event in the 
molecular pathogenesis of HD and calpains were identified as one of the major groups of 
enzymes executing cleavage of the disease protein (Gafni and Ellerby, 2002; Gafni et al., 
2004; Ehrnhoefer et al., 2011). Although previous studies have analysed calpain-dependent 
fragmentation of huntingtin and identified several cleavage sites within the protein, the impact 
of certain cleavage fragments remains nebulous. Therefore, we focused on reproducing 
calpain cleavage of huntingtin in different cell models of HD and to identify new calpain 
cleavage sites. 
In our experiments, we showed that wild type and polyQ-expanded huntingtin are cleaved 
both by calpain-1 and calpain-2 in vitro, producing comparable fragmentation patterns. Cell-
based assays did not show differences in fragmentation efficiency between wild type and 
polyQ-expanded huntingtin. However, N-terminal fragments of huntingtin with 128 glutamines 
showed an expected, polyQ-dependent size shift. Our observations accentuate that calpain 
cleavage of huntingtin is a physiological process, though toxicity and aggregation propensity 
of formed fragments reportedly depend on the length of the embedded polyQ stretch (Cooper 
et al., 1998). Interestingly, a recent publication demonstrated that polyQ-independent 
breakdown products of huntingtin can evoke additional negative effects by compromising the 
endoplasmic reticulum (El-Daher et al., 2015). Moreover, different N-terminal and C-terminal 
portions of the huntingtin protein seem to share similarities with Saccharomyces cerevisiae 
autophagic proteins and overexpression of C-terminal Atg11-like huntingtin fragments in rat 
primary cortical neurons induced cell death (Ochaba et al., 2014). These findings demand 
further investigations on C-terminal cleavage events and the identification of proteases 
responsible for it. 
In a further, preliminary approach, we sought to localize a calpain cleavage site, which might 
explain the origin of a large C-terminal fragment of huntingtin. Using mass spectrometry 
analysis, we identified a probable cleavage site between amino acids T1167 and N1168 
within the huntingtin 15Q reference sequence. However, the identified cleavage site requires 
a further validation, which could be achieved by site directed mutagenesis. 
Taken together, our investigations confirm the occurrence of huntingtin fragmentation by 
calpains and contribute to the search for calpain cleavage sites in the disease protein, which 
can help to clarify the role of polyQ-dependent and -independent huntingtin fragments in the 
pathogenesis of HD. 
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Abstract 
Spinocerebellar Ataxia Type 3 (SCA3) is pathologically characterized by the formation of 
intranuclear aggregates which contain ataxin-3, the mutated protein in SCA3, in a specific 
subtype of neurons. It has been proposed that ataxin-3 is cleaved by proteolytic enzymes, in 
particular by calpains and caspases, eventually leading to the formation of aggregates. In our 
study, we examined the ability of calpains to cleave ataxin-3 in vitro and in vivo. We 
demonstrated in cell culture and mouse brain homogenates that cleavage of overexpressed 
ataxin-3 by calpains and in particular by calpain-2 occur and that polyglutamine expanded 
ataxin-3 is more sensitive to calpain degradation. Based on these results, we investigated 
the influence of calpains on the pathogenesis of SCA3 in vivo. For this purpose, we 
enhanced calpain activity in a SCA3 transgenic mouse model by knocking out the 
endogenous calpain inhibitor calpastatin. Double-mutant mice demonstrated an aggravated 
neurological phenotype with an increased number of nuclear aggregates and accelerated 
neurodegeneration in the cerebellum. This study confirms the critical importance of calcium-
dependent calpain-type proteases in the pathogenesis of SCA3 and suggests that 
manipulating the ataxin-3 cleavage pathway and the regulation of intracellular calcium 
homeostasis may represent novel targets for therapeutic intervention in SCA3. 
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Introduction 
Neurodegenerative diseases such as Parkinson disease (PD), Huntington disease (HD) or 
the Spinocerebellar Ataxia group (SCA) are proposed to share common pathogenic 
mechanisms, including generation of toxic fragments by cytoplasmic cleavage, aggregate 
formation and neurodegeneration in disease specific neurons (1, 2). For polyglutamine 
diseases such as HD and SCA pathogenesis models suggest cytoplasmic cleavage of the 
mutant protein leading to nuclear translocation of fragments containing the polyQ tract (3, 4). 
Further studies revealed a much higher toxicity of fragments or truncated polyQ proteins with 
a shifted propensity to aggregate compared to expanded full-length polyglutamine proteins 
(reviewed in 5, 6). Therefore, cleavage of disease proteins by proteases (e.g. caspases or 
calpains) is proposed to represent an important step in the pathogenesis of 
neurodegenerative diseases. For Spinocerebellar Ataxia Type 3 (SCA3), caused by an 
expanded polyglutamine tract in the encoded ataxin-3 protein, cleavage by caspases (7-11) 
or calpains (12-14) is controversially discussed. The latter studies did, however, show that 
the calpain-dependent formation of polyglutamine containing fragments is triggered by 
calcium in neuroblastoma cells (12) and in patient-specific induced pluripotent stem cell 
(iPSC)-derived neurons (13). In iPS cells, generation of fragments and aggregate formation 
were not suppressed after treatment with caspase-1, caspase-3, or pan-caspase inhibitors. 
In contrast, treatment with ALLN or calpeptin (both calpain inhibitors) resulted in complete 
disappearance of aggregates (13). Additionally, overexpression of calpastatin, the only 
known endogenous calpain inhibitor, inhibited cleavage and prevented aggregation of ataxin-
3 in neuroblastoma cells (12) and mouse brain (14). Both studies indicated that the 
occurrence of specific cleavage products was closely correlated with the aggregation 
process and demonstrated that calpain proteolysis may initiate a harmful aggregation 
cascade. 
The calpain system originally comprised three different important proteins in neurons: the two 
best characterized members of the calpain family, calpain-1 and calpain-2 and calpastatin, 
whose only known function is to inhibit these calpains (15). Calpain-1 is activated by calcium 
concentrations in the μM range, whereas calpain-2 is activated by mM levels of calcium in 
vitro. As the activation of calpains is an irreversible process, calpain activation must be 
strictly controlled. Calpastatin binds to the inhibitory domain on both sides of the active site 
cleft in a reversible manner to inhibit calpains in vivo (16). The calpain system is also critical 
for development, as mice lacking the common regulatory 30 kDa calpain subunit (17) or 
calpain-2 (18) die prenatally, whereas mice lacking calpain-1 (19) or calpastatin (20) are 
phenotypically normal.  
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To gain more insight into the impact of proteolytic cleavage of ataxin-3 in vivo, we 
investigated whether enhancing calpain cleavage modifies polyQ-expanded ataxin-3 in terms 
of cellular toxicity and formation of aggregates. Therefore, SCA3 transgenic mice 
overexpressing human ataxin-3 with 140Q (21) were crossbred with mice lacking the 
intracellular calpain inhibitor calpastatin (Cast KO; 20). We focused on the question whether 
ataxin-3 is cleaved by calpain-1 or calpain-2 in mouse brain in vivo and how this process 
would influence aggregate formation and neuropathology. In summary, we demonstrate for 
the first time that ataxin-3 is a substrate of calpain-1 and calpain-2 in vitro and in vivo and 
that these proteases present promising targets for therapeutic intervention. 
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Results 
Ataxin-3 is a sensitive calpain substrate in vitro 
To determine whether ataxin-3 is a calpain sensitive substrate in vitro, we investigated 
cleavage of overexpressed ataxin-3 with different polyglutamine lengths (15Q, 77Q, 148Q) in 
HEK293T cells. After incubation with 2 mM CaCl2 and either recombinant calpain-1 or 
calpain-2 for up to 45 min ataxin-3 was cleaved more efficiently with recombinant calpain-2. 
Whereas most of full-length ataxin-3 was still detectable after 45 min of calpain-1 incubation 
(Fig. 1A-C), the length of the polyglutamine tract modulates calpain-2 cleavage of ataxin-3 
(Fig. 1D-F). Full-length ataxin-3 with 15Q is nearly fully cleaved by calpain-2 after 45 min of 
incubation (Fig. 1D). On the other hand, cell lysates with an expanded polyglutamine tract 
revealed a complete cleavage of full-length ataxin-3 after 30 min (77Q) or 15 min (148Q) of 
incubation, respectively (Fig. 1E, F). Clearly, an N-terminal derived cleavage fragment of 
around 30 kDa was detected after calpain-1 and -2 cleavage independently of the polyQ 
lengths (Fig. 1A-F). Inhibition of calpain cleavage by incubation with ALLN resulted in no 
fragmentation of full-length ataxin-3 regardless of the polyglutamine length indicating that the 
observed cleaved ataxin-3 fragments were generated by calpain cleavage. 
 
Generation of double-mutant Cast KO (-/-)/SCA3 mice 
To further investigate the role of calpain cleavage in the pathogenesis of SCA3 in vivo, we 
crossbred calpastatin knock-out mice (20) with our SCA3 disease model (21). This SCA3 
mouse model exhibits striking intergenerational instability of the expanded CAG stretch 
which modifies age at onset of symptoms and progression of the disease as it has been 
described for other polyQ models as well (22-26). SCA3 mice with 140Q demonstrated an 
ataxic and neurological phenotype as well as premature death, starting at the age of 6 to 9 
months. In subsequent experiments, we therefore only used mice with 140Q, which are 
referred to as SCA3 in the following data. We confirmed that mutant ataxin-3 was expressed 
and calpastatin was knocked out in brains of double-mutant mice (dm-mice) by Western blot 
and immunohistochemical analyses whereas both mutant ataxin-3 and endogenous 
calpastatin were expressed in single-transgenic SCA 3 mice (st-mice) (data not shown). We 
also confirmed for each mouse the polyQ size of 140. 
 
Calpastatin activity determines calpain cleavage rate of ataxin-3 ex vivo 
To determine cleavage rates of endogenous and overexpressed ataxin-3 ex vivo when 
calpastatin is normally expressed or fully abolished, we used brain homogenates from 3 
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independent animals of wildtype mice, homozygous calpastatin knock-out mice [Cast KO (-/-
)] as well as SCA3 st- and dm-mice [Cast KO (-/-)/SCA3] in a cleavage assay. Here we found 
that endogenous ataxin-3 in brain homogenates from wildtype mice was sensitively cleaved 
by calpain-1 and calpain-2 in the presence of 2 mM calcium, respectively. However, 
cleavage by calpain-2 occurs more rapidly and more efficiently. For both enzymes, calpain-1 
and calpain-2, the same N-terminal derived ataxin-3 specific cleavage fragments at around 
30 kDa (Fig. 2A, E) were detected as seen before in the cell culture analyses (Fig. 1). 
Specificity of calpain cleavage was confirmed by incubation with the calpain inhibitor ALLN. 
Knocking out calpastatin completely, we observed a faster degradation of endogenous 
mouse ataxin-3 after incubation with calpain-1 (Fig. 2B) as well as an increased amount of 
the 30 kDa cleavage fragment (Fig. 2I). However, cleavage by calpain-2 occurred 
immediately and more efficiently and revealed a very strong 30 kDa cleavage fragment after 
5 min of incubation (Fig. 2F, J). Analyzing mice with overexpressed human ataxin-3 
demonstrated that after 5 min of incubation with calpain-1 and calpain-2 almost no 
overexpressed protein is detectable (Fig. 2C, G). Similar results were found after knocking 
out calpastatin (Fig. 2D, H). The 30 kDa N-terminal derived cleavage fragment occurred 
independently from overexpressed human ataxin-3 as it is also seen in wildtype and Cast KO 
(-/-) mice (Fig. 2C, D, G, H). Quantification of the 30 kDa cleavage fragment demonstrated a 
more rapidly produced fragment if calpastatin is knocked out completely independently of the 
expression of a polyglutamine expanded human ataxin-3. The results were similar using 
either calpain-1 or calpain-2 (Fig. 2I, J). 
 
Calpastatin knock-out increases mutant ataxin-3 fragmentation upon calcium stimulation 
To quantify soluble mutant ataxin-3, we applied a highly sensitive time-resolved Förster 
resonance energy transfer (TR-FRET) assay, using the ataxin-3 antibody 1H9 (terbium 
cryptate-labeled) and the expanded polyQ specific MW1 (D2-labeled; Fig. 3A). Both 
antibodies are flanking a previously described potential cleavage site of ataxin-3 at amino 
acid position 260 (12) and exhibit fluorescence energy transfer in close proximity. Using the 
TR-FRET assay, we assessed the amount of soluble mutant ataxin-3 in the various 
genotypes in native cerebellar brain lysates, and additionally upon increased calpain-1 or 
calpain-2 activation via calcium stimulation over time (TR-FRET). As expected, since the 
MW1 antibody is specific against an expanded polyQ stretch (≥6CAGs), almost no ataxin-3 
signal was observed in Cast KO (-/-) and wildtype mice. In contrast, in st-line SCA3 and in 
dm-mice a TR-FRET signal was detected. Notably, the signal intensity in the dm-mice was 
only half of that of the st-line SCA3. After calcium stimulation, the FRET signal decreases in 
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cerebellar brain lysates of st-line and dm-mice to half of the normal level (Fig. 3B). This 
indicates that decreased detection of soluble mutant ataxin-3 after calcium induction was due 
to increased calpain cleavage at amino acid position 260 (Fig. 3A). 
 
Knock-out of calpastatin leads to an increased number of aggregates and neurodegeneration 
in SCA3 mice 
Aggregate formation was analyzed in brain regions with high expression of calpain-1 and 
calpain-2 (confirmed by the ALLEN brain atlas; www.brain-map.org) as well as SCA3 
transgene expression, including cerebellum and pons. Using ataxin-3 immunostaining of 
brain slices, we found the highest number of ataxin-3 positive nuclear inclusions (NII) in dm-
mice at the age of 12 months. Significantly fewer aggregates were detected in mice of the st-
line SCA3 confirmed by quantitative analysis of aggregates per cell in the cerebellum and 
pons (Fig. 4A, B). Furthermore, even in SCA3 mice, in which calpastatin is knocked out 
heterozygously [Cast KO (+/-)/SCA3], the number of neurons with NII is dramatically 
increased compared to st-line SCA3 (Fig. 4) suggesting that loss of one calpastatin allele 
was sufficient to enhance the formation of aggregates. Immunofluorescence staining with 
calpain-1 or calpain-2 antibodies revealed no co-localization of calpains with aggregates 
(data not shown). To investigate whether the aggravated phenotype in dm-mice was due to 
alterations in neuronal pathology and neurodegeneration, we performed toluidine blue 
staining and immunostaining with an antibody against neurofilament in the cerebellum of all 
genotypes at the age of 12 months. Immunostaining with a neurofilament antibody and 
toluidine blue revealed a strong atrophy of Purkinje cells in the st-line SCA3 and the dm-
mice, but nearly no aberrant cells in Cast KO (-/-) mice and wildtype controls, respectively 
(Fig. 5A). Quantitative analysis of the percentage of degenerated, atrophic cells of toluidine 
blue staining revealed significantly more neurodegeneration in dm-mice compared to st-line 
SCA3 (p≤0.001), Cast KO (-/-), or wildtype mice (p≤0.001). However, the neurofilament 
staining revealed only significant differences of both disease lines compared to the controls 
but not between st-line SCA3 and dm-mice (Fig. 5B). 
 
Depletion of calpastatin induces an advanced and more severe behavior phenotype in SCA3 
Mice 
To assess the ataxic and neurological phenotype of the mouse models, we performed 
rotarod tests and monitored survival rate as well as body weight. Measuring the body weight 
every second week, a significant decrease in body weight in the st-line SCA3 and both dm-
lines [Cast KO (+/-)/SCA3 and Cast KO (-/-)/SCA3] compared to controls was found starting 
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at the age of 24 weeks. Whereas wildtype mice and mice of Cast KO (-/-) line continuously 
gained weight up to the age of 60 weeks, the st-line SCA3 and both dm-lines progressively 
lost weight, in the end more than 1/3 of the body weight of control mice. On the other hand, 
we did not find any significant differences between both control groups [wildtype and Cast 
KO (-/-)] and between the disease lines (SCA3, and both dm-lines, Fig. 6A), respectively. 
The progressive loss of body weight resulted in a premature death of all disease lines, shown 
in the Kaplan-Meier curve (Fig. 6B). Although, there was a clear tendency that heterozygous 
or homozygous knock-out of calpastatin in SCA3 mice lead to a decreased life span 
compared to st-line SCA3, this difference did not reach significance. In confirmation to the 
published data of Takano et al. (20), the Cast KO (-/-) showed no premature death (Fig. 6B). 
Furthermore, the disease lines (SCA3, both dm-lines) showed neurological symptoms with 
tremor, clasping and gait abnormalities from the age of 40 weeks onwards. To detect motor 
coordination abnormalities in the different lines, we performed rotarod tests. Dm-mice 
showed impaired motor capabilities on the rotarod with a significant difference starting at the 
age of 32 weeks for Cast KO (+/-)/SCA3 mice and at the age of 44 weeks for Cast KO (-/-
)/SCA3 mice, whereas no significant coordination deficits were detectable in the st-line SCA3 
or Cast KO (-/-) mice at this age (Fig. 6C). While it is surprising that Cast KO (+/-)/SCA3 mice 
seemingly show an earlier onset of motor deficit in the rotarod test at the age of 32 weeks, it 
should be noted that there was no significant difference between Cast KO (+/-)/SCA3 and 
Cast KO (-/-)/SCA3 mice. Also, it has to be kept in mind that Cast KO (-/-)/SCA3 mice started 
to die earlier (Fig. 6B). This has reduced the number of available mice for the rotarod test in 
the Cast KO (-/-)/SCA3 mice group to a larger extent and therefore has reduced the 
statistical power in this group. Moreover, the surviving mice in the Cast KO (-/-)/SCA3 group 
might have a milder phenotype leading to this slightly better performance on the rotarod. 
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Discussion 
Caspases (7-11) and calpains (12-14) have been demonstrated to be involved in the 
proteolysis of ataxin-3. To gain more insight into the role of proteolytic cleavage in the 
pathogenesis of SCA3, we focused on calpain cleavage, specifically if ataxin-3 is a calpain-1 
or calpain-2 sensitive substrate, as it was previously shown for huntingtin (27). Identifying the 
key protease that cleaves ataxin-3 is of particular importance as this will path the way for 
developing a targeted therapy. We demonstrated that overexpressed ataxin-3 is cleaved 
more efficiently by calpain-2 than by calpain-1 and that expanded ataxin-3 seems to be more 
sensitive to calpain degradation. That calpain-2 can cleave ataxin-3 more efficiently can be 
further supported by the expression pattern of calpain-1 and calpain-2 in wildtype C57Bl/6 
mice as shown in the database of the ALLEN brains atlas (www.brain-map.org). Calpain-2 is 
highly expressed in the most affected brain areas by SCA3 including cerebellum, pons and 
medulla oblongata (expression value ≥ 2.5). In contrast, calpain-1 shows only a very low 
expression in the cerebellum (expression value ≤ 0.5) but normal expression values in the 
pons and medulla (≤ 2.0), respectively. 
Our in vitro results were confirmed in vivo as we showed that endogenous wildtype murine 
and overexpressed human expanded ataxin-3 are calpain-2 sensitive substrates 
independently of the polyQ length. Furthermore, by knocking out calpastatin, endogenous 
and polyQ-expanded ataxin-3 is further destabilized. These results suggest that modifying 
the level of calpains (in particular of calpain-2) or of calpastatin will influence the rate of 
proteolysis of ataxin-3 and subsequently the generation of potentially toxic fragments 
ultimately leading to neurodegeneration. Indeed, knocking out calpastatin in our SCA3 
transgenic mouse model (21) lead to a worsening of behavioral and neuropathological 
abnormalities. This is in agreement with reports that in the brain of patients, transgenic mice 
and cell models of Alzheimer Disease, as well as in animal models for retinal 
neurodegeneration, calpastatin depletion can act upstream of calpains to activate a calcium-
dependent cascade of protein kinase activation, hyperphosphorylation, and proteolysis 
resulting in neurodegeneration (28, 29). Therefore, it has been proposed that calpastatin acts 
as a positive regulator against unwanted protein cleavage during calpain activation (15) and 
under pathological conditions as a negative regulator of calpains (20, 30). Calpastatin 
therefore is an attractive target for developing therapeutic approaches in SCA3, in particular 
as neither overexpression (28) nor ablation of calpastatin (20) has an effect on normal 
nervous system function in mice under physiological conditions. 
Based on our findings we propose a role of ataxin-3 cleavage by calpains in the 
pathogenesis of SCA3. By applying a new assay (TR-FRET) to detect the level of soluble 
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mutant ataxin-3, we found less soluble mutant ataxin-3 in dm-mice compared to st-line SCA3 
suggesting cleavage of ataxin-3 within the 63 amino acids separating the binding sites of the 
antibodies 1H9 and MW1. Interestingly, Haacke et al. (12) proposed a cleavage site for 
calpain-2 in ataxin-3 at amino acid position 260, which is positioned between the two 
antibodies we used. The fragments derived from cleaving ataxin-3 around this position have 
been shown to be highly susceptible to aggregation (12) and are associated with toxicity 
(31). Interestingly, we have previously described a genetrap mouse model, which expresses 
259 amino acids N-terminal of ataxin-3 and which partially mimics a possible cleavage at 
position 260. In these mice we observed SCA3-like symptoms and a strong cytoplasmic 
accumulation of the N-terminal part of the protein in the brain (32). Additionally, a calculation 
of the molecular weight of the first 259 amino acids of the mouse and human ataxin-3 protein 
using a Protein Molecular Weight Calculator (Science gateway) revealed a fragment size of 
29.7 kDa for mouse and 29.93 kDa for human N-terminal ataxin-3 (first 259 aa). The 
calculated size is consistent with the detected 30 kDa N-terminal fragment in the presented 
cleavage assays of overexpressed ataxin-3 in cell culture and mouse brain homogenates. In 
addition, C-terminal fragments including the polyQ stretch have a much higher toxicity and 
propensity to aggregate than expanded full-length polyglutamine proteins (31). In support of 
this hypothesis we found a significantly increased number of aggregates in the granular layer 
of the cerebellum in dm-mice. 
In summary, our results indicate that endogenous murine ataxin-3 and human expanded 
ataxin-3 are cleaved by calpains, especially by calpain-2, and that increased proteolytic 
cleavage of ataxin-3 results in a more severe and faster progressing neurological phenotype. 
Therefore, aberrant activation of calpains and consequently enhanced proteolytic cleavage of 
ataxin-3 may play a pivotal role in SCA3 pathogenesis. Thus, the ataxin-3 cleavage pathway 
and the molecules involved in it, in particular calpastatin, may represent potential targets for 
therapeutic intervention in SCA3. This perspective is particularly exciting since calpain 
inhibitors entering the brain are already in clinical trials (33). 
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Materials and methods 
Expression constructs 
In order to generate ataxin-3 constructs with C-terminal V5 tag, the stop codon of ataxin-3 
(ataxin-3c isoform containing a third UIM, NM_004993.5) was replaced by an XbaI restriction 
site via PCR using the reverse primer MJDnoStopXbaRev 
(TAAAGtctagaTTTTTTTCCTTCTGTTTT). Full-length ataxin-3 was then cloned into the 
vector pcDNA 3.1/V5-His (Life Technologies) using BamHI and XbaI. Expanded CAG 
repeats (77 and 148 CAG, respectively) were inserted into the constructs by employing 
Esp3I and PpuMI. 
 
Cell culture 
HEK293T cells were maintained in Dulbecco´s modified eagle medium supplemented with 
10% fetal calf serum, 1% non-essential amino acids and 1% penicillin/ streptomycin at 37°C 
in 5% CO2. Transient transfections with V5-tagged ataxin-3 constructs with different 
polyglutamine length (15Q, 77Q, 148Q) were performed using Attractene transfection 
reagent (QIAGEN) following the manufacturer’s instructions followed by 72 h incubation. To 
obtain protein lysates HEK293T cells were mechanically homogenized in calpain reaction 
buffer (2 mM HEPES/KOH pH 7.6, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT) using a 
QIAshredder homogenizer (QIAGEN) according to manufacturer’s instructions. 
 
Preparation of brain homogenates 
Dissected mouse brains were homogenized in 1x PBS buffer with 1% Triton-X 100 and 
Complete Protease Inhibitor without EDTA (Roche Applied Science) using a Dounce 
homogenizer (Fisher Scientific). 
 
Calpain activation assay 
For in vitro calpain activation assays of cell culture lysates or brain homogenates, 200 ng of 
total protein were incubated with calpain-1 or calpain-2 in calpain reaction buffer containing 
2 mM CaCl2 at room temperature for indicated time points. To inhibit calpain activity, 100 μM 
N-acetylleucylleucylnorleucinal (ALLN; Sigma Aldrich, Inc.) were added to the respective 
reactions. All reactions were quenched by adding 5 x Laemmli buffer and denatured for 5 min 
at 95°C prior to Western blot analysis. For quantification of the 30 kDa fragment 3 brain 
samples of each indicated genotype were used. A ratio with loading control GAPDH and time 
point zero was calculated following quantification with ImageJ.  
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Generation and genotyping of the double-mutant mouse model 
Hemizygous SCA3 mice overexpressing human ataxin-3 containing 140 CAGs under the 
control of the Prp promoter (21) were crossbred with homozygous calpastatin knock-out mice 
[Cast KO (-/-), (20)] to generate double-mutant mice (dm-) that were hemizygous for the 
calpastatin knock-out and heterozygote for mutant ataxin-3 (Cast KO (+/-)/SCA3). In a 
second breeding step, Cast KO (+/-)/SCA3 mice were mated with hemizygous Cast KO (+/-) 
or homozygous Cast KO (-/-) mice to obtain Cast KO (-/-), st-SCA3, double-mutant Cast KO 
(+/-)/SCA3 and double-mutant Cast KO (-/-)/SCA3 mice. Offspring with the expected 
Mendelian distribution of genotypes for both breeding steps were achieved (data not shown). 
For genotyping, we used the primers and conditions described in the respective publications. 
The number of CAG-repeats for all animals was analyzed using the primers pre-CAG-for (5´-
GCTAAGTATGCAAGGTAGTTCC-3´) and post-CAG-rev (5´-CAAGTGCTCTGAACTGGTG-
3´). The forward primer is labeled at the 5´end with the fluorescent dye Cy5. The PCR 
amplicon length was then analyzed on the Beckman coulter sequencer (CEQ 8000 Cycle 
Sequencer, Krefeld, Germany). 
 
Western blot analysis 
Western blot analyses were performed as previously described (21). Antibodies were used at 
the following dilutions: mouse anti-ATXN3 (1:4000; MAB 5360; clone 1H9; Millipore), rabbit 
anti-calpain-1 (1:2500 in 3% BSA; ab39170), rabbit anti-calpain-2 (1:2500; ab39168) (both 
from Abcam), rabbit anti-murine calpastatin (1:2000; Ref. 20), mouse anti-GAPDH (1:5000; 
sc-47724; Santa Cruz Biotechnology, Inc.), as well as peroxidase-conjugated secondary 
antibodies goat anti-mouse (1:2000; 115-035-003; Jackson Immuno-Research) and donkey 
anti-rabbit (1:3333; NA934; GE Healthcare Biosciences). 
 
Immunohistochemistry 
Immunohistochemistry was performed as previously described (21). The following antibodies 
were used: rabbit anti-ATXN3 (1:1000; Ref. 34), rabbit anti-calpain-1 (1:100; ab39170), rabbit 
anti-calpain-2 (1:100; ab39168) (both from Abcam), rabbit anti-murine calpastatin (1:2000; 
Ref. 19) and mouse anti-neurofilament (1:500; M0762; DakoCytomation), as well as 
fluorescence-coupled antibodies rabbit anti-Cy2 (1:50) and mouse anti-Cy3 (1:100) (both 
from Dianova). Staining with toluidine blue (Sigma Aldrich, Inc.) was done for 10 min in 0.2% 
toluidine blue in sodium acetate buffer. Dehydration steps with 70, 96 and 100% ethanol 
were then performed for 5 min each. Aggregates and neurodegenerative cells were manually 
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counted from three independent individuals in the cerebellum and pons from three animals of 
each indicated genotype at the age of 12 months. For quantifying aggregates or 
neurodegenerative cells four fields per brain region were counted on three different sections 
of each mouse.  
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Time-resolved FRET assay 
Cerebellar samples from indicated genotypes were homogenized in homogenization buffer 
(10% PBS, 1% Triton X, Complete without EDTA). After diluting lysates 1:1 in 
homogenization buffer, reactions were carried out by adding 3 μM or 2 mM CaCl2, to activate 
calpain-1 or calpain-2 respectively, and incubation for 5 min at 30°C. Reactions were 
terminated by adding 100 pmol ALLN and 2.5 μmol EDTA. As control, samples were 
incubated under the same conditions with 3 μm or 2 mM CaCl2 and 100 μM ALLN. Reactions 
were stopped by addition of pure 2.5 μmol EDTA. Polyglutamine specific antibody MW1 was 
developed by Paul Patterson (35) and obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of Iowa 
(Department of Biological Sciences, Iowa City, IA 52242). Ataxin-3 antibody was obtained 
from Millipore (1H9; Mab5360). MW1 antibody was labeled with acceptor fluorophore D2. 
Ataxin-3 antibody was labeled with terbium-cryptate (Tb) as donor fluorophore. TR-FRET 
detection protocol was performed as previously described (36). In short, 5 μl sample and 1 μl 
detection buffer (50 mM NaH2PO4, 400 mM NaF, 0.1% BSA and 0.05% Tween + antibodies) 
was pipette into low-volume wells of an opaque 384-microtiter plate and incubated for 20 h at 
4°C. Final detection antibody amounts per well were 0.3 ng Ataxin-3-Tb and 10 ng MW1-D2. 
TR-FRET quantification was performed with an Envision reader (PerkinElmer). The terbium 
donor fluorophore was excited at 320 nm. After a time-delay of 100 μs, emission signal of D2 
was detected at 665 nm. All signals are reported as the percentage signal intensity over the 
lysis buffer background signal. 
 
Phenotype analysis 
Body weight was determined every second week for 8 to 10 animals per group starting at the 
age of 4 weeks. Behavioral experiments were performed in the dark cycle when mice were 
more active. Behavioral testing began at the age of 8 weeks and was repeated every 8 
weeks until the age of 44 weeks. For rotarod tests, mice were placed on an accelerating 
rotating rod (TSE) at the same time of the day for five consecutive days. Three training 
sessions (each with acceleration from 4 to 16 rpm in 2 min) were followed by two test 
sessions. Each test trial started with rotation at 4 rpm and accelerated to a maximum of 40 
rpm within 5 min. The amount of time that elapsed before the mouse fell off the rod was 
recorded. The trials within the same day were performed approximately 1 h apart. Eight to 10 
age- and sex-matched animals were analyzed per group. All experiments were conducted in 
a blind-coded manner with respect to genotype until an overt phenotype was visible. The 
survival rate was measured by recording the life span of mice that died naturally. As the 
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license to carry out experiments on mice requires that mice are euthanized when disease 
exceeds defined, moderately severe, humane end points, only a relatively small number of 
animals were used to determine survival rate: wildtype: n=28; Cast KO (-/-): n=8; SCA3: n=5; 
Cast KO (+/-)/SCA3: n=16; Cast KO (-/-)/SCA3: n=7. 
 
Statistical analysis 
All data were analyzed by using JMP® version 8.0 (SAS Institute, Inc., Cory, NC, USA). 
Rotarod tests, survival rate, measurement of body weight, TR-FRET assay and 
immunohistochemistry were investigated by an unpaired Student´s t-test with a significance 
threshold of p<0.05. All results are presented as means ± standard error mean. 
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Figures and Legends to Figures 
 
Figure 1. Overexpressed ataxin-3 can be cleaved more efficiently by calpain-2. Protein 
lysates from HEK293T cells transfected with V5-tagged ataxin-3 with different polyQ lengths 
(15Q, 77Q, 148Q) were incubated with recombinant calpain-1 (A-C) or calpain-2 (D-F) and 
2 mM calcium for up to 45 min. Full-length ataxin-3 is indicated by an arrow, arrowheads 
show cleavage derived fragments. Where indicated, calpain inhibitor ALLN was added. 
Whereas incubation with recombinant calpain-1 revealed a weak cleavage of full-length 
ataxin-3 independently from the polyglutamine length (A-C), cleavage by calpain-2 lead to a 
more efficient fragmentation of full-length ataxin-3, which is dependent on the polyglutamine 
length (D-F). Calpain-1 and -2 cleavage results in an identical N-terminal cleavage fragment 
(around 30 kDa). As loading control GAPDH is shown. 
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Figure 2. Calpastatin deficiency increases endogenous ataxin-3 cleavage. Whole brain 
homogenates of the indicated animals were incubated up to 15 min with 2 mM calcium and 
recombinant calpain-1 (A-D) or -2 (E-H), respectively. Stars highlight endogenous mouse 
ataxin-3, arrows indicate human overexpressed full-length ataxin-3 with expanded polyQ and 
arrowheads point to an N-terminal derived cleavage fragment. A-D) Cleavage of ataxin-3 by 
recombinant calpain-1 occurs slowly; after 15 min of incubation only little endogenous or 
overexpressed ataxin-3 is cleaved. E-H) Ataxin-3 cleavage by recombinant calpain-2 
revealed an increased cleavage rate, which is enhanced when calpastatin (Cast) is knocked 
out. Both calpain-1 and calpain-2 cleavage results in a 30 kDa N-terminal derived fragment, 
respectively. Densitometric quantification of the 30 kDa fragment relative to time point zero 
and loading control GAPDH revealed more accumulation of the cleavage fragment if 
calpastatin is knocked out completely over time (I, J). SEM = standard error of mean. 
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Figure 3. Calpastatin knock-out increases mutant ataxin-3 fragmentation upon calcium 
stimulation. A) Schematic representations of antibody binding sites in context of the ataxin-3 
protein and the principal of the TR-FRET assay. B) TR-FRET analysis of cerebellar protein 
lysates of mice with indicated genotypes at the age of 12 months, without calcium stimulation 
or with appropriate calcium levels for calpain-1 or calpain-2 activation. In wildtype and Cast 
KO (-/-) mice only a background signal is detectable. Specific signals were found in st-line 
SCA3 and dm-mice. Importantly, the signal intensity in the dm-mice was only half of that of 
SCA3 single transgenic mice. Upon calcium stimulation the ataxin-3 specific signal 
decreases significantly in dm-mice. Bars represent means of three different mice per 
genotype. ** p ≤ 0.01. 
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Figure 4. Increased number of nuclear inclusions in the dt-mutant lines. A) Sections 
stained with an ataxin-3 specific antibody (1H9) revealed ataxin-3 positive nuclear inclusions 
in the cerebellum and pons (indicated by an arrow). Notably, in the dm-lines with 
heterozygous or homozygous loss of calpastatin function, an increased number of 
aggregates were detected. No nuclear inclusions were found in wildtype and Cast KO (-/-) 
mice. Scale bar = 20 μm. B) Quantitative analysis of aggregates per cells in the cerebellum 
and pons revealed significant less aggregates in the st-line SCA3 compared to both dm-lines 
(** p≤0.001). Results are means ± SEM. 
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Figure 5. Calpastatin knock-out leads to enhanced neurodegeneration in the 
cerebellum of SCA3 mice. A) In 12 months old mice striking atrophy of Purkinje cells was 
detected in the st-line SCA3 and the dm-line indicated by empty baskets in the neurofilament 
staining and by dark blue staining of Purkinje cells by toluidine blue. Scale bar = 20μm. B) 
Quantitative analysis revealed more severe neurodegeneration in the dm-mice and st-line 
SCA3 compared to controls. Furthermore, toluidine blue staining demonstrated significant 
more neurodegeneration of Purkinje cells in dm-mice compared to the st-line SCA3 (** p 
≤ 0.01; *** p ≤ 0.001). Results are means ± SEM. 
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Figure 6. Calpastatin knock-out aggravates behavioral deficits in SCA3 mice. A) Body 
weight measurements revealed a significant reduction of body weight starting from the age of 
24 weeks in the st-line SCA3 and dm-lines compared to controls. No significant differences 
were found between the disease lines. B) Cumulative survival using Kaplan-Meier estimator 
revealed premature death in the disease lines (st-line SCA3 and the dm-lines) compared to 
controls. Between the disease lines no significant differences in the survival rate were 
detected (p=0.226). C) Rotarod analysis demonstrated abnormalities in balance and motor 
coordination in animals of dm-lines. No differences were found between wildtype and the st-
line for SCA3 (p=0.899. Results are means ± SEM. (*p≤0.05; **p≤0.01) 
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Abstract 
Huntington disease is a fatal human neurodegenerative disorder caused by a CAG repeat 
expansion in the HTT gene, which translates into a mutant huntingtin protein. A key event in 
the molecular pathogenesis of Huntington disease is the proteolytic cleavage of mutant 
huntingtin, leading to the accumulation of toxic protein fragments. Mutant huntingtin cleavage 
has been linked to the overactivation of proteases due to mitochondrial dysfunction and 
calcium derangements. Here, we investigated the therapeutic potential of olesoxime, a 
mitochondria-targeting, neuroprotective compound, in the BACHD rat model of Huntington 
disease. BACHD rats were treated with olesoxime via the food for 12 months. In vivo 
analysis covered motor impairments, cognitive deficits, mood disturbances and brain 
atrophy. Ex vivo analyses addressed olesoxime’s effect on mutant huntingtin aggregation 
and cleavage, as well as brain mitochondria function. Olesoxime improved cognitive and 
psychiatric phenotypes, and ameliorated cortical thinning in the BACHD rat. The treatment 
reduced cerebral mutant huntingtin aggregates and nuclear accumulation. Further analysis 
revealed a cortex-specific overactivation of calpain in untreated BACHD rats. Treated 
BACHD rats instead showed significantly reduced levels of mutant huntingtin fragments due 
to the suppression of calpain-mediated cleavage. In addition, olesoxime reduced the amount 
of mutant huntingtin fragments associated with mitochondria, restored a respiration deficit, 
and enhanced the expression of fusion and outer-membrane transport proteins. In 
conclusion, we discovered the calpain proteolytic system, a key player in Huntington disease 
and other neurodegenerative disorders, as a target of olesoxime. Our findings suggest that 
olesoxime exerts its beneficial effects by improving mitochondrial function, which results in 
reduced calpain activation. The observed alleviation of behavioral and neuropathological 
phenotypes encourages further investigations on the use of olesoxime as a therapeutic for 
Huntington disease. 
 
Keywords: Huntington disease, olesoxime, calpain, mitochondrial dysfunction, mutant 
huntingtin aggregates 
 
Abbreviations: BACHD rat = Huntington disease rat model expressing full-length mutant 
huntingtin from a bacterial artificial chromosome, Htt = endogenous rat huntingtin protein, Htt 
= total huntingtin protein, mHTT = mutant human huntingtin protein, polyQ = poly-glutamine, 
WT = wild type. 
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Introduction 
Huntington disease, a fatal human neurodegenerative disorder, results from a CAG repeat 
expansion in exon 1 of HTT (The Huntington’s Disease Collaborative Research Group, 
1993). The mutation translates into an elongated polyQ tract close to the N-terminus of the 
mutant huntingtin protein, mHTT (Persichetti et al., 1995). Huntington disease patients suffer 
from a broad range of symptoms including motor, psychiatric, cognitive and metabolic 
disturbances (Vonsattel and DiFiglia, 1998), which are associated with neuronal dysfunction, 
and the selective degeneration of cortical and striatal projection neurons (Poudel et al., 2014; 
Tabrizi et al., 2011). 
The intrinsic toxicity of mHTT has been linked to the formation of N-terminal protein 
fragments (Nagai et al., 2007; Rigamonti et al., 2000; Wang et al., 2008). These fragments 
interfere with important intracellular pathways (Zuccato et al., 2010), accumulate in the 
nucleus (Landles et al., 2010), and form protein aggregates in nucleus and cytoplasm 
(Cooper et al., 1998; Li and Li, 1998), which is a hallmark of Huntington disease (Gutekunst 
et al., 1999). Mutant HTT fragments derive from proteolytic cleavage of the full-length 
protein. Several classes of proteolytic enzymes have been identified to mediate this process, 
including calpains (Gafni and Ellerby, 2002), caspases (Goldberg et al., 1996), cathepsins 
(Kim et al., 2006) and matrix-metalloproteinases (Miller et al., 2010). Calpains, which play a 
general role in neurodegenerative processes (Yang et al., 2013), are overactivated in 
Huntington disease (Gafni and Ellerby, 2002), and inhibition of the calpain-mediated 
cleavage of mHTT has been found to ameliorate Huntington disease-related pathologies 
(Gafni et al., 2004). 
Calpains are activated in response to cytosolic Ca2+ currents (Goll et al., 2003), and Ca2+ 
homeostasis is disrupted at several levels in Huntington disease (Miller and Bezprozvanny, 
2010). Moreover, Ca2+ derangements have been considered to be causal for the neuronal 
damage in Huntington disease, as the selective demise of vulnerable neurons is thought to 
result from their particular sensitivity to excitotoxicity, which is characterized by intracellular 
Ca2+ overload and subsequent cell death (Fan and Raymond, 2007). Mitochondria are 
particularly involved in this process, as they are crucial for maintaining low intracellular Ca2+ 
levels, and pivotal for triggering cell death programs, when their buffering capacity is 
exhausted (Calì et al., 2012). Mutant HTT affects mitochondrial function by directly binding to 
the outer mitochondrial membrane (Choo et al., 2004; Gellerich et al., 2008; Panov et al., 
2002; Rockabrand et al., 2007; Wang et al., 2009), and by disturbing the transcription of 
nuclear-encoded mitochondrial effector genes (Bae et al., 2005; Cui et al., 2006). As a 
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consequence, mitochondrial Ca2+ handling ability is impaired, making cells more susceptible 
to excitotoxic insults (Panov et al., 2003; Tang et al., 2005). 
The current study was designed to evaluate the therapeutic potential of the orphan drug 
candidate, olesoxime (Bordet et al., 2007), on disease-related phenotypes of the BACHD rat 
model of Huntington disease (Yu-Taeger et al., 2012). Olesoxime is a small cholesterol-like 
molecule, which accumulates at the site of mitochondria (Bordet et al., 2010). Olesoxime’s 
mechanism of action is not fully understood, although it has been shown to inhibit 
mitochondrial permeability transition (Bordet et al., 2010; Gouarné et al., 2013, 2015), which 
is a Ca2+-sensitive process that can trigger cell death (Lemasters et al., 2009). Olesoxime 
has demonstrated therapeutic efficacy in several neurodegenerative diseases (Bordet et al., 
2007; Eckmann et al., 2013; Richter et al., 2014; Sunyach et al., 2012) and peripheral 
neuropathies (Bordet et al., 2008; Rovini et al., 2010; Xiao et al., 2009, 2012), and just 
recently yielded impressive beneficial effects on motor function in a phase II clinical trial in 
spinal muscular atrophy patients (Dessaud et al., 2014). 
Here, we found that olesoxime treatment ameliorated psychiatric and cognitive abnormalities 
in the BACHD rat. The treatment, further, increased their frontal cortex thickness, and 
improved mitochondrial function. Prominently, it appeared that the main effect of olesoxime 
was to reduce Huntington disease-related calpain overactivation. Thereby, the formation of 
mHTT fragments was drastically decreased. This yet undiscovered function opens a new 
view on olesoxime’s mechanism of action, and highlights it as a novel tool for reducing 
calpain activation and the accumulation of toxic mHTT fragments.  
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Materials and Methods 
Ethical statement 
Behavioral experiments were performed at the University of Tuebingen, by individuals with 
appropriate training and experience. Experiments were approved by the local ethics 
committee at Regierungspraesidium Tuebingen, and carried out in accordance with the 
German Animal Welfare Act and the guidelines of the Federation of European Laboratory 
Animal Science Associations, based on European Union legislation (Directive 2010/63/EU). 
 
The BACHD rat 
The BACHD rat of line TG5 (Crl:CD(SD)-Tg(HTT*97Q)21.2Hpn/Hpn), in the following 
referred to as BACHD rat, overexpresses full-length HTT with 97 CAA/CAG repeats on a 
BAC (bacterial artificial chromosome) (Yu-Taeger et al., 2012). The construct has previously 
been used to generate the BACHD mouse (Gray et al., 2008). 
 
General husbandry and genotyping 
All rats were bred at the University of Tuebingen and study groups derived from a total of 
24 different breedings in order to reduce possible litter bias. Male BACHD rats, hemizygous 
for mHTT, and male WT littermates from respective breedings were spread across study 
groups. The rats were weaned and genotyped at 21 days of age. Genotyping was confirmed 
at the end of the study when the animals were sacrificed, and followed established protocols 
(Yu-Taeger et al., 2012). From weaning on, the animals were kept in autoclavable plastic 
cages with high lids (38 cm x 55 cm wide, 24.5 cm high). Cages contained 3 l of autoclaved 
wooden bedding and were cleaned twice a week. Food (initially standard rat chow: Ssniff 
V1534-000, SSNIFF Germany, later changed to: Altromin C1000, Altromin, Lage, Germany, 
details under Olesoxime treatment and experimental groups) and tap water were delivered 
ad libitum. Housing conditions followed the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123, appendix 
A: Guidelines for accommodation and care of animals). The environmental conditions in the 
housing room were kept at 21–23 °C ambient temperature, 55 +/- 10 % humidity and a 
12/12 h light/dark cycle with lights off at 1:00 p.m. and lights on at 1:00 a.m. during winter, or 
with lights off at 2:00 p.m. and lights on at 2:00 a.m. during summer. 
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Olesoxime treatment and experimental groups 
The study included two cohorts of rats. Cohort I served a longitudinal study to assess the 
treatment effect on relevant behavioral, neuropathological and molecular phenotypes (Suppl. 
Fig. 1). This cohort was composed of 30 WT (15 treated, 15 non-treated) and 30 BACHD rats 
(15 treated, 15 non-treated), kept in groups of four of mixed genotype (two WT rats and 
two BACHD rats per cage). Two weeks after weaning (5 weeks of age), food was changed 
from regular rodent chow (as stated above) to either control diet or the same diet loaded with 
0.6 mg/g olesoxime (provided by Trophos SA, Marseille, France). Behavioral characterization 
was carried out until the age of 13 months and was followed by MRI and post mortem 
analyses. 
Cohort II was used for the measurement of olesoxime concentration in plasma and brain as 
well as its distribution in different brain areas (nine olesoxime-treated and three non-treated 
control animals per genotype). These rats were kept in groups of three of the same 
genotype. Olesoxime-containing or control diet was administered for 2 weeks starting at the 
age of 4 months. 
Body weight and food intake were measured as safety parameters for the olesoxime 
treatment. Body weight was measured weekly. For food intake measurements, the rats were 
housed individually for 70 hours in an automated behavioral test system (PhenoMaster, TSE 
Systems, Germany) at 2, 4, 6, 8 and 12 months of age. Test protocol, system specifications 
and data analysis were the same as described in detail in (Clemens et al., 2014). 
 
Clasping behavior 
Clasping behavior was investigated as a measure of a striatum-based motor dysfunction 
(Soll et al., 2013). In order to detect hind limb clasping, each animal was lifted on its tail for 
approximately 2 s. The test was performed weekly from 5 weeks until the age of 10 months 
(total of 33 observations). The clasping frequency in % of all observations was analyzed. 
 
Rotarod test 
The animals were trained to walk on an accelerating rod (Rat Rotarod 7750, Ugo Basile, 
Italy) in order to assess fore limb/hind limb coordination at 2, 4 and 8 months of age as a 
measure of striatum-based motor dysfunction (Bergeron et al., 2014). Rats were given four 
daily trials at 2 months of age, or three daily trials at older ages, during a total of 5 
consecutive days. Trials were separated by one-hour intervals. The experiments were run 
during the dark phase. During the first 3 days, the rats were trained to a stable performance. 
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At this stage, the maximum rotation speed of the rod was set to 12 rpm (increasing from 2 to 
12 rpm over 30 s), and trials lasted either 120 s, or until the rat had been falling off the rod for 
a total of five times. The number of falls served as the performance readout. On the last 2 
days, the rats’ maximum motor capacity was tested. For this, the rotation speed of the rod 
increased from 4 to 40 rpm over 240 s and the trials lasted either 300 s or until the rat had 
been falling off the rod for a total of five times. The total amount of time the animals spent on 
the rod (excluding the time spent not running during falls) was measured and analyzed as 
the animals’ running capacity. The number of rats included in the analysis decreased, as an 
increasing number of particularly BACHD rats refused to stay on the rod at older ages (as 
discussed previously in (Abada, Nguyen, Schreiber, et al., 2013; Yu-Taeger et al., 2012)). 
 
Simple Swim test 
At the age of 7 months, cognitive abilities were investigated using a simple swim test. The 
animals were trained to swim to a hidden platform placed at one end of a rectangular water 
tank of 150 x 25 x 40 cm (adapted from (Van Raamsdonk et al., 2005)). Training was carried 
out in dimmed red light during the dark phase, alternating between cages with placebo- and 
olesoxime-treated rats. During an initial training phase, the animals were placed into the 
middle of the tank facing away from the platform, forcing them to turn around to reach it. The 
training was carried out on 2 consecutive days in 3 x 3 trials on the first and 3 trials on the 
following day. On the third day, the platform was repositioned to the opposite side (reversal) 
and the rats’ performance was measured again on 2 consecutive days. In this reversal 
training, the rats needed to swim straight ahead in order to reach the platform. The rats were 
trained in 3 x 3 trials on the first day and 3 trials on the second day. Individual blocks of trials 
were separated by one hour. The water kept room temperature, and was colored with non-
toxic black paint (Marabu Fingerfarbe, Marabu GmbH & Co. KG). The water tank was 
virtually divided into four areas: the starting area, the area opposite to the platform, the area 
towards the platform and the platform. The trials were videotaped and tracked using TSE 
VideoMot 2 equipment (TSE Systems, Germany). Raw data on time and distance covered 
before reaching the platform as well as swim speed were exported from the software, sorted 
according to genotype and treatment, and analyzed as average values for each block of 
three trials, using a script for R statistics developed at the University of Tuebingen. 
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Elevated plus maze 
The rats’ preference for exploring the closed rather than the open arms of an EPM was 
assessed as a measurement of anxiety-like behavior at 13 months of age. The setup 
comprised four arms (12 cm wide and 42 cm long), connected by a 12 x 12 cm central area. 
Two of the arms were enclosed by 42 cm high walls (closed arms), while the other two arms 
had no walls (open arms). The arena was positioned 52 cm above ground. The experimental 
room was lit with white light, leaving the open arms exposed to light, while the closed arms 
remained substantially darker. The test was carried out for all rats on one day during the 
early dark phase, and cages with placebo- and olesoxime-treated rats were tested in an 
alternating order. At the start of each trial, a rat was placed inside the central area of the 
maze, facing one of the open arms, and allowed to freely explore the maze for a total of 
5 min. The time spent in the open arms of the EPM was measured and subsequently 
analyzed as % of the total trial duration. 
 
Magnetic resonance imaging 
MRI was performed at the Werner Siemens Imaging Center (Tuebingen, Germany). For this 
purpose, the rats were anaesthetized with 2 % isoflurane and maintained at 1.2 % vaporized 
in 100 % O2 at a flow rate of 1.5 l/min. Body temperature and ventilation rate were monitored 
throughout the MRI acquisition, with body temperature kept in the stable range of 37 ± 
0.5 °C. Anatomical T2WIs were acquired with a rat brain surface coil using a 3D-spoiled 
turbo spin echo sequence (256 x 160 matrix, 25 x 25 mm² FOV, repetition time 
(TR) = 3000 ms, echo time (TE) = 205 ms, slice thickness = 0.22 mm). For MRI data 
evaluation, image analysis was performed using Inveon Research Workplace software 
(Siemens Healthcare, Erlangen, Germany) and referring to the rat brain atlas (The Rat Brain 
in Stereotaxic coordinates, 6th edition, 2006). Size differences in whole brain, cerebellum and 
striatum were determined with high accuracy by measuring the respective volume, as these 
brain regions have a clear delimitation in MRI. By contrast, differences in the size of the 
cerebral cortex were evaluated more accurately by measuring the thickness of the frontal 
part at -1.56 mm relative to bregma at the most dorsal point of the corpus callosum. 
 
Measurement of olesoxime concentration 
The concentration of olesoxime in plasma and brain samples was measured via HPLC-MS at 
Trophos SA. (Marseille, France) using the Alliance® HPLC System (Waters S.A.S.). Samples 
were collected as explained below and thawed at room temperature. Plasma was mixed with 
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150 µl of acetonitrile, vortexed for 10 s and centrifuged for 10 min at 16,100 rpm. Brain tissue 
was first homogenized at a concentration of 1 g/ml in HBSS (10 mM HEPES, 141 mM NaCl, 
4 mM KCl, 28 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4). Homogenates were then mixed 
with 300 µl dichloromethane, vortexed for 10 s and centrifuged for 10 min at 16,100 rpm. The 
organic phase was collected, evaporated at low pressure and 40 °C and resolubilized in 
110 µl acetonitrile. Assays were run once. Calculations were performed against a calibration 
curve prepared from olesoxime-spiked, normal rat plasma or brain homogenate, respectively. 
 
Blood sampling 
Blood was collected from rats of cohort I during the longitudinal study at 3, 6, 9 and 
13 months of age, and from rats of cohort II after two weeks of olesoxime treatment at 
4 months of age. For cohort I, blood was collected by puncturing the animals’ tail veins (the 
procedure did not require anesthesia), while for cohort II, blood was sampled retro-orbitally 
post mortem. In either case, sampling was carried out within two hours during the late light 
phase to minimize variation based on circadian rhythms. Blood was collected into EDTA-
coated tubes on ice. Samples were centrifuged at 1,500 x g for 10 min, plasma was 
removed, transferred into cryotubes and stored at -80 °C. 
 
Brain tissue sampling 
For immunohistochemical techniques, the rats were deeply anesthetized with an 
intraperitoneal injection of ketamin/xylazin (100 mg/kg or 5–8 mg/kg respectively) and 
perfused transcardially with 4 % PFA in PBS (pH 7.4). Brains were removed and stored at 
4 °C in 0.5 % PFA in PBS (pH 7.4). 
For all other analyses, the animals were sacrificed by CO2 inhalation. Brains were 
immediately dissected on ice and whole brain, or brain regions, were sampled. Tissue was 
shock-frozen in liquid nitrogen and either stored at -80 °C or immediately processed in order 
to obtain live mitochondria for high-resolution respirometry. Tissue sampling was performed 
within 2 hours during the late light phase to minimize variation based on any circadian phase-
related changes. 
 
Isolation of mitochondria and high resolution respirometry 
Mitochondria were isolated from the frontal brain and respiration was measured at the 
Department of Pharmacology, Goethe University Frankfurt, Germany. For this purpose, 
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tissue samples were homogenized in respiration media (20 mM HEPES, 110 mM sucrose, 
0.5 mM EGTA, 3 mM magnesium dichloride, 60 mM lactobionic acid, 20 mM taurine, 10 mM 
potassium dihydrogenphosphate and 1 g/l essentially fatty acid-free BSA, pH 7.4) containing 
4 % protease inhibitors (Complete® Protease Inhibitor, Roche). Homogenates were 
centrifuged at 1,400 x g for 7 min, supernatant was collected and centrifuged at 1,400 x g for 
3 min and finally recollected and centrifuged at 10,000 x g for 5 min in order to pellet the 
mitochondria-containing fraction. Pellets were gently resuspended in respiration media, 
aliquots for the determination of protein concentration and citrate synthase activity 
(procedure described below) were collected, frozen in liquid nitrogen and stored at -80 °C, 
while respiration was recorded immediately. 
Respiration was measured with the Oxygraph (Oroboros, Austria), which allows the 
measurement of mitochondrial respiration in two samples simultaneously. Analysis was 
made using sample pairs of different genotypes (WT and BACHD) but identical treatment 
(placebo or olesoxime). Data was acquired with DatLab software, version 4.3.2.7. The rate of 
mitochondrial respiration was monitored at 37 °C according to a protocol by Prof. Dr. Erich 
Gnaiger (University of Innsbruck, Austria) (Kuznetsov et al., 2002). A series of substrates 
and inhibitors were added to the samples in sequence to assess the function of different 
components of the mitochondrial respiratory chain. The capacity for oxidative 
phosphorylation was measured after addition of the complex I substrates (CIOXPHOS) 
glutamate (G; 5 mM), malate (M; 2 mM) and ADP (D; 2 mM), followed by the addition of 
succinate, the substrate for complex II (CI+IIOXPHOS, state P). Blocking the ATP synthase via 
addition of oligomycin, further allowed for the measurement of respiration driven by the 
mitochondrial proton leak only. Subsequent titration of the artificial uncoupler FCCP 
(trifluorocarbonylcyanide phenylhydrazone), injected in steps of 1 µM up to 4 µM until 
saturation occurred) revealed the maximum capacity of the ETC. Afterwards, addition of the 
complex I inhibitor rotenone revealed uncoupled CII activity (CIIETS). Residual oxygen 
consumption (oxygen consumption caused by enzymes not belonging to the ETC) was 
measured after inhibition of complex III with 2.5 μM antimycin A, and subtracted from all 
measurements. Cytochrome C oxidase (complex IV) activity was determined after addition of 
0.5 mM TMPD (tetramethylphenylenediamine), an artificial substrate and 2 mM ascorbate, 
which keeps TMPD in the reduced state. Complex IV respiration was corrected for the auto-
oxidation rate of TMPD, determined by addition of azide (≥100 mM). 
Respiration data were normalized to citrate synthase activity, a marker for mitochondrial 
mass (Kuznetsov et al., 2002). Citrate synthase activity was assessed 
spectrophotometrically. For this purpose, samples were thawed and diluted 1:2 in deionized 
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water. Reaction media (0.1 M Tris-HCl, 0.1 mM DTNB (5,5-dithiobis-2-nitrobenzoic acid), 
0.5 mM oxaloacetate, 50 μM EDTA, 0.31 mM acetyl coenzyme A, 5 mM triethanolamine 
hydrochloride) were warmed for 5 min at 30 °C, samples were added, and the formation of 
TNB (5-thio-2-nitrobenzoic acid) was measured immediately via absorbance at 412 nm. 
 
Immunohistochemistry 
PFA-fixed brains were embedded in gelatin blocks (16 brains per block) and cut serially into 
40 µm thick coronal sections (performed by NeuroScience Associates, Knoxville, USA). 
Sections were stored in antigen-preserve solution (Fisher Scientific, USA) at -20 °C. Free-
floating staining was performed at room temperature, as described previously (Osmand et 
al., 2006). Briefly, a series of 24 sections were warmed up at room temperature for 2 h and 
incubated for 30 min in 0.5 % NaBH4 for blocking purpose. After washing, the sections were 
probed overnight with sheep polyclonal S830 antibody (1:20,000, kindly provided by Prof. Dr. 
Gillian Bates, King’s College London, UK) for the detection of N-terminal mHTT. On the next 
day, the sections were incubated with biotinylated rabbit anti-sheep IgG secondary antibody 
(1:1000, BA-6000, Vector Laboratories) for 2 h and subsequently with avidin-enzyme 
complex (Vectastain® Elite ABC Kit Rabbit IgG, Linaris) for 1 h. In order to further enhance 
the signal, biotinylated thyramine plus 0.001 % H2O2 was added for 10 min and the sections 
were once more incubated with avidin-biotin complex. Color development was achieved with 
nickel-DAB-H2O2 (0.6 % nickel, 0.01 % DAB and 0.001 % H2O2) dissolved in TI buffer (0.05 M 
Tris, 0.05 M imidazole). Nissl staining was performed using 1 % thionine acetate to visualize 
nuclei. Sections were mounted and stored at room temperature. 
Images were acquired using a Zeiss Axioplan microscope (Pl 10x ocular, Plan-NEOFLUAR 
40x/0.75 objective, AxioCam MRc) and Axiovision 4.8 software (Zeiss, Germany). Images 
were exported from Axiovision in tiff format, and imported into Corel Draw X5, where they 
were cropped to display the region of interest, and moderately adjusted in brightness, 
contrast and saturation to better visualize the structures of interest. The aforementioned 
adjustments did in no way change the information that was subject to analysis, namely the 
total number of S830-positive nuclei and cytoplasmic aggregates. The quantification, i.e. 
counting the number of cytoplasmic aggregates and the number of nuclei positive for mHTT 
staining, was performed manually. 
 
  
d. Clemens et al., 2015, Brain. 
250 
Immunoblotting 
Immunoblotting was performed with striatal and cortical tissue as well as mitochondrial 
membranes isolated from cerebral hemispheres. 
Striata and cortices were thawed and homogenized on ice in TES buffer (50 mM Tris, 2 mM 
EDTA, 100 mM NaCl, pH 7.5) containing protease inhibitors (4 % Complete® Protease 
Inhibitor, Roche). Homogenates were diluted 1:10 in TNES buffer (90 % TES buffer, 10 % 
Igepal CA630), incubated for 1 h at 4 °C and centrifuged 2 x 30 min at 16,100 x g. 
Supernatant (cell lysates) were collected and stored at -80 °C in 10 % glycerin. 
Mitochondria-enriched heavy membrane fractions were isolated from cerebral hemispheres 
(brain stem, cerebellum and olfactory bulbs had been removed). Tissue was homogenized 
on ice in HEPES buffer (10 mM HEPES, 0.32 M sucrose, 1 mM EDTA, pH 7.4) and 
centrifuged at 585 x g for 10 min. Supernatant was collected and further centrifuged twice at 
17.400 x g for 20 min. Pellets were resuspended and layered over a Ficoll density gradient 
(7.5 % and 13 %, w/v). After 60 min of ultracentrifugation at 87,300 x g, the pellet, which at 
this point contained the mitochondrial fraction, was sampled, resuspended in 5 mM Tris-HCl 
and stored at -20 °C. 
At the time of immunoblotting, all samples were thawed on ice, and the protein concentration 
was measured spectrophotometrically using Bradford reagent. Western blot analysis was 
performed according to standard procedures. Briefly, 15 µg of mitochondrial protein or 30 µg 
of protein from tissue lysates were assayed using SDS-PAGE on Tris-glycine or purchased 
Tris-acetate gels (Life Technologies). Proteins were transferred on nitrocellulose or PVDF 
membranes, and probed overnight at 4 °C with the primary antibody (Supplementary Table 
1). One hour of incubation with a respective HRP-conjugated secondary or IRDye antibody 
(Supplementary Table 1) at room temperature followed. Chemiluminescence and 
fluorescence signals were detected with the LI-COR ODYSSEY FC Imaging system (LI-COR 
Biosciences). Protein levels were quantified by densitometry using ImageJ (Abràmoff et al., 
2004). 
 
Filter retardation assay 
For the detection of SDS-insoluble HTT species, 30 µg of cortical or striatal proteins were 
diluted in 100 µl DPBS (Life Technologies) with 2 % SDS and incubated for 5 min at room 
temperature. A nitrocellulose membrane (0.45 µm; Bio-Rad) was equilibrated in 0.1 % SDS 
in DPBS and samples were filtered through this membrane using a Minifold II Slot Blot 
System (Schleicher & Schuell). The membrane was then washed twice with DPBS and 
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blocked with 5 % SlimFast (Unilever) in TBS for 1 h at room temperature. Retained SDS-
insoluble HTT was detected using anti-HTT primary antibody (1:1000; clone 1HU-4C8, 
MAB2166, EMD Millipore) and the respective anti-mouse HRP-conjugated secondary 
antibody. Chemiluminescence signals were detected with the LI-COR ODYSSEY FC 
Imaging system and quantified using the ODYSSEY® Server software version 4.1 (both LI-
COR Biosciences). 
 
Calpain activation assays 
In vitro calpain activation assays of brain lysates were performed as previously described 
(Hübener et al., 2013). Briefly, 30 µg of protein from TNES lysates were diluted in 40 µl 
calpain reaction buffer (20 mM HEPES/KOH pH 7.6, 10 mM KCl, 1.5 mM MgCl2, 1 mM 
dithiothreitol). The positive control was incubated with 20 ng of recombinant calpain-1 (EMD 
Millipore), and 2 mM CaCl2 for indicated times at room temperature, while the negative 
control was pretreated with 100 µM of the calpain inhibitor CI-III (carbobenzoxy-valinyl-
phenylalaninal) (EMD Millipore) prior to calpain-1 addition. Calpain activity of all samples was 
quenched by addition of 4 x NuPAGE LDS sample buffer (Life technologies) and heat 
denaturation for 10 min at 70 °C. Samples were subsequently assayed by immunoblotting, 
as described above. 
 
TR-FRET for soluble mHTT detection 
TR-FRET was performed with cortical and striatal lysates (sampled as described under 
Immunoblotting), and conducted according to Baldo et al. at Novartis (Basel, Switzerland) 
(Baldo et al., 2012). Briefly, samples were ultra-centrifuged at 80,000 x g for 90 min. 
Supernatant was transferred to 384-microtiter plates, diluted 1:5 in detection buffer (50 mM 
NaH2PO4, 400 mM NaF, 0.1 % BSA, and 0.05 % Tween) and probed with fluorophore-
labeled antibodies 2B7-Tb and MW1-d2 in a ratio of 1:10. TR-FRET was read with an 
EnVision Reader (PerkinElmer, Waltham). After the excitation of the donor fluorophore Tb at 
320 nm and a time delay of 100 ms, the resulting Tb and d2 emission signals were read at 
620 nm and 665 nm, respectively. 
 
Experimental design 
Sample size estimation was based on behavioral data previously obtained for the BACHD 
rat. Fifteen animals per genotype and treatment group were assigned to the Rotarod test, 12 
d. Clemens et al., 2015, Brain. 
252 
to the simple swim test, five to the elevated plus maze and 10 to MRI analysis. Ex vivo 
analyses were planned with five rats per group. The final assignment differed slightly from 
this, as one cage of placebo-treated rats originally intended for the elevated plus maze and 
mitochondrial respiration analysis was used in addition for MRI measurements. Furthermore, 
three animals died during the study (without any bias regarding genotype or treatment 
groups). For ex vivo analyses, a final number of three to five rats per group were used, as 
sample material was limited. 
During behavioral studies, the experimenter was blind to the animals’ genotype, but not 
treatment, as the cages had to be labeled to ensure that the right kind of food, either placebo 
or olesoxime-loaded pellets, was provided at all times. Aggregate count was performed by 
one observer, who was blind to genotype and treatment group. 
The n analyzed, refers to the biological replicate of individual animals of a given genotype 
and treatment group, except for drug concentration analysis in brain regions, where samples 
from two to three individuals were pooled in order to reach a proper amount of sample 
material. 
 
Statistical analysis 
Data were analyzed and graphed using GraphPad Prism 6.00 for Windows (GraphPad 
Software, San Diego California USA, http://www.graphpad.com). Values refer to group mean 
and standard error of the mean (s.e.m.) for all figures, and group mean and standard 
deviation (SD) for Table 1. The α-level was set to 0.05. Complete data sets proved to be 
normally distributed. Longitudinal data were analyzed using repeated measurements two-
way ANOVA (2way rmANOVA) with time (e.g. age or trial) as a within-group factor and group 
(e.g. genotype and treatment) as between-group factor. Single data sets were analyzed 
using regular two-way ANOVAs (2way ANOVA) to identify genotype and treatment effects. 
For both, 2way rmANOVA and 2way ANOVA, the results are implemented in each graph and 
specify the respective between-group factors. Fisher’s LSD was performed as ANOVA 
posttest, and did not account for multiple comparisons, favoring false positive over false 
negative results in this first evaluation of olesoxime effects on HD-related phenotypes. There 
was one two-group comparison (treatment effects specific to BACHD rats), which was 
analyzed using a Student’s t-test. Results from two-way ANOVAs and Fisher’s LSD posttest, 
and posttest as well as t-test results for the comparisons * WT versus BACHD rats, # 
untreated versus treated WT and + untreated versus treated BACHD rats are indicated in 
respective figures, with ns: not significant, */#/+: P < 0.05; **/##/++: P ≤ 0.01 and ***/###/+++: 
P ≤ 0.001. 
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Some behavioral data were excluded from the analysis based on predefined criteria or 
technical problems. Concerning technical problems, the data could either not be properly 
acquired or the acquired data were inconclusive (as explained in detail below). We did not 
predefine exclusion criteria for outliers, or exclude data in order to reach a normal 
distribution. Moreover, the values we excluded were spread equally among groups, 
suggesting that it did not have a biological meaning or exclusion was skewing the results. 
Food intake measurements: Nine of the 60 animals were excluded from the analysis, 
because in at least one of the five measurements (at 2, 4, 6, 8 or 12 months of age), the food 
got stuck in the food basket leaving the animal unable to reach it and resulting in 
unreasonably low values for food intake during the respective night. Rotarod test: no data 
were excluded, but the number of rats available for analysis decreased with age, as an 
increasing number of mainly BACHD rats refused to stay on the rod at older ages (as 
discussed previously in (Abada, Nguyen, Schreiber, et al., 2013; Yu-Taeger et al., 2012)); 
Simple swim test: the tracking software produced a variety of errors, which made it 
necessary to exclude animals  with individual erroneous runs.; EPM: one of the 20 animals 
was excluded from the analysis, as it did not move at all during the test; MRI: two of the 40 
animals were excluded from the analysis, as they moved their heads during measurements 
and no sharp images could be acquired; Drug concentration analysis: two of the 16 samples 
were excluded as they had far higher drug concentrations than the rest of the rats. The high 
drug load in the two animals is considered to be due to food intake just prior to blood 
sampling, as we did not food deprive the animals; Ex vivo analyses: no data were excluded. 
Numbers of animals analyzed in each experiment are listed in Supplementary Table 2.  
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Results 
A time line and overview over the parameters assessed in this study is given in 
Supplementary Figure 1. 
 
Olesoxime ameliorates cognitive and psychiatric phenotypes of BACHD rats 
We previously reported that BACHD rats show a broad range of behavioral abnormalities 
reminiscent of the symptoms found in Huntington disease patients (Abada, Nguyen, 
Ellenbroek, et al., 2013; Abada, Nguyen, Schreiber, et al., 2013; Yu-Taeger et al., 2012). The 
cognitive phenotype of the BACHD rat is characterized by difficulties in strategy shifting 
(Abada, Nguyen, Ellenbroek, et al., 2013). Accordingly, we found 7 months old BACHD rats 
to display reversal learning deficits in a simple swim test. Untreated, but not olesoxime-
treated BACHD rats, needed longer to find a hidden platform after the platform had been 
relocated (Fig. 1A). Swim speed did not differ between groups (data not shown), suggesting 
that BACHD rats’ general ability to swim was not impaired. 
Anxiety-related changes were assessed by measuring the time spent on the open arms of an 
elevated plus maze at 13 months of age. In line with our previous findings (Yu-Taeger et al., 
2012), BACHD rats spent a significantly higher amount of time on the open arms than WT 
rats. Olesoxime treatment clearly ameliorated this phenotype (Fig. 1B). 
Longitudinal assessment of clasping behavior and Rotarod performance were carried out as 
common tests of striatum-based motor dysfunction (Bergeron et al., 2014; Soll et al., 2013). 
BACHD rats showed hind limb clasping, similar to previous cohorts (Yu-Taeger et al., 2012) 
(Fig. 1C). Furthermore, Rotarod performance, which is among the earliest pathological 
phenotypes detected in the BACHD rat (Yu-Taeger et al., 2012), was found to be impaired at 
2, 4 and 8 months of age (Fig. 1D). Olesoxime treatment, which started when the motor 
abnormalities were already manifested, did not reverse the pathology (Fig. 1C and D). 
 
Olesoxime increases frontal cortex thickness 
Olesoxime has been ascribed with neuroprotective properties, as it was found to increase the 
survival of neurons expressing disease proteins (Bordet et al., 2010; Gouarné et al., 2013, 
2015). We performed MRI scans in 13 months old rats in order to evaluate, if olesoxime was 
able to ameliorate brain atrophy observed in BACHD rats (Yu-Taeger et al., 2012). BACHD 
rats had significantly smaller cerebra (Fig. 1E), striata (Fig. 1F) and prefrontal cortices 
(Fig. 1G) compared to their WT littermates. While olesoxime treatment did not significantly 
d. Clemens et al., 2015, Brain. 
255 
affect cerebral or striatal volume (Fig. 1E, F), frontal cortex thickness was significantly 
increased, pointing to a region-specific neuroprotective effect of olesoxime (Fig. 1G). 
 
Olesoxime is enriched in prefrontal and frontal cortex 
After finding significant beneficial but apparently region-specific effects of olesoxime, we 
analyzed the drug concentration in plasma and brain regions in a separate cohort of rats 
after 2 weeks of olesoxime treatment at 4 months of age (cohort II). Analysis revealed similar 
plasma levels as found for the main cohort at 3 months of age (cohort I) (Fig. 1H), which 
were presumed to lie in the pharmacologically active range of olesoxime based on the results 
of previous studies (Bordet et al., 2007, 2010; Richter et al., 2014). Furthermore, BACHD 
rats tended to have higher plasma (Fig. 1H) and brain (Fig. 1I) olesoxime levels than WT 
rats. In addition, we detected significant differences in the olesoxime concentration among 
brain regions, with highest concentrations measured in prefrontal and frontal cortex (Fig. 1I). 
The general trend to higher olesoxime concentrations in BACHD rats was not the result of 
increased food intake (data not shown) and there was no difference in body weight between 
genotype or treatment groups, thus the results might point to altered pharmacokinetics of 
olesoxime in the BACHD rat. 
 
Olesoxime reduces mHTT aggregates and nuclear accumulation 
Aggregation and nuclear accumulation of mHTT are prominent neuropathological features of 
Huntington disease (Gutekunst et al., 1999). Consistent with our previous results (Yu-Taeger 
et al., 2012), 13 months old BACHD rats show mHTT aggregates (reflected by distinct S830-
positive punctae) and nuclear accumulation (reflected by S830-positive nuclei) in variable 
magnitude throughout the brain (Fig. 2, Fig. 3A and B). Aggregates were found 
predominantly in cortex, hypothalamus and amygdala. Mutant HTT nuclear accumulation 
prevailed in cortex, lateral striatum and hippocampus. Similar to Huntington disease patients 
(Gutekunst et al., 1999), cerebral cortex hosted a high amount of mHTT aggregates and 
nuclear accumulation of mHTT, while neither form was abundant in the central caudate 
putamen, the major part of striatum. Olesoxime-treated BACHD rats showed a significant 
reduction in both aggregate load and nuclear mHTT accumulation (Fig. 2, Fig. 3A and B). 
Moreover, not only the number of aggregates and mHTT-positive nuclei was reduced due to 
olesoxime treatment, but also aggregate size and the density of mHTT in the nuclei of 
olesoxime-treated BACHD rats seemed to be lowered. 
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The results from immunohistochemical staining were validated using a filter retardation assay 
to detect the amount of non-soluble, and thus aggregated, mHTT in cortical and striatal 
lysates from untreated and olesoxime-treated BACHD rats. In both, cortical and striatal 
samples, aggregated mHTT was significantly reduced due to olesoxime treatment (Fig. 3C). 
 
Olesoxime decreases mHTT fragments and increases full-length mHTT by reducing calpain-
mediated cleavage 
To further investigate the cause and consequences of reduced mHTT aggregate formation 
and nuclear accumulation, we analyzed the levels of soluble full-length and truncated forms 
of mHTT in cortical and striatal lysates from 13 months old rats BACHD and WT rats. 
Total levels of soluble mHTT were measured by TR-FRET analysis as described previously 
(Baldo et al., 2012). Consistent with the reduction of aggregated mHTT throughout the 
cortex, soluble mHTT levels were highly increased in the cortices but not striata from 
olesoxime-treated BACHD rats (Fig. 3D). 
As mHTT fragments are particularly prone to aggregate formation (Cooper et al., 1998; Li 
and Li, 1998; Martindale et al., 1998) and nuclear accumulation (Davies et al., 1997; DiFiglia 
et al., 1997; Zhou et al., 2003), we further quantified the levels of truncated mHTT by western 
blot analysis (Fig. 3E–G). By using the HTT-specific D7F7 antibody (epitope around proline 
1220 of human HTT) to detect mHTT as well as endogenous rat huntingtin (Htt), and the 
polyQ-specific 1C2 antibody to detect mHTT only, we obtained a variety of protein fragments 
in cortex and striatum of both WT and BACHD rats (Fig. 3E). Untreated BACHD rats showed 
clearly enhanced fragmentation of mHTT in cortex (Fig. 3E and F) but not striatum 
(Fig. 3E and G). In addition, the cortex samples from untreated BACHD rats contained a 
variety of shorter HTT fragments that were not detectable in cortical samples from WT rats, 
or striatal samples of either genotype (Fig. 3E). Olesoxime treatment reduced HTT 
fragmentation in BACHD rats below WT level in both cortex and striatum (Fig. 3E–G). Similar 
to the TR-FRET analysis, olesoxime-treated BACHD rats showed a significant increase in 
full-length mHTT, specifically in cortex (Fig. 3E and F). 
Based on the apparent influence of olesoxime on mHTT proteolysis, we then investigated the 
origin of mHTT fragments by analyzing the activity of calpains and caspases, the main 
contributors to proteolytic cleavage of mHTT (Gafni and Ellerby, 2002; Goldberg et al., 1996). 
We did not find marked differences between genotype or treatment groups in the expression 
levels of caspase-3, or the activation status of caspase-6 in either cortex or striatum (data not 
shown). On the other hand, strong activation of the calpain system was detected specifically 
in cortex (Fig. 4A) but not striatum (Fig. 4B) of untreated BACHD rats. While the expression 
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levels of full-length calpain-1, calpain-2 and calpain-10 were unchanged (data not shown), 
overactivation of the calpain system was evidenced by a distinct increase in processed 
calpain-1, elevated levels of the cleaved form of the calpain substrate α-spectrin, and 
decreased levels of the endogenous calpain inhibitor calpastatin (Fig. 4A). Olesoxime 
treatment reversed the dysregulation by decreasing active calpain-1, increasing calpastatin 
levels, and reducing α-spectrin cleavage (Fig. 4A). Even though calpain activity was not 
increased in the striata of untreated BACHD compared to WT rats, olesoxime reduced 
calpain-1 activation and spectrin cleavage also in this brain region, while no significant 
effects on calpastatin levels were detected (Fig. 4B). 
In order to validate that the cortical mHTT fragments reduced by olesoxime treatment were 
calpain-derived, we performed in vitro calpain cleavage assays on cortical lysates (Fig. 4C 
and D). Incubation with recombinant calpain-1 resulted in increased fragmentation 
accompanied by a decrease in the levels of both full-length HTT and mHTT (Fig. 4C). The 
accumulation of HTT and mHTT fragments was calpain-1 concentration dependent, and 
concerned a variety of rather N-terminal and rather C-terminal fragments as detected by 
double-immunostaining with D7F7 and the N-terminal 4C8 antibody (epitope between amino 
acids 181 and 810) (Fig. 4D). Calpain dependency was further confirmed by addition of the 
specific calpain inhibitor CI-III, which abolished the fragmentation. In vitro calpain activation 
resulted in a clear fragmentation of HTT in WT rats, resembling the fragmentation pattern 
found in BACHD rats. Fragmentation was also enhanced in BACHD rats, although the effect 
was less strong due to high basal fragmentation of mHTT. These results suggest that calpain 
cleavage constituted the major contributor to proteolytic cleavage in the BACHD rat and that 
the additional small fragments found in BACHD rat cortex, which were cleared by olesoxime 
treatment, derived from enhanced calpain-mediated cleavage. 
 
Olesoxime reduces mitochondria-associated HTT fragments and improves mitochondrial 
function 
Given that olesoxime accumulates at the site of mitochondria (Bordet et al., 2010), we 
investigated the impact of olesoxime on mitochondrial properties. 
First, we analyzed the activation status of the calpain system in mitochondria-enriched heavy 
membrane fractions isolated from the cerebra of 13 months old, placebo- and olesoxime-
treated, WT and BACHD rats (Fig. 5A), as calpains are also located in mitochondria 
(Arrington et al., 2006; Badugu et al., 2008; Smith and Schnellmann, 2012). Enrichment in 
mitochondrial protein in the mitochondrial fractions is demonstrated by higher citrate 
synthase levels compared to whole cell lysate (Fig. 5A and B). Calpain activation was not 
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increased in the mitochondrial fractions of untreated BACHD rats (Fig. 5A). However, 
olesoxime treatment repressed mitochondrial calpain activity in both BACHD and WT rat 
samples, as indicated by a reduced amount of active calpain-1 and cleaved α-spectrin, as 
well as increased amounts of calpastatin (Fig. 5A). 
As HTT and mHTT are known to associate with mitochondria (Choo et al., 2004; Gellerich et 
al., 2008; Orr et al., 2008), we further investigated their presence and cleavage in the 
mitochondrial fractions from WT and BACHD rats (Fig. 5B). Full-length protein as well as 
truncated forms of Htt and mHTT were detected. More mitochondria-associated fragments of 
HTT were found in untreated BACHD compared to WT rats. Olesoxime treatment reduced 
the amount of HTT fragments associated with mitochondria, in both WT and BACHD rats. In 
the BACHD rat, olesoxime additionally increased mitochondria-associated full-length Htt and 
mHTT. Together with the results on whole cell lysate, these findings indicate that olesoxime 
mediates a genotype-independent reduction in mitochondrial calpain activation, and reduces 
tissue-specific, whole cell calpain overactivation in the Huntington disease context of the 
BACHD rat. 
To test if olesoxime affected mitochondrial function, we further investigated mitochondrial 
respiratory chain activity (Fig. 5C) and the expression of mitochondrial proteins (Table 1). 
Mitochondrial function has not been assessed in the BACHD rat previously. Mitochondria 
isolated from 13 months old untreated BACHD rat cerebra showed an overall lower oxygen 
consumption rate compared to WT rats, and olesoxime treatment reduced this respiration 
deficit (Fig. 5C). Expression levels of mitochondrial proteins were not strikingly altered in 13 
months old untreated BACHD compared to WT rats, but olesoxime strongly affected the 
protein expression in BACHD and WT rats in a differential manner (Table 1). While we 
observed a general increase in the expression of many mitochondrial proteins in cortex and 
striatum of olesoxime-treated WT rats, indicative of an overall increase in mitochondrial 
mass, we detected more specific effects in BACHD rats with olesoxime treatment. In cortex, 
olesoxime increased the expression of ATP synthase and the fusion-promoting proteins 
Mfn 1, Mfn 2 and Opa 1, while the expression of fission-promoting proteins was either 
unaffected (Fis 1) or decreased (Drp 1), suggesting a higher capacity for respiration and 
fusion processes in this tissue due to olesoxime treatment. Olesoxime further dramatically 
increased the expression of the outer mitochondrial membrane transporter TOM 20, in both 
cortex and striatum of the BACHD rat. This finding led us to consider a general effect of 
olesoxime on transport across the mitochondrial membrane, and particularly the exchange of 
Ca2+, as the overactivation of calpain found in BACHD rat cortex might be due to a 
mitochondrial Ca2+ buffering deficit. 
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Olesoxime affects the expression of proteins involved in Ca2+ homeostasis 
It had been demonstrated that calpain-derived fragments of mHTT are formed in response to 
Ca2+ stress (Gafni et al., 2004). Olesoxime might influence Ca2+ homeostasis, as it interacts 
with VDAC (Bordet et al., 2007), which is involved in intracellular Ca2+ translocation (Gincel 
et al., 2001; Min et al., 2012; Szabadkai et al., 2006). Western blot analysis revealed no 
alteration in VDAC 1/2 expression in 13 months old untreated BACHD compared to WT rats, 
but a dramatic increase in the expression of both isoforms in cortex (Fig. 6A) and striatum 
(Fig. 6B) from olesoxime-treated BACHD rats. The strong effect on VDAC expression was 
also seen in cortex of WT rats (Fig. 6A). 
We further analyzed the levels of the endoplasmic reticulum-associated Ca2+-transporter 
IP3R 1, as it is implicated in neurodegenerative diseases (Stutzmann and Mattson, 2011). 
Specifically, IP3R 1 protein expression is upregulated in response to elevated Ca2+ levels 
(Genazzani et al., 1999), and excessive IP3R 1-mediated Ca2+-release into the cytosol 
primes apoptosis (Stutzmann and Mattson, 2011). Furthermore, both interaction with mHTT 
and calpain cleavage, have been shown to facilitate IP3R 1 activity upon stimulation, and 
render neurons more vulnerable to excitotoxic stimuli (Kopil et al., 2012; Tang et al., 2003). 
We found the levels of IP3R 1 to be increased in cortex (Fig. 6A) of untreated BACHD 
compared to WT rats. While no significant effect of olesoxime treatment on IP3R 1 was found 
in WT rats, olesoxime normalized IP3R 1 expression in the cortex from BACHD rats 
(Fig. 6A and B).  
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Discussion 
Olesoxime is a mitochondria-targeting neuroprotective compound (Bordet et al., 2007, 2010) 
that has shown potential as a treatment for several neurodegenerative diseases (Bordet et 
al., 2008; Eckmann et al., 2013; Richter et al., 2014; Rovini et al., 2010; Sunyach et al., 
2012; Xiao et al., 2009, 2012). We show here that olesoxime exhibited highly beneficial 
effects on disease-related phenotypes in a Huntington disease animal model. Importantly, 
the treatment effects appeared to be conveyed through a previously unknown function of 
olesoxime, to reduce proteolysis. In Huntington disease, proteolytic cleavage of mHTT 
results in the generation and accumulation of toxic mHTT fragments (Gafni and Ellerby, 
2002; Goldberg et al., 1996; Kim et al., 2006; Miller et al., 2010), which are thought to be 
crucial for disease pathogenesis (Nagai et al., 2007; Rigamonti et al., 2000; Wang et al., 
2008). Consistent with this, olesoxime-treated BACHD rats showed reduced activation of the 
calpain system, reduced amounts of mHTT fragments, aggregates and nuclear mHTT 
accumulation, as well as behavioral and neuropathological improvements. Inhibition of mHTT 
cleavage has previously been targeted in Huntington disease models by genetic 
manipulations (Gafni et al., 2004; Graham et al., 2006; Miller et al., 2010), or the use of 
protease inhibitor (Bizat et al., 2003), revealing beneficial effects (Bizat et al., 2003; Gafni et 
al., 2004; Graham et al., 2006; Miller et al., 2010). However, olesoxime is the first small 
molecule identified to reduce the level of mHTT fragments in a safe and simple approach: the 
compound can be administered orally, has been shown to be safe and well-tolerated 
clinically (Lenglet et al., 2014), and its neuroprotective activity has recently been 
demonstrated in a pivotal clinical trial in spinal muscular atrophy patients (Dessaud et al., 
2014). Thus, our findings highly encourage further investigations of olesoxime for use as a 
therapeutic for Huntington disease. Still, some questions arose from the present study, which 
need to be addressed further. 
 
Are the beneficial effects of olesoxime restricted to specific brain regions? 
The current results indicate that olesoxime reaches higher concentrations in the frontal and 
prefrontal cortex compared to other brain regions, when given orally. In line with this, both in 
vivo and ex vivo analyses indicated a predominant cortical effect of olesoxime treatment. 
MRI results revealed increased frontal cortex thickness, while atrophy of other brain areas 
such as the striatum was not alleviated. Further, olesoxime-treated BACHD rats showed a 
selective improvement of reversal learning and anxiety deficits, while motor phenotypes 
remained. Important in this regard is that lesion studies have tied attentional set shifting 
difficulties and reduced anxiety in the elevated plus maze to the prefrontal and frontal cortex 
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(Birrell and Brown, 2000; Shah and Treit, 2003), while motor performance crucially involves 
the striatum (Bergeron et al., 2014; Soll et al., 2013). Thus, it is possible that the apparent 
selective effect on behavior was a result of the uneven distribution of olesoxime. However, it 
is important to note that olesoxime still exerted strong effects on mHTT fragmentation and 
nuclear accumulation in striatum, despite its lower concentration. The reason for olesoxime 
not mitigating more striatum-based phenotypes could thus be that neuronal pathologies differ 
among brain regions. Most notably, the overactivation of the calpain system seemed to be a 
cortex-specific phenotype in the BACHD rat, and appeared to play a major role in 
olesoxime’s beneficial effects. It is possible that striatal neurons suffer more from other 
mHTT-mediated deficits, and that neuronal dysfunction thus persisted, despite sufficient 
olesoxime concentrations. 
An alternative hypothesis on the selective effects of olesoxime might be that some deficits, 
such as the Rotarod phenotype, were already manifest prior to the start of olesoxime 
treatment in the current study. Similar results have been obtained in a recent study on the 
effect of cholesterol oximes on the pathological phenotypes of Parkinson disease mice. The 
compounds ameliorated non-motor phenotypes and gene expression changes in 
mitochondrial genes, but were not able to reverse motor dysfunction with onset prior to the 
start of treatment (Richter et al., 2014). The fact that olesoxime treatment did not generally 
ameliorate brain atrophy in BACHD rats could have the same cause, as we recently reported 
that smaller body and brain sizes among BACHD rats derive from growth impairment rather 
than progressive degeneration (Jansson et al., 2014). 
 
What is the primary target of olesoxime? 
It has previously been proposed that the presence of mHTT might initiate a vicious cycle, in 
which mitochondrial dysfunction leads to reduced Ca2+ buffering, subsequent protease 
activation and generation of mHTT fragments that further enhance the cytotoxic events (Bizat 
et al., 2003; Petersén et al., 1999). Accordingly, we observed a respiratory chain deficit, 
along with increased calpain activation and mHTT fragmentation in BACHD rats, pathologies 
which were all alleviated by olesoxime (Fig. 7). Thus, we suggest that olesoxime interfered 
with the vicious cycle by stabilizing mitochondria. 
It is conceivable that mitochondria were the primary effectors of olesoxime treatment, since 
olesoxime concentrates at this site (Bordet et al., 2010), and cholesterol-oximes have been 
shown to affect the expression of genes important for mitochondrial function (Richter et al., 
2014). Such gene expression changes include the up-regulation of Mfn 1 and down-
regulation of Drp 1, consistent with our findings on protein level. Importantly, abnormally 
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increased fission activity has recently been shown to contribute to the cellular pathology in 
Huntington disease (Costa and Scorrano, 2012). Counteracting this by inhibiting fission or 
enhancing fusion, further, has been found to ameliorate Huntington disease-related 
phenotypes (Costa et al., 2010; Song et al., 2011; Wang et al., 2009). This is possibly due to 
improved mitochondrial Ca2+ handling, as suppressing fission or enhancing fusion generally 
renders neurons less susceptible to excitotoxic stress (Grohm et al., 2012; Jahani-Asl et al., 
2011; Kushnareva et al., 2013; Nguyen et al., 2011). 
Another interesting effect of olesoxime is a modulation of mitochondrial membrane fluidity. 
We reported earlier that olesoxime was able to reverse an increase in mitochondrial 
membrane fluidity observed in the BACHD rat and two other Huntington disease models 
(Eckmann et al., 2014). We further showed that olesoxime-treated BACHD rats had 
significantly higher mitochondrial membrane cholesterol levels than untreated BACHD rats, 
which might be causal for the reduction in membrane fluidity (Eckmann et al., 2014). Here, 
we demonstrate that olesoxime dramatically increased the levels of the outer mitochondrial 
membrane transporter VDAC, which is involved in mitochondrial cholesterol import (Rone et 
al., 2009). The additional increase in the levels of the outer mitochondrial membrane import 
component TOM 20 suggests that olesoxime exerted a general beneficial effect on transport 
processes across the mitochondrial membrane. It had been argued before that energetic 
deficits and impaired Ca2+ homeostasis might be the result of impaired communication 
between mitochondria and cytoplasm due to the accumulation of mHTT on the outer 
mitochondrial membrane (Gellerich et al., 2008, 2010). A recent study further specifically 
demonstrated that mHTT impairs mitochondrial protein import by interaction with the inner 
membrane transport complex TIM 23, and that overexpression of TIM23 leads to restoration 
of protein import and prevention of cell death (Yano et al., 2014). Thus, there are several 
indications that the mitochondrial membrane environment is modulated by olesoxime, which 
might connect to its beneficial effects. 
We hypothesized that the compound had exerted its beneficial effects by improving 
mitochondrial function, thereby stabilizing Ca2+ homeostasis, decreasing Ca2+-related 
calpain-1 activation and aborting the generation of toxic mHtt fragments as well as their 
exaggerated negative influence on mitochondria (Fig. 87). Since Ca2+ levels, Ca2+ handling 
or the effects of olesoxime on Ca2+ balance could not be directly evaluated in this study, the 
proposed mechanism remains hypothetical. However, the finding of overactive calpain-1 
itself and the increased protein levels of IP3R 1 in untreated BACHD rats, as well as the 
restorative effects of olesoxime on these parameters, strongly support the idea of improved 
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Ca2+ homeostasis, if not as primary effect then at least as part of olesoxime’s mechanism of 
action. 
Nonetheless, lacking a clear mechanism of action, it will be difficult to develop 
pharmacodynamic biomarkers, which will be crucial for conducting successful clinical efficacy 
trials. This has for instance been proven true for well-tolerated antioxidant molecules such as 
cysteamine (CYTE-I-HD study), creatine (CREST-E study), ethyl-EPA (TREND-HD study), 
and coenzyme Q10 (2CARE study). While these small molecules targeting mitochondrial 
function showed efficacy in some rodent models (Ferrante et al., 2000; Hickey et al., 2012; 
Yang et al., 2009) (although there is also conflicting data (Menalled et al., 2010)), they mainly 
yielded negative findings in the clinics, emphasizing the urgent need for pharmacodynamics 
biomarkers. However, olesoxime is the first small molecule to modulate soluble levels of 
mHTT, which can be quantified in CSF, plasma and other tissues from animal models and 
HD patients using a TR-FRET (Baldo et al., 2012; Weiss et al., 2012) or mHTT immunoassay 
(Wild et al., 2015), and could therefore potentially serve as a biomarker. 
 
Can it be beneficial to reduce mHTT aggregation? 
We observed a reduction in mHTT aggregation in olesoxime-treated BACHD rats. It is widely 
accepted that aggregates are not the most toxic species of mHTT, and reducing aggregation 
has even been found to enhance Huntington disease-related pathologies (Arrasate and 
Finkbeiner, 2012). However, it is likely that in these cases, reduced aggregation was 
accompanied by an increase in mHTT fragments, as truncated mHTT, not its full-length form, 
is thought to mediate mHTT toxicity (Arrasate et al., 2004). This is different from our study, 
as olesoxime specifically reduced mHTT fragments, but led to an increase in soluble full-
length mHTT and Htt. There is evidence that not only mHTT but also Htt fragments have 
cytotoxic properties (Hackam et al., 1998; Kim et al., 1999; Nasir et al., 1995), while the full-
length form of Htt exerts protective effects (Leavitt et al., 2001; Tanaka et al., 2006). Our 
results further support the idea that soluble full-length mHTT is non-toxic, as we did not 
detect any adverse effects of olesoxime treatment in vivo. Suppression of mHTT cleavage 
and aggregation might also exert secondary beneficial effects by increasing endogenous Htt 
levels. 
It should be noted that the reduction of mHTT aggregates in olesoxime-treated BACHD rats 
might not only derive from reduced cleavage, but could be an effect of increased protein 
degradation. Calpain activation has been shown to interfere with autophagic degradation 
processes (Xia et al., 2010; Yousefi et al., 2006), and inhibiting calpain activity enhances 
autophagy (Kim et al., 2013; Kuro et al., 2011; Menzies et al., 2014). The increase in soluble 
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mHTT that paralleled the decline in aggregation in the BACHD rat might, however, argue 
against a strong increase in mHTT degradation. 
 
Is it relevant and safe to suppress calpain activity in neurodegenerative diseases? 
The calpain proteolytic system has been recognized as an important player in 
neurodegenerative diseases (Getz, 2012; Haacke et al., 2007; Samantaray et al., 2008; 
Stifanese et al., 2014), including Huntington disease (Gafni and Ellerby, 2002). The pivotal 
role is underpinned by current studies addressing the mechanistic link between calpains and 
Ca2+ dysbalance (Gladding et al., 2012), mitochondrial dysfunction (Wang et al., 2014), 
axonal degeneration (Yang et al., 2013), inflammation (Zhang et al., 2014), and apoptosis 
(Sobhan et al., 2013). A variety of calpain inhibitors have been developed to counteract the 
detrimental effects of calpain activation, but unspecific inhibitors and strong inhibition might 
exert off-target and side effects (Donkor, 2014). Such effects are less likely to arise from 
olesoxime treatment, as this probably affects calpains indirectly, and only lowers their 
activation. In this regard, we recently demonstrated that decreasing calpain activity in a 
mouse model of Parkinson disease by cross-breeding with calpastatin-overexpressing mice, 
ameliorates Parkinson disease-related pathologies (Diepenbroek et al., 2014). These, as well 
as other data (Menzies et al., 2014), suggest that long-term reduction of calpain activity does 
not have deleterious effects in mice in vivo. 
 
Conclusion 
Our study reveals behavioral and neuropathological improvements in olesoxime-treated 
BACHD rats due to improved mitochondrial function, which halts a vicious cycle of 
mitochondrial defects and calpain-mediated cleavage of mHTT. The current findings once 
more emphasize the connection between mitochondrial dysfunction and the generation of 
calpain-derived mHTT fragments, which underlies the molecular pathogenesis of Huntington 
disease, and constitutes a pivotal therapeutic target. As safety, tolerance and 
neuroprotective properties of olesoxime have been demonstrated, both clinically and in 
several neurodegenerative disease models, the compound represents a promising candidate 
for the treatment of Huntington disease.  
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Figures and Figure Legends 
 
Figure 1: Olesoxime accumulates in the frontal cortex and exerts specific beneficial 
effects on behavioral and neuropathological phenotypes of the BACHD rat. (A) A 
simple swim test (SST) was used to assess cognitive flexibility at 7 months of age. The graph 
shows the time the animals needed to find a hidden platform after the position of the platform 
had been changed (reversal training). (B) Anxiety-related behavior was assessed in an 
elevated plus maze at 13 months of age. The graph shows the time the animals spent on the 
open arms of the maze relative to trial duration. (C) Clasping behavior was assessed weekly 
as an indicator for motor dysfunction. The graph displays the clasping frequency between the 
age of 1 and 10 months. (D) Motor abnormalities were further investigated longitudinally 
using a Rotarod test. The graph displays the mean running capacity during tests. (E–G) MRI 
was performed at 13 months of age. Images in the lower left corner illustrate the site of 
measurement. (H and I) Plasma olesoxime levels were measured in the main cohort of rats 
used for all in vivo and ex vivo analyses (cohort I) at 3 months of age after 7 weeks of 
treatment. In addition, plasma and brain olesoxime levels were determined in a second 
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cohort of rats (cohort II) at 4 months of age after 2 weeks of treatment. Olsx: olesoxime, 
EPM: elevated plus maze, */#/+: P < 0.05; **/##/++: P ≤ 0.01 and ***/###/+++: P ≤ 0.001. 
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Figure 2: Effects of olesoxime on mutant huntingtin aggregates and nuclear 
accumulation in different brain regions. Aggregation and nuclear accumulation of mHTT 
were investigated in coronal brain sections from 13 months old rats, stained with S830 N-
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terminal mHTT antibody. Images were taken from prefrontal, frontal and parietal brain areas. 
Columns display series of images from individual rats (n(WT) = 1, n(BACHD) = 4. Distinct punctae 
represent mHTT cytoplasmic aggregates and large circular staining represents mHTT 
nuclear accumulation. Black – purple staining: S830 huntingtin signal; blue staining: thionine 
nuclear signal. Magnification: 400 x, scale bar: 10 µM. Olsx: olesoxime, PL: prelimbic cortex, 
M1: motor cortex 1, Cg: cingulate cortex, CPu: caudate putamen, S: somatosensory cortex, 
Th: thalamus, Hyp: hypothalamus (VMH = ventro-medial hypothalamus), Hip: hippocampus, 
Am: amygdala.  
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Figure 3: Olesoxime reduces mHTT aggregation, nuclear accumulation and 
fragmentation, and increases soluble full-length forms of mHTT. (A and B) Total 
numbers of S830-positive punctae (mHTT aggregates) and nuclei (nuclear accumulation of 
mHTT) were counted manually from the brain regions displayed in Figure 3. Images on the 
left illustrate the structures counted, with arrows pointing to mHTT aggregates or mHTT-
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positive nuclei, respectively. Nc: not counted, np: not present, PL: prelimbic cortex, M1: 
motor cortex 1, Cg: cingulate cortex, CPu: caudate putamen, S: somatosensory cortex, Th: 
thalamus, Hyp: hypothalamus (VMH = ventro-medial hypothalamus), Hip: hippocampus, Am: 
amygdala. (C) SDS-insoluble proteins from cortical and striatal lysates were trapped on a 
nitrocellulose membrane and probed with the HTT-specific 4C8 antibody to quantify the 
amount of aggregated mHTT. (D) Levels of soluble mHTT were measured in cortical and 
striatal lysates from untreated and olesoxime-treated BACHD rats via TR-FRET analysis. (E–
G) Full-length and fragment forms of mHTT were assessed in cortical and striatal lysates 
using the HTT-specific D7F7 and the polyQ-specific 1C2 antibodies. Black arrowheads: full-
length mHTT, gray arrowhead: full-length Htt, red arrowheads: HTT fragments (1C2-positive 
bands in WT rats label polyQ-containing proteins other than mHTT), VCP/p97: loading 
control. Olsx: olesoxime, */#/+: P < 0.05; **/##/++: P ≤ 0.01 and ***/###/+++: P ≤ 0.001.  
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Figure 4: Olesoxime reduces the calpain-mediated cleavage of HTT, the major source 
of HTT fragments in the BACHD rat. (A and B) Calpain activation was investigated by 
Western blot analysis of the protease calpain-1, its endogenous inhibitor calpastatin and 
cleavage substrate α-spectrin, in cortical and striatal lysates from 13 months old rats. 
Arrowhead 1: full-length α-spectrin, arrowhead 2: α-spectrin fragment, arrowhead a: full-
length calpain-1, arrowhead b: processed calpain-1, arrowhead c: further processed calpain-
1 (active calpain1 refers to the ratio c/b), α-tubulin: loading control. (C) The dependency of 
HTT cleavage on calpain activity was assessed qualitatively in a calpain activation assay 
performed with cortical lysates from untreated, 13 months old WT and BACHD rats. Samples 
were treated with recombinant calpain-1 and CaCl2 (rcalpain-1) for 15 min, or additionally 
pretreated with calpain inhibitor III (CI-III) to demonstrate calpain-1 specificity. HTT fragments 
were detected with the HTT-specific D7F7 antibody. Black arrowhead: full-length mHTT, gray 
arrowhead: full-length Htt, red arrowheads: HTT fragments. Shorter exposure of the 
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membrane was used to distinguish high molecular weight bands, while longer exposure 
revealed low molecular weight HTT fragments. (D) Another calpain activation assay was 
performed with cortical lysates from one untreated, 13 months old WT and BACHD rat, 
respectively, to illustrate the variety of N-terminal and more C-terminal HTT fragments. For 
this, the samples were first treated with recombinant calpain-1 and CaCl2 (rcalpain-1) for an 
increasing amount of time or pretreated with calpain inhibitor III (CI-III) to demonstrate 
calpain-1 specificity. Samples were then probed with the HTT-specific D7F7 antibody as well 
as the HTT-specific 4C8 antibody, labelling central and N-terminal mHTT, respectively. The 
figure shows the overlay of the two detections with exclusive staining of HTT with D7F7 in 
blue, exclusive staining of HTT with 4C8 in red and double-staining of HTT with both 
antibodies in pink.. Black arrowhead: full-length mHTT, gray arrowhead: full-length Htt, blue, 
red and pink arrowheads: HTT fragments. Shorter exposure of the membrane was used to 
distinguish high molecular weight bands, while longer exposure revealed low molecular 
weight HTT fragments. */#/+: P < 0.05; **/##/++: P ≤ 0.01 and ***/###/+++: P ≤ 0.001.  
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Figure 5: Olesoxime reduces the activation of mitochondrial calpains and 
mitochondria-associated HTT fragments and restores mild respiratory deficits in 
BACHD rats. (A) Calpain activation was investigated in cerebral mitochondria-enriched 
heavy membranes (mitochondrial fraction) from 13 months old rats by Western blot analysis 
of the protease calpain-1, its endogenous inhibitor calpastatin and cleavage substrate α-
spectrin, in cortical and striatal lysates. Arrowhead 1: full-length α-spectrin, arrowhead 2: α-
spectrin fragment, arrowhead a: full-length calpain-1, arrowhead b: processed calpain-1, 
arrowhead c: further processed calpain-1 (active calpain-1 refers to the ratio c/b), Citrate 
synthase (CS): loading control. (B) Full-length and fragment forms of mHTT were assessed 
in cortical and striatal lysates from 13 months old rats using the HTT-specific D7F7 and the 
polyQ-specific 1C2 antibodies. Black arrowheads: full-length mHTT, gray arrowhead: full-
length Htt, red arrowheads: HTT fragments. One sample of WT cortex lysate was loaded to 
demonstrate the enrichment of the mitochondrial marker CS in the mitochondrial fraction. (C) 
Mitochondrial respiratory chain activity was assessed by measuring oxygen consumption of 
isolated cerebral mitochondria from 13 months old rats. Addition of substrates and inhibitors 
was performed as indicated in the figure and described in detail in the methods section. 
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CIOXPHOS = complex I-fueled respiration; CI+IIOXPHOS = complex I- and II-fueled respiration; 
CI+IILEAK = membrane leakage; CI+IIETC = maximum respiratory capacity; CIIETC = maximum 
capacity dependent on complex II; CIVETC = maximum capacity dependent on complex IV. 
Oxygen consumption rates were normalized to CS activity. */#/+: P < 0.05; **/##/++: P ≤ 0.01 
and ***/###/+++: P ≤ 0.001. 
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Figure 6: Olesoxime affects the expression of proteins involved in Ca2+ homeostasis. 
(A and B) Expression levels of the endoplasmic reticulum Ca2+ transporter IP3R 1, and the 
outer mitochondrial membrane channels VDAC 1 and VDAC 2, which are also involved in 
Ca2+ transport, were assayed in cortical and striatal lysates from 13 months old rats. α-
tubulin: loading control. */#/+: P < 0.05; **/##/++: P ≤ 0.01 and ***/###/+++: P ≤ 0.001.  
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Figure 7: Schematic of the hypothetical Huntington disease-related pathology and 
beneficial effects of olesoxime, in a BACHD rat cortical neuron. (A) The presence of 
mHTT provokes an increase in cytosolic Ca2+, leading to the overactivation of calpain, a 
major executer of mHTT cleavage in the BACHD rat. Enhanced calpain-mediated cleavage 
generates large amounts of mHTT fragments, which accumulate in cytosol and nucleus, and 
are recruited to form cytosolic and neuropil aggregates. Mutant HTT fragments impair 
mitochondrial function by transcriptional dysregulation and direct interaction, thereby 
reducing mitochondrial Ca2+-buffering capacity, further elevating cytosolic Ca2+-levels and 
fueling the vicious cycle. (B) Olesoxime interrupts this by improving mitochondrial function, 
reflected in increased respiratory activity, fusion protein and outer membrane transporter 
expression. This can in turn improve Ca2+ buffering, explaining the reduced calpain 
activation, mHTT cleavage and accumulation of mHTT fragments, as well as the decrease in 
cytosolic and neuropil aggregates seen in the current study. 
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Tables 
Table 1: Expression levels of mitochondrial proteins. The table contains group means 
(mean), standard deviation (SD) and the number of animals analyzed (n). Individual values 
were related to β-actin levels and normalized to the mean expression of placebo-treated WT 
rats. Significant differences from 2way ANOVA and Fisher LSD posttest are indicated in bold 
for the comparisons * WT versus BACHD rats, # untreated versus treated WT and + untreated 
versus treated BACHD rats (in blue), with */#/+: P < 0.05; **/##/++: P ≤ 0.01 and 
***/###/+++: P ≤ 0.001. Fusion: Mfn 1, Mfn 2, Opa 1. Fission: Drp 1, Fis 1, Matrix: citrate 
synthase (CS). Inner membrane: ATP synthase (ATP 5A). Outer membrane: translocase of 
the outer mitochondrial membrane (TOM 20). 
  
Cortex Striatum 
  
WT 
placebo 
WT 
olsx 
BACHD 
placebo 
BACHD 
olsx 
WT 
placebo 
WT 
olsx 
BACHD 
placebo 
BACHD 
olsx 
Mfn 1 
mean 1,00 1,33## 0,77* 1,18++ 1,00 1,66 1,10 0,96 
SD 0,18 0,11 0,16 0,14 0,32 0,36 0,57 0,71 
n 4 4 4 4 3 4 4 3 
Mfn 2 
mean 1,00 1,17 0,93 1,87++ 1,00 2,41 1,63 1,63 
SD 0,16 0,29 0,38 0,39 0,11 0,37 0,90 1,63 
n 4 4 4 4 3 4 4 3 
Opa 1 
mean 1,00 1,84## 0,96 2,33+++ 1,00 1,90 1,39 1,37 
SD 0,40 0,30 0,29 0,52 0,49 0,55 0,60 0,88 
n 4 4 4 4 3 4 4 3 
Drp 1 
mean 1,00 0,92 0,84 0,52++ 1,00 1,36 0,98 1,04 
SD 0,06 0,14 0,14 0,05 0,04 0,52 0,15 0,27 
n 4 4 4 4 3 4 4 4 
Fis 1 
mean 1,00 1,40# 1,23 1,17 1,00 2,16# 2,08 1,31 
SD 0,13 0,33 0,15 0,31 0,29 0,70 0,93 0,34 
n 4 4 4 4 3 4 4 3 
CS 
mean 1,00 1,95# 1,23 1,86 1,00 1,64# 1,11 0,94 
SD 0,56 0,94 0,33 0,22 0,11 0,36 0,33 0,22 
n 4 4 4 4 3 4 4 3 
ATP 5A 
mean 1,00 1,85 0,78 3,20++ 1,00 1,51 1,68 1,68 
SD 0,10 0,66 0,09 1,53 0,19 0,47 1,01 0,39 
n 4 4 4 4 3 4 4 3 
TOM 20 
mean 1,00 2,05 1,36 3,19+ 1,00 1,36 1,34 8,24++ 
SD 0,30 0,99 0,51 1,42 0,78 1,26 0,88 4,68 
n 4 4 4 4 4 4 4 4 
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Abstract 
Ataxin-3, the disease protein in Machado-Joseph disease, is known to be proteolytically 
modified by various enzymes including two major families of proteases, caspases and 
calpains. This processing results in the generation of toxic fragments of the polyglutamine-
expanded protein. Although various approaches were undertaken to identify cleavage sites 
within ataxin-3 and to evaluate the impact of fragments on the molecular pathogenesis of 
Machado-Joseph disease, calpain-mediated cleavage of the disease protein and the 
localization of cleavage sites remained unclear. Here, we report on the first precise 
localization of calpain cleavage sites in ataxin-3 and on the characterization of the thereof 
resulting breakdown products. After confirming the occurrence of calpain-derived 
fragmentation of ataxin-3 in patient-derived cell lines and post mortem brain tissue, we 
combined in silico prediction tools, western blot analysis, mass spectrometry, and peptide 
overlay assays to identify calpain cleavage sites. We found that ataxin-3 is primarily cleaved 
at two sites, namely at amino acid positions D208 and S256 and mutating amino acids at 
both cleavage sites to tryptophan nearly abolished ataxin-3 fragmentation. Furthermore, 
analysis of calpain cleavage-derived fragments showed distinct aggregation propensities and 
toxicities of C-terminal polyglutamine-containing breakdown products. Our data elucidate the 
important role of ataxin-3 proteolysis in the pathogenesis of Machado-Joseph disease and 
further emphasize the relevance of targeting this disease pathway as a treatment strategy in 
neurodegenerative disorders. 
 
Keywords: ataxin-3/ calpains/ cleavage sites/ Machado Joseph disease/ Spinocerebellar 
ataxia type 3 
 
Abbreviations: ataxin-3 = Atx3, calpastatin = CAST, Machado-Joseph disease = MJD, 
polyglutamine = polyQ 
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Introduction 
Proteolytic cleavage of disease proteins has been proposed as a key event in the molecular 
pathogenesis of various neurodegenerative diseases like Alzheimer’s (De Strooper, 2010) 
and Parkinson’s disease (Xilouri et al., 2013), or the group of polyglutamine (polyQ) 
disorders (Weber et al., 2014). This posttranslational processing constitutes the source for 
fragments of mutant proteins, which exhibit elevated cytotoxic characteristics and 
aggregation propensities, ultimately leading to cell death and neurodegeneration. The 
discovery of this mechanism led to the formulation of the so called toxic fragment hypothesis 
(Wellington and Hayden, 1997).  
The presence of proteolytically derived breakdown products has been reported for all polyQ 
diseases, and was intensively investigated in Machado-Joseph disease (MJD; also known as 
Spinocerebellar ataxia type 3, SCA3), Spinocerebellar ataxia type 7, and Huntington’s 
disease (DiFiglia et al., 1997; Goti et al., 2004; Wellington et al., 1998; Yvert et al., 2000). 
Since then, research has focused on the identification of enzymes responsible for the 
fragmentation of the involved proteins, as they represent an auspicious target for 
pharmacological treatments of these incurable diseases (Tarlac and Storey, 2003). 
Ataxin-3, the disease protein in MJD, was shown to be a substrate for mainly two families of 
proteases: caspases and calpains (Berke et al., 2004; Haacke et al., 2007; Hübener et al., 
2013; Jung et al., 2009; Koch et al., 2011; Wellington et al., 1998). Caspases are cysteine 
proteases which usually cleave after a C-terminal aspartate residue and are known to be 
involved in apoptotic and inflammatory pathways, but also to play a crucial role in cell 
proliferation, differentiation, and migration (Li and Yuan, 2008; McIlwain et al., 2013). 
Calpains, a class of Ca2+-dependent regulatory cysteine proteases, show a more complex 
selection for the cleavage site recognition motif and are specialized in modulating structure, 
localization, and activity of their substrates (Smith and Schnellmann, 2012; Sorimachi et al., 
2011). 
Although both groups of enzymes are reportedly active in processing ataxin-3, most recent 
research has zeroed in on calpains, as their intrinsic Ca2+-sensitivity directly links these 
proteases with the disrupted Ca2+ homoeostasis observed in MJD and other 
neurodegenerative diseases (Bezprozvanny, 2009; Chen et al., 2008; Koch et al., 2011). 
First in vivo studies demonstrated beneficial effects on neuropathology and behavioural 
phenotype of MJD animals, when inhibiting calpain activity pharmacologically or 
overexpressing the endogenous calpain inhibitor calpastatin (CAST) (Simoes et al., 2012; 
Simões et al., 2014). 
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Several putative calpain cleavage sites within ataxin-3 were described and their localization 
narrowed down to positions around amino acids 60, 200, 260 (Haacke et al., 2007), 190 
(Colomer Gould et al., 2007), or 154 and 220, respectively (Simoes et al., 2012). 
Concordantly, C-terminal fragment constructs comprising amino acids which encompass the 
polyQ tract, showed a notably enhanced cytotoxicity and aggregation propensity compared 
to full-length mutant ataxin-3 (Haacke et al., 2006; Ikeda et al., 1996; Invernizzi et al., 2012; 
Paulson et al., 1997). However, the exact sites and the impact of the consequent fragments 
remain elusive.  
Here, we report on the successful precise identification and characterization of calpain 
cleavage sites within the ataxin-3 protein. After confirming our previous results that ataxin-3 
is cleaved both by calpain-1 and calpain-2 in vitro, and that calpain-derived cleavage 
fragments can be observed in animal models of MJD (Hübener et al., 2013), we now verified 
the existence of these specific breakdown products in patient-derived cell lines and MJD post 
mortem brain tissue. In addition, we engaged in the determination of cleavage sites using an 
elaborated combination of in silico prediction tools, western blot analysis, mass spectrometry, 
and peptide overlay assays. By this means, we detected four prominent calpain cleavage 
sites in the ataxin-3 protein, with two major sites at amino acids D208 and S256. 
Furthermore, we effectively abolished calpain cleavage of ataxin-3 by exchanging amino 
acids at identified sites by triple-tryptophan motifs and analysed the impact of ataxin-3 
proteolysis by overexpressing cleavage site-corresponding fragment constructs. Our data 
pave the way for subsequent in vivo studies and help to better understand calpain-dependent 
proteolytic events in MJD as a target for pharmacological treatments. 
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Materials and methods 
Ethical statement on human research 
Informed consent was acquired for all patients from whom skin biopsies were obtained. Skin 
biopsies and experiments on human material were approved by the ethics committee of the 
University of Tübingen (NEUROMICS No. 598/2011BO1). Tissue was obtained and used in 
accordance with the Declaration of Helsinki. 
 
Prediction of calpain cleavage sites in silico 
In silico prediction of the calpain cleavage sites in the ataxin-3 protein (isoform 2; UniProt 
identifier: P54252-2) was performed using the GPS-CCD (group-based prediction system-
calpain cleavage detector) software (Liu et al., 2011). Scores for every amino acid position 
were graphically visualized using GraphPad Prism 6.00 for Windows (GraphPad Software 
Inc.). 
 
Expression constructs 
The pDsRed2-ER vector was obtained from Clontech (Takara Bio). For generation of 
Strep/FLAG-tagged ataxin-3 constructs, ataxin-3 (cDNA for isoform 2; UniProt identifier: 
P54252-2) 15Q and 62Q was cloned into the pDEST-(N)SF TAP by Gateway cloning as 
described previously (Gloeckner et al., 2007). Calpain cleavage site mutated ataxin-3 
constructs were cloned by inserting gBlocks® Gene Fragments (Integrated DNA 
Technologies), comprising the altered cleavage site sequence, into pEGFP-N1 ataxin-3 
vectors (thankfully provided by Thorsten Schmidt). For penta-alanine (5A) mutations at 
amino acid sites H187, D208 and S256 restriction enzymes SpeI and XmnI were used. For 
triple-tryptophan (3W) mutations at sites H187, D208 and S256, SpeI was replaced by SacII. 
Gene fragments featuring 5A and 3W mutations at amino acid site T277 were inserted using 
SacII and BbsI. For calpain cleavage-corresponding fragment constructs, DNA fragments 
were generated by amplifying respective sequences of the ataxin-3 isoform 2 cDNA by PCR. 
Primer pairs used for amplification added HindIII (5’) and KpnI (3’) restriction sites flanking 
the PCR products. Sequences were cloned into a pEGFP-N1 vector via aforementioned 
restrictions sites. Expanded CAG repeats (148 CAG) were integrated into the constructs 
employing enzymes XmnI and PpuMI. All restriction enzymes used for cloning were obtained 
from NEB. Correct cloning of the constructs was confirmed by Sanger sequencing and 
functional overexpression tested by transient transfection in HEK 293T cells.  
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Cell culture and transfection  
Cell culture experiments were performed with HEK 293T cells (ATCC: CRL-11268), SV40-
immortalized human fibroblasts, generated from skin biopsies of an MJD patient (23 and 67 
CAG repeats) and an age- and gender-matched control (14 and 21 CAG repeats) 
(Supplementary Table 1), human primary fibroblasts and human fibroblast-derived iPS cells.  
HEK 293T cells and SV-40-immortalized human fibroblasts were cultured in Dulbecco's 
modified eagle's medium (DMEM) GlutaMAX™ supplemented with 10% fetal calf serum 
(FCS), 1% non-essential amino acids (MEM NEAA) and 1% Antibiotic-Antimycotic (all 
Gibco®, Thermo Fisher Scientific) at 37°C in 5% CO2. Transfection of HEK 293T cells was 
done using Attractene reagent (Qiagen) according to the manufacturer’s protocol.  
For overexpression of SF-tagged ataxin-3 and subsequent protein purification, HEK 293T 
cells were cultured in 14 cm dishes in DMEM medium (PAA) supplemented with 10% FCS 
(PAA) and appropriate antibiotics. Cells were transfected at a confluence between 50 - 70% 
with 8 µg plasmid DNA/dish using polyethyleneimine PEI (Polysciences) solution as 
described previously (Ben-Zimra et al., 2002). After transfection, cells were cultured for 48 h. 
 
Reprogramming of fibroblasts to iPSCs 
Skin biopsies were obtained from 3 MJD patients and 4 healthy controls (Supplementary 
Table 1). Each biopsy was dissected and left undistributed in fibroblast medium consisting of 
DMEM high glucose with 10% FCS for 10 days at 37 °C and 5% CO2 to allow fibroblasts to 
grow out from the biopsy. Expansion of skin fibroblast was achieved by medium change 
every 2-3 days. For reprogramming 1x105 fibroblasts were electroporated (Nucleofector 2D, 
Lonza) with a total of 1 µg per plasmid carrying the sequences for hOCT4, hSOX2, hKLF4, 
hL-MYC and hLIN28 and cultured in fibroblast medium for 1 day (Okita et al., 2011). After 
2 days of cultivation in fibroblast medium containing 2 µg/L FGF-2 (Peprotech), cells were 
transferred to Essential 8 (E8) medium containing 100 µM NaB (Sigma-Aldrich). After 
approx. 21 - 28 days, iPSC colonies were picked manually and further expanded on Matrigel-
coated 6-well dishes cultivated with E8 medium. After reaching confluency cells were split in 
a ratio of 1:6 – 1:12 with PBS/EDTA (0.02% EDTA in DPBS) and further expanded. At 
passage 7 - 10, iPSCs were harvested for analysis or frozen in E8 medium with 40% KOSR 
(Gibco®, Thermo Fisher Scientific), 10% DMSO (Sigma-Aldrich), and 1 µM Y-27632 (Abcam 
Biochemicals). Generated iPSCs were carefully characterized including exclusion of plasmid-
integration, screening for genomic aberrations, resequencing of mutation site, confirmation of 
expression of pluripotency markers, and verifying the in vitro differentiation potential (as 
example see Hauser et al., 2016) (data not shown).  
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Neuronal differentiation of iPSCs 
For differentiation of iPSCs to cortical neurons (iCNs) a protocol published from Shi and 
colleagues was applied (Shi et al., 2012). Briefly, neural induction was achieved by dual 
SMAD inhibition (10 µM SB431542 and 500 nM LDN-193189 (both Sigma-Aldrich)) and 
cultivation in 3N medium. Medium was changed every day and cells collected at day 10 by 
dissociation with Accutase (Thermo Fisher Scientific) followed by replating in 3N medium 
supplemented with 20 ng/ml FGF2. At day 12, FGF2 was withdrawn and cells were further 
cultivated in 3N medium with medium change every other day. Cell cultures were passage 
once more by dissociation with Accutase and replated at a density of 400,000 cells per cm2 
on poly-ornithine and Matrigel-coated 6-well plates. Medium was changed every other day 
and cell-based calpain activation assay was performed at day 36. 
 
Fluorescence microscopy of differentiated neurons 
Differentiated cortical neurons were fixed at day 36 in 4% paraformaldehyde in DPBS for 
15 min and washed 3 times with DPBS. Blocking solution (DPBS supplemented with 1% FBS 
and 0.1% Triton X-100) was added for 45 min and cells were incubated with first primary 
antibody mouse anti-β-III-tubulin (TUJ1)(1:1000; clone SDL.3D10, T8660, Sigma Aldrich) for 
1 h at room temperature. After 3 times washing in DPBS, secondary antibody anti-mouse 
Alexa Fluor® 488 (1:500; Thermo Fisher Scientific)) was applied and incubated for 1 h at 
room temperature in the dark. Afterwards, cells were incubated with second primary antibody 
rat anti-CTIP2 (1:500; clone 25B6, ab18465, Abcam). Subsequently, coverslides were 
incubated with secondary antibody anti-rat Alexa Fluor® 568 (1:500; Thermo Fisher 
Scientific). After 3 washing steps in DPBS, nuclear counterstaining was achieved by adding 
DAPI (1:10,000) for 15 min at room temperature. Cells were embedded in ProLong®  
Diamond Antifade Mountant (Thermo Fisher Scientific) and images were taken with Axio 
Imager Z1 with ApoTome (Zeiss). 
 
Confocal microscopy 
For confocal microscopy of HEK 293T cells, cells were seeded on 8-well Millicell® EZ slides 
(Merck Millipore), transfected with respective constructs and cultured for 48 h. Subsequently, 
cells were pre-fixed with 0.4% paraformaldehyde in DPBS for 15 min at 37°C and fixed with 
4% paraformaldehyde in DPBS for another 15 min at room temperature. After washing twice 
with DPBS for 5 min, the media chamber was removed and cells mounted with 
VECTASHIELD® Antifade Mounting Medium with DAPI (Vector Laboratories). Fluorescent 
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images were taken on a confocal laser-scanning microscope (Zeiss, LSM 710), using a 40× 
1.3 NA oil objective and the pinhole set to one airy unit. Zeiss ZEN 2011 was used as 
imaging software.  
FACS analysis  
For measuring viability of cells transfected with EGFP-tagged ataxin-3 constructs, cells were 
cultured for 72 h post transfection and subsequently stained with Zombie NIRTM Fixable 
Viability Kit (BioLegend) according to the manufacturer’s standard cell staining protocol. 
Afterwards, cells were fixed with 1% paraformaldehyde in DPBS for 30 min at 4°C and 
analysed using a FACS LSR II cytofluorometer with FACS-DIVA software version 6.1.3 (BD 
Bioscience). To exclude untransfected cells, only GFP-positive cells were analysed for 
Zombie NIR staining. As a positive control for cell death and for defining the gating strategy, 
cells were treated with 5 mM H2O2 overnight prior to the staining (Supplementary Fig. 1). 
 
Cell-based calpain inhibition and activation assay 
For activation of endogenous calpains, cell medium was aspirated and replaced by 
Opti-MEM® I Reduced Serum Media (Gibco®, Thermo Fisher Scientific). For negative 
control, cells were pre-treated with 10 µM of the calpain inhibitor CI III (carbobenzoxy-valinyl-
phenylalaninal) (Merck Millipore) for 1 h. Calpain activation was triggered by incubating cells 
with 1 µM of the Ca2+ ionophore ionomycin (Sigma-Aldrich) and 5 mM CaCl2 for 1 h at 37°C 
in 5% CO2. To decrease baseline activity of calpains, cells were solely treated with 10 µM of 
the calpain inhibitor CI III or with DMSO as vehicle control for 2 h. 
 
Lysate preparation and western blotting 
Cell lysates were prepared as follows: Transfected and treated HEK 293T cells were 
detached by rinsing with cold DPBS (Gibco®, Thermo Fisher Scientific). Treated MJD 
patient- and control-derived SV40-immortalized fibroblasts were collected by trypsinization 
followed by pelleting at 300 × g for 5 min and washing with cold DPBS. All cells were again 
pelleted at 300 × g for 5 min and lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate and 1% Triton X-100), containing cOmplete® 
protease inhibitor cocktail (Roche) for 25 min on ice, while vortexing every 5 min. Samples 
were centrifuged at 13,200 × g for 15 min at 4°C. Afterwards, the supernatant was 
transferred into a pre-cooled reaction tube, adding glycerol to final concentration of 10%. 
Lysates of human cerebellar tissue were obtained by homogenizing the sample in RIPA 
buffer containing cOmplete® protease inhibitor cocktail using a ULTRA-TURRAX® disperser 
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(VWR). Homogenates were incubated for 25 min on ice and centrifuged at 13,200 × g for 30 
min at 4°C. The supernatant was transferred into a pre-cooled reaction tube and mixed with 
glycerol to a final concentration of 10%. Protein concentrations of RIPA lysates were 
measured spectrophotometrically using Bradford reagent (Bio-Rad Laboratories).  
Western blotting was performed according to standard procedures. Briefly, 30 µg of protein 
were mixed with 4 × LDS sample buffer (1 M Tris Base pH 8.5, 2 mM EDTA, 8% LDS, 40% 
glycerol, 0.075% CBB G, 0.025% phenol red) and 100 mM DTT, and heat denatured for 
10 min at 70°C. Subsequently, protein samples were separated electrophoretically using 
home-made 10% Bis-Tris gels, 4-12% Bolt® Bis-Tris gradient gels or 7% NuPAGE® Tris-
Acetate gels (both Thermo Fisher Scientific) with respective electrophoresis buffers, MES 
buffer (50 mM MES, 50 mM Tris Base pH 7.3, 0.1% SDS, 1 mM EDTA) or Tris-Acetate 
running buffer (50 mM Tricine, 50 mM Tris Base pH 8.25, 0.1% SDS). Proteins were 
transferred on Amersham™ Protran™ Premium 0.2 µm nitrocellulose membranes (GE 
Healthcare) using Bicine/Bis-Tris transfer buffer (25 mM Bicine, 25 mM Bis-Tris pH 7.2, 
1 mM EDTA, 15% methanol) and a TE22 Transfer Tank (Hoefer) at 80 V for 2 h. 
For detecting total protein on the blot after transfer, membranes were stained using SYPRO® 
Ruby Protein Blot Stain (Thermo Fisher Scientific) according to manufacturer’s protocol. 
Afterwards, membranes were blocked for 1 h with 5% SlimFast (Unilever) in TBS (Tris-
buffered saline) at room temperature, and probed overnight at 4°C with primary antibodies 
diluted in TBS-T (TBS with 0.1% Tween 20). Afterwards, western blots were incubated at 
room temperature for 1 h with the respective HRP-conjugated secondary antibodies. For a 
detailed list of primary and secondary antibodies, see Supplementary Materials and 
Methods. Chemiluminescence and fluorescence signals were detected using the LI-COR 
ODYSSEY® FC and quantified with ODYSSEY® Server software version 4.1 (LI-COR 
Biosciences). 
 
Cytoplasmic/nuclear fractionation 
For separation of cytoplasmic and nuclear proteins, the REAP (Rapid, Efficient And Practical) 
fractionation method was utilized with minor modifications (Suzuki et al., 2010). Briefly, 
transfected HEK 293T cells were detached by rinsing with cold DPBS and pelleted at 
300 × g. Pellets were resuspended in DPBS-N (DPBS, 0.1% NP-40, and cOmplete® 
protease inhibitor). An aliquot was taken as total cell sample. The remainder was centrifuged 
for 10 s at 10,000 × g. The supernatant was transferred into a fresh tube and declared as the 
cytoplasmic fraction. The pellet was washed once with DPBS-N and centrifuged again for 
10 s at 10,000 × g. The supernatant was discarded and the pellet, containing the nuclear 
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fraction, was resuspended in 1 × LDS buffer with 100 mM DTT. Total cell sample and 
cytoplasmic fraction were mixed with 1 × LDS buffer with 100 mM DTT, ultrasonicated for 
10 s and analysed by western blotting. Purity of obtained fractions was confirmed by western 
blotting using α-tubulin as a cytoplasmic marker and histone H3 as a nuclear marker 
(antibody mouse anti-histone H3; 1:2000; clone mAbcam 10799, Abcam). 
 
Protein purification 
Purification of Strep/FLAG (SF)-tagged ataxin-3 from HEK 293T cells was performed as 
described previously (Gloeckner et al., 2009, 2010). Briefly, after removal of the medium 
cells were lysed in 1 ml lysis/washing buffer (50 mM TRIS pH 7.4, 100 mM NaCl) 
supplemented with 0.55% NP-40 and cOmplete® protease inhibitor cocktail, per 14 cm dish. 
Incubation with lysis buffer was then performed for 40 min at 4 °C on a shaker. Cell debris 
and nuclei were removed by centrifugation of the lysates at 10,000 × g for 10 min. Cleared 
lysates were incubated with Strep-Tactin® Superflow® resin (IBA) for 1 h at 4 °C. Beads 
were transferred to micro-spin columns (GE Healthcare) and washed 5 × with 500 µl washing 
buffer prior final elution using 400 µl elution buffer (washing buffer supplemented with 200 
mM D-desthiobiotin [IBA]). 
 
Calpain activation assay in vitro 
In vitro calpain activation assays using purified recombinant proteins or cell extracts were per 
formed as previously described (Hübener et al., 2013). Briefly, for calpain cleavage of 
recombinant ataxin-3, 5 µg of His6-ataxin-3 (R&D Systems) or purified SF-tagged ataxin-3 
were diluted in 400 µl calpain reaction buffer (20 mM HEPES/KOH pH 7.6, 10 mM KCl, 
1.5 mM MgCl2, 1 mM DTT). The positive control was incubated with recombinant calpain-1 or 
calpain-2 (Merck Millipore), and 2 mM CaCl2 for indicated molar ratios and times at room 
temperature. Calpain activity of all samples was quenched by adding 100 µM ALLN (N-
Acetyl-L-leucyl-L-leucyl-L-norleucinal) (Merck Millipore) and 20 mM EDTA. When needed, 
100 µM of the pan-caspase inhibitor Q-VD-OPh (Merck Millipore) were added to block 
caspase activation. 
For in vitro calpain activation using cell culture lysates, cell pellets were incubated in calpain 
lysis/reaction buffer (20 mM HEPES/KOH pH 7.6, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 
0.1% Triton X-100) for 25 min on ice, while vortexing every 5 min. Samples were centrifuged 
at 13,200 × g for 15 min at 4°C. Afterwards, the supernatant was transferred into a pre-
cooled reaction tube and protein concentrations were measured spectrophotometrically using 
Bradford reagent. Lysates were diluted in calpain reaction buffer to obtain a final protein 
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concentration of 1.5 µg/ µl. For negative control, lysates were pre-incubated with 100 µM of 
the calpain inhibitor CI III for 10 min on ice. To activate endogenous calpains, 2 mM CaCl2 
were added and incubated at 37°C under constant agitation for indicated times. For 
quenching the reaction and further western blot analysis, as described above, samples were 
mixed with 4 × LDS sample buffer and 100 mM DTT, and heat denatured for 10 min at 70°C. 
 
Quantitative mass spectrometric analysis 
Strep/FLAG (SF)-tagged ataxin-3 with 15Q or 62Q repeats was either expressed in 
HEK 293T cells cultured in heavy (lysine-8; aginine-10) or light (lysine-0, arginine-0) SILAC 
medium and purified via the Strep-tag II as described previously (Gloeckner et al., 2009). For 
calpain cleavage induction, 5 µg of purified heavy-labelled ataxin-3 was incubated with 
recombinant calpain-1 or calpain-2 as described above. Calpain-treated and control samples 
were mixed in a 1:1 ratio and samples were precipitated by chloroform/methanol and re-
dissolved in 50 mM ammonium bicarbonate, containing 0.2% RapiGest (Waters), reduced 
with DTT and alkylated with iodoacetamide. In addition, a reverse experiment was performed 
by switching the labels between the conditions. Proteolysis was carried out by adding GluC 
or AspN (both NEB) at 37°C o/n. The RapiGest surfactant was hydrolysed and removed and 
samples were further purified via C18-StageTips (Thermo Fisher Scientific) following 
standard protocols. Samples were subsequently analysed by LC-MSMS using a nano-flow 
HPLC system (Dionex Ultimate 3000 RSLC, Thermo Fisher Scientific) coupled to a Q-
Exactive Plus tandem mass spectrometer (Thermo Fisher Scientific). In order to identify 
peptides specific to the calpain cleavage, quantification of the resulting MS-data was 
performed. The raw data were directly analysed by the MaxQuant software ver. 1.5.2.8 (Cox 
et al., 2009) allowing protein identification and quantification with the following Andromeda 
search-engine parameters: database: custom ataxin-3 database (66 entries), containing 
typical protein IDs previously identified in ataxin-3 affinity purifications, carbamidomethyl as 
fixed modification as well as N-terminal protein acetylation as variable modification with the 
heavy/light (H/L) isotope pairs lysine-0/arinine-0 and lysine-8/arginine-10 for quantification. 
As enzyme either GluC or AspN and semi-specific cleavage mode were chosen. The initial 
mass accuracy (MS) for mass recalibration was set to 20 ppm. For MSMS spectra, the mass 
accuracy was set to 0.1 Da. The FDR (false discovery rate) threshold was set to 0.01. Razor-
peptides and peptides with N-terminal acetylation or methionine oxidation were included into 
protein quantification. Downstream analysis and graphical representation was carried out 
using Perseus ver. 1.5.2.6. Peptides corresponding to ataxin-3 appearing at least in one 
forward (H: calpain treatment; L: control condition) and one reverse experiment (label switch) 
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were filtered out. Each condition (“Ratio H/L normalized” values of MaxQuant output) was 
then re-normalized by division by their medians. A combined analysis was performed for the 
calpain-1/2 isoforms and the different ataxin-3 polyQ repeats, 15Q and 62Q. Peptides with a 
normalized H/L ratio greater than 2 in the forward experiment and a normalized H/L ratio 
below 0.5 in the reverse condition were considered as robust hits. 
 
Peptide array synthesis, calpain overlay and immunodetection 
Putative calpain cleavage sites in ataxin-3 and alanine or tryptophan mutations thereof were 
synthesized as 20-mer peptides on cellulose membranes using a Multipep automated 
peptide synthesizer (INTAVIS Bioanalytical Instruments AG) (Frank and Overwin, 1996).  
Calpain overlay experiments were performed as previously described (Wanichawan et al., 
2014). Shortly, the peptide array membranes were first activated in methanol for 10 seconds 
followed by three washes of 10 min in TBS-T. Thereafter, the membranes were blocked in 
1% casein overnight at 4°C before overlaying with 1 µg/ml  of calpain-1 (human erythrocytes, 
208713, Calbiochem) or calpain-2 (porcine kidney, 208715, Calbiochem) in calpain buffer (20 
mM HEPES pH 7.5, 10 mM EGTA, 0.1% Triton X-100, 20 mM CaCl2) overnight at 4°C with 
gentle agitation. Membranes incubated without any calpain protein were used as negative 
control. The membranes were then washed five times for 5 min in TBS-T and incubated with 
primary antibody rabbit anti-calpain (1:1000; sc-30064, Santa Cruz) for 1 h at room 
temperature, washed five times for 5 min in TBS-T, and incubated with the HRP-conjugated 
secondary antibody donkey anti-rabbit IgG (NA934V, GE Healthcare). Chemiluminescence 
signals were developed by ECL Prime western blotting detection reagent (RPN 2232, GE 
Healthcare) and detected using ImageQuant™ LAS-4000 imager (Fujifilm). Densitometric 
analysis of detected signals was performed using the ImageJ software (Schneider et al., 
2012). 
 
Filter retardation assay 
For the detection of SDS-insoluble ataxin-3 species, transfected HEK 293T cells were 
homogenized in DPBS-T (DPBS with 1% Triton X-100 and cOmplete® protease inhibitor 
cocktail) by ultrasonication for 10 s. Protein concentrations of the homogenates were 
determined spectrophotometrically using Bradford reagent and 12.5 µg of total protein were 
diluted in DPBS containing 2% SDS and 50 mM DTT. Samples were heat denatured for 
5 min at 95°C and cooled down to room temperature to prevent precipitation of SDS. A 
nitrocellulose membrane (Amersham™ Protran™ 0.45 µm, GE Healthcare) was equilibrated 
in 0.1% SDS in DPBS and samples were filtered through this membrane using a Minifold® II 
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Slot Blot System (Schleicher & Schuell). The membrane was rinsed once with TBS and 
blocked with 5% SlimFast in TBS for 1h at room temperature. Membranes were detected 
using the standard immunodetection protocol, see section western blotting. Retained SDS-
insoluble ataxin-3 was detected using the antibodies mouse rabbit anti-ataxin-3 (1:500; 
SA3637, Schmidt et al. 1998) or rabbit anti-ubiquitin (1:500; Z 0458, Dako, Agilent 
Technologies). 
 
Denaturing detergent agarose gel electrophoresis (DDAGE) 
Electrophoretical separation and analysis of high molecular species of ataxin-3 was 
performed according to the protocol for semi-denaturing detergent agarose gel 
electrophoresis (SDD-AGE) (Halfmann and Lindquist, 2008), with the modifications stated 
below. For sample preparation, 25 µg of cell homogenate were mixed with 4 × loading buffer 
(2 × TAE buffer, 40% glycerol, 8% SDS, 0.05% bromophenol blue) with 50 mM DTT, and 
heat denatured for 5 min at 95°C. Samples were electrophoretically separated on a 0.75% 
TAE agarose Gel with 0.1% SDS using a PerfectBlue Gelsystem Mini S (Peqlab) at 3 V per 
cm gel length. Afterwards, proteins were transferred on Amersham™ Protran™ Premium 0.2 
µm nitrocellulose membranes (GE Healthcare) using Bicine/Bis-Tris transfer buffer with 10% 
methanol, and a TE22 Transfer Tank (Hoefer) at 80 V for 2 h. Membranes were detected 
using the standard immunodetection protocol, see section western blotting. For detecting 
high molecular species of ataxin-3, antibodies rabbit anti-ataxin-3 (1:500; SA3637, Schmidt 
et al. 1998) or rabbit anti-ubiquitin (1:500; Z 0458, Dako, Agilent Technologies) were applied. 
Huntingtin was detected as a loading control using a rabbit anti-huntingtin antibody (1:1000; 
clone D7F7, #5656, Cell Signaling). 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6.00 for Windows (GraphPad 
Software Inc.). Statistical significance of data sets obtained by western blot, DDAGE and 
FACS was determined using One-way-ANOVA and Tukey post-test. For calpain overlay 
experiments, statistical differences were tested using One-way ANOVA with Bonferroni post-
test. P-values <0.05 were considered as statistically significant, with *P < 0.05, **P < 0.01 
and ***P < 0.001. 
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Results 
In silico prediction of calpain cleavage sites in the ataxin-3 protein 
The precise mechanism of cleavage site-recognition by calpains remains elusive, making 
predictions of putative cleavage sites a challenging task. Many structural features of the 
substrate protein seem to contribute to its specificity including determinants like 
primary/secondary protein structures or PEST regions (sequences rich in proline, glutamic 
acid, serine, and threonine) (duVerle et al., 2011; Liu et al., 2011; Tompa et al., 2004). 
In order to perform an in silico prediction approach for calpain cleavage sites within the 
ataxin-3 protein, we utilized the GPS-CCD tool (Group-based Prediction System - Calpain 
Cleavage Detector; freely available at http://ccd.biocuckoo.org/), which is based on a data 
set of 368 experimentally verified sites in 130 substrate proteins (Liu et al., 2011). Using the 
canonical protein sequence of the ataxin-3 isoform 2 (UniProt identifier: P54252-2), we could 
identify 24 major sites with a cleavage likelihood score above the maximum default cut-off 
value of 0.654. High scores for the polyQ repeat were considered as an artefact of the 
prediction. To narrow down the choice of promising sites, we selected those with protruding 
cleavage likelihood scores in comparison to the surrounding region (Fig. 1A). A detailed list 
with the main sites is given in Supplementary Table 2. 
 
Calpain-1 and calpain-2 cleave wild-type and mutant ataxin-3 at similar sites in vitro 
To reconfirm ataxin-3 as a substrate for calpains in vitro, we performed calpain activation 
assays by incubating recombinant His6-ataxin-3 22Q with increasing amounts of recombinant 
calpain-1 and calpain-2. Using a set of antibodies with epitopes along the ataxin-3 sequence 
(Fig. 1B), we investigated resulting fragments via western blotting and observed comparable 
cleavage patterns for both calpains with corresponding N-terminal and C-terminal ataxin-3 
fragments (Fig. 1C and D). Furthermore, when repeating the experiment with Strep/FLAG 
(SF)-tagged ataxin-3 15Q and 62Q in a time-dependent manner, no major differences 
between wild-type and polyQ-expanded ataxin-3 fragments became apparent 
(Supplementary Fig. 2). However, on closer examination of resulting cleavage patterns, we 
identified a consistent group of presumably N-terminal ataxin-3 breakdown products and 
labelled them with letters ‘a’ to ‘e’ according to their expected cleavage site position from the 
N- to the C-terminus (Fig. 1C and D, Supplementary Fig. 2). Overall, these data suggest that 
wild-type and polyQ-expanded ataxin-3 are cleaved mainly at similar cleavage sites by both 
calpain-1 and calpain-2. 
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Calpain-dependent ataxin-3 cleavage is present in patient-derived cells and post mortem 
brain tissue 
After modelling calpain-cleavage in vitro, we sought to investigate the presence of calpain-
dependent ataxin-3 cleavage in patient-derived cell lines and post mortem brain tissues. For 
this purpose, we treated SV40-immortalized fibroblasts, which were derived from a MJD 
patient and age- and gender-matched control, with the calpain inhibitor CI III for 2 h. Western 
blotting revealed that pharmacologic suppression of calpain activity, as verified by decreased 
levels of calpain-cleaved α-spectrin (black arrowhead; Fig. 2A), a lower ratio of active to 
inactive calpain-1 and elevated levels of CAST (Fig. 2A), led to the reduction of a 
predominant ataxin-3 fragment in both cell lines (‘c’; Fig. 2A), pointing to its calpain cleavage-
dependent origin. When triggering calpain activity in lysates of immortalized fibroblasts by 
adding CaCl2 (Fig. 2B) or treating the cells with the ionophore ionomycin (Fig. 2C), we could 
concordantly increase the levels of fragment ‘c’. Furthermore, we detected two further 
calpain-derived fragments (‘b’ and ‘d’; Fig. 2C) of minor intensity using an antibody guided 
against the N-terminus of ataxin-3. 
In addition to the investigations on immortalized fibroblasts, we analysed ataxin-3 cleavage in 
primary fibroblasts, induced pluripotent stem (iPS) cells and iPS-derived differentiated 
cortical neurons (iCNs) of further MJD patients and healthy controls. By this, we reconfirmed 
the appearance of the predominant, presumably calpain-derived fragment ‘c’ (Fig. 3A). 
According to expectations, treating iPS cells but also iCNs with ionomycin led to further 
fragmentation of ataxin-3 and elevated levels of fragment ‘c’ (Fig. 3B-D) and to a weaker 
extent fragment ‘d’ (Fig. 3D), which was prevented by pre-incubation with CI III. Ultimately, 
western blotting of post mortem cerebellar tissue of a MJD patient and a respective control 
unveiled the appearance of calpain-dependent ataxin-3 cleavage in vivo (Fig. 3E, 
Supplementary Fig. 3). 
In summary, calpains cleave ataxin-3 in both, patient and control-derived cell lines, and in 
post mortem brain tissue, emphasizing the physiological relevance of calpain-mediated 
proteolysis of ataxin-3. 
 
Deletion constructs help to unveil calpain cleavage sites in ataxin-3 
As we reconfirmed calpain-dependent ataxin-3 cleavage in vitro and additionally observed 
fragmentation of the disease protein in patient-derived cell lines and post mortem tissue, we 
raised the question at which particular sites ataxin-3 is proteolytically processed by calpains. 
To exclude that the observed ataxin-3 fragments are resulting from caspase-dependent 
cleavage as an indirect effect of calpain activation, we initially performed a control 
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experiment with lysates of EGFP-ataxin-3 15Q and 148Q expressing HEK 293T cells. 
Activation of calpains by addition of CaCl2 induced ataxin-3 cleavage, which could be 
prevented by the calpain inhibitor, ALLN. However, administration of the pan-caspase 
inhibitor Q-VD-OPh could not prevent cleavage of ataxin-3, which demonstrated the calpain-
dependent origin of arising fragments (Supplementary Fig. 4). 
In a first attempt to screen for cleavage regions, we utilized EGFP-tagged deletion constructs 
of ataxin-3 lacking C-terminal portions of the protein, which were overexpressed in 
HEK 293T cells. After activating calpains via ionomycin administration, we analysed the 
cleavage patterns of the deletion constructs by western blotting (Fig. 4A). By comparing 
fragmentation between the deletion constructs and correlating disappearance of specific 
fragments with lacking C-terminal portions of ataxin-3, we were able to narrow down 
cleavage sites to regions between amino acids 321-366 (fragment ‘a’), 244-259 (fragment 
‘c’), 198-243 (fragment ‘d’), and right before position 198 (fragment ‘e’) (Fig. 4B). However, 
the region which comprises the fragment ‘b’ cleavage site could not be clearly defined via 
this approach. 
 
Mass spectrometry reveals calpain cleavage sites within ataxin-3  
After roughly estimating calpain cleavage sites using ataxin-3 deletion constructs, we 
performed a quantitative mass spectrometric approach to precisely map these sites in 
ataxin-3. Strep/FLAG (SF)-tagged ataxin-3 15Q or 62Q was expressed in HEK 293T cells 
grown either in heavy or light SILAC medium and purified afterwards. Heavy-labelled 
ataxin-3 was incubated with calpain-1 or calpain-2 and mixed with an untreated light-labelled 
ataxin-3 control in a 1:1 ratio. To rule-out labelling artefacts, a reverse experiment was 
performed by switching the labels between the conditions. A scheme of the mass 
spectrometric mapping approach and the representative control western blots of calpain-
cleaved heavy-labelled ataxin-3 are shown in Fig. 5A, B and C. The mixture was then 
subsequently subjected to proteolytic cleavage with either GluC, cleaving C-terminal from 
glutamate, or AspN, cleaving N-terminally from aspartate. For the final analysis, only 
peptides were considered which were identified in a forward as well as in a reverse 
experiment. The method allowed the identification of calpain cleavage sites via the peptides 
significantly enriched in the calpain-treated condition. Peptides enriched by at least two-fold 
in the forward experiment and decreased by at least two-fold in the reverse experiment were 
considered as robust hits. In addition, an outlier analysis, the Significance A test (Cox and 
Mann, 2008) was performed for forward and reverse experiments separately. These peptides 
showed semi-canonical cleavage patterns for GluC and AspN supporting the assumption that 
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the observed non-canonical cleavage sites correspond to calpain cleavage sites. By this 
approach the sites H187 and D208 (GluC condition) as well as S256 and G259 (AspN 
condition) could be identified. H187 and D208 showed Significance A values of p<0.001 in 
the forward as well as reverse experiment. G259 showed a Significance A of p<0.005 in both 
experiments. For S256 the Significance A test returned values for the forward and reverse 
experiment of p=0.061 and p=0.0001, respectively. Scatter plots showing a combined 
analysis for the GluC and AspN secondary proteolytic cleavage for the different polyQ repeat 
lengths and calpain-1/2 isoforms are presented in Fig. 5D and E. 
 
Triple tryptophan substitutions as a strategy to reduce cleavage likelihood 
Standard approaches to prevent calpain cleavage of substrates comprise alanine 
substitutions of up to 10 amino acids or deletion mutagenesis of whole cleavage sites (Gafni 
et al., 2004; Wanichawan et al., 2014). To optimize this approach, we computed effects on 
the cleavage likelihood when replacing one to five amino acids of a predicted site by 
proteinogenic amino acids. Exchanging a single amino acid did not lead to marked 
alterations of the cleavage likelihood (Supplementary Fig. 5A). However, replacing three or 
five amino acids led to a strong reduction of the cleavage likelihood, only when introducing 
cysteine (triple: - 51%, quintuple: - 81%), tryptophan (triple: - 77%, quintuple: - 85%), or 
tyrosine residues (triple: - 58%, quintuple: - 62%), as exemplarily predicted for site D208 
(Supplementary Fig. 5B and C). Interestingly, classical alanine substitutions barely reduced 
likelihood or rather caused an increase (triple: + 19% quintuple: - 1%). As cysteines and 
tyrosines are known to be eminent targets of posttranslational modifications, we selected the 
lesser effected tryptophan as a triplet for mutagenesis of putative cleavage sites together 
with quintuple alanine substitutions as a classical approach (Fig. 6A). 
 
Calpain overlay of 20-mer ataxin-3 peptide arrays shows reduced binding after triple 
tryptophan substitution 
In order to verify cleavage sites and to prove that a triple tryptophan substitution is indeed 
reducing cleavage likelihood or substrate recognition as seen in silico, we performed calpain 
overlay assays using an array of immobilized 20-mer peptides which represent sequences 
around predicted cleavage sites in ataxin-3. Peptides were synthesized as unchanged 
sequences, or featuring triple tryptophan or quintuple alanine substitutions at predicted sites. 
Peptides were spotted and immobilized on a membrane and overlaid by calpain-1 or 
calpain-2. Calpain-specific immunodetection visualized binding of calpains to the respective 
motifs and verified sequences around sites H187, D208 and S256 (Fig. 6B-D), which we 
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previously mapped by mass spectrometry, as calpain recognition motifs. Furthermore, 
peptides representing putative sites T277 and, to a weaker extent, E349 exhibited calpain 
binding, indicating further cleavage positions (Fig. 6E, Supplementary Fig. 6A). On the other 
hand, peptides comprising sites L62, S309, and G327, did not show any immunoreactivity for 
calpains (Supplementary Fig. 6B-D). When introducing a tryptophan triplet at putative 
cleavage sites, we observed marked reductions of the calpain immunoreactivity for all 
investigated peptides, except for site S256 and calpain-1 (Fig. 6D). However, quintuple 
alanine substitutions showed only a clear reduction for sites H187 and T277, with an even 
stronger decrease for the latter site when compared to a tryptophan triplet (Fig. 6B and E). 
Notably, introduction of five alanines increased the binding of calpain-2 at site D208 and 
calpain-1 at site S256 (Fig. 6C and D). 
 
Triple tryptophan mutagenesis of putative calpain cleavage sites reduced ataxin-3 
fragmentation 
After observing decreased calpain binding to ataxin-3 peptides featuring tryptophan 
mutations at putative cleavage sites, we sought to confirm these effects on the full ataxin-3 
protein. As cell-based calpain cleavage induction primarily gave rise to fragments ‘c’ and ‘d’, 
we focused on sites, which not only were identified by mass spectrometry and calpain 
overlay assays but also presumably represent the origin of the two aforementioned 
breakdown products. For this, we generated C-terminally EGFP-tagged ataxin-3 15Q and 
148Q constructs featuring quintuple alanine or triple tryptophan substitutions on cleavage 
positions D208, S256 or both sites. Following overexpression of respective ataxin-3 variants 
in HEK 293T cells, we subjected lysates to in vitro calpain activation assays and analysed 
resulting ataxin-3 fragmentation patterns using N-terminally binding and EGFP-specific 
antibodies on western blots. When comparing unmodified ataxin-3 with variants carrying 
quintuple alanine substitutions at positions D208 or S256, only a reduction of the N-terminal 
fragment corresponding to cleavage at amino acid S256 was observed (Fig. 7A and B). 
However, mutagenesis using tryptophan triplets at positions D208 or S256 nearly abolished 
respective N-terminal cleavage products (Fig. 7A and B). According to expectations, triple 
tryptophan exchanges also led to a concurrent reduction of corresponding C-terminal ataxin-
3 15Q and 148Q fragments (Fig. 7C and D). Interestingly, mutating both sites led to an 
enhanced formation of an additional fragment, likely to correspond to cleavage site T277 (‘b’; 
Fig. 7C and D). It should be mentioned that the cleavage of ataxin-3 is very weak at baseline, 
making it difficult to identify alterations of the fragmentation pattern in an uninduced state. 
Cell-based activation of calpains by administering ionomycin, however, revealed a strongly 
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reduced formation of fragments ‘c’ and ‘d’ in ataxin-3 carrying tryptophan triplets at positions 
D208 and S256, when compared to unmutated ataxin-3 using western blotting (Fig. 7E). In 
retrospect to our previous fragment labelling, we were able to assign the detected fragment 
‘c’ to cleavage site S256 and fragment ‘d’ to cleavage site D208. An overview of all predicted 
and identified calpain cleavage sites in our study can be found in Fig. 8A. 
In summary, cleavage site mutagenesis using tryptophan triplets turned out as an effective 
approach to decrease calpain cleavage of ataxin-3. 
 
Fragment constructs as a tool for modelling aggregation and toxicity of calpain-cleaved 
ataxin-3 
As calpain cleavage of overexpressed ataxin-3 was low at baseline, and in addition, stimuli 
which activate calpains are leading to detrimental side effects for treated cells, we generated 
EGFP-labelled ataxin-3 fragment constructs representing breakdown products at identified 
calpain cleavage sites D208 and S256 (Fig. 8B) and overexpressed them in HEK 293T cells 
(Fig. 8C and F). 
Overexpression of C-terminal polyQ-expanded fragment constructs corresponding to 
cleavage at both sites, D208 and S256, led to a strong accumulation of high molecular and 
SDS-insoluble ataxin-3 species when compared to full-length ataxin-3 148Q. Furthermore, 
these ataxin-3 aggregates showed a marked ubiquitination (Fig. 8D). Confocal microscopy of 
cells expressing the C-terminal fragment constructs together with the endoplasmic reticulum 
(ER)-labelling protein DsRed2-ER revealed a mainly cytoplasmic to perinuclear formation of 
occasionally massive ataxin-3 aggregates (Fig. 8E, Supplementary Fig. 7). On the other 
hand, respective N-terminal ataxin-3 fragment constructs did not aggregate (Fig. 8G). To 
analyse the impact of C-terminal polyQ-expanded fragment constructs on viability, we 
performed FACS analyses of transfected (EGFP-positive) HEK 293T cells. Our investigations 
showed distinctly elevated cell death, when overexpressing both polyQ-expanded fragment 
constructs in comparison to full-length ataxin-3 148Q (Fig. 8H).  
Fragmentation of ataxin-3 by calpains or caspases was hypothesized to lead to a separation 
of the intrinsic N-terminally located nuclear export signals and the C-terminally located 
nuclear localisation signals, which might cause a relocation of C-terminal polyQ fragments to 
the nucleus. To investigate this, we overexpressed full-length and fragment constructs of 
ataxin-3 in HEK 293T cells and analysed localization using cytoplasmic/nuclear fractionation 
and confocal imaging (Supplementary Fig. 8). Subcellular fractionation pointed to a mainly 
cytoplasmic localization of both full-length ataxin-3 and its fragment constructs, regardless of 
their N- or C-terminal origin (Supplementary Fig. 8A and B). C-terminal fragments did not 
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specifically demonstrate a shift toward the nucleus. Furthermore, microscopy showed a 
mainly diffuse distribution of all ataxin-3 variants within the cell, confirming the absence of a 
nuclear shift of C-terminal fragment constructs (Supplementary Fig. 8C and D). 
Taken together, C-terminal polyQ-expanded fragment constructs of ataxin-3, representing 
calpain cleavage at positions D208 or S256, feature a higher aggregation propensity and 
elevated cytotoxicity when compared to the polyQ-expanded full-length protein. However, 
these fragments do not show alterations in the cellular localization when compared to intact 
ataxin-3.  
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Discussion 
The discovery of proteolytic ataxin-3 cleavage as a relevant contributor to the molecular 
pathogenesis of MJD opened up further possibilities to develop more directed therapeutics 
against this highly disabling disorder. Till this day, mainly caspases and calpains were 
associated with ataxin-3 fragmentation and genetic or pharmacologic inhibition of these 
enzymes, or modification of recognition sites within their substrates seems to be a promising 
approach. In particular, inhibition of calpains in vivo was investigated intensively, showing 
that overexpression of CAST using adeno-associated viral vectors in a lentiviral mouse 
model of MJD did not only reduce ataxin-3 proteolysis but also decreased ataxin-3 
aggregation and mediated neuroprotection (Simoes et al., 2012). In line with these 
observations, the oral administration of the calpain inhibitor BDA-410 exerted comparable 
beneficial effects on fragmentation, aggregation and neurodegeneration (Simões et al., 
2014). On the other hand, non-specific or excessive inhibition of enzymes might lead to 
adverse effects due to disturbance of their physiological functions (Baudry and Bi, 2016; 
Donkor, 2011; Kudelova et al., 2015; Li and Sheng, 2012). 
In our study, we focussed on the identification of calpain cleavage sites in ataxin-3 and on 
their genetic modification to prevent proteolytic processing at determined positions. Previous 
investigations on caspase-dependent fragmentation of ataxin-3 could already identify major 
caspase cleavage sites within this disease protein and mutagenesis of specific aspartate 
residues partially blocked ataxin-3 fragmentation (Berke et al., 2004). These findings were 
translated into a Drosophila model of MJD, which exhibited a slowed down progression of 
neurodegeneration when expressing caspase cleavage-resistant, polyQ-expanded ataxin-3 
(Jung et al., 2009). Although localization of putative calpain cleavage sites has been 
narrowed down by western blotting or Edman N-terminal sequencing, exact sites remained 
unknown or lacked further confirmation by site-directed mutagenesis (Haacke et al., 2007; 
Simoes et al., 2012). 
Here, in our combinatorial approach, we were not only able to precisely localize calpain 
cleavage sites within ataxin-3, but also confirmed elected sites by mutating surrounding 
amino acids to render them less calpain cleavage-prone. In our in vitro and cell-based 
assays, we first reconfirmed wild-type and polyQ-expanded ataxin-3 as substrates for both 
calpain-1 and calpain-2. We did not detect differences between specificities and cleavage 
patterns regardless of expected polyQ-dependent size shifts. These observations add to 
results from studies using only recombinant calpain-2 (Haacke et al., 2007). Furthermore, the 
lack of differences in cleavage efficiency between calpain-1 and calpain-2 stands in contrast 
with our previous study, where we detected stronger ataxin-3 cleavage by calpain-2 
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(Hübener et al., 2013). Although previous attempts failed to identify proteolytic fragments in 
human MJD brain tissue or to associate them with specific proteases (Berke et al., 2004; 
Goti et al., 2004), we unequivocally observed calpain-dependent ataxin-3 fragmentation in 
patient- and control-derived fibroblasts, iPS cell lines and post mortem brain tissue at 
baseline. In this respect, a previous study reported on calpain-dependent ataxin 3 cleavage 
and aggregation in patient-specific iPSC-derived neurons after inducing Ca2+ influx via 
NMDA or glutamate administration (Koch et al., 2011). More recent investigations using 
similar approaches, however, could not reproduce the glutamate-induced ataxin-3 
aggregation (Hansen et al., 2016). 
To analyse observed ataxin-3 fragments and to identify calpain-cleavage sites within the 
protein sequence, we first predicted cleavage sites in ataxin-3 in silico using the GPS-CCD 
tool. After comparing predicted sites with results obtained by quantitative mass spectrometry 
and calpain overlay assays, we were able to identify four major cleavage sites at positions 
H187, D208, S256, and T277, matching with previous results obtained by Edman 
sequencing (Haacke et al., 2007). However, cleavage sites at amino acids Q154 or G220 as 
proposed in a more recent publication (Simoes et al., 2012) were neither observed in our 
experiments nor reached high scores in our in silico prediction. By correlating expected 
fragment sizes with the prior observed cleavage patterns, sites D208 and S256 emerged as 
primary calpain targets. Interestingly, these two cleavage sites co-localize with known 
phospho-sites in ataxin-3, namely sites T207 and S256. The not yet intensively investigated 
site T207 was predicted to be phosphorylated by CK2 (Mueller et al., 2009; Trottier et al., 
1998). Site S256 was shown to be targeted by GSK 3β and the dephospho-mimetic variant 
S256A of polyQ-expanded ataxin-3 was shown to be highly aggregation-prone when 
compared to unchanged or phospho-mimetic S256D ataxin-3 (Fei et al., 2007). Together with 
our findings, these observations underline the huge relevance of both investigated sites for 
the protein homoeostasis of ataxin-3 and reveal the modulation of phosphorylation as a 
putative approach to manipulate ataxin-3 cleavage. In line with this, phosphorylation of 
huntingtin, the disease protein in Huntington’s disease, was shown to reduce its cleavage by 
caspases (Luo et al., 2005). 
In order to prevent ataxin-3 fragmentation by cleavage site-directed mutagenesis, we sought 
to modify common approaches based on polyalanine substitutions or cleavage site deletions 
(Gafni et al., 2004; Wanichawan et al., 2014). Although mutagenesis of single amino acids 
following the 'P2-P1 rule' of substrate recognition has been shown to be sufficient in 
preventing calpain cleavage (Hirao and Takahashi, 1984; Sasaki et al., 1984; Stabach et al., 
1997; Kaczmarek et al., 2012), further studies could not confirm the preference of calpains 
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for any particular residues or demonstrated that alteration of the sequence at only one 
position was not sufficient to block calpain-dependent cleavage (Sakai et al., 1987; Banik et 
al., 1994; Garg et al., 2011). Due to these inconsistencies, we decided on using in silico 
prediction to test the effects of a single to multiple amino acid substitutions by all 
proteinogenic amino acids. By this approach, we identified a triple tryptophan motif as the 
most potent mutation to decrease cleavage likelihood. Calpain overlay assays of cleavage-
site containing peptides carrying this triplet confirmed a significant reduction of calpain 
binding, which was more efficient than a penta-alanine substitution. Finally, this effect was 
corroborated by generating wild-type and polyQ-expanded ataxin-3 variants featuring penta-
alanine and triple tryptophan mutations at cleavage sites D208 and S256. Thus, triple 
tryptophan substitutions constitute a potent way to prevent calpain cleavage at mutated 
recognition motifs, which can be applied to further calpain substrates. 
To further characterize the impact of cleavage-site corresponding fragments, we generated 
respective EGFP-tagged ataxin-3 constructs comprising N- and C-terminal portions of the 
wild-type and polyQ-expanded protein. It should be noted that our C-terminal fragment 
construct 257Cter corresponds directly to a prior generated construct, whose sequence was 
based on results of unspecified limited proteolysis experiments with recombinant ataxin-3 
(Haacke et al., 2006). Only overexpression of C-terminal polyQ-expanded ataxin-3 led to a 
massive accumulation of ubiquitin-positive aggregates, which markedly exceeded 
aggregation of full-length ataxin-3 and increased cell death. This corresponds to cell and 
animal models of MJD, which show strong ataxin-3 accumulations, apoptosis and a more 
rapid manifestation of MJD-reminiscent phenotypes when compared to the expression of full-
length mutant ataxin-3 (Breuer et al., 2010; Ikeda et al., 1996; Paulson et al., 1997). The 
excessive ubiquitination of C-terminal fragment-derived aggregates, but not of aggregates 
composed of full-length polyQ-expanded ataxin-3, might be due to the elevated misfolding of 
truncated ataxin-3 species, which has been suggested earlier as a trigger for ubiquitination 
(Jana and Nukina, 2004). Confocal microscopy of aggregates formed by our C-terminal 
fragment constructs exhibited a mainly cytoplasmic localization. Interestingly, a recent 
histological study on the aggregation pathology in the brainstem of SCA2 and MJD patients 
revealed the severity of cytoplasmic aggregates as the best predictor of neurodegeneration 
in both polyQ disorders, while an inverse correlation of neurodegeneration and nuclear 
aggregates was seen in MJD brain tissue (Seidel et al., 2016). In addition to it, a further 
study, which investigated aggregate toxicity of artificial β-sheet proteins, as well as fragments 
of polyQ-expanded huntingtin and TAR DNA binding protein-43 (TDP-43), discovered that 
cytoplasmic but not nuclear aggregation interfered with nucleocytoplasmic protein and RNA 
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transport maybe contributing to the cellular pathology in proteinopathies (Woerner et al., 
2016). These findings suggest a rather protective role of aggregates localized in the cell 
nucleus. On the other hand, N-terminal fragment constructs did not show any SDS-insoluble 
or high molecular aggregation when overexpressed in cell culture, consistent with earlier in 
vitro experiments (Perez et al., 1998), but out of line with our observations in a N-terminal 
fragment mouse model of MJD (Hübener et al., 2011). As fragmentation of ataxin-3 was 
connected to a separation of N-terminally located nuclear export signals (NES) and C-
terminally located nuclear localisation signals (NLS) (Antony et al., 2009), we analysed the 
subcellular localization of ataxin-3. Our C-terminal fragment constructs 209Cter and 257Cter, 
which both contain NLS 273 and lack NES 77 and NES 141, did not exhibit a trend towards 
nuclear localization. These observations accord with previous investigations which showed 
that the endogenous NLS signal is not active and C-terminal ataxin-3 fragments without the 
NES might shuttle in and out of the nucleus (Breuer et al., 2010). The nuclear accumulation 
of mutant ataxin-3, however, might be triggered by alternative NLS-independent processes. 
In summary, we report on the identification of calpain cleavage sites within the ataxin-3 
protein and on the successful cleavage prevention by substituting recognition motifs by 
tryptophan triplets. Furthermore, we could characterize calpain cleavage-derived fragments 
of ataxin-3. A still pending but not less important further step in analysing ataxin-3 cleavage 
and arising fragments will be the characterization of our generated cleavage site-mutant 
constructs in vivo. Only a physiological expression of the modified ataxin-3 variants in the 
correct organic context and a time-dependent manner can give us the chance to assess the 
impact of proteolytic cleavage on the molecular pathogenesis MJD. This approach was 
exemplified by previous studies, which were investigating caspase-dependent cleavage of 
ataxin-3 in Drosophila or polyQ-expanded huntingtin in mice (Graham et al., 2006; Jung et 
al., 2009). In addition, further investigations of C- or even N-terminal ataxin-3 fragments 
should be undertaken, as, for instance, polyQ-independent fragments of huntingtin showed 
deleterious effects on autophagy or vesicle transport (El-Daher et al., 2015; Martin et al., 
2014). 
On a final note, our precise identification of calpain cleavage sites enables the development 
of an alternative possibility to prevent ataxin-3 fragmentation by skipping exons that contain 
the respective calpain recognition motif. This concept has already been tested for 
Huntington’s disease by using antisense oligonucleotides that induce skipping of exon 12 in 
huntingtin pre-mRNA, and thereby abolish the formation of a toxic N-terminal huntingtin 
fragment (Evers et al., 2014). On the other hand, focusing on the correction or removal of the 
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expanded CAG repeat might still represent a more specific approach (An et al., 2012; Evers 
et al., 2013). 
Overall, our data emphasize the biological relevance of calpain-mediated ataxin-3 cleavage 
and underline this proteolytic pathway as a potential therapeutic target for treating MJD.  
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Figures and Figure Legends 
 
Figure 1: Calpain cleavage site prediction and calpain cleavage of ataxin-3 in vitro. (A) 
In silico prediction of calpain cleavage sites in the ataxin-3 protein (UniProt identifier: 
P54252-2) using the GPS-CCD tool. The red dotted line indicates maximum default cut-off 
value of 0.654. (B) Graphic representation of the ataxin-3 protein structure, highlighting 
domains, calpain cleavage sites (red scissors) and antibody epitopes. (C and D) Purified 
ataxin-3 (Atx3) 22Q is cleaved by recombinant calpain-1 (rCAPN1) and calpain-2 (rCAPN2) 
in vitro. Characteristic fragment patterns can be detected using four different ataxin-3-specific 
antibodies. iv CCA = in vitro calpain cleavage assay; S/E ratio = substrate/enzyme ratio; fl = 
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full-length. Ataxin-3 fragments are labelled with letters ‘a’ to ‘e’ according to their expected 
cleavage site position from the N- to the C-terminus.   
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Figure 2: Ataxin-3 is cleaved by calpains in patient-derived SV40-immortalized 
fibroblasts. (A) Treating control (Ctrl) and patient-derived (MJD) SV40-immortalized 
fibroblasts with calpain inhibitor III (CI III) reduced levels of ataxin-3 fragment ‘c’ and 
attenuated the calpain system activation as confirmed by decreased calpain-1 activation, 
elevated CAST levels and decreased fragmentation of α-spectrin. Tubulin served as loading 
control. Densitometry analysis shows an ataxin-3 cleavage reduction by approx. 50%. Bars 
represent means ± SEM, relative to wild-type control and with n = 3. *P < 0.05; **P < 0.01; 
***P < 0.001 (One-way ANOVA with Tukey post-test). (B) Calpains can be activated in cell 
culture lysates of control- and patient-derived SV-40-immortalized fibroblasts by addition of 
CaCl2. Activation resulted in cleavage of wild-type and polyQ-expanded ataxin-3 featuring 
specific fragments (‘a’, ‘b’, and ‘c’). Fragment formation was prevented by CI III treatment. 
Tubulin served as loading control. (C) Ionomycin (IM)-facilitated Ca2+ influx in control- and 
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patient-derived SV-40-immortalized fibroblasts leads to an activation of calpains and to an 
ataxin-3 cleavage. The fragmentation pattern is comparable to the one observed after in vitro 
calpain activation (fragment ‘a’, ‘b’, ‘c’, and, in addition, ‘d’). Pre-treatment of cell with CI III 
abolished ataxin-3 cleavage. Tubulin served as loading control. wt = wild-type; ex = 
expanded. Asterisks indicate unspecific bands.  
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Figure 3: Calpain-dependent ataxin-3 cleavage is apparent in patient-derived 
fibroblasts, iPS cells and post mortem brain tissue. (A) Western blot analysis of ataxin-3 
fragmentation in fibroblasts and corresponding iPS cell lines (iPSCs) derived from MJD 
patients and healthy controls. Detection with the ataxin-3-specific antibody 1H9 shows a 
predominant cleavage band between 28 and 38 kDa (‘c’). Actin served as loading control. (B) 
Treatment of iPSCs from a MJD patient and a control with ionomycin (IM) leads to an 
increased breakdown of ataxin-3 and to elevated levels of fragments ‘a’, ‘b’ and ‘c’. This 
effect was countered by pre-treatment with calpain inhibitor III (CI III). Actin served as loading 
control. (C) Cortical neurons differentiated (iCNs) from patient-derived iPS cells exhibit 
typical neuronal morphology by expressing β-III-tubulin (TUJ1, green) and the cortical layer 
V/VI- specific marker CTIP2 (red). Nuclei were counterstained with DAPI (blue). Scale bar = 
50 µm. (D) iCNs from a MJD patient and a control were treated with ionomycin (IM). 
Treatment induced cleavage of ataxin-3 accompanied with the formation of fragments ‘a’, ‘c’ 
and ‘d’ as detected by western blot analysis. Actin served as loading control. Asterisks 
indicate unspecific bands. (E) Comparison of the fragmentation of in vitro cleaved ataxin-3 
with ataxin-3 from human tissue. Post mortem cerebellar samples of a MJD patient and a 
control were analysed along with calpain-activated SV-40-immortalized fibroblast (iHFs) 
samples. Typical N-terminal ataxin-3 fragments deriving from calpain cleavage can be 
observed both in human brain tissue and fibroblast samples. wt = wild-type; ex = expanded.  
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Figure 4: Deletion constructs help to unveil calpain cleavage sites in ataxin-3. (A) C-
terminal deletion constructs of ataxin-3 display various calpain-dependent cleavage patterns 
attributed to the presence or absence of specific calpain cleavage sites. Constructs were 
overexpressed in HEK 293T cells and endogenous calpains activated by ionomycin (IM) 
administration. CI III treatment served as a negative control. Fragmentation patterns were 
analysed via western blotting. Red arrowheads labelled with ‘a’ to ‘e’ indicate N-terminal 
fragments of ataxin-3. C-terminal GFP-positive fragments, presumably corresponding to the 
N-terminal breakdown products, are marked with blue arrowheads and are respectively 
labelled with ‘a'’ to ‘e'’. GAPDH served as loading control. (B) Graphic representation of 
utilized ataxin-3 deletion constructs, putative cleavage regions (red scissors and dotted line) 
within the ataxin-3 protein and binding sites of used antibodies.  
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Figure 5: Cleavage sites can be identified using mass-spectrometry. (A) Overview of 
the SILAC-based quantitative mass spectrometry approach to map calpain cleavage sites. (B 
and C) For mass-spectrometry analysis, purified recombinant SF-tagged ataxin-3 15Q and 
62Q were incubated with recombinant calpain-1 (rCAPN1) or calpain-2 (rCAPN2). To monitor 
the reaction, aliquots of the sample were analysed using SDS-PAGE. Total protein stain with 
SYPRO Ruby shows that ataxin-3 is cleaved by both calpains producing comparable 
patterns of polyQ-dependent and -independent fragments. N-terminal and C-terminal 
breakdown products were detected via immunodetection using antibodies against the FLAG-
tag and against ataxin-3 (SA3637). iv CCA = in vitro calpain cleavage assay; bdp = 
breakdown product. (D and E) Scatterplots for the combined quantitative mass spectrometry 
approach. Log2 median ratios of the forward experiments were plotted over the log2 median 
ratios of the reverse experiments (label switch). Calpain-1/2 treatment following either a GluC 
or AspN secondary proteolysis allowed the identification of the calpain cleavage sites H187, 
D208 and S256 and G259. A minimum ratio of 2 in the forward experiments and a minimum 
ratio of 0.5 in the reverse experiments have been set as significance level (red line).  
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Figure 6: Overlay of 20-mer ataxin-3 peptide arrays with calpain-1 and calpain-2 shows 
reduced calpain binding after triple tryptophan substitution. (A) In silico prediction of 
calpain cleavage sites in ataxin-3 (UniProt identifier: P54252-2) using the GPS-CCD tool and 
effects of replacing amino acids surrounding predicted cleavage sites by five alanines or 
three tryptophans on calpain cleavage likelihood. The red dotted line indicates maximum 
default cut-off value of 0.654. (B – F) Calpain binding to putative cleavage sites in ataxin-3 
was analysed by overlaying cleavage site-containing 20-mer ataxin-3 peptides with calpain-1 
(rCAPN1) and calpain-2 (rCAPN2). Cleavage positions are located after the red-labelled 
amino acid. Replacement of amino acids at the putative cleavage sites H187, D208 and 
S256 indicates the most efficient reduction of calpain binding when introducing three 
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tryptophans. However, calpain binding at site T277 (D) is most reduced by introducing five 
alanines. For each site, detected peptide arrays of two representative experiments are 
shown. Bars represent means ± SEM, relative to wild-type sequence and n = 6. *P < 0.05; 
**P < 0.01; ***P < 0.001 (One-way ANOVA with Bonferroni post-test). 
 
  
g. Weber et al., 2017, Brain. 
357 
 
Figure 7: Mutagenesis of putative calpain cleavage sites alters fragmentation of 
ataxin-3. (A and B) Putative calpain cleavage sites within ataxin-3 15Q were mutated by a 5 
alanine (5A) or a triple tryptophan (3W) exchange at positions D208 or S256. Densitometry 
analysis of respective fragments (‘d’ and ‘c’) induced by in vitro calpain cleavage assays (iv 
CCA) shows effects of the mutagenesis on ataxin-3 cleavage. Bars represent means ± SEM, 
relative to wild-type and n = 3. *P < 0.05; **P < 0.01, ***P < 0.001 (One-way ANOVA with 
Tukey post-test). (C and D) Triple tryptophan (3W) cleavage site mutations at positions D208 
and S256, or at both sites in ataxin-3 15Q and 148Q show reduced levels of corresponding 
C-terminal (antibody: GFP) and N-terminal (antibody: N-term-I) fragments. Actin served as 
loading control. C-terminal ataxin-3 fragments corresponding to N-terminal fragments ‘a’ to 
‘d’ are marked with an apostrophe (‘a'’ to ‘d'’). (E) HEK 293T cells transfected with EGFP-
ataxin-3 15Q and 148Q with or without 3W mutations at positions D208 and S256 were 
subjected to a cell-based calpain cleavage assay (cb CCA). Detection with antibody N-term-II 
shows a strongly reduced occurrence of fragments ‘c’ and ‘d’ upon ionomycin (IM)-facilitated 
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Ca2+ influx for ataxin-3 208/256 3W when compared to the unmutated variants. Activation of 
the calpain system was validated by detecting calpain-1 activation and α-spectrin cleavage. 
Tubulin served as loading control. bdp = breakdown product. SE = short exposure; LE = long 
exposure. 
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Figure 8: C-terminal calpain cleavage-corresponding fragment constructs are highly 
aggregation-prone and toxic. (A) Overview of identified calpain cleavage sites within the 
ataxin-3 protein. Grey scissors indicate unconfirmed but in silico predicted cleavage sites. 
Yellow scissors show cleavage sites confirmed by mass spectrometry analysis (MSA) or 
calpain overlay assays (COA). Orange scissors show sites confirmed by both MSA and 
COA. Red scissors highlight cleavage sites which were not only identified via MSA and COA 
but also confirmed by mutating cleavage sites (CSM). (B) Graphic representation of GFP-
tagged N-terminal and C-terminal fragment constructs corresponding to calpain cleavage of 
g. Weber et al., 2017, Brain. 
360 
ataxin-3 after position D208 (1-208 and 209Cter) and S256 (1-256 and 257Cter). C-terminal 
fragments were generated in two different polyQ-variants (wild-type 15Q and expanded 
148Q). (C) Overexpression of calpain cleavage-corresponding C-terminal fragment 
constructs in HEK 293T was analysed via western blotting (WB). Insoluble forms of ataxin-3 
in the stacking gel (SG) were detected for ataxin-3 209Cter 148Q and ataxin-3 257Cter 148Q, but 
barely for full-length ataxin-3 148Q. Actin and huntingtin served as loading controls. (D) Filter 
retardation assays (FT) and denaturing detergent agarose gel electrophoresis (DDAGE) 
show elevated levels of aggregates formed by fragment constructs ataxin-3 209Cter 148Q and 
ataxin-3 257Cter 148Q. These aggregates show a strong ubiquitination. Densitometry of the 
DDAGE reveals the significant increase in aggregation by C-terminal expanded fragment 
constructs. Bars represent means ± SEM, relative to wild-type and n = 3. *P < 0.05; **P < 
0.01; ***P < 0.001 (One-way ANOVA with Tukey post-test). (E) Confocal microscopy of HEK 
293T cells expressing EGFP-tagged full-length ataxin-3, fragment constructs and DsRed2-
ER (for highlighting the endoplasmic reticulum) shows massive and mainly cytoplasmic 
formation of aggregates. DAPI was used as a nuclear counter stain. Scale bar = 10 µm. (F 
and G) EGFP-tagged N-terminal ataxin-3 fragment constructs ataxin-3 1-208 and ataxin-3 1-256 
were overexpressed in HEK 293T cells in comparison to 15Q and 148Q full-length ataxin-3 
and expression analysed by WB. Overexpression of both N-terminal fragment constructs did 
not lead to the formation of aggregates as analysed by FT and DDAGE. Actin and huntingtin 
served as loading controls. (H) FACS based viability analysis of EGFP-positive (GFP+) 
HEK 293T cells using the Zombie NIR dye reveals an increased cell death when 
overexpressing fragment constructs ataxin-3 209Cter 148Q and ataxin-3 257Cter 148Q in 
comparison to full-length ataxin-3 148Q. Bars represent means ± SEM, as percentage of 
GFP+ cells, n = 8. *P < 0.05; **P < 0.01 (One-way ANOVA with Tukey post-test). 
